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ABSTRACT
The majority of patients resuscitated from cardiac arrest (CA) subsequently die due to
post-cardiac arrest syndrome (PCAS), whose mechanisms are only partially understood.
We adopted an approach of untargetedltargeted plasma metabolomics in rats to identify
metabolites involved in the mechanisms of PCAS to be tested as predictors of outcome.
Activation of the kynurenine pathway (KP) for tryptophan (TRP) degradation was
demonstrated in rats, pigs and in a small cohort of patients. Decreases in TRP occurred
during the post-CA period and were accompanied by significant increases in KP
metabolites, 3-hydroxyanthranilic acid (3-HAA) and kynurenic acid in each species, that
persisted up to 3-5 days post-CA (p<O.Ol). KP metabolites changes were significantly
related to the severity of myocardial and cerebral injuries and survival. Finally, when
tested in 155 patients resuscitated from CA, KP metabolites were significantly higher in
patients with poor outcomes. The quality of chest compression (CC) is another major issue
for cardiopulmonary resuscitation (CPR) success and survival. The decision whether to
interrupt CC to deliver a defibrillation (DF) is difficult. The potential benefit of a DF
guided by a real time ventricular fibrillation (VF) waveform analysis would maximize DF
success, minimize CC interruptions and myocardial damage by repetitive and unnecessary
DFs. We evaluated amplitude spectrum area (AMSA) as predictor of DF outcome in two
large databases of out-of-hospital VFs, from US (609 patients) and Italy (1.617 patients).
AMSA was significantly higher prior to a successful DF than prior to an unsuccessful one
(p<O.OOOI).Thresholds for prediction of successful and unsuccessful DFs were 16-17 mV-
Hz for success and <7 m'V-Hz for failure, with a positive predictive value of 80% and a
negative predictive value of 97%. AMSA was a better predictor of DF outcome (AUC
0.86, p<O.OOOl) compared to other VF parameters, Le. amplitude and frequencies. In
conclusion, AMSA would be a useful tool for guiding CPR.
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SUMMARY
Presentation to tile study design and thesis reading
The present thesis includes both experimental and clinical studies directed to discover
and/or validate biochemical and electrophysiological markers predictive of return of
spontaneous circulation and post-resuscitation outcome.
In order to achieve such aims, the student has performed two separate studies concurrently.
The first series of studies was directed to discover and investigate experimentally and
clinically new circulating biomarkers predictive of post-resuscitation outcome, while the
second series of study validated ECG-derived biomarkers predictive of successful
resuscitation in two large databases.
Indeed, these two studies focused on different "markers" targeting the two main aspects of
cardiopulmonary resuscitation, namely: successful resuscitation and long-term outcome.
Both the studies therefore concurred to the same goal of identify new tools to predict
cardiac arrest outcome and are therefore presented together in this thesis as a single study
with an introduction, materials and methods, results, and discussion section. Nevertheless,
in order to help the readers going throughout the work, each section is divided into two
sub-sections presenting separately the studies on "Circulating" biomarkers from those on
"ECG-derivided" biomarkers.
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The following five studies were performed:
• CIRCULATING BIOMARKERS:
• STUDY 1: Discovery of new circulating biomarkers with the aid of untargeted
metabolomics in a rat model of cardiac arrest
BACKGROUND: The mechanisms responsible for post-cardiac arrest (CA) myocardial
and cerebral dysfunction are not well understood, especially in the early post-resuscitation
phases. In this investigation, we hypothesized that untargeted plasma metabolomic
analyses would be a feasible approach to identify perturbations in circulating metabolites
and thus potential mechanisms accounting for outcome of CA.
METHODS: Twelve rats, 450 ± 30 g, were used. Ventricular fibrillation (VF) was induced
in 6 rats and was untreated for 6 min. Cardiopulmonary resuscitation (CPR), including
mechanical chest compressions (CC), ventilations and epinephrine, was then initiated and
continued for additional 6 min prior to defibrillation (DF). Two hr following resuscitation,
animals were sacrificed and plasma collected. The other 6 rats were not subjected to CA
and served as controls. We adopted unbiased mass spectrometry-based metabolomic
profiling to identify perturbations in circulating metabolites. More specifically, plasma
metabolome was examined by liquid chromatography-tandem mass spectrometry.
Differences in chromatogram profiles were then analyzed using SIEVE v1.3 analysis
software. Chromatographic peaks, with accurate masses, retention time and tandem mass
fragmentation patterns were then identified using mass-spectral libraries of metabolites ..
RESULTS: Our findings strongly indicated early alterations in a major route of the
tryptophan (TRP) catabolism, namely the kynurenine pathway (KP), after resuscitation.
Specific metabolites involved in the TRP catabolism were quantified absolutely using
liquid chromatography-multiple reaction monitoring-mass spectrometry. TRP plasma
concentration felt significantly in the early post-resuscitation phase, while its metabolites,
7
l-kynurenine (KYN), kynurenic acid (KYNA), and 3-hydroxyanthranilic acid (3-HAA)
rose significantly (p<O.05).
CONCLUSIONS: Our results suggest that KP is activated early following resuscitation
from CA. It is well known that KP is involved in the pathogenesis of numerous central
nervous system disorders and hypotension during sepsis. Thus, KP activation might
contribute the severity ofpost-CA syndrome.
• STUDY 2: Validation of KP activation after cardiac arrest with experimental
models in rats and pigs and in a small cohort of cardiac arrest patients
BACKGROUND: KP is a major route of the TRP catabolism. In the present study, TRP
and KP metabolites concentrations were measured in plasma from rats, pigs and humans
after CA in order to assess KP activation and its potential role in post-resuscitation
outcome.
METHODS: Plasma was obtained from: (A) 24 rats, subjected to 6 min CA and 6 min of
CPR; (B) 10 pigs, subjected to 10 min CA and 5 min CPR; and (C) 3 healthy human
volunteers and 5 patients resuscitated from CA. KP metabolites were quantified by liquid
chromatography multiple reaction monitoring mass spectrometry. Assessments were
available at baseline, and 1-4 hr, and 3-5 days post-CA.
RESULTS: KP was activated after CA in rats, pigs, and humans. Decreases in TRP
occurred during the post-resuscitation period and were accompanied by significant
increases in its major metabolites, 3-HAA and KYNA in each species, that persisted up to
3-5 days post-CA (p<O.Ol). In rats, changes in KP metabolites reflected changes in post-
resuscitation myocardial function. In pigs, changes in TRP and increases in 3-HAA were
significantly related to the severity of cerebral histopathogical injuries. In humans, KP
activation was observed, together with systemic inflammation. Post-CA increases in 3-
HAA were greater in patients that did not survive.
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CONCLUSIONS: In this fully translational investigation, the KP was activated early
following resuscitation from CA in rats, pigs, and humans, and might have contributed to
post-resuscitation outcome.
• STUDY 3: Validation of KP activation after cardiac arrest in a large cohort of out
of hospital cardiac arrest patients
BACKGROUND: KP is the major route of TRP catabolism and is activated by
inflammation and after CA in animals. We have investigated post-CA KP activation in a
large cohort of CA patients. We hypothesized that the KP activation level correlates with
the severity of the ischemic insult, shock and long-term outcome.
METHODS: We performed a prospective multicentre observational study in 21 intensive
care units (lCU) in Finland. Blood samples were obtained from 155 patients, for which
prospective data collection included time to return of spontaneous circulation (ROSC),
lowest systolic arterial pressure (SAP) and bicarbonate (BIC) during the first 24 hours of
ICU care. Poor 12-month outcome was defined as a cerebral performance category (Cl'C)
of 3-5. Plasma levels of TRP and its KP metabolites KYN, KYNA, 3-HAA, and the
KYN/TRP ratio, were measured using liquid chromatography and mass spectrometry.
Non-parametric tests, univariate, multivariate and linear regression analyses were used to
determine associations of metabolites and study endpoints.
RESULTS: KP metabolites at leu admission correlated with time to ROSe (KYN
p=O.005, KYNA p=O.023, 3-HAA p=O.Oll, KYNITRP p=O.015). Patients with higher
levels of KYN, KYNA, and KYNITRP ratio had lower 24 hr SAP and BIe. All KP
metabolites, but not TRP, were significantly higher in patients with poor outcome (KYN,
p<O.OOl, KYNA p=O.043, 3-HAA p=O.047, KYN/TRP p<O.OOl). Multivariable logistic
regression showed that higher KYNA (OR 1.004, 95% Cl 1.001-1.007, p=0.038) and 3-
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HAA (OR 1.015, 95% Cl 1.010-1.030, p=0.043) were independently associated with 12-
month poor outcome.
CONCLUSIONS: KP is activated after CA and is associated with the severity of shock,
early death and poor long-term neurological outcome. KP metabolites may have clinical
value for prognostication.
• ECG-DERIVED BIOMARKERS:
• STUDY 4: AMSA evaluation in 609 VF patients in the United States
BACKGROUND: The capability of Amplitude Spectrum Area (AMSA) to predict the
success ofDF was retrospectively evaluated in a large database of out-of-hospital CAs.
METHODS: Electrocardiographic data, including 1260 DFs, were obtained from 609 CA
patients due to VF. AMSA sensitivity, specificity, accuracy, and positive and negative
predictive values (PPV, NPV) for predicting DF success were calculated, together with
receiver operating characteristic (ROC) curves. Successful DF was defined as the presence
of spontaneous rhythm 2: 40 bpm starting within 60 sec from the DF. In 303 patients with
CC depth data collected with an accelerometer, changes in AMSA were analyzed in
relationship to CC depth.
RESULTS: AMSA was significantly higher prior to a successful DF than prior to an
unsuccessful DF (15.6±0.6 vs. 7.97±0.2 mY-Hz, p<O.OOOl).Intersection of sensitivity,
specificity and accuracy curves identified a threshold AMSA of 10mV-Hz to predict DF
success with a balanced sensitivity, specificity and accuracy of almost 80%. Higher AMSA
thresholds were associated with further increases in accuracy, specificity and PPV. AMSA
of 17 mY-Hz predicted DF success in two third of instances (PPV of 67%). Low AMSA,
instead, predicted unsuccessful DFs with high sensitivity and NPV >97%. Area under the
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ROC curve was 0.84. CC depth affected AMSA value. When depth was <1.75 in, AMSA
decreased for consecutive DFs, while it increased when the depth was> 1.75 in (p<0.05).
CONCLUSIONS: AMSA could be a useful tool to guide CPR interventions and predict the
optimal timing ofDF.
• STUDY 5: AMSA evaluation in 1.617 VF patients in Lombardia Region, Italy
BACKGROUND: In a highly populated area of northern Italy, we evaluated the capability
of AM SA to predict DF outcome in of out-of-hospital CA patients, concurrently to other
ECG-derived parameters. We hypothesized that AMSA would be a good predictor of DF
outcome and that threshold values of AMSA could be identified such to be used as a guide
for CPR intervention, Le. CC or DF.
METHODS: ECG data recorded by automated external defibrillators from different
manufactures were obtained from cardiac arrest events occurring in 9 cities in Lombardia
Region, Italy. Among these events, only VF CAs receiving DFs were selected. A database
including 2.442 DFs, obtained from 1.050 patients enrolled between 2008-2009, was used
as derivation group. An additional database, including 1.386 DFs, obtained from 567
patients enrolled in 2010, was used as validation group. A 2 sec ECG window ending at
0.5 sec before DF was analyzed and AMSA was calculated, together with root mean square
(RMS), peak frequency (PF), median frequency (MDF), and mean frequency (MNF).
Parametric and non-parametric tests, univariate, multivariate, linear regression analyses
and area under the receiver operating characteristic (ROC) curve were used to determine
associations of AMSA and ECG-parameters and study endpoints, Le. DF success, ROSC,
survival till hospital discharge, 6 months and 1 year. Threshold values of AMSA able to
discriminate among successful and not successful DFs were individuated in the derivation
database and sensitivity, specificity, positive and negative predictive values (PPV, NPV)
were evaluated in the validation database.
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RESULTS: Among the 2.447 DF attempts, 26.2% were successful. AMSA was
significantly higher prior to a successful DF than a failing one (l3±5 vs. 6.8±3.5,
p<O.OOOl). RMS, PF, MDF, but not MNF, were also significantly higher prior to a
successful DF compared to an unsuccessful one. AMSA was an independent predictor of
DF outcome (OR 1.40, 95%CI 1.36-1.44) and ROSC (OR 1.21, 95%CI 1.16-1.25). Age,
gender, EMS arrival, myocardial infarction, congestive heart failure, diabetes, and anti-
hypertensive drug, were the factors associated with AMSA values. RMS, PF, MDF, but not
MNF, also predicted DF outcome and ROSC. Nevertheless, area under the ROC curve for
DF outcome prediction was significantly greater for AMSA compared to the other ECG-
derived parameters (0.86, p<O.OOOl). Unexpectedly, AMSA was also associated with
hospital discharge and long term survival. Intersection of sensitivity, specificity and
accuracy curves identified a threshold value of AMSA of 8.9 mY-Hz, able to predict DF
outcome, with a balanced sensitivity, specificity and accuracy of 79%. Moreover,
intersection of PPV and accuracy curves identified a threshold value of AMSA of 15.5
mY-Hz able to predict a successful DF with a PPV and accuracy of 79%. AMSA values
greater than 23 mV-Hz correctly predicted the success of DF with a PPV value of 100%.
AMSA below 6.5 mV-Hz correctly predicted the DF failure with a NPV of> 95%. In the
validation database, the AMSA threshold of 15.5 predicted DF success with a PPV > 80%
and a specificity of 97%, while the AMSA threshold of 6.5 predicted DF failure with a
NPV > 98% and a sensitivity> 97%.
CONCLUSIONS: In this population, one of the largest studied to now, AMSA was a better
predictor of DF outcome compared to other ECG-derived parameters. Indeed, AMSA was
confirmed to predict DF outcome with high accuracy. A specific AMSA threshold in order
to predict DF outcome, Le. success or failure, may be identified during CPR. An AMSA-
based DF decision therefore would be an useful approach to guide the best CPR
intervention.
12
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INTRODUCTION
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Cardiac arrest represents a dramatic clinical event that can occur suddenly and often
without premonitory signs. This condition is characterized by sudden loss of consciousness
caused by the lack of cerebral blood flow, which occurs when the heart ceases to pump.
Indeed, it represents a leading cause of death in the western world, with as many as
350.000 to 700.000 people in the United States, Canada and Europe sustaining cardiac
arrest each year (Lippert 2010, Nolan 2010, Travers 2010). Cardiopulmonary resuscitation (CPR),
including chest compression (CC), often in conjunction with electrical defibrillation (OF),
has the potential of re-establishing spontaneous circulation. Despite major efforts to
improve outcomes from cardiac arrest, average survival rate remains dismal and presents a
large variation with a spread between 2 to 50% (Atwood 2005, Eisenberg 2009, Fredriksson 2003,
Nicho12008, Travers 2010). Though the initial success of CPR, in fact, the majority of victims
die within 72 hr from hospital admission, due what is now called "post cardiac arrest
syndrome" (Brown 1992, Nolan 2008, Peberdy 2010, Sasson 2010, Schenenberger 1994). Most
prominent are post resuscitation myocardial failure, ischemic brain damage and processes
related to the systemic ischemialreperfusion response (Nolan 2008). Severe heart contractile
failure has been implicated as one of the most important mechanism accounting for the
early fatal outcome (Gazmuri 2012, Laurent 2002, Tang 1993, van Alem 2003). Long term morbidity
and mortality after successful CPR, instead, largely depend on recovery of neurologic
function (Nolan 2008, Sandroni 2013 and 2013b). As many as 30% of survivors of cardiac arrest,
in fact, manifest permanent brain damage and in some instances only 2-12% of
resuscitated patients have been discharged from the hospital without neurological
impairments (Bolliger 1999, Brain Resuscitation Clinical Trial J 1986, Brown 1992, Nolan 2008,
OIasveengen 2009, Peberdy 2010, Schenenberger 1994).
The mechanisms responsible for post-cardiac arrest myocardial and cerebral injury are not
well understood, although several events have been described. The reintroduction of
oxygenated blood after the return of spontaneous circulation (ROSC) stimulates a sequence
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of complex actions that lead to acute inflammatory responses and release of reactive
oxygen species (ROS), causing oxidative damage, cellular edema, cell membrane damage,
calcium ion (Ca2+) overload, mitochondrial dysfunction, and apoptosis (Dezfulian 2007,
LebufJe 2003, Levraut 2003, No/an 2008, Ouyang 1999, Po/derman 2009). Several other processes,
including interactions between pleiotropic mediators, coagulation abnormalities, activation
of the inflammatory cytokine cascade, chemokine upregulation and ultimately recruitment
of inflammatory leukocytes and reactive astrogliosis have also been reported after cardiac
arrest and are major players in the final outcome (Adrie 2002 and 2004 and 2005, Frangogiannis
1998, Meybohm 2009, Neumar 2008, No/an 2008, Vakeva 1998).
There is still controversy about how much the clinical use of current biomarkers, i.e.
cardiac troponins (cTn), neuron-specific enolase (NSE), protein S-100 beta (S-100b)
contributes to the prediction of outcome of cardiac arrest (No/an 2008, Peberdy 2010, Scol/etta
2012). Predicting survival, myocardial and neurological outcome is therefore a difficult
issue, especially in the early post-resuscitation phase.
CPR and defibrillation
Ventricular fibrillation (VF) is one of the primary rhythms in many cases of cardiac arrest.
Indeed, on initial heart rhythm analysis, about 25-30% of out of hospital cardiac arrests
are due to VF (Agarwa/2009, Cobb 2002, No/an 20/0, Rea 2004, Ringh 2009, Travers 2010, Vaillancourt
2007). It is likely that many more victims have VF or rapid ventricular tachycardia (VT) at
the time of collapse but, by the time the first electrocardiogram (ECG) is recorded the
rhythm has deteriorated to asystole. When the rhythm is recorded soon after collapse, in
particular by an on-site automated external defibrillator (AED), the proportion of patients
in VF can be as high as 65% (No/an 2010, Travers 2010). DF by electrical counter-shock
represents the treatment of choice for this otherwise lethal arrhythmia. Electrical DF refers
to the passage across the myocardium of an electrical current of sufficient magnitude to
depolarize a critical mass of myocardium and to enable restoration of coordinated electrical
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activity. Indeed, successful DF is defined as the termination of fibrillation or, more
precisely, the absence of VF/ventricular tachycardia (VFNT) within 5 sec after the shock
delivery; however, the goal of attempted DF is to restore spontaneous circulation (Deakin
2005 and 2010. Link 2010). The probability of successful DF diminishes rapidly over time. For
every min that passes between collapse and DF, survival rates from witnessed VF cardiac
arrest decrease by 7% to 10% if no CPR is provided. When bystander CPR is provided, the
decrease in survival rates is more gradual and averages 3% to 4% per min from collapse to
DF attempt (Deakin 2005, Larsen 2003, Link 2010, Valenzuela /997, Waalewijn 200/). VF is, in fact,
characterized by three time-sensitive electrophysiological phases, including 1) the
electrical phase ofO-4 min, 2) the circulatory phase of 4-10 min and 3) the metabolic phase
of > 10 min. During the electrical phase, immediate DF is likely to be successful. As
ischemia progresses, the success of attempted DF diminishes without CPR. This phase is
characterized by transition to slow VF wavelets during accumulation of ischemic
metabolites in the myocardium. Slow VF is often resistant to DF because there is no longer
an excitable gap to interrupt the re-entry that sustains VF. The failure of DF to succeed in
slow VF can be attributed to re-entry and recurrence of VF. In the metabolic phase, there is
much less likelihood of successful Rose (Weisfeldt 2002).
During cardiac arrest, coronary blood flow ceases, accounting for a progressive and severe
energy imbalance. Intra-myocardial hypercarbic acidosis is associated with depletion of
high energy phosphates and correspondingly severe global myocardial ischemia (Johnson
/995, Kern /990). The ischemic left ventricle (LV) becomes contracted ushering in the "stone
heart" (Figure 1) (Klouche 2000 and 2002). After the onset of contracture, the probability of
successful DF becomes remote.
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Figure I.
Development of the stone
heart with reduced LV end-
diastolic volume, stroke
volume and increased LV
wall thickness over 8 min of
cardiac arrest in pigs
(modified from Klouche
2002).
Early CPR, with partial restoration of coronary perfusion pressure (CPP) and myocardial
blood flow, delays onset of ischemic myocardial injury and facilitates DF (Deshmukh 1989).
Accordingly, major factors contributing to the poor outcome after cardiac arrest include
delays in CPR, ineffective and frequently interrupted CC, and limited access to, or delayed
DF (Iwami 2012, Valenzuela 2000, Wik 2005).
Indeed, timing of DF in relationship to CC has been a subject of major interest. Based on
available evidence, the 2005 guidelines recommended an initial interval of CC prior to DF,
especially when the duration of untreated cardiac arrest exceeded 4 min (Wik 2005, AHA
guidelines 2005). Nevertheless, the recent 2010 guidelines highlighted the insufficient
evidence to support or refute CPR before DF and called again for early DF (Baker 2008,
Deakin 2010, Jacobs 2005, Link 2010). Subsequent DF has been recommended to be attempted
on a time based protocol, i.e. after every 2 min cycle of CC (Deakin 2010, Link 2010), which
may lead to futile DF attempts and unnecessary CC interruptions, potentially creating
worse outcome (Cheskes 2011, Xie 1997, Yu 2002, Snyder 2004, Steen 2003). The timing of DF is
even more difficult to be chosen in the instance of recurrence of YF (Shanmugasundaram
2012). In addition, the severity of post resuscitation myocardial dysfunction and survival
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has been recognized to be related, in part, to the magnitude of the total electrical energy
delivered with DF (Osswald 1994, Tang 2004 and 2006, Xie 1997). Indeed, increasing the
defibrillation energy produced significant reductions in survival rate, cardiac index, and
LV function. Better survival and post resuscitation myocardial function have been
observed when lower DF energies were used (Tang 1999 and 2004, Xie 1997).
However, the onset time of VF is rarely known, especially in the out-of-hospital setting,
making it difficult to determine the priority of CPR intervention based on the duration of
the untreated cardiac arrest. There is also insufficient knowledge about the optimal
duration of the CC interval prior to DF. The decision whether to interrupt CC to deliver a
DF is therefore difficult. ECG analysis of the VF waveform might represent the best non-
invasive decision guide (Callaway 2005).
Monitoring effectiveness of CC and predicting DF success
The evidence is secure that the quality of CC is a major determinant of successful
resuscitation (Abella 2005, Gallagher 1995, Idris 2012, Vaillancourt 20ll, Van Hoeyweghen 1993, Wik
1994 and 2005). Existing and established predictors of good quality CPR and thereby
successful resuscitation include CPP (Deshmukh 1989, Paradis 1990, Sanders 1985 and 1985b, Yu
2002), and end-tidal C02 (EtC02) (Falk 1988, Lah 2011, Headstveit Ztll Z, Kolar 2008, WeiI1985).
Blood flows generated by CC are dependent on the pressure gradient between the aortic
and the venous pressures (Andreka 2006). CPP, defined as the difference between
simultaneously measured minimal aortic pressure and right atrial pressure during
compression diastole (Keue 1991, Gazmuri 1996, Tang 1993 and 1999), is highly correlated with
coronary blood flow during cardiac resuscitation and is currently recognized as the best
single indicator of the likelihood of successful DF and ROSC (Niemann 1985. Paradis 1990.
Povoas 2000). Based on both experimental and clinical observations, ROSe can be predicted
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when CPP is maintained above 15 mmHg during CC (Kern 1988, Niemann 1985. Paradis 1990).
Resuscitative strategies that increase CPP, including high quality CC (Ristagno 2007, Wik
1996) as well as the use of vasopressors (Lewis 1969, Mentzelopoulos 2013, Olasveengen 2012),
have been therefore supported and considered more effective in restoring spontaneous
circulation.
Expired CO2 is determined by the body's production of CO2 and the relationship between
minute ventilation and pulmonary perfusion. When the circulatory status is normal,
pulmonary perfusion is in the physiologic ranges and EtC02 is determined by minute
ventilation. Under condition of cardiac arrest and CPR, the cardiac output (CO) is usually
less than one-third of normal and pulmonary flow and EtC02 are consequently
dramatically reduced. EtC02 is therefore an indirect measurement of pulmonary blood
flow and CO produced by CCs (Falk 1988, Weil 1985). End-tidal CO2 is highly correlated with
CPP during CPR, and may thereby serve as a non-invasive surrogate of CPP (Gudipati 1988,
von Planta 1989). EtC02 has emerged as another valuable tool for monitoring the
effectiveness of CCs during CPR (Falk 1988, Garnett 1987, Neumar 2010, Ristagno 2007, Weil
1985). When EtC02 exceeds the threshold level of approximately 10 to 15 mmHg during
CPR, greater likelihood of successful ROSC has been reported (Cantineau 1996, Grmec 2001,
Neumar 2010). In addition, EtC02 may also provide the earliest clinical evidence of ROSC
(Neumar 2010, Falk 1988). However, this measurement has not been yet specifically evaluated
in the setting of prediction of DF success in humans.
Although the importance of blood pressure during CPR is clear, invasive measurements,
including aortic and right atrial pressures are only available or feasible at the time of
resuscitation in a small minority of patients, especially in the pre-hospital settings.
Similarly, EtC02, a good readout of the effectiveness of CC and therefore of the likelihood
of ROSC (Chase 1993, Gudipati 1988, Kern 1989, Neumar 2010, WeiI1985), is not widely available
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yet. Portable infrared capnometers can be successfully employed in pre-hospital settings
during CPR; however, monitoring EtC02 requires airway adjuncts. Out of hospital
endotracheal intubation carries a high failure rate and a 30% incidence of traumatic injury
to the airway (Domino 1999, Kohler 2008). Moreover administration of epinephrine during
CPR causes significant decreases in EtC02 by increasing pulmonary shunting (Tang 1991).
This therefore might cause important mis-interpretation when EtC02 is employed to
monitor and guide the resuscitative maneuvers (Gonzalez /989).
These restraints in the use of CPP and EtC02 are in contrast with the routine availability of
the ECG in current external defibrillators. The attention, with the intent to identify a better
predictor of ROSC, has been therefore focused on the analyses of electrocardiographic
features of VF waveform. The development of a non-invasive and real time monitoring
that allowed prediction of whether or not a shock would cause ROSC is therefore of great
importance. Current methods are constrained in part by the lack of practical and reliable
real-time tools for monitoring the efficacy of CPR interventions and for guiding the
appropriate timing for defibrillation attempts. At present, the electrocardiographic analyses
of VF waveform might represent the best non-invasive approach to guide the priority of
interventions, namely CC or DF.
Post-cardiac arrest syndrome
After the initial success of CPR, the majority of resuscitated patients die within 72 hr, due
to what is now termed "post cardiac arrest syndrome" (Lippert 2010, Nolan 2008, Travers 2010).
Indeed, ROSC after cardiac arrest is an unnatural pathophysiological state created by
successful CPR. In the early 1970s, Dr. Vladimir Negovsky recognized that the pathology
caused by complete, whole-body ischemia and reperfusion was unique in that it had a
clearly definable cause, time course, and constellation of pathophysiological processes
(Negovsky /972 and /988 and /995). Negovsky named this state "post resuscitation disease".
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Although appropriate at the time, the term "resuscitation" is now used more broadly to
include treatment of various shock states in which circulation has not ceased. Moreover,
the term "post resuscitation" implies that the act of resuscitation has ended. Negovsky
stated that "a second, more complex phase of resuscitation begins when patients regain
spontaneous circulation after cardiac arrest" (Negovsky 1972). Therefore, the term "post-
cardiac arrest syndrome" seems more appropriate. The 3 key components of this syndrome
are: 1) post cardiac arrest brain injury; 2) post cardiac arrest myocardial dysfunction; 3)
systemic ischemialreperfusion response. This state is often complicated by a fourth
component: the unresolved pathological process that caused the cardiac arrest (Neumar 2008,
Nolan 2008). Pathophysiology, clinical manifestations and potential treatments of the post
cardiac arrest syndrome are summarized in Table 1.
Syndrome Potential treatmentsClinical manifestation
Table 1. Post-cardiac arrest syndrome: pathophysiology. clinical manifestations, and potential treatments.
Post-cardiac arrest brain
Injury
I'
Pathophysiology
.Impalred cerebrovascular
autoregulation
.Cerebraloedema (limited)
• Postlschaemlc
neurodegeneration
Post·cardlac arrest • Global hypokinesis
myocardial dysfunction (myocardlat stunning)
• Reduced cardiac output
.ACS
ACS Indicates acute coronary syndrome; AMI. acute myocardiat infarction; IABP, intra·aortic balloon pump; LVAD, left ventricular assist
device: EMeO. extracorporeal membrane oxyaenatlon; COPD. chronic obstructive pulmonary disease; CNS, central nervous system; eVA.
cerebrovascular accident PE. pulmonary embolism; and PCAS. post- cardiac arrest syndrome.
Systemic Ischaemia/
reperfuslon
response
Persistent precipitating
pathotogy
(
• Systemic Inflammatory
response syndrome
.Impalred vasoregulatlon
• Increased coagulation
• Adrenal suppression
.Impalred tissue oxygen
delivery and utilisation
.Impalred resistance to
infection
• Cardiovascular disease
(AMI/ACS, cardiomyopathy)
• Pulmonary disease (COPD,
asthma)
• CNS disease (CVA)
• Thromoboembolfc disease
(PE)
.Toxlcologlc (overdose,
poisoning)
.Infectlon (sepsis.
pneumonia)
• Hypovolaemia
(haemorrhage, dehydration)
• Coma • Therapeutic hypothermia
• Seizures • Early haemodynamic
.Myoclonus optimization
• Cognitive • Airway protection and mechanical
dysfunction ventilation
• Persistent vegetative • Seizure control
state • Controlled reoxygenation (Sao, 94%·96%)
• Secondary Parkinsonism • Supportive care
• Cortical stroke
• Spinal stroke
• Brain death
• Early revascularizatlon • Earty haemodynamic
of AMI optimization
• Hypotension • Intravenous fluid
• Dysrhythmlas • lnotropes
• Cardiovascular collapse • IABP
.LVAO
.ECMO
• Ongoing tissue
hypoxia/Ischaemia
• HypotenSion
• Cardiovascular COllapse
• Pyrexia (fever)
• Hyperglycaemia
• Early haemodynamic
optimization
• Intravenous fluid
• Vasopressors
• Hlgh·volume haemoflltration
• Temperature control
.Multlorgan failure
.Infection
• Glucose control
• Antibiotics for documented Infection
• Speciflc to aetiology,
but complicated by
concomitant PCAS
• Dlsease·speciflc interventions guided by
patient condition concomitant PCAS
From Nolan 2008
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A more treatment-orientated approach would be to define the phases of post-cardiac arrest
syndrome by time (Figure 2). Indeed, 4 phases are recognized: 1. the immediate post-arrest
phase, including the first 20 min after ROSe; 2. the early post-arrest phase, defined as the
period between 20 min and 6-12 hr after ROSe, when early interventions might be most
effective; 3. The intermediate, between 6-12 and 72 hr, when injury pathways are still
active and aggressive treatment is typically instituted; and 4. the period beyond 3 days after
Rose, considered the recovery phase when prognostication becomes more reliable and
ultimate outcomes are more predictable.
ROse
20min
6-12 hou s
72 hou ...
Disposition
Phase Goals
Figure 2. Temporal phases of the post-cardiac
arrest syndrome. From Nolan 2008.
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Within the first 24 hr post-arrest, a microcirculatory dysfunction from the multi focal
ischemiaireperfusion leads to rapid release of toxic enzymes and free radicals into the
cerebrospinal fluid and blood. Over the next 1-3 days, cardiac and systemic functions
improve, but intestinal permeability increases, predisposing the patient to sepsis and the
multiple organ dysfunction syndrome. During the subsequent days, a serious infection may
occur causing rapid clinical deterioration. The patient either dies of a complication or of
23
the primary disease that caused the cardiac arrest, or undergoes a partial or complete
recovery.
The mechanisms responsible for post-cardiac arrest myocardial and cerebral injury are not
well understood, although several events have been described. The condition of systemic
ischemia that follows onset of cardiac arrest may lead to processes of metabolism
breakdown and subsequent primary cell necrosis (Radovsky 1995). In addition, the profound
imbalance between adenosine triphosphate (ATP) synthesis and utilization, a consequence
of mitochondrial dysfunction, the impairment of ionic homeostasis and the formation of
ROS, represent other determinant processes through which mitochondria accelerate, or
even determine, the evolution of cell injury toward necrosis or apoptosis. Moreover, the
reintroduction of oxygenated blood after ROSe stimulates a sequence of complex actions
that lead to acute inflammatory responses and release of ROS, causing oxidative damage,
cellular edema, cell membrane damage and apoptosis, collectively called "reperfusion
injury" (Dezfulian 2007, LebufJe 2003, Levraut 2003, Nakka 2008, Ouyang 1999). Several other
processes, including interactions between pleiotropic mediators, coagulation abnormalities,
activation of the inflammatory cytokine cascade, chemokine upregulation and ultimately
recruitment of inflammatory leukocytes and reactive astrogliosis have been also reported
after cardiac arrest and have been shown to play major roles in the determination of the
final outcome (Adrie 2002 and 2005, Neumar 2008, Nolan 2008, LebufJe 2003, Ouyang 1999). Release
of excitatory aminoacids has been also advocated as another pathway leading to neuronal
damage (Neumar 2000 and 2008, Polderman 2009).
Post-cardiac arrest brain injury
The unique vulnerability of the brain is attributed to its limited tolerance of ischemia as
well as its unique response to reperfusion. The mechanisms of brain injury triggered by
cardiac arrest and resuscitation are complex and include excitotoxicity, disrupted Ca2+
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homeostasis, free radical formation, pathological protease cascades, and activation of cell
death signaling pathways (Lipton 1999, Neumar 2000 and 2008, Nolan 2008, Polderman 2009). Both
neuronal necrosis and apoptosis have been reported after cardiac arrest. Histologically,
selectively vulnerable neuron subpopulations in the hippocampus, cortex, cerebellum,
corpus striatum, and thalamus, degenerate over hours to days (Brierley 1973, Blomqvist 1985,
Hossmann 2001, Neumar 2000, Nolan 2008, Polderman 2009, Pulsinelli 1985. Taraszewska 2002). Levels
of high energy metabolites such as ATP and phosphocreatine decrease within seconds
when oxygen supply to the brain is interrupted (Small 1999). The breakdown of ATP and the
switch of intracellular metabolism to anaerobic glycolysis lead to an increase in
intracellular levels of inorganic phosphate, lactate, and hydrogen ion, resulting in both
intra- and extracellular acidosis (Figure 3).
Figure 3. Source of hydrogen
ions (H+) during low-flow
states. H+ derived from the
anaerobic oxidation of
glucose and from the
hydrolysis of high-energy
phosphates. ATP, adenosine
5' triphosphate; ADP,
adenosine 5' diphosphate;
AMP, adenosine
monophosphate.
From Ristagno 2006.
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The above processes lead to influx of Ca2+ into the cell. Loss of ATP and acidosis also
inhibit the mechanisms that normally deal with excessive intracellular Ca2+ by sequestering
Ca2+ from the cell, further aggravating intracellular Ca2+ overload. These problems are
compounded by failure of ATP-dependent (sodium-potassium) Na+-K+ pumps and K+,
Na+, and Ca2+ channels, leading to an additional influx of Ca2+. The excess Ca2+ induces
2S
mitochondrial dysfunction (increasing intracellular Ca2+ influx yet further, in a vicious
cycle) and activates numerous intracellular enzyme systems (kinases and proteases). In
addition, immediate early genes are activated and a depolarization of neuronal cell
membranes occurs, with a release of large amounts of the excitatory neurotransmitter
glutamate into the extracellular space (Neumar 2000, Polderman 2009, Siesjo 1989). This leads to
prolonged and excessive activation of membrane glutamate receptors, further stimulating
Ca2+ influx through activation of Ca2+ channels in another vicious cycle. Under normal
circumstances, neurons are exposed to only very brief pulses of glutamate; prolonged
glutamate exposure induces a permanent state of hyperexcitability in the neurons (the
excitotoxic cascade), which can lead to additional injury and cell death. A destructive
process that is closely linked to but distinct from the mechanisms discussed above is the
release of ROS following ischemialreperfusion. Mediators such as superoxide,
peroxynitrite, hydrogen peroxide, and hydroxyl radicals play an important role in
determining whether injured cells will recover or die (Globus 1995 and 1995b, Novack 1996,
Polderman 2009). Free radicals can oxidize and damage numerous cellular components.
Although brain cells have various enzymatic and non-enzymatic antioxidant mechanisms
that prevent this type of injury under normal circumstances, ROS production following
ischemialreperfusion is so great that these defensive mechanisms are likely to be
overwhelmed, leading to peroxidation of lipids, proteins, and nucleic acids.
Ischemialreperfusion can also lead to significant disruptions in the blood-brain barrier
(BBB), which can facilitate the subsequent development of brain edema (Ch; 2001, Huang
1999). All the above processes contribute to the development of post-cardiac arrest
intracranial hypertension, which further augments brain damage (Figure 4).
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and cellular injury
Injury to the blood-brain earner
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Cytotoxic edema Vasogenic edema.z..~ / .,
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Figure 4. Schematic depiction of the
potential role of intracranial pressure
as both a marker of ongoing brain
injury and a potential cause of
additional injury, and of the factors
that may contribute to a nse In
intracranial pressure.
CSF, cerebrospinal fluid.
From Polderman 2009.
Mechanisms accounting for BBB loss of integrity include: decreased fluidity and integrity
of cell membranes and increased vascular permeability of microvascular endothelial cells
in the brain, mediated by inflammatory cytokines and vascular endothelial growth factor
(Kaur 2008), via release of nitric oxide (NO) (Fischer 1999). More specifically NO can interact
with ROS producing peroxynitrite radicals, which activate matrix metalloproteinases
(MMPs) that ultimately disrupt BBB junctions (Figure 5).
Figure 5. Schematic depiction of
mechanisms involved in BBB disruption.
e- endothelial, n- neuronal, i- inducible,
nitric oxide synthase (NOS); Matrix
metalloproteinases (MMP); the activator
protein I (AP-I); nuclear factor kappa
beta (NtKB); Poly ADP-ribose
polymerase (PARP).
Prolonged cardiac arrest can also be followed by fixed and/or dynamic failure of cerebral
microcirculatory reperfusion despite adequate cerebral perfusion pressure (Fischer 1996).
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This impaired reflow can cause persistent ischemia and small infarctions in some brain
regions. The cerebral microvascular occlusion that causes no-reflow has been attributed to
intravascular thrombosis during cardiac arrest and has been shown to be responsive to
thrombolytic therapy in preclinical studies. Cardiopulmonary arrest and resuscitation are
accompanied by a marked activation of coagulation, which can lead to intravascular fibrin
formation with blockage of the microcirculation (Figure 6). Other phenomena may be
involved in cerebral perfusion disturbances, that include not only no-reflow events but also
hyperemia episodes following ischemia: increased blood viscosity and perivascular edema,
as well as possible down-regulation of NO synthesis, expression of endothelial adhesion
molecules and generation of free radicals (Bolliger 1997, Donadello 2011, Hossmann 1995,
Liachenko 200 I, van Genderen 2012).
Figure 6. Digital photomicrographs of the cerebral cortical circulation at (A) baseline before induction of
cardiac arrest; and (8) 2 min after onset of cardiac arrest. From Ristagno 2008.
Beyond the initial reperfusion phase, several factors can potentially compromise cerebral
oxygen delivery and possibly secondary injury in the hours to days after cardiac arrest.
These include hypotension, hypoxemia, impaired cerebrovascular autoregulation, and brain
edema. Furthermore, hyperglycemia is common in post-cardiac arrest patients and is
importantly associated with poor neurological outcome after cardiac arrest (Calle 1989,
Longstreth 1983 and 1984 and 1993, Mullner 1997, Skrifvars 2003).
B
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Post-cardiac arrest myocardial dysfunction
Post-cardiac arrest myocardial dysfunction contributes to the early deaths after
resuscitation from cardiac arrest (Herlitz 1995, Laurent 2002, Lavert 2004, Neumar 2008, Nolan
2008). Laboratory and clinical evidence, however, indicates that this phenomenon is both
responsive to therapy and reversible (Cerchiari 1993, Huang 2005, Kern 1996 and 1997, Laurent
2002, Nolan 2008, Ruiz-Bailen 2005). Immediately after ROSe, heart rate (HR) and blood
pressure are extremely variable and this is mainly caused by a transient increase in
myocardial and circulating catecholamine concentrations (Prengel 1992, Rivers 1994).
Premature ventricular beats and episodes of VT and VF commonly occur during the early
minutes after resuscitation and account for early death. Furthermore, an overall condition
of severe myocardial dysfunction, including variable degrees of systolic and diastolic
dysfunction, is present. During this period with significant myocardial dysfunction,
coronary blood flow however is not reduced, indicating a true stunning phenomenon rather
than a permanent injury or infarction (Figure 7).
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In one series of 148 patients who underwent coronary angiography after cardiac arrest,
49% of subjects had myocardial dysfunction manifested by tachycardia and elevated LV
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end-diastolic pressure, followed approximately 6 hr later by hypotension and low co (Kern
/996, Laurent 2002). This global dysfunction was transient, and full recovery occurred. In a
swine model with no antecedent coronary or other LV dysfunction features, the time to
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recovery appeared to range between 24 and 48 hr. Several case senes have described
transient myocardial dysfunction after human cardiac arrest. Cardiac index values reached
their nadir at 8 hr after resuscitation, improved substantially by 24 hr, and almost
uniformly returned to normal by 72 hr in patients who survived out-of-hospital cardiac
arrest. This trend in arterial pressure, cardiac index and other hemodynamic parameters are
described in the Table 2 from Dr. Laurent's work (Laurent 2002), where clinical data over
the 72 hr post cardiac arrest are reported.
Hemorljnanic D;rtl During the firll 72 Houn Table 2 (From Laurent 2002)
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Among the mechanisms underlying early post-resuscitation arrhythmia and myocardial
dysfunction, cytosolic and mitochondrial Ca2+ overload following cardiac arrest and CPR
has been recognized as a determinant (Ayoub 2008, Gazmuri 2012). Ca2+ overload after cardiac
arrest is related to myocyte Na+ content alteration. Under normoxic conditions the late Na+
current (INaL) contributes very little to the total Na+ content of the myocardial cell.
However, during ischemia the INaL channel does not close properly. Under this condition
the influx ofNa+ becomes substantial (Kloner 2011). Indeed, Na+ influx through the late Na+
channel appears to be the major contributor to the rise of cardiomyocyte intracellular Na+
concentration observed during ischemia (Zaza 2008), It has been shown, in fact, that
ischemia increases the amplitude of INaL in rat ventricular myocytes, from 50-100 pA up to
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180-205 pA. Furthermore, following reperfusion, production of ROS is known to further
increase INaL (Ma 2005, Slezak 1995, Song 2006).
In the setting of cardiac arrest and CPR, main routes for cardiomyocyte Na+ entry include
the sodium-hydrogen exchanger isoforrn-l, the voltage-gated Na+ channel, and the Na+-
bicarbonate co-transporter. This cytosolic Na+ accumulation, further augmented by the
concurrent ischemia-induced Na+-K+-ATPase inability to extrude Na+, represents an
important pathophysiological mechanism responsible for cell injury (Wang 2007). Cytosolic
Na+ causes, in fact, a subsequent increase in myocyte intracellular Ca2+ via the activity of
Na+-Ca2+ exchanger (Figure 8) (Ayoub2008).
Figure 8. Events leading to
cardiomyocyte Ca2+ overload
during ischemia/reperfusion.
'''-:IF:=~= Ca2+ NHE = Na+/ H+ exchanger;
NBC = Na+/ HB03" exchanger;
NCX = Na+/ Ca2+ exchanger;
Ch = channel. From Ayoub
2008.
Post-resuscitation cytosolic Ca2+ accumulation in cardiomyocytes has, indeed, several
deleterious consequences, including: electrical instability with ventricular arrhythmias
early after resuscitation, i.e. premature ventricular complexes, VT and VF; varying degrees
of mechanical LV dysfunction that can compromise hemodynamic function, i.e. reduced
contractility and increased diastolic tension; and mitochondrial dysfunction (Ayoub 2008 and
2010, Gralinski 1996).
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Mitochondria are the major contributors in many cellular as well as extracellular regulatory
functions that affect survival following an ischemic insult. In the setting of cardiac arrest,
mitochondria are thought to be progressively damaged during ischemia and further injured
when reperfusion resumes. This leads to important alterations of the function of this
organelle. Specifically, the dysfunction has been shown to be mainly associated with
impaired complex activities that begin to deteriorate within the initial 15 min of ischemia.
Nevertheless, ultrastructural changes of mitochondria during ischemia, including swelling,
loss of matrix density and cristae disintegration, have been also demonstrated to correlate
well with the duration of cardiac arrest (Yeh 2009, Xu 2010). More specifically, within the first
hours during the early recovery phase, a greater decrease in respiratory control ratio has
been observed. In addition to its bioenergetic function, mitochondria also participate in
processes leading to cell death via necrosis or apoptosis. Various distinctive mechanisms
have been identified including opening of the so called mitochondrial permeability
transition pore (leading to collapse of proton motive force and uncoupling of respiration)
(Halestrap 2004) and release of various pro-apoptotic proteins, including cytochrome c,
apoptosis-inducing factor, SmacIDIABLO, endonuclease G, and a serine protease
OmiIHtrA2 (Cai 1998, Green 1998, Radhakrishnan 2007 and 2009).
Post-cardiac arrest systemic inflammatory response
Current guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular
Care recognize the post-cardiac arrest syndrome has a sepsis-like syndrome (Adrie 2002,
Nolan 2008, Peberdy 2010). The whole-body ischemialreperfusion that follows cardiac arrest
with associated oxygen debt causes, in fact, generalized activation of immunological and
coagulation pathways, increasing the risk of multiple organ failure and infection (Adrie 2002
and 2004 and 2005, Adams 2006, Cerchairi 1993b, Esmon 2003). As early as 3 hr after cardiac arrest,
blood concentrations of various cytokines, soluble receptors, and endotoxin increase, and
the magnitude of these changes are associated with outcome. Soluble intercellular adhesion
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molecule-I, soluble vascular-cell adhesion molecule-l , and P- and E-selectins are
increased during and after CPR, suggesting leucocyte activation or endothelial injury (Adrie
2002 and 2004, Geppert 2000, Gando 2000). Altogether, the high levels of circulating cytokines,
the presence of endotoxin in plasma, and the dysregulated production of cytokines found in
cardiac arrest patients resemble indeed the immunological profile of patients with sepsis
(Figures 9 and 10) (Adrie 2002 and 2004).
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Figure 9. Kinetics of
cytokines and
sTNFRlI levels on
admission and over a
7-day period in 61
resuscitated survivors
(n= 18,open diamonds)
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(n=43, black squares)
of cardiac arrest. Data
are expressed as
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quartile).
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From Adrie 2002.
Figure ] O. Measurement of endotoxin levels
(endotoxin units [EU]/mL) in plasma of 35
resuscitated OHCA patients on admission (day 0)
and the 2 days after (days I and 2).
dl indicates detection limit (0.02 EUlmL).
From Adrie 2002.
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The post-cardiac arrest syndrome seems to be causally related to an early systemic
inflammatory response, leading to an inflammatory imbalance (Adrie 2004, Geppert 2000), and
is also associated with an "endotoxin tolerance," as observed in severe sepsis (Munoz 1991).
Additional disturbances, i.e. activation of the coagulation cascade (Bottiger 1995, Gando 1997),
platelet activation with formation of thromboxane A2 (Gando 1997b), and an alteration of
soluble E-selectin and P-selectin (Geppert 2000) have been described.
Activation of blood coagulation without inadequate activation of endogenous fibrinolysis
is an important pathophysiological mechanism that may contribute to microcirculatory
reperfusion disorders (Adrie 2005, Bottiger 1995). As shown in Dr. Adrie's work, at admission,
67 resuscitated patients showed a systemic inflammatory response with increased
interleukin (IL)-6 and coagulation activity (thrombin-antithrombin complex), reduced
anticoagulation (antithrombin, protein C, and protein S), activated fibrinolysis (plasmin-
antiplasmin complex), and, in some cases, inhibited fibrinolysis (increased plasminogen
activator inhibitor-l with a peak on day 1). These abnormalities were more severe in
patients who died within two days (50 of 67, 75%) and were most severe in patients dying
from early refractory shock (Table 3). Protein C and S levels were low compared to
healthy volunteers and discriminated cardiac arrest survivors from non-survivors (Figure
11). Furthermore, a subgroup of patients had a transient increase in plasma-activated
protein C at admission followed by undetectable levels. This, along with an increase in
soluble thrombomodulin over time, suggested a secondary endothelial injury and
dysfunction of the protein C anticoagulant pathway similar to that observed in severe
sepsis. Intravascular fibrin formation and microthromboses are distributed throughout the
entire microcirculation, suggesting a potential role for interventions.
Coagulation/anticoagulation and fibrinolysis/antifibrinolysis systems are activated in
patients who undergo CPR, particularly those who recover spontaneous circulation.
Anticoagulant factors such as antithrombin, protein S, and protein C are decreased and are
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associated with a very transient increase in endogenous activated protein C soon after the
cardiac arrest/resuscitation event. Finally, the stress of total body ischemia/reperfusion
affects adrenal function. Although an increased plasma cortisol level occurs in many
patients after out-of-hospital cardiac arrest, relative adrenal insufficiency, defined as failure
to respond to corticotrophin, is common (Hekimian 2004, Schultz 1993).
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Figure 11. Changes in coagulation over the
first two intensive care unit days in 67
patients successfully resuscitated after out-
of-hospital cardiac arrest, 17 survivors (S)
(open boxes) and 50 non survivors (NS)
(black boxes). Patients recelvlllg oral
anticoagulation were excluded from the
protein C and S graphs.
Medians are shown as lines, 25th to 75th
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sTM=soluble thrombomodulin;
TAT=thrombin-antithrombin complex.
From Adrie 2005
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BIOMARKERS TO PREDICT OUTCOME OF CARDIAC ARREST
Biomarkers are measurable and quantifiable biological parameters which serve as indices
for health and disease in the individual patient. The prognosis of patients resuscitated from
cardiac arrest can be estimated by information obtained from the clinical history, ECG
abnormalities, and, more recently, from biochemical indicators of myocardial injury and
dysfunction, as well as markers of renal failure and inflammatory activity (James 2003). In
the past 2 decades, biomarkers have become an increasingly important tool in clinical
practice, helping to improve patient care. For example, biomarkers have demonstrated a
significant impact in early detection of sub-clinical disease (i.e., prostate-specific antigen
screening for prostate cancer), diagnosis of acute or chronic syndromes (i.e., B-type
natriuretic peptide in heart failure, cardiac troponins for myocardial infarction), risk
stratification (i.e., cardiac troponin in acute coronary syndromes), and monitoring of
disease or therapy (i.e., hemoglobin Ale in diabetes mellitus). Apart from oncology,
cardiovascular medicine is the arena in which novel biomarkers have been most
extensively evaluated. However, only a minority of markers has demonstrated significant
diagnostic and/or therapeutic impact (Hochholzer 2010).
The term "biomarker", however, can be referred not only to a dosable humoral
biochemical feature or facet but to every different "message" that can be assessed from the
patient during treatment or the subsequent follow-up. Indeed, this anticipation is more
evident under the specific setting of cardiac arrest. For this particular condition, we
therefore need to discriminate among messages that provide feedback regarding the effects
of treatment, CPR in this specific case, and messages that bring information on the
progress of disease, and in particular on the post-resuscitation cardiac and cerebral
dysfunction and ultimately survival.
36
Circulating biomarkers
Circulating biomarkers have become an increasingly important tool in clinical practice,
useful for diagnosis, risk stratification, monitoring, and prognosis of patients. Predicting
survival and especially the neurological outcome after ROSC in victims of cardiac arrest
still remains a difficult issue. The decision to continue, limit or stop intensive care is a
major problem for deep ethical implications and also for resources allocation. Accurate
prediction of the neurologic outcome of comatose patients following cardiac arrest is
therefore essential to establish the model of care (Thenayan 2008). Prognostication of
outcome in cardiac arrest is of importance because it could help physicians to make
decisions and enhance therapeutic efforts in patients with predictable overall good
recovery and to readdress the overall management or ultimately to make a decision on
withdrawal of care in those with expected poor outcome (Bouwes 2012). A procedure used to
support no-treatment decisions, however, should ideally have no false-positive results
(Wijdicks 2006, 'Zandbergen 2001) reaching a specificity of 100% for poor outcome. A false
prediction of a poor outcome may cause the patient to be denied life supporting treatment.
On the other hand, a falsely optimistic prediction, although less serious from an ethical
point of view, may lead to unnecessary prolongation of costly therapy. Due to the
heterogeneity of cardiac arrest population and scenarios, no single factor has been
identified as a reliable predictor of outcome. In addition, with recent advances in the use of
therapeutic hypothermia (TH), prediction of patients' outcome has become even more
challenging. In fact, there is evidence that TH makes the well-established tests in
normothermic patients less reliable. Early assessment of patients brain damage remains
quite difficult in the intensive care unit (lCU), and could be actually reachable only
through the integration of the answer given by clinical examination, neuro-functional and
neuro-irnaging evaluation, and biochemical markers dosing (Sandroni 2013 and 2013b). This
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evaluation should be carried out after the initial 72 hr post-ROSC. Normothermic and
hypothermic patients with a favorable prognosis predominantly regain consciousness
within 3 days (Fugate 201 I). A reliable prediction in TH is, however, quite difficult.
Likewise, a residual effect of sedative and analgesic substances must be excluded, due to
longer drugs' half-life during TH. Indeed, a significantly delayed awakening in patients
treated with TH could be observed (Lurie 201I). For this reason, the early termination of life
support 72 hr after re-warming needs to be reconsidered critically and is not indicated.
The current clinically used biomarkers to predict outcome of cardiac arrest are cTns and
creatine kinases (CKs) for the heart, and NSE and S-IOOb, for the brain (Peberdy 2010.
Scolletta 2012). Nevertheless, evidence does not support the use of these serum biomarkers
alone as predictors of outcome in the setting of cardiac arrest (Neumar 2010. Nolan 2010).
Furthermore, the use of the above markers is an adoption from conditions of "localized"
myocardial or brain ischemic insults, while cardiac arrest is a wider and more complex
event, involving the whole body. Accordingly, research in this domain extends from
localized to generalized ischemic injury, a condition of "global" ischemia and reperfusion
(Becker 2002).
A novel investigating approach, that considers mechanisms of both injury and preservation
and that is able to provide feedback regarding the effects of treatment, and the progress of
the disease, particularly post-resuscitation cardiac and neurological dysfunction, is
advocated. Up to date cardiac, neurological and inflammatory biomarkers, as potential
predictors of outcome after cardiac arrest, are summarized in Table 4 (Seol/etta 2012).
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Troponin AMI Diagnosis 0.6-14.5ng/ml < 12 h 72-88 75-95 NA No effects Need to be combined
with ECG
Specific only if
5T-elevation
Elevated after coronary
angiography
CK-MB AMI Diagnosis 60ng/ml < 12 h 88 88 NA NA Not specific of AMI
Elevated because of CPR
Elevated becauseof
defibrillation
BNP Outcome 80-230 pg/ml Admission 83-87 87-96 NA NA Limited studies
Elevation in other
conditions with HF
NSE Outcome > 33mgll <72 h 72-80 84-100 0-23 % Reduced
levels
Elevated if hemolysis
Elevated if use of
LVADIIABP
Elevated in some
cancers
Elevated if heart and
aorta injury
Elevated in some
cancers
5100B Outcome 0.2-1.5mgll <72h 70-80 85-100 0-16% NA
Procaicitonin Outcome 0.5-1.0ng/ml < 24 h 70-85 80 NA NA Elevated in
inflammatory conditions
Elevated if underlying
infection
AMI: Acute myocardial infarction; BNP: Brain natriuretic peptide; CK-MB: Creatine klnase-MB; CPR:Cardiopulmonary resuscitation; FPR:False-positive rate; HF: Heart
failure; IABP: Intra-aortic balloon pump; LVAD: Left ventricular assist device; NA: Not available; NSE:Neuron-specific enolase: TH: Therapeutic hypothermia.
Fram Seal/ella 20 12.
CIRCULATING BIOMARKERS OF CARDIAC INJURY
Within the last decade a broad range of circulating markers associated with an increased
risk for death and cardiovascular endpoints have been identified (Table 5). Adding to
markers of cell necrosis are markers of ischemia, inflammation, plaque destabilization or
rupture, myocardial dysfunction, and stress. As shown in Table 5, most of these markers
have demonstrated at least some prognostic value (Hochholzer 2010).
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For patients resuscitated from cardiac arrest, it is important to determine a definite cause,
that is, myocardial ischemia vs. primary ventricular arrhythmia, owing to the risk of
recurrence and the different therapeutic approaches available. Acute myocardial infarction
(AMI) may account for up to 50% of out-of-hospital cardiac arrest, ischemic heart disease
without AMI for one-third of cases and non-ischemic cardiomyopathy for nearly 10% of
all arrests (de Vreede-Swagemakers 1998, Voicu 2012). cTns, CKs and natriuretic peptides are the
most used biomarkers of myocardial injury/dysfunction.
Troponins
Troponin J, C, and T form a complex that regulates the Ca2+ -modulated interaction of actin
and myosin in striated muscle. Among the cardiac markers, cTns I and T are sensitive and
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specific markers of myocardial injury and are used routinely for the diagnosis of acute
coronary syndromes. They provide prognostic information and are of great value for risk
stratification of patients (An/man 1996, Apple 2005, Aviles 2002, Donnelly 1998, Lindahl 2000).
Elevated cTn blood levels have been reported in several cohorts of patients with heart
failure, and the magnitude of elevation has been correlated with the severity of the disease
and with adverse outcomes (Ishii 2002, Setsuta 1999, Sato 2001). Because of their high cardiac
specificity, elevated blood cTns may suggest ongoing myocardial damage and may serve
as a marker for the progression of disease during the post reperfusion recovery. Currently,
for every patient who has suffered a myocardial ischemic event or who has been
resuscitated from cardiac arrest, cTn T or I are considered the first-line test (Williams 2005).
Cardiac troponin T has been investigated extensively and has been found to be a sensitive
marker of myocardial necrosis (Katus 1991 and 1992, Mair 1992). The presence of elevated
levels of cTnT in the general population has a prevalence of less than 1% and this
condition is commonly associated with an underlying cardiovascular disease or high-risk
phenotypes for cardiac accidents, especially in persons with chronic heart failure.
Currently, new highly sensitive assays for determination of cTns are available and have
shown that cTnT retains a prognostic value at previously undetectable concentrationS(Latini
2007). When cTnT levels were investigated in more than 4.000 patients with a LV ejection
fraction (EF) of <40% using both the standard assay and the high sensitivity assay, cTnT
detection increased from approximately 10% of the population to more than 90%. The
circulating concentration of this highly sensitive (hs) cTnT showed even greater prognostic
accuracy in association with increases of another biomarker, namely brain natriuretic
peptide (BNP). In 658 patients who presented with BNP above the normal median
concentration and cTnT below, mortality was 14%. However, in an additional 632 patients
with BNP below the median and cTnT above, mortality was 20%. Finally, in the 1.331
patients with both markers above their respective median concentrations, mortality
increased to 32% (Latini 2007). A continuous, slow release of cTns from the myocardium
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might reflect an ongoing cardiac myocyte cell death. This condition has been associated
with the condition of LV dysfunction following myocardial ischemia in both animal
models and humans patients suffering with chronic heart failure (Narula 1999. Olivetti 1997). If
ongoing cardiac damage at a very low rate is the determinant of these circulating troponins,
other mechanisms may, however, account for this phenomenon, such as stretching of
cardiac myocytes with transient loss of cell membrane integrity. There are few
investigations on the role of cTns for the differential diagnosis of AMI in patients
successfully resuscitated after out-of-hospital cardiac arrest. Early studies reported a
substantial lack of sensitivity and specificity (Milliner 1996). This might have been due to the
fact that procedures used for CPR (CC or DF) or persistent circulatory shock might have
directly provoked myocardial damage and the release of cardiac markers, in the absence of
a coronary artery occlusion (Mallner 1998). Troponin elevation in patients resuscitated from
cardiac arrest but who do not have AMI is however lower and normalizes faster than after
AMI (Oh 2012). In a recent, single-centre study, 163 patients resuscitated from cardiac arrest
were assessed with coronary angiography on admission for AMI, that was diagnosed in
37% of the cases (Voicu 2012). High circulating cTn concentrations were measured very
early after cardiac arrest, even in patients with normal angiograms (median cTnI was 0.6
ng/ml, in the latter group), indicative of non-ischemic myocardial injury during CC.
However, combined with ST-elevation on ECG, elevated cTn concentration on admission
(cTnI> 2.5 ng/ml.) showed a good performance to exclude the diagnosis of AMI
(sensitivity 93%, negative predictive value 94%). The specificity remained low even in
combination with ST-elevation on ECG (64%).
International guidelines recommend considering emergent coronary angiography and
percutaneous coronary intervention in cardiac arrest patients after ROSC, even in the
absence of ST elevated myocardial infarcton (STEMI) (Peberdy 20/O). Since clinical
findings such as chest pain are often lacking and the predictive value of ECG for AMI is
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poor, cTn testing may provide a simple and objective selection of post-resuscitation patient
candidate for immediate coronary angiography. This triage strategy has recently been
tested in 422 cardiac arrest survivors without obvious extra-cardiac causes (Dumas 20/2). In
this large study, a coronary angiography was systematically performed and cTn measured
on admission. However, even if independently associated with coronary occlusion,
elevation of cTn levels had a poor accuracy to identify a recent coronary lesion, precluding
its use as the sole criteria for the decision to perform or not early coronary angiography in
these patients (Figure 12).
~
a
~ ~
i~ cl
1 f!g~t
~§ I ~
2; 0~51 §
0 0.00 025 o,~ 0.76
R;(.'"x~ l·S~\ly
N·ll)
__ AOClllMoOmi
Figure 12. Troponin levels dispatched according to the presence of a recent coronary lesion. Troponin I
receiving operating characteristic (ROC) curve predicting a recent coronary lesion. From Dumas 2012.
Acute coronary artery occlusion is therefore difficult to diagnose in survivors of cardiac
arrest using circulating markers alone, especially in case of ambiguous ECG. There are no
data available to date on the diagnostic performance of cTns after cardiac arrest, when
using high sensitivity assays that may readily detect concentrations in the order of few
nanograms per liter, ten to hundred times lower than the conventional assays. However,
one may speculate that specificity will become an even more critical issue since the recent
introduction of this new generation of high sensitivity reagents has led to a substantial
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increase in the proportion of detectable cTn levels attributable to conditions distinct from
acute coronary syndromes (de Lemos 2013). Moreover, the diagnostic value of cTns could be
altered by CPR. Increased c-Tn levels were, in fact, reported in approximately 40% of
cardiac arrest patients, when samples were drawn during CPR (La; 2004).
Creatine kinase
Measurement of CKs in the serum was extensively used in the 1970s as a tool in the
diagnosis of AMI. In a large number of patients, however, an elevated CK value added
little information because of the presence of concomitant skeletal muscle damage. This
problem has recently been solved by the development of techniques able to separate CK
into its three isoenzymes, Le. MM, MB, and BB. Separation and quantification of CK-MB
isoenzyme, in particular, provided a more specific indicator of acute myocardial ischemic
injury compared to levels of total CK (Varat 1975). The advantage of this biomarker is the
degree and duration of its elevation in serum that approximates the extent of the AMI.
However, a variety of factors may affect the reliability of this measurement, i.e. differences
in the fractionation and assay methods, as well as the presence of CK-MB in tissues other
than the myocardium and the release of CK-MB under conditions other than during an
AMI (Guzy 1977). At present, measurement of CK-MB is an alternative to cTns
measurement" but is only recommended, if cTn measurement is not available (Jaffe 2000).
CK-MB levels have been reported to be significantly higher in cardiac arrest patients
having a AMI than in those without AMI. Indeed, a cutoff of 60 ng/ml for CK-MB had a
sensitivity/specificity of 88% to diagnose AMI after cardiac arrest (Grubb 1996, Sideris 2011).
Nevertheless, release of CK-MB may also occur because of CPR, in the absence of any
significant coronary lesion (Oh 2012). As for cTns, more than 75% of cardiac arrest
survivors may present an elevation in CK-MB levels within 24 hr, which is not only
associated with ischemic myocardial damage, but also with cumulative energy delivered
during DF and with the duration of CPR (Mattana 1992, Mullner 1996).
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Brain natriuretic peptide
The stretching but also ischemia of cardiomyocytes occurring during cardiac arrest induces
the release of natriuretic peptides, especially the brain natriuretic peptide (BNP), which are
commonly used in the diagnosis, therapy monitoring and risk stratification of several
clinical conditions, such as heart failure, acute coronary syndromes, weaning from
mechanical ventilation (Prahash 2004). B-type natriuretic peptide and its more stable
counterpart, N-terminal pro-B-type natriuretic peptide, have shown great promise, covering
a wide range of acute coronary syndromes (Om/and 2002). BNP has numerous advantages
compared to other biomarkers. BNP levels allow for accurate diagnosis of heart failure and
may be helpful to screen for asymptomatic LV dysfunction in high-risk patients. BNP
levels are also important tools for risk stratification of patients, prediction of death, and in
combination with symptoms and signs, assessment of clinical decompensation (MaiseI2008).
Natriuretic peptides have been tested for their relation to survival or neurological outcome
after cardiac arrest. Nagao et al. measured BNP on arrival at emergency room in 401
cardiac arrest patients with presumed cardiac origin (Nagao 2004). Primary outcome was
survival to hospital discharge, and among the secondary outcomes was neurological
evaluation according to the Cl'C scale. Mean BNP was significantly higher in the
decedents (260 pg/mL) than in the 52 survivors (74 pg/mL). Survival decreased steeply
across the quartiles of BNP concentration, being 34, 10, 7 and 1%, respectively from
bottom to top. The same trends were observed in patients with witnessed arrest, ePR by
bystander, with shockable rhythm or with ROSe after arrival at emergency room. Higher
BNP levels were significantly associated to death, even after adjustment for variables
associated with survival (witnessed arrest and ROSe before hospital), suggesting a role for
BNP for risk stratification of survival of resuscitated patients. The highest prognostic
accuracy was observed at a BNP concentration of 100 pg/mL, that corresponded to a
negative predictive value (NPV) of 96% and a specificity of 66%. Finally, the proportion
of patients with favorable neurological outcome (good recovery or moderate disability)
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decreased from 33% in the bottom quartile of BNP concentration to 0% in the top one
(Nagao 2004). More recently, the same group evaluated BNP to predict neurological
outcome in comatose survivors of cardiac arrest due to cardiac causes and treated with
mild TH by extracorporeal cooling (Nagao 2007). The primary endpoint was a favorable
neurological outcome at the time of hospital discharge. There was a rapid fall in the
proportion of patients with favorable neurological outcome across the quartiles of BNP
concentration, in all patients, and in those with witnessed arrest, bystander CPR, shockable
rhythm, ROSC after arrival at emergency room or cardiac arrest due to acute coronary
syndrome. The fact that BNP levels measured on admission in comatose cardiac arrest
survivors may predict neurological outcome has been confirmed in an independent study
that enrolled 115 patients followed for 6 months (Sodeck 2007). In this setting, BNP was
significantly associated with an adverse neurological outcome and mortality, independent
of the pre-arrest health and cardiac conditions. Though BNP provides invaluable
information on the post-resuscitation cardiovascular function, and therefore indirectly on
cerebral perfusion, it is however clear that brain-specific markers, such as N8E or 8-1OOb,
are more promising candidates for the prediction of neurological outcome after successful
cardiopulmonary resuscitation (Shinozaki 2009).
CIRCULATING BIOMARKERS OF BRAIN INJURY
Biochemical markers of brain injury are logical choices as prognostic markers of
neurological outcome. Of these biomarkers N8E and 8-100b are among the most widely
studied and used. Considering the different characteristics of these two biomarkers, a
possible rationale for analyzing both molecules in patients after cardiac arrest is their
different distribution within the grey (NSE) and white (S-l OOb)matter.
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Neuron-specific enolase
NSE is a neuron-derived enzyme, which is released after stroke and cardiac arrest and can
be detected in the blood. Its level in serum correlates with the extent of the neurological
damage. NSE is a 78-kDa with a half-life of 24 hr, intracellular enzyme found in neurons
and other cells of neuroectodermal origin. Elevation of serum NSE 1-3 days after cardiac
arrest is regarded as a severity marker of post-anoxic neuronal injury. The American
Academy of Neurology, which considered studies from the pre-hypothermia era, suggested
a cutoff of > 33 ug/L at days 1-3 after ROSC as a robust predictor for poor outcome
(Wijdicks 2006); the reported false positive rate (FPR) varied from 0 to 3%. Cerebral hypoxia
causes death of neuronal cells as well as damage to the BBB, resulting in an elevation of
the serum levels of this and other markers. The serum levels often correlated with the
extent of brain damage and in some studies with the prognosis of the patients. The
predictive value ofNSE in patients with ROSC has been shown in several trials prior to the
use of TH (Reisinger 2007, Zandbergen 2006). An elevation of NSE was associated with poor
outcome for comatose patients after cardiac arrest (Auer 2006, Grubb 2007, Meynaar 2003, Raine
1989). Fogel et al. (Fogel 1997) reported that NSE concentrations exceeding 33 ug/l at any
time within a week since arrest had a sensitivity of 80% and specificity of 100% to predict
persistent coma. Also, Zandbergen et at. (Zandbergen 2006) found in a large cohort of
resuscitated patients that NSE concentrations above 33 J.lgli within 72 hr after arrest
predicted poor outcome with a FPR of 0%. However, a subgroup analysis of the
Hypothermia after Cardiac Arrest trial (Tiainen 2003) showed a decreased prognostic value
of NSE in patients treated with TH. Since the introduction of the 20 I0 guidelines, various
studies have dealt with NSE during TH. Although an elevated NSE predicts a poor
outcome, there are case reports of good neurological survival despite extremely high NSE
levels in serum (Grubb 2007, Krumnikl 2002). In a prospective observational study on 97
patients, patients with poor outcome at 3 months had significantly higher NSE levels at 24
and at 72 hr than those with good neurological. A peak NSE level of 47 J.lg/l had the
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highest specificity (84%) and sensitivity (72%) to predict poor outcome, with a positive
predictive value (PPV) of 93%. A cutoff value for NSE of 97 J..l.g/Ipredicted a poor
neurological outcome with a specificity of 100% and a sensitivity of 49% (Daubin 2011),
NSE levels >33 Jig/I resulted in a rate of false prediction of poor outcome ranging from 7%
for measurements taken 48 hr after arrest to 10% if NSE was assessed during TH (Bouwes
2012). Other cutoffs have been also reported, widely ranging from 9 to 91 ug/l (Reisinger
2007, Zingler 2003). It is therefore difficult to identify a specific cut off predictive of
neurological outcome.
In addition, there is also evidence for a constant turnover ofNSE in blood, making changes
specifically associated with brain damage in serum levels difficult to evaluate. For
example, hemolysis caused by invasive procedures might produce a false rise in NSE
(Zandbergen 200/). Moreover, it is well known that platelets are markedly activated and
hemolysis may occur during early reperfusion after cardiac arrest. Therefore, even though
at least a proportion of NSE is released from neurons, the determination of NSE,
particularly during early reperfusion after cardiac arrest, may not be absolutely brain-
specific. More recently, increases of NSE levels over time, Le. 2 to 6.4 ug/L during the
initial 24 and 48 hr after ROSC, have shown better predictivity for poor outcome (Oksanen
2009, Rundgren 2009).
Protein S-100b
S-iOOb is an astroglial protein, which is also released after stroke and cardiac arrest. s-
IOOb is an acidic protein with a molecular weight of 21 kDa with a Ca2+ binding motif,
with a half-life of approximately 2 hr. It is expressed in brain astrocytes and in peripheral
adipocytes, but can also be detected in serum. A cut-off value more than 0.21 ng/ml at day
1 after cardiac arrest was 100% predictive of death and poor neurological outcome. The
time course of S-1OObis therefore different from that ofNSE (Figure 13).
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Figure 13. Different time courses and levels of neuron specific enolase (NSE) and S-I OObat different time
points plotted on logarithmic scales. Line =median; box = interquartile range. Black: Good outcome. Grey,
filled: Poor. From Mortberg 2011.
Studies have shown that S-IOOb can be used to identify patients at risk of significant
cognitive impairment (Rundgren 2009). The S-100b protein is implicated in neuronal
differentiation and proliferation; there are 19 types of S-1OOb,among which at least four
subtypes are expressed in human tissues: S-lOOAl (striated muscles, heart and kidneys), S-
1OOA1B (astroglial cells), S-IOOB (astroglial and Schwann cells) and S-100BB (astroglial
cells). The lower molecular weight, compared with NSE, allows a more rapid and easier
release of S-lOOb across the BBB in the systemic circulation, thus potentially giving a
higher sensitivity to detect brain injury. However, the use of S-iOOb for treatment
limitation is controversial. Similar to the NSE, the definition of a cut off is impossible.
Several clinical studies have reported that serum S-lOOb concentrations at 24 hr after arrest
were significantly higher in patients remaining comatose after cardiac arrest than those
regaining consciousness. Moreover, increased serum concentration of S-IOOb predicted
extensive post-anoxic brain damage; however, different cutoffs have been proposed,
varying from 0.2 to 1.5 mg/L (Martens 1998, Pfeifer 2005, Rosen 1998), depending also on the
different time of sampling and on the dosage methods. However, S-lOOb within the first 2
days after cardiac arrest showed a median FPR of 2-5% in identifying patients with poor
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outcome (Pfeifer 2005, Rosen 1998, Zandbergen 2001) and was initially considered as a poor
prognostic indicator. Because of its very short half-life, S-100b has its highest sensitivity
during the first 24 hr after the anoxic insult, while it usually declines over the next 48 hr
(Mortberg 2011). S-lOOb concentrations above 0.29 mg/l at 24-48 hr after ROSC were an
independent predictor of memory dysfunction, while a cutoff of 1.2 mg/l predicted in-
hospital mortality death with specificity of 100% (Grubb 2007).
Several studies have compared S-100b and NSE concentrations in the prediction of
outcome after cardiac arrest. Some studies reported that serum S-100b was more specific
than NSE to predict mortality and poor outcome (Martens 1998, Mortberg 201 I, Shinozaki 2009b).
Nevertheless, other studies have yielded conflicting results, reporting similar or a better
predictive value for NSE when compared with S-100b (Rundgren 2009). These discrepancies
might be related to main differences in the cohort of patients included: origin of cardiac
arrest; initial rhythms; witnessed; age.
CIRCULATING BIOMARKERS OF SYSTEMIC INFLAMMATORY RESPONSE
Successful resuscitation from cardiac arrest is usually characterized by the development of
an ischemia/reperfusion syndrome of the whole body. The main determinant of this
syndrome is a generalized activation of inflammatory reactions resulting in symptoms
similar in many aspects to those of sepsis. The main limitation in using inflammatory
biomarkers to predict outcome after cardiac arrest is their poor specificity for the anoxic
insult, as all inflammatory conditions can increase the circulating levels of such molecules
(Gaussorgues 1988, Nielsen 2011).
Procalcitonin
Evidence suggests that procalcitonin (PCT) is not a specific marker of cardiac arrest but of
the ischemia/reperfusion process following global ischemia. PCT levels were reported to
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be significantly higher in resuscitated patients dying with refractory shock than in those
who died with isolated irreversible hypoxic encephalopathy. Some studies have
investigated the prognostic role of PCT in comatose survivors. Indeed, PCT was
significantly higher in patients with a bad neurological outcome than in those with a good
neurological outcome (Fries 2003. Hayashida 2010). More recently, PCT predicted poor
outcome with a sensitivity of 85% and a specificity of 81%, for a cutoff of 1 nglml. Above
a PCT level of 16 ng/ml, no patient regained consciousness (Stammet 201I). In a recent study,
early elevations of serum PCT levels correlated with the severity of post-cardiac arrest
syndrome and were associated with worse neurological recovery after TH. Unexpectedly,
elevated serum PCT did not correlate with early-onset infections in that setting (EngeI2013).
Peak PCT correlated with Sequential Organ Failure Assessment (SOFA) score at day 1 and
was associated with neurological recovery at 3 months (peak PCT 1.08 [0.35-4.45] ng/rnl
in patients with CPC 1-2 vs. 3.07 [0.89-9.99] nglml in those with CPC 3-5, p = 0.01).
However, peak PCT did not differ significantly between patients with early-onset vs. no
infections (2.14 [0.49-6.74] vs. 1.53 [0.46-5.38] nglml, p = 0.49) (Annborn2013). In another
recent study, serial serum concentrations of PCT were assessed in 84 patients treated with
TH after cardiac arrest, and to study their association to severe infections, post-cardiac
arrest syndrome and long-term outcome. PCT displayed an early release pattern with a
significant increase within 2 hr, increasing further at 6 hr in patients with poor outcome.
PCT was strongly associated with SOFA score and time to ROSC, and predicted poor
neurologic outcome with high accuracy (area under the receiver operating characteristic
(ROC) curve of 0.88, 0.86 and 0.87 at 12,24 and 48 hr respectively) (Figure 14). Again,
no association of PCT to infection was observed.
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Figure 14. Release pattern for PCT after cardiac arrest in the good and the poor outcome group. The line in
the box represent the median, the outer limits of the box represent the inter-quartile range. Outliers are not
shown. #p < 0.05, §p < 0.0 I and *p < 0.00 I. Reciever operating characteristic analysis for PCT at 12, 24 and
48 h following cardiac arrest. The area under the curve is 0.88, 0.86 and 0.87 respectively. From Annborn
2013.
Matrix mctalloprotcinases
Other circulating biomarkers, not strictly of cardiac origin, have been evaluated for risk
stratification after cardiac arrest. Among them, are the MMPs that playa major role in the
turnover extracellular matrix components and cardiac remodeling after ischemia-
reperfusion injury. They have been proposed as therapeutic targets in different organs,
including the heart (Dejonckheere 2011). The clinical usefulness for risk stratification of
MMP-9 has been assessed in 96 cardiac arrest patients (Turkdogan 2012). Circulating levels
on admission were significantly higher in patients with failed (93 ng/mL) than with
successful CPR (70 ng/mL). In addition, MMP-9 concentration on admission was the sole
predictor of early mortality, in multivariable models that included presence of asystole,
mean duration of cardiac arrest, out-of-hospital CPR, electrolytes and arterial pH (odds
ratio 1.50, p<O.OOI). At optimal cut-off value, MMP-9 predicted failed CPR with a
sensitivity of 88% and a specificity of 98%, suggesting that it might help in risk
stratification of patients with cardiac arrest (Turkdogan 2012). Elevation of different MMPs
S2
(MMP-7 and MMP-9) has been confirmed in 51 patients resuscitated form cardiac arrest at
24 hr from ROSC (Hastbacka 2012). In this study, TH was associated with reduced MMP-9
levels, suggesting an attenuation of inflammatory response by this treatment. Nevertheless,
the influence of hypothermia after cardiac arrest on the activation of circulating
inflammatory markers and their role in tissue injury remains controversial, with conflicting
data between human and animal studies (Callaway 2008, Fairchild 2004, Fries 2009, Meybohm
2009).
ECG-derived hiomarker.ft
Guideline statement on "Fibrillation Waveform Analysis to Predict Outcome": There is
evidence that VF waveforms change over time. Several retrospective case series, animal
studies, and theoretical models suggest that it is possible to predict, with varying reliability,
the success of attempted defibrillation by analyzing the VF waveform. However, there are
currently no prospective studies that have identified optimal waveforms and/or timing. The
value of VF waveform analysis to guide defibrillation management is uncertain (Class lib,
LOE C) (Deakin 2010, Link 2010).
Analyses of ECG features during VF and CPR
The optimal timing of defibrillation can be determined by evaluating the probability of
shock outcome. If the shock attempt has a high likelihood of DF success, an electrical
shock should be prompted and delivered. Otherwise, unnecessary shocks should be
avoided and alternate therapy such as CPR or medications, especially high-quality CC,
should be utilized. The search for a reliable indicator of successful DF obtained from the
analyses of ECG features has begun more than 20 years ago. The initial approaches to
ECG analysis included measurements of VF amplitude (Weaver 1985) and frequency (Brown
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/99/). To improve sensitivity and specificity of the ECG predictors for ROSC. more
sophisticate methods of VF waveform analyses were introduced and investigated.
including wavelet decomposition (Watson 2004). nonlinear dynamics methods (Callaway 200/).
and a combination of different ECG parameter analyses (Ejtes/o/2000).
Earlier investigations using electrocardiograms focused on "amplitude or voltage" of VF
wavelets as a predictor of the likelihood of successful DF. VF voltage. or signal amplitude.
is defined as the maximum peak-to-trough VF amplitude in a given time window of the
ECG signal (Noc /999). Mean VF voltage is the average of VF voltage over the same time
interval. It was observed that VF amplitude declines over time and greater amplitudes were
associated with correspondingly greater success of DF (Callaham /993, Dalzell /991, Noc 1994,
Strohmenger /996, Stults 1987, Weaver /985). Several studies have shown that this ECG feature
reflects vital organ blood flow and specifically myocardial blood flow and energy
metabolism (Brwon 1989, Dalzell 1991, Noc /999, Strohmenger /997, Weaver /985). Weaver et al.
(Weaver /985) observed that patients in which the VF amplitude was greater than 0.2 mV
had a significantly greater likelihood of resuscitation. The observation that DF success rate
is higher during the initial period of cardiac arrest, where "coarse VF" with an amplitude
greater than 0.2 mV is present, while success ofDF is greatly reduced at the stage of "fine
VF", has finally evolved to extensive quantitative analysis of ECG waveform. VF voltage
appeared not only as a predictor of ROSC but it also affirmed its utility as indicator of VF
duration from collapse.
Subsequently, it was realized that other parameters could be computed utilizing fast
Fourier transform (FFT) analyses in a selected ECG interval, including VF median
frequency, peak power frequency, edge frequency, and spectral flatness measure. The
starting point for all these calculations was the "power spectrum ", defined as the square of
Fourier amplitudes (described in the following paragraphs). Brown et al. (Brown /99/)
54
developed a technique that analyzed VF voltage and VF frequency such to obtain the so
called VF "median frequency" (Brown 1991, Strohmenger 1994). The median frequency,
representing the frequency at which half of the power of the spectrum is above and half
below, was calculated by the following equation:
MF = L Fi x Pi / L Pi
where Fi is the ith frequency component and Pi the relative power at Fi.
In a porcine model ofVF and CPR, a median frequency of more than 9.14 Hz had 100%
sensitivity and 92 % specificity in predicting the success of a DF attempt. Frequency
analysis of VF wavelets and, specifically, median frequency was also correlated with CPP
in animal models as well as human victims and therefore it became the preferred ECG
feature to be used as predictor of outcome (Brown 1989 and 1991 and 1996, Carlisle 1990, Martin
1991, Monsieurs 1998, Stewart 1992, Strohmenger /996 and /997). In addition, this parameter
appeared as a more accurate indicator for estimating the duration of untreated VF,
compared to the earlier VF amplitude (Brown /989 and 1993, Dzwonczyk 1990, Martin 199/).
Recently, in the pursuit of a more optimal ECG feature prognosticator, several studies
focused on the changes and differences of VF waveform features in relationship to the
pathophysiology of cardiac arrest. Specifically, investigators focused on the differences
between VF as resultant of an ischemic heart disease, which represents the main cause of
sudden death, and VF electrically induced, which represents the main experimental model
employed in laboratories (Niemann 2007, Wang 2007b). Indick et al. {Indik 2007) induced VF in
swine in which acute myocardial infarction followed legation of the left anterior
descending coronary artery (LAD). The study revealed that VF spectral features, such as
median, mean, or dominant frequency and bandwidth were significantly reduced compared
with those derived from a VF electrically induced. In a porcine model of ischemic induced
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cardiac arrest, by acute occlusion of the LAD, we (Ristagno 2007b and 2011) have confirmed
lower mean VF frequency in comparison to the electrical induced VF (Figure 15).
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Although VF features might be different in relationship to the cause of cardiac arrest, we
have observed in the ischemic model of VF that ECG features continuously changed
during resuscitative maneuvers. In particular, VF amplitude and mean frequency increased
during CC and such increases correlated with successful DF (Ristagno 2008b and 2008e and
2011). These observations provided evidence that ECG predictors of outcome were, at least
in part, related to the mechanism by which VF evolved. Of more importance, relations
between VF amplitudes, frequencies and success of DF are maintained under the setting of
ischemic induced VF, confirming thereby the utility of ECG predictors of outcome.
Capability of ECG predictors, i.e. AMSA and its slope, in the presence of AMI was further
tested in a porcine model of cardiac arrest with or without AMI (Indik 2009). Untreated VF
duration and AMI were independent predictors of ROSC following VF cardiac arrest and
AMSA and slope were able to predicted ROSC.
A problem of the majority of the above predictors is the corruption of the ECG signal
recording during CC. CC, in fact, affects the ECG-extracted parameters, providing
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erroneous interventions. The reliability of such predictors, therefore, requires interruption
of CC for ECG analyses. This interruption, however, reduces the period of vital myocardial
perfusion and has been proven to yield sub-optimal outcome and greater post-resuscitation
myocardial dysfunction (Fene/ey 1988. SaID1997). At present, several filters and algorithms to
reduce and eliminate ECG artefacts and noise due to CC or ambient interferences have
been developed and successfully used (Berger 2007. Li 2008 and 2012. Noc 1999. Pernat 2001.
Povoas 2000 and 2002. Strohmenger 1996 and 1997). The filtered ECG signals or CPR-artifact-
free ECG signals presented better results than the ECG signals with CPR artifacts and with
no need for signal preprocessing (Neurauter 2008).
Additionally, the ECG signals recorded from AEDs may also include baseline drifts,
powerline interferences, muscle movements, and so on (Shandilya 2012. Werther 2009 and
2009b). A preprocessing step is usually employed to obtain the 'pure' ECG signal before the
waveform analysis, including a notch filter to remove alternating current interference at
50-60 Hz, a high-pass filter to remove baseline drifting and CPR artifact, and a low-pass
filter to remove the myographic noise (Amann 2010. Granegger 2011. frusta 2009. Ruiz 2010.
Werther 2012). After filtering, the features or characteristics of the VF signal extracted with
different digital signal processing methods are then used to predict the probability of DF
success based on the established threshold or decision algorithm. To improve sensitivity
and specificity of the ECG predictors for DF success and ROSe, more sophisticated
methods of VF waveform analyses have recently been introduced and investigated,
including wavelet decomposition, nonlinear dynamics methods, and a combination of
different ECG parameter analyses.
Different approaches to analyze VF waveform
Different approaches have been employed to analyze VF waveform features: Time
domains, Frequency domains, Time-frequency domain methods, Non-linear dynamic, and
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combined ones.
Predictors obtained from time domain describe the characteristics of waveform
amplitudes, phases or voltages (Callaway 2005, Endoh 2011, Joar 2007, Neurauter 2007, Weaver
1985) and include:
- Peak-to-peak amplitude (PPA), which is defined as the difference between the maximum
and minimum recorded VF voltage within a given window.
- The mean amplitude, representing the mean absolute deviation from the mean amplitude
of the waveform
- Median slope (MdS) and mean slope (MnS), which represent the average steepness of the
waveform, and reflect both the amplitude and frequency information ofVF.
Time domain methods are affected by other factors: interference, body size/composition,
skin resistance, size and position of electrodes, lead ways, and recording conditions.
Additionally, they do not utilize the temporal information to predict the DF outcome.
The frequency domain features describe the frequency component characteristics of VF
waveform. Each frequency component is computed over the clipped ECG segment.
Parameters are computed utilizing FFT analyses in a selected ECG interval. FFT consists
in splitting a short segment of the VF waveform into small subunits and then expressing
each of these as the sum of multiple simpler waves of a given amplitude and frequency,
obtaining the so called "power spectrum"
(Figure 16).
Figure 16. YF fast Fourier transform and its resulting
power spectrum.
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The calculated features from the FFT of the selected VF window include (Brown 1996.
Eftestol 2000 and 2001. Endoh 2011. Golo 2003. Gundersen 2008. Hamprecht Ztull, Indik 2008. Marlin
1991. Neurau/er 2007, S/ewarI1992. Strohmenger 1997, Watson 2005):
- Peak power frequency (PF) or dominant frequency (DF), that is defined as the highest
peak in the resulting power spectral density (PSD);
- Energy, calculated as sum of the single power values of the PSD;
- Maximum power, maximum value of PSD;
- Power spectrum area (PSA), which is computed in a similar way to AM SA using PSD
instead of amplitude spectral density;
- Centroid power, which is defined as power coordinate of the center of the spectral mass;
- Centroid frequency (CF). which is defined as frequency coordinate of the center of the
spectral mass;
- Median frequency (MDF), which is calculated as the mean of all of the contributing
frequencies weighted by the power at each frequency;
- Fibrillation power, which is the integral over the fibrillation contribution to the PSD;
- Instantaneous mean frequency;
- AMSA. which is calculated as the sum of contributing frequencies weighted by the
absolute values of the FFT of the VF signal, describes the amplitude-weighted mean
frequency.
Frequency domain features are robust and less affected by external factors than the time-
domain features. The fundamental problem of frequency domain methods is that FFT
analysis is only suitable for stationary signals whereas the ECG signals are non-stationary
and non-linear.
The time-frequency domain methods use the continuous or discrete wavelet transform that
provides concomitant spectral and temporal information, allowing a local scale-dependent
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spectral analysis of signal features. They include (Box 2008, Marlin 1991, Watson 2004 and 2005):
wavelet-based PF; energy; wavelet-based MNF; spectral flatness; entropy, i.e. the
cardioversion outcome prediction (COP) (wavelet-entropy marker), which is used as a
metric of the temporal behavior of the signal.
Earlier research has confirmed that VF is a complex non-linear pattern formed by drifting
spiral waves of electrical activity (vortices and rotors) that travel across the myocardium
and subsequently break down. The non-linear dynamic methods, however, are sensitive to
the noise and interference. There are several reported non-linear features to predict DF
success (Callaway 2001, Jagric 2007, Jalife 1996, Lin 2010, Parfilov 1998, Podbregar 2003, Rodriguez
2009, Sherman 2008):
- The scaling exponent (SeE), which is an estimate of the fractal self-similarity dimension;
- Hurst exponent, which is used as a measure oflong term memory of time series;
- Irregularity, which is a direct indicator of chaotic behavior;
- the logarithm of the absolute correlations (LAC), which quantifies how individual parts
of a signal are self-similar at different points along its length. It provides information
regarding the duration of VF by measuring the roughness of the VF waveform;
- detrended fluctuation analysis (DFA), which determines the statistical self-affinity of VF
waveform.
Beside the different ECG predictors that can be used, there is also no consistent definition
for DF success. Two definitions are commonly adopted for successful DF: (1) the presence
of an organized rhythm at 5 sec after the DF attempt (Koster 2006); (2) the presence of a
sustained organized rhythm originating within a min after the DF attempt (Watson 2005); (3),
survival till 6 hr after resuscitation or discharge from the hospital (the most rigorous
definition).
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Among the numerous studies available on different predictors of DF success (Table 6),
sensitivity for this approach ranges from 54% to 100% with a specificity ranging from 23%
to 98%. The majority of studies, however, included only a few patients (median of 86
patients). Only two studies had more than 200 patients.
Table 6. OF outcome prediction with different ECG predictors (clinical studies).
Study VF feature Patients (no.) Sensitivity Specificity Outcome
Dalzell ppA 70 NA NA ROSC1991
Martin MDF 7 NA NA ROSC1991
Brown Combination of Pf' 55 100 47 ROSC1996 andCF
Strohmenger ppA, MDF 26 100 25 ROSe1997
Eflestol Combination of Cf 156 ROSe2000 and pF 92 42
Strohmenger OF 89 92 42 ROSC2001
EOestel Combination ofCF 156 91 36 ROSC2001 and Energy
Hamprccht OmF 54 59 52 ROSC2001
Podbregar
Combination of ppA,
total energy ofPSD 47 100 97 ROSC2003 and Hurst exponent
Jekova Energy (2·7 Hz) NA (more than 700 trace data set) 62 80 ROSe2004
Young AMSA 46 91 94 ROSC2004
Watson Entropy NA (868 trace data set) 91 60 ROSe2004
Watson COP 110 97 63 ROSC2005-2006
Neurauter MdS 197 95 53 ROSC2007
Box COP 54 100 60 ROSC2008
Ristagno AMSA 90 91 97 ROSe200gb
Neurauter MdS (l0-22Hz) 192 95 50 Rose2008
Lin OFA (DFAu2) 155 61 63 ROSC2010
Endoh eF 152 77 63 ROSC2011
Shanmugasundarama Slope 44 83 70 ROSC2012
Nakagawa AMSA 83 94 59 ROSC
2012
Weaver pPA 394 97 23 Survival
1985
Monsieurs Survival index 100 70 70 Survival1998
Goto DF 47 77 90 Survival2003
Callaham pPA 265 54 98 Survival1993
Callaway SeE 75 NA NA Survival2001
NA, not available.
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The potential benefit of a DF guided by a real time VF waveform analysis, if successful,
would allow for optimization of the timing for shock delivery, such to maximize DF
success and minimize the number of unsuccessful shocks. The risk of this intervention is
minimal, as the ECG signal which would be analyzed is already readily available.
Currently the following gaps are present in the studies:
• Data on factors responsible for changes in VF waveform, (i.e., time of arrest, quality of
CPR, drug administration, concomitant AMI)
• Determination of which VF waveform parameter is the most accurate
• Influence ofTH and patient temperature on VF waveform
Evolution of Amplitude spectrum area (AMSA)
The need for ECG analyses and prediction for successful DF escalated following the
introduction of AEDs. Initial efforts at the Institute of Critical Care Medicine focused on
the ECG indicator widely investigated at that time and specifically evaluated the possibility
of VF amplitude to predict resuscitability in a rodent model of cardiac arrest and CPR.
Increases in CPP during CCs were associated with concomitant increases in VF voltage
and greater VF voltages were observed in successfully resuscitated animals. Moreover,
greater VF voltages after initiation of cardiac resuscitation were associated with increases
in myocardial creatine phosphate, and significant decreases in lactate content. Accordingly,
increases in VF voltage during cardiac resuscitation reflected increases in myocardial
perfusion and favorable changes in myocardial energy metabolism with consequent greater
success of CPR (Noc /994). In a porcine model of cardiac arrest and CPR, successfully
resuscitated animals had significantly greater CPP, dominant VF amplitude, mean VF
amplitude, and dominant VF frequency. No animals were resuscitated if CPP was <8 mm
Hg, dominant amplitude <0.48 mY, mean amplitude <0.25 mY, or dominant frequency
<9.9 Hz, independently of the duration of untreated VF. However, DF attempts uniformly
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failed when mean amplitude was below the threshold level even though dominant
frequency would have predicted otherwise. Efforts to obtain a better predictor led to the
"defibrillator predictor" in which mean amplitude and dominant frequency were combined.
Utilizing stepwise multiple regression analysis, the investigators identified a single
numerical score which was established as a DF predictor and wss represented by the
following equation (Noc 1999):
Defibrillator Predictor=3. 60-4.85 * mean VF amplitude-D. 06 * VF dominant frequency.
This predictor served as an objective noninvasive measure on par with that of CPP for
predicting the success ofDF. Defibrillations were unsuccessful if the combination of mean
amplitude and dominant frequency did not exceed a specific threshold value.
Unfortunately, PPV was still suboptimal, being 20%. Drs. Pernat and Povoas (Pernat 2001,
Povoas 2000 and 2002), continuing the earlier studies, finally introduced the new DF outcome
predictor, namely AMSA. This ECG-derived parameter was obtained from conventional
scalar limb ECG leads, continuously monitored during uninterrupted CC. The
electrocardiographic signal was sampled and recorded at a frequency of 300 Hz. The
amplitude spectrum was obtained by FFT of the ECG scalar signal (Figure 17). AMSA
was then calculated from the resulting amplitude frequency spectrum according to the
following equation:
AMSA =~ Ai x Fi
where Ai is the amplitude at the ith frequency Fi.
To rmnmnze Iow-frequency artefacts produced by CC and to exclude the electrical
interference of ambient noise at frequencies greater than 48 Hz, the analyses were
performed between the frequencies of 4 and 48 Hz.
63
1.0
Figure 17. A representative example of the
amplitude frequency relationship and the area under
the curve that defines AMSA.
-1.0
o 2 3 4 5
SECONDS
> ::::: I J ~E 0.002 1.1
0.001 ~ Illl J_". m ..o o 5 10 15 20 25 30
FREQUENCY. Hz
In an initial study, Dr. Povoas (Povoas 2000) investigated CPP, obtained from arterial and
right atrial pressures and VF mean amplitude, MNF, and AMSA, obtained from ECG
recordings in 55 domestic pigs during CPR. Form these measurements threshold values for
ROSC were obtained and subsequently validated in another 10 animals. CPP and mean
amplitude each had PPVs of 100% but NPVs of only 44% and 22%, respectively. MNF
predicted successful OF with a PPV of 75% but a NPV of only 30%. AMSA yielded a
better combination of positive and negative predictive values of 86% and 85%,
respectively. Among the exciting and impressive results obtained with this new ECG
parameter, the high NPV was of special note since the investigators realized that AMSA
was able to minimize repetitive and ineffective electrical shocks during CPR.
During the same period, Dr. Pernat confirmed these results, demonstrating the capability of
AMSA to optimize the timing of DF (Pernat 200/). In a porcine model of cardiac arrest and
resuscitation, AMSA was highly correlated with CPP levels during CPR and AMSA,
similarly to CPP, was significantly greater in animals that were resuscitated compared to
those that were not. In no instances a perfusing rhythm was restored when AMSA was <
21.0 mY-Hz. The AMSA value of 21 mY-Hz predicted restoration of perfusing rhythm
with sensitivity and specificity above 90%. The NPV of AMSA was 95% and statistically
equivalent to that of CPP, mean amplitude, and MNF. However, the PPV, was greatly
64
improved with AMSA, namely 78% in contrast to the lower predictive values yielded by
CPP, mean amplitude, and MNF, which were below 40%.
One year later, Dr. Povoas (Povoas 2002) further investigated the real time application of
AMSA in a porcine model of cardiac arrest. The investigators confirmed that an AMSA
value of21 mY-Hz had a NPV of96% and a PPV of 78%. An AMSA value of21 mY-Hz
or greater predicted restoration of a perfusing rhythm in 7 of 8 instances and AM SA of 20
mV-Hz or less correctly predicted failure of electrical resuscitation in 24 of 26 instances.
The progressive increases in AMSA observed before successful resuscitation further
demonstrated that AMSA had the potential of providing an objective guide allowing for
better quality control of CPR. Failure to increase AMSA values to near threshold levels
prognosticated failure of defibrillation.
These initial empirical trials identified AMSA as a good predictor for guiding the DF
attempt. Subsequent validation studies confirmed that AMSA had impressively higher
specificity and PPV compared with the other predictors, maintaining sensitivity and NPV
comparable to CPP, mean amplitude, and MNF. More importantly, AMSA was not
invalidated by artefacts resulting from CC fulfilling the goal of a predictor that would
allow for uninterrupted CC during ECG analyses. AMSA was well correlated with CPP,
which is widely recognized as the gold standard for predicting the success of defibrillation.
Yet, CPP was robust only for negative prediction. It is the specificity and the PPV, which
are assured by AMSA that are more likely to minimize the adverse effects of repetitive
high energy shocks during CPR and the resulting post-resuscitation myocardial
dysfunction.
In more than 65% of the cardiac arrest events, the usual cause is an underlying AMI (Podrid
2005). Accordingly, myocardial ischemia and reperfusion have been involved in the
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triggering of malignant ventricular dysrhythmias (Ouyang 1981. Qin 2002) and both the
duration and the severity of myocardial ischemia play important roles in developing
myocardial cell damage (Reimer 1979). Indeed, we have earlier described that AMSA was
superior to CPP as indicator of return to a perfusing rhythm following OF, under condition
of partial occlusion of the LAD (Ristagno 2007b). In a porcine model of cardiac arrest and
resuscitation, a partial occlusion of the LAD, which was approximately 75% of the internal
lumen, was maintained during CPR. During CC, CPP increased and exceeded threshold
value for successful resuscitation. AMSA however, was significantly lower in the animals
in which the partial occlusion of the LAD was maintained during CPR (Figure 18). This
was reflected by the greater number of electrical shocks required to terminate VF with
lesser success of resuscitation. CPP is in fact, an indirect indicator of myocardial flow
produced by CC and represents a gradient pressure between aorta and right atrium. This
gradient can be maintained even in the presence of occlusion of the coronary tree. AMSA,
which is instead related to myocardial blood flow and metabolism, has been shown to
substantially decrease when the myocardial perfusion is truly reduced .
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Accordingly, the quality of CC is a major issue for CPR success (Gallagher 1995, Van
Hoeyweghen 1993, Wik 1994). Effectiveness of CC relates to compression depth, compression
rate and duty cycle, and complete chest recoil during the releasing phase (Brown 2006, Field
2010, Nolan 2010, Travers 2010). Outcome may be improved by assuring adequate depth of
compression in addition to more optimal rates of compression (Abella 2005, Wik 2005). Since
CC is usually performed without feedback and relatively small changes in the depth of
compression profoundly alter hemodynamic effectiveness and outcome, there is an
increasingly recognized need for a monitor of effectiveness of CC (Aase 2002, Baubin 1999,
Noordergraaf 2006, Travers 2010). Recently, we have investigated the possibility of assessing
the quality of CPR, and especially of CC depth, utilizing AM SA, which has the important
advantage of being non-invasive and calculable from the universally available ECG, as
part of the current practices of advanced life support. In a porcine model of VF and CPR,
animals were randomized to either optimal or suboptimal CC depth after onset of VF.
Optimal depth of mechanical compression was defined as a decrease of 25% in anterior
posterior diameter of the chest during compression. Suboptimal compression was defined
as a decrease of 17.5% in anterior posterior diameter. All animals had Rose after optimal
compressions. This contrasted with suboptimal compressions after which none of the
animals had ROSC. AMSA, once again has been proven to be, like CPP, predictive of
outcome. The calculated AMSA values during CPR and immediately prior to the DF
attempt were significantly greater after optimal CCs, in contrast to the sub-optimal ones. In
that experimental setting, the quality of CCs was closely related to the AMSA value and in
tum, to the likelihood of ROSe. Like threshold value of CPP, AMSA threshold value was
achieved contingent on the depth of compressions such that AMSA increased
progressively during CC and predicted the likelihood of successful DF. AMSA therefore
was confirmed to serve also as an indicator of effective CC, as well as a tool for guiding
DF delivery. The extension of the AMSA measurement to guide the quality of cc was
explained as the capability to restore the electrical robustness of the myocardium through
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restoring threshold level of coronary blood flow. When AMSA is of insufficient
magnitude, the rescuer is prompted to push harder and perhaps to push faster.
Beside the quality of CC, AMSA might also be useful for retrieving the duration of
untreated VF in the case of unwitnessed cardiac arrest (Niemann 1992, Ristagno 2011). In nine
domestic male pigs, VF was induced and left untreated for IS min (Ristagno 2011). AMSA,
more than VF amplitude and frequency, was highly correlated with the downtime of VF
and decreased over time, as shown in Figure 19. Significantly lower AMSA was observed
after 3 min of untreated VF. Following the 4th min of VF, AMSA values decreased more
rapidly. This additional use of AMSA therefore may provide guidance to the best initial
intervention rescuer should adopt upon arrival at the cardiac arrest scene, i.e. OF or CC
first.
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Applicability of AM SA to the clinical scenario
The subsequent step in the evolution of AMSA as an indicator of effectiveness of
intervention and to guide OF was the confirmation of its efficacy in clinical settings. The
first confirmation of the capability of AMSA to predict success of defibrillation and ROSC
in a clinical scenario was reported by Young et al. (Young 2004) in the late 2004. This study
was a retrospective analysis of ECG traces, representing lead 2 equivalent recordings, on
108 OF attempts on 46 victims of cardiac arrest due to VF during out-of-hospital cardiac
arrest. An AMSA value of 13 mV-Hz predicted successful OF, with a sensitivity of 91%
and a specificity of 94%. This data represented the first evidence of the capability to extend
the predictive value of AMSA to human patients.
In 2008, Ristagno et al. (Ristagno 2008b) analyzed a new database including episodes of VF
or VT with OF attempts, obtained from human victims of out-of-hospital cardiac arrest.
ECGs were recorded from AEDs which provided escalating biphasic shocks in the
sequence, 120 - 150 - 200 Joules. AMSA was confirmed as a valid tool to predict the
likelihood that any electrical shock would have restored a perfusing rhythm during CPR in
90 out-of-hospital cardiac arrest patients. The analysis was performed on a 4.1 second
interval of ECG recordings immediately preceding the delivery of the OF. For purpose of
this study, the outcome of the shock was defined as successful if OF restored an organized
rhythm with heart rate ~ 40 beats/min commencing within the 1 min post shock period.
Outcome was considered not successful ifVF, VT (heart rate> 150 beats/min), asystole or
pulseless electrical activity, with pauses> 5 sec, occurred after OF. AMSA values were
significantly greater in successful OF, compared to unsuccessful one, 16 mV-Hz and 7
m'V-Hz respectively. A threshold value of AMSA of 12 mV-Hz was able to predict the
success of each OF attempt with a sensitivity of 91% and a specificity of 97%.
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The PPV, which refers to the proportion of the shocks that were correctly predicted to
restore a perfusing rhythm, was 95%. The NPV, which instead refers to the proportion of
the shocks that were predicted to fail and actually failed to restore a perfusing rhythm, was
97%. The results of this study were consistent with the previous retrospective analysis
(Young 2004) .. Of particular interest was the fact that although different models of
defibrillators were employed in the two studies, the results were consistent. This was
therefore a further confirmation that AMSA represented an excellent predictor of OF
success, and this capability was independent from the defibrillatory energies and
waveforms utilized. Finally, in a recent study including 267 CPR sequences from 77
victims of out of hospital cardiac arrest, Dr. Eftestel and colleagues (E[tesloI2004) confirmed
AMSA as one of the most powerful predictor of success of defibrillation.
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AIM OF THE STUDIES AND HYPOTHESES
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The present thesis includes both experimental and clinical studies directed to discover
and/or validate experimentally and clinically new circulating and ECG-derived biomarkers
predictive of outcome of cardiac arrest.
• CIRCULA rING BIOMARKERS:
• STUDY 1: Discovery of new circulating biomarkers with the aid of untargeted
metabolomics in a rat model of cardiac arrest
With the aim to discover new circulating biomarkers better able to explain the
physiopathology of the post-cardiac arrest syndrome and to predict outcome of cardiac
arrest, we used an untargeted metabolomics approach. Metabolomics is the global study of
metabolite changes in a biological system. The metabolome can be viewed as the
biochemical consequence of such changes, the real effectors of a phenotype (Brown 2009,
Kell 2005, Old 2005, Zhang 2006). The comprehensive quantitative assessment of plasma
metabolites and in particular of post-resuscitation metabolite differences in plasma may
provide important information about the cellular metabolism response to CPR. The aim of
this study was to examine post-resuscitation plasma metabolites in a rat model of cardiac
arrest and resuscitation to identify perturbation in circulating metabolites and thus potential
mechanisms accounting for outcome. We hypothesized that extensive characterization of
the largest possible number of metabolites from relevant or potentially affected metabolic
pathways might help in identifying mechanisms explaining the outcome of cardiac arrest
and CPR and might serve as early prognosticator biomarkers.
• STUDY 2: Validation of KP activation after cardiac arrest with experimental
models in rats and pigs and in a small cohort of cardiac arrest patients
Results from study 1 (Brunelli 2013) were able to identify alterations in a major route of the
TRP catabolism, namely kynurenine pathway, shown in Figure 20. KP is mainly activated
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upon inflammatory stimulation and is implicated in the pathogenesis of numerous central
nervous system disorders, as well as in sepsis development and profound hypotension
during septic shock (Changsirivathanathamrong 2011, Wilson 2012). KP activation has been also
described in various clinical conditions, including infection, autoimmune syndromes,
malignancies, depression, and pregnancy (Huttunen 2010. Maes 2011).
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The following studies, therefore, aimed to investigate KP activation after cardiac arrest and
its relationship with the severity of post-cardiac arrest syndrome, by a fully translational
approach (Ristagno 2013). More specifically, KP was assessed during the initial hours and
days following resuscitation from cardiac arrest in rats, pigs, and in a small cohort of
patients. Based on the above findings, specific KP metabolites were then targeted, using
Le multiple reaction monitoring (MRM)-mass spectrometry. We hypothesized that the KP
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would be activated following cardiac arrest and this activation would be associated with
the severity of post-resuscitation organ dysfunctions and outcome.
• STUDY 3: Validation of KP activation after cardiac arrest in a large cohort of out
of hospital cardiac arrest patients
In the present observational cohort study we examined the KP in critically ill patients
resuscitated from out-of-hospital cardiac arrest after VFNT (n=155). We hypothesized that
the severity of the ischemic insult was associated with KP activation and that KP
metabolites on admission correlate with mortality and 12-month outcome.
• ECG-DERIVED BIOMARKERS:
AMSA has been demonstrated to be one of the most accurate predictors for successful OF,
in both animal and small retrospective clinical studies (Ejtesto/2004, Perna! 2001, Povoas 2002,
Ristagno 2008b, Young 2004). Capability of AMSA to predict OF outcome has been evaluated
in two different cohorts of out-of-hospital cardiac arrest patients:
• STUDY 4: AMSA evaluation in 609 VF patients in the United States
In the present study (Ristagno 2013b), we retrospectively evaluated the capability of AMSA
to predict DF success in a large database of out-of-hospital VFs. We hypothesized that
AMSA, derived from conventional AED pads, would be an useful indicator to predict OF
success and guide CPR interventions. We further hypothesized that AM SA could serve as
a monitor ofCC quality.
• STUDY 5: AMSA evaluation in 1.617VF patients in Lombardia region, Italy
We evaluated the capability of AMSA to predict OF outcome in out-of-hospital cardiac
arrest, in a Region of Northern Italy. We hypothesized that threshold values of AMSA
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could be identified to be used as a guide for CPR intervention and as a predictor of DF
outcome. More specifically, AMSA thresholds for DF success and failure were calculated
from a derivation cohort of 1.050 VF patients receiving DF attempts; these thresholds were
then validated in an additional cohort of 567 VF patients. Effects of different factors
potentially affecting VF waveform have been also investigated (i.e., time of arrest, drug
administration, co-morbidities, etc.). Furthermore, relationship between AMSA and long-
term outcome, Le. hospital discharge and 1 year survival, has been evaluated. Finally,
comparison between AMSA and classical VF waveform parameters has been performed.
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MATERIALS AND METHODS
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Procedures involving animals and their care were in compliance with national (D.L. n. 116,
G.U., suppl. 40, 18 February 1992, Circolare no. 8, G.U., 14 Luglio 1994) and international
laws and policies (EEC Council Directive 86/609, OJL 358, 1, December 12, 1987; Guide for
the Care and Use of Laboratory Animals, US National Research Council, 1996). Approvals of
the studies were obtained by the local institutional review board committee and governmental
institution (Fries 2012, Ristagno 2013b).
• CIRCULATING BIOMARKERS:
• STUDY 1: Discovery of new circulating biomarkers with the aid of untargeted
metabolomics in a rat model of cardiac arrest
Standards and chemicals for metabolomic analysis
High-performance liquid chromatography (HPLC)-grade acetonitrile, ammonium acetate
(>99% dry matter) and formic acid (98%) were purchased from Fluka (Buchs, Switzerland).
HPLC grade MilliQ water was obtained with a MILLI-RO PLUS 90 apparatus (Millipore,
Molsheim, France). Analytical standards Ltryptophan, L-kynurenine, KYNA, and 3-HAA
were from Sigma-Aldrich (Italy). Deuterated standards D8-L-tryptophan and D6-kynurenic
were from CON Isotopes (Chemical Research 2000 Sr.l, Italy). D4-L-kynurenine and 02-3-
hydroxyanthranilic acid were from Buchem BV (Netherlands). Individual stock solutions were
prepared in MilliQ water and stored at -20°C. Working solutions containing all the metabolites
and their internal standards were prepared freshly before analysis.
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Rat model of cardiac arrest
An established rat model of cardiac arrest and CPR was used (for more details, refer to
STUDY 2). Twelve male Sprague-Dawley rats weighing 450 ± 30 g were anesthetized with
pentobarbital, endotracheally intubated and surgically instrumented for femoral artery
cannulation for blood withdrawal. VF was induced in 6 rats by delivering up to 4 rnA AC
current into the right ventricle. CPR, including mechanical CC, ventilation with oxygen, and
epinephrine (0.02 mg/kg), was then started and continued for a 6 min before OF. CC was
maintained at a rate of 200/min with equal compression-relaxation and ventilation at 50/min.
Resuscitation was attempted with up to three two-joule counter-shocks. Animals were
considered successfully resuscitated if supra-ventricular rhythm returned with mean aortic
pressure above 50 mmHg. Two hr after resuscitation, blood was withdrawn and animals were
euthanized. Blood was collected into ethylenediaminetetraacetic acid (EDTA) tubes and
centrifuged for 10 min at 2,000xg at room temperature. Plasma samples from each animal
were immediately stored at -80 °C. Six other rats were not subjected to cardiac arrest and
served as controls (CTR). Body temperature was held at 37 ± 0.5 °C throughout the
experiment.
Metabolomic profiling by LTQ-Orbitrap mass spectrometry
Discovery pilot metabolomics analysis began with an unbiased search for plasma analytes
linked to post-resuscitation using two experimental groups from the rat model. The control
group (CTR, n=3) was selected from rats not subjected to cardiac arrest, while the case group
was selected from rats subjected to cardiac arrest and CPR and sacrificed 2 hr after
resuscitation (CAlCPR2, n=3, early post-resuscitation phase). To reduce biological variation
that might mask important changes in metabolite abundances, we prepared metabolite samples
by pooling plasma (5 ilL/animal) from individual rats in the experimental groups. Every
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specimen made an equal contribution to the pool and two composite groups (CTR and
CA/CPR2) were then created. Metabolites were extracted by adding four volumes of cold
methanol to the plasma sample; samples were vortexed and incubated at -20°C for 1 hr. They
were then centrifuged 10 min at 14.000 x g, and the supernatant (rich in small-molecules
analytes) was collected, dried in a SpeedVac and resuspended in 20 ul, of 0.1% formic acid. A
portion (2 ul.) of metabolite extract from the CTR and CA/CPR2 groups was directly
analyzed by liquid chromatography (LC) - mass spectrometry (MS)/MS, using an LTQ
Orbitrap XLTM(Thermo Scientific, Waltham, MA, US), interfaced with a 1200 series capillary
pump (Agilent, Santa Clara, CA, US). The MS instrument was operated in positive (POS) and
negative (NEG) ionization modes. Analyses were run in triplicate. Metabolites were separated
on an Agilent Technologies Zorbax C 18 SB column (150 x 0.5 mm ID, particle size 5 urn),
Flow rate 10 J,lLlmin with mobile phases: water containing 0.1% formic acid (A) and
acetonitrile (B) for the positive ion. For negative ion mode, 2 mM of ammonium acetate was
substituted for the 0.1% formic acid. The gradient consisted of 5% B for 5 min, followed by a
linear gradient to 95% B over 45 min, hold at 95% B for 5 min, and re-equilibration at 5% for
2min.
MS conditions were: source DESI Omni Spray (Prosolia, Indianapolis, IN) used in nanospray
mode with positive and negative ion modes; ion spray voltage 2100 V; capillary temperature
220°C; capillary voltage, 42 V. MS spectra (rn/z 100-1000) were acquired in the Orbitrap
analyzer at 60,000 resolution, in parallel with the low-resolution MS/MS scans of the four
most abundant precursor ions being acquired in the LTQ. The lock-mass option was used to
obtain the most accurate mass measurements in MS mode. The polydimethylcyclosoloxane
ion generated in the electrospray process from the ambient air (protonated (Si(CH3)20)6, m/z
445.120025) was used for internal recalibration in real time. MS/MS analysis was done in
data-dependent mode (DTA) using Xcalibur software (Thermo Scientific, Waltham, MA, US)
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with target ions previously selected for the MSIMS dynamically excluded for 30 sec. To
ensure the stability and repeatability of the LC-MS systems, ten runs of pooled samples were
done on the system before the sample run sequence. Samples were run in an order that
alternated the CTR and CA/CPR2 groups to reduce any systematic error associated with
instrumental drift.
Untargeted metabolomics data processing and statistical analysis
All LC-MS files were analyzed using the MS label free differential analysis software SIEVE
v 1.3 (Thermo Fisher, Cambridge, MA, US). SIEVE was run on all the LC-MS full-scan
chromatograms using the small molecule setting. The chromatograms were time-aligned,
referencing the CA/CPR2 sample acquired in the middle of the sequence. The framing
parameters were set at 0.01 Da for the mlz window and 0-35 min for the retention time (RT)
window; 500,000 was used as the intensity threshold. Prior to performing any statistical
analysis, an additional filtering criteria was applied to include in the dataset only frames with
an intensity coefficient of variation (CV%) <10. The preprocessed results were then fed into
the SIMCA-P 13 (Umetrics, Umea, Sweden) platform for multivariate analysis. Principal
component analysis (PCA) was performed on intensity data, preprocessed using the Pareto
scaling, to examine cluster and outliers within the observations. All analyses were performed
on data from both ion modes separately. Univariate analysis was performed using a 2-tailed
Welch t-test (p<O.OI; Prism v. 5.0, GraphPad Software Inc, USA) to identify metabolites
presenting intensities significantly different in the two experimental groups.
Identification of plasma metabolites
For metabolite identification, the frame m/z values were used for batch searches on the
METLIN database (http://metlin.scrpss.edu) and Human Metabolome Database (HMOB,
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http://www.hmdb.cal). Both sites allow the user to search by ionization mode, either positive
or negative. Accurate mass data and isotopic distribution for the precursor and product ion
were compared to spectral data of the reference compounds in the databases. Definite
identifications were reported only for metabolites with accurate mass match <5 ppm.
Mapping metabolic pathways
For biological interpretation of the metabolite dataset by our untargeted strategy, we mapped
the identified metabolites to the KEGG pathway database (Kyoto Encyclopedia of Genes and
Genomes; (www.genome.jp/kegg/).using MetaboAnalyst 2.0, a comprehensive online tool
suite for metabolomic data analysis and interpretation (www.metaboanalyst.ca). Metabolite
sets were analyzed to identify biologically meaningful patterns that were significantly
enriched in our metabolomic data. The Over Representation Analysis (ORA) algorithm was
applied and the hypergeometric test was used to see whether a particular metabolite set was
represented more than expected by chance in the given compounds list. Then the Pathway
Analysis Module was used to combine the enrichment analysis results with the pathway
topology analysis (centrality measures to estimate node importance) to identify the most
important pathways involved in early CPR (Xia 2011).
Absolute quantification of plasma TRP metabolites by LC-MRM coupled with isotope-
dilution mass spectrometry
The absolute quantification ofTRP metabolites was performed in plasma obtained from a total
of 6 rats subjected to cardiac arrest and CPR and sacrificed 2 hr after resuscitation (by adding
three additional experiments to the earlier ones), as previously described. A control group
(eTR, n=6) was selected from rats not subjected to cardiac arrest (by adding three additional
controls to the earlier ones). Plasma (20 J.1L)from each animal in each experimental group was
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spiked with 10 IlM of deuterated standards (tryptophan-D8, L-kynurenine-D4, kynurenic acid-
05, 3-hydroxyanthranilic acid-D2). Spiked plasma samples were then deproteinized by mixing
with four volume of cold methanol, vortexed, and incubated at -20oe for I hr. Samples were
centrifuged 10 min at 14.000 x g, the supernatant was collected, and the centrifugation was
repeated. The supernatant was dried in a SpeedVac and resuspended in 20 microL of 0.1%
formic acid. Ten ul, of supernatant were analyzed directly by Le-MS/MS with the Agilent
1200 series system for Le. Separation was with a Synergy 4u Fusion-RP 80A column
(50x2.00 mm, Phenomenex) using as mobile phase A 0.1% formic acid in water and mobile
phase B 100% acetonitrile at a flow rate ofO.2 mLlmin. Elution started with 99% of A and 1%
of B, followed by a 13-min linear gradient to 99% of B, a 2-min isocratic elution and a l-min
linear gradient to 99% of A, which was maintained for 8 min to equilibrate the column. The
mass spectrometric analysis was done using an Agilent 6410 triple quadrupole mass
spectrometer (Agilent Technologies) in positive ion mode for all the metabolites. Typical
chromatograms from the analysis of rat plasma are presented in Figure 20. Instrumental
conditions optimized for each compound are summarized in supplementary Table 1
(Appendix). Quantitative analyses were processed with MassHunter workstation quantitative
analysis software v B.01.04 (Agilent Technologies).
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Figure 20_ HPLC-MRM chromatograms of tryptophan, L-kynurenine, kynurenic acid, 3-hydroxyanthranilic acid,
5-hydroxyanthranilic acid, 5-hydroxyindoleacetic acid and their deuterated isotopes in rat plasma sample.
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Performance of the quantification method
The performance of the method was assessed in rat plasma samples for all the TRP
metabolites. Recoveries and repeatability were assessed by analyzing rat plasma samples in
five replicates. Since plasma already contained substantial amounts of metabolites, the
samples were spiked with 1 J..lMof KYN, KYNA, 3-HAA, and 180 J..lMof TRP before
extraction and processed as previously described. Known amounts of deuterated isotopes (l0
picoM) were then added to samples before Le-MS/MS analysis. Blank samples (water + 0.1%
formic acid) were analyzed in each analytical run to test and correct bias. Instrumental
quantification limits (lQL) were determined by directly injecting standard solutions with
increasing amounts of each metabolite. The limits of quantification (LOQ) for the whole
method were calculated directly from extracted samples as the concentrations giving peaks
with a signal-to-noise ratio of 10. The linearity of the calibration curves was tested in the
concentration ranges normally measured in rat plasma and a calibration curve was injected
during each analytical run to check for the linearity (correlation factors) and the instrumental
repeatability. Intra- and inter-day instrumental repeatability and precision were also assessed
by replicated injections of standard mixtures and rat plasma samples.
Targeted metabolomics statistical analysis
Metabolite concentrations in different experimental groups were compared by one-way
ANOV A followed by a multiple comparison test (Tukey Kramer HSD test) computed using
Prism v. 5.04 (GraphPad Software Inc, USA). The limit of statistical significance was set at p
<0.05.
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• STUDY 2: Validation ofKP activation after cardiac arrest with experimental models
in rats and pigs and in a small cohort of cardiac arrest patients
Rats
Animal preparation - Twenty four male Sprague-Dawley rats (Harlan, Italy) weighing 460 ±
17 g were used for the study. Animals were housed two per cage in a temperature (21 ± 1 "C)
and humidity (60%) controlled environment. The light schedule was 12 hr light and 12 hr
dark, light on at 7:00 a.m. Animals were fasted overnight except for free access to water. The
details of the animal preparation were published previously (Sun 2010). In brief, the animals
were anesthetized by intra-peritoneal injection of pentobarbital (50 mg/kg), and additional
doses (10 mg/kg) were administered at intervals of approximately I hr or when required to
maintain anesthesia, except that no anesthetic agents were administered for 30 min before
induction of cardiac arrest. The trachea was orally intubated with a 14-gauge cannula. A PE-
SOcatheter (Becton Dickinson, Franklin Lakes, NJ) was advanced into the descending aorta
from the left femoral artery for measurement of arterial pressure and sampling arterial blood.
Through the left external jugular vein, another PE-50 catheter was advanced into the right
atrium for measurement of right atrial pressures. Aortic and right atrial pressures were
measured with reference to the mid chest with high-sensitivity transducers. A 3-F PE catheter
(model C-PMS-30tJ, Cook Critical Care, Bloomington, IN) was advanced through the right
external jugular vein into the right atrium. A pre-curved guide wire supplied with the catheter
was then advanced through the catheter into the right ventricle and confirmed by endocardial
electrocardiogram for inducing VF. All of the catheters were flushed intermittently with saline
containing 2.5 IV/mL of crystalline bovine heparin. A conventional lead II electrocardiogram
was continuously monitored. Temperature was continuously monitored with the aid of a rectal
probe and maintained at 37 ± 0.5 °C throughout the experiment.
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Experimental procedures - Fifteen min before inducing VF, baseline measurements were
obtained and mechanical ventilation was initiated with an inspired Fi02 of 0.21. VF was
electrically induced with progressive increases in 60-Hz current to a maximum of 4 mA
delivered to the right ventricular endocardium. The current flow was continued for 3 min to
prevent spontaneous defibrillation. Mechanical ventilation was stopped after the onset of VF.
Precordial compression was begun after 6 min of untreated VF with a pneumatically driven
mechanical chest compressor as previously described (Sun 2010). Coincident with the start of
precordial compression, animals were mechanically ventilated at a frequency of SO/minwith a
tidal volume 0.6 ml/lOOg and a Fi02 of 1.0. Precordial compression was maintained at a rate
of 200/min with equal compression-relaxation duration (i.e., 50% duty cycle) and a depth of
compression equal to 25% of the animal's anterio-posterior chest diameter. Epinephrine (0.02
mg/kg) was injected into the right atrium 2 min after the start of precordial compression. After
6 min of CPR, resuscitation was attempted with up to three 2 Joule defibrillations
(CodeMaster XL, Philips Heartstream, Seattle, WA). Successful resuscitation was defined as
the return of supraventricular rhythm with a mean aortic pressure (MAP) > 50 mmHg for a
minimum of 5 min. Following resuscitation, animals were monitored for 4 hr. All catheters
and endotracheal tubes were then removed. The animals were returned to their cages and were
observed for up to 3 days after resuscitation. Animals were sacrificed with an intra-peritoneal
injection of pentobarbital sodium (150 mg/kg) at different intervals: baseline, before cardiac
arrest (healthy rats, n=7); 2 hr post-resuscitation (n=6); 4 hr post-resuscitation (n=6); and 3
days post-resuscitation (n=5). Plasma was withdrawn for KP assessment and biochemical
analyses. Blood was collected into EDTA-tubes and centrifuged for 15 min at 3.000 rpm at 4
DC. Plasma samples were then stored at -80 DC. The heart was quickly removed from the
thoracic cavity and frozen at -80 DCfor biochemical analyses.
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Measurements - Aortic, right atrial pressures, and ECG were continuously recorded on a
personal computer-based data acquisition system supported by CODAS hard hardware and
software (DataQ, Akron, OH). Coronary perfusion pressure was calculated as the difference
between aortic and time-coincident right atrial pressures. Myocardial function was assessed by
transthoracic echocardiography (Aloka SSO-5500, Tokyo, Japan) by using a 13-Mllz linear
transducer at high frame rate imaging (57 Hz). Short- and long-axis 20 views and M-mode
were analyzed in real-time and recorded on a magneto-optical disk for off-line analysis.
Anterior and posterior end-diastolic and end-systolic wall thicknesses and LV internal
dimensions were measured, as recommended by the American Society of Echocardiography,
as previously reported (Fiordaliso 2005). LV end-diastolic volume, LV end-systolic volume, and
LV EF were calculated by modified Simpson's single-plane rule from a long-axis view. Aortic
outflow and transmitral LV inflow velocities were measured from 5 and 4 apical chamber
views respectively by pulsed- wave Doppler. All Doppler spectra were recorded for 5-10
cardiac cycles at a sweep speed of 100 mm/s. The color Doppler preset was at a Nyquist limit
of 0.44 m/s, Plasma high sensitivity cardiac troponin T (hs-cTnT) concentration was assessed
with an electrochemiluminescence assay (ECLIA, Elecsys 2010 analyzer, Roche Diagnostics,
Germany). Heart isoprostanes were assessed by a commercially available ELISA (Cayman
Chemical, Ann Arbor, MI, USA) method according to the manufacture's instruction.
Pigs
Animal preparation - Ten male domestic pigs, 4 months of age, were used for this study (Fries
2012). The animals were supplied by a single-source breeder, weighed 36 ± 2 kg, and were
housed in an air-conditioned room with a 12-hr light-dark cycle from 6:00 am to 6:00 pm. Pigs
were anesthetized with an intramuscular injection of 4 mg/kg azaperone, followed by an ear
vein injection of 15 mg/kg sodium pentobarbital. The anesthetized animals were then
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intubated and mechanically ventilated (Sulla 808-V, Drager AG, LUbeck, Germany) with a
Fi02 of 0.21 and a tidal volume of 15 mLlkg. A continuous infusion of pentobarbital (4
mg/kglhr) was maintained during the preparation period but was discontinued 30 min before
the induction of VF. Thirty min after successful resuscitation, anesthesia was resumed until 2
hr before animals were weaned from the ventilator and brought back to their housing. The
respiratory frequency was adjusted to maintain an end-tidal CO2 between 35 and 40 mmHg.
Sonographic imaging of the groin allowed for the percutaneous insertion of catheters into
femoral artery and vein. Under fluoroscopy, a fluid-filled catheter was advanced from the left
femoral artery into the abdominal aorta (AKS-1830, CODAN pvb Medical, Forstinning,
Germany), and a pentalumen pulmonary artery flotation catheter was flow-directed from the
left femoral vein into the pulmonary artery (744F75, Edwards Lifesciences, Irvine, CA). To
induce VF, a 5F pacing catheter was advanced (again, under fluoroscopy) from the surgically
exposed left cephalic vein into the right ventricle. The blood temperature was maintained at
38.2 ± 0.2°C during the preparation phase using a convective blanket that allowed for either
heating or cooling the animals (Warm Touch 5200, Tyco Healthcare, Pleasanton, CA). To
ensure adequate hydration, a continuous infusion of Ringer's solution was administered at 4
ml./kg/hr throughout the experiment (Fries 2012).
Experimental procedures - Cardiac arrest was induced with 1-2 mA of alternating current
delivered to the endocardium of the right ventricle, resulting in VF. Simultaneously,
mechanical ventilation was discontinued. Ten min after the onset of VF, precordial
compression was initiated using a piston-driven chest compressor (Thumper 1007, MI
Instruments, Grand Rapids, MI) at 100 compressions per min. The compressions were
synchronized with the simultaneously restarted mechanical ventilation to provide a
compression/ventilation ratio of 30:2, with equal compression/relaxation intervals (i.e., a 50%
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duty cycle) and a compression depth of 25% of the chest diameter. The ventilation was
adjusted to deliver a tidal volume of 15 mLlkg and the Fi02 was increased to 1.0. After I min
of precordial CC, a bolus dose of 0.03 mg/kg epinephrine was injected into the right atrium via
the pulmonary artery flotation catheter. After 6 min of precordial compression, DF was
attempted with up to two l50-J biphasic shocks (M-Series CCT, Zoll Medical Corporation,
Chelmsford, MA). If an organized rhythm with a MAP of> 60 mmHg persisted for 5 min, the
animal was regarded as successfully resuscitated. If VF was not successfully reversed, I min
of CC preceded the delivery of another sequence of up to two shocks (Fries 2012). After
successful resuscitation, animals were randomized to therapeutic hypothermia (n=5) or
normothermia (n=5). To mimic a relevant clinical scenario, hypothermia was initiated I hr
after successful resuscitation and was induced by infusing 1 L of ice-cold (6°C) saline over a
period of 30 min. In addition, surface cooling was performed using ice-water-fiIled bags that
were positioned on the inguinal region. A target temperature of 33°C was maintained by the
use of the above-mentioned convective blanket. To avoid shivering during the procedure, all
animals, including the control group, received a continuous infusion of 0.1 mg/kg/hr
pancuronium. At the end of the 16 hr cooling period, the animals were allowed to rewarm
slowly at a rate not exceeding IOClhr. Animals were ventilated with a Fi02 of 0.3 during the
whole post-arrest period. To further evaluate the role of KP pathway in the pathophysiology of
post-cardiac arrest syndrome and more specifically of post-cardiac arrest brain injury, KP
metabolites were also assayed in an additional group of pigs (n=5), subjected to the same
experimental procedure described above, with the exception of an additional known brain
protective treatment, namely xenon. Thus, after successful resuscitation, FI02 was reduced to
30% and the animals were ventilated for 1 hr with a gas mixture of 70% xenon (Fries 2008).
To ensure adequate pain relief, all pigs received an intramuscular injection of 0.1 mg/kg
buprenorphine, Catheters were then removed and animals weaned from the ventilator.
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Following the extubation, every animal was observed for at least 30 min to ensure adequate
spontaneous breathing before being returned to their room. Animals were observed for
additional 5 days (Fries 2012).
Measurements - Dynamic data, including MAP, were continuously measured and recorded
(AS/3 Compact; Datex-Ohmeda, Achim, Germany). CO and blood temperature were
measured and recorded using a Vigilance monitor (Edwards Lifesciences, Irvine, CA). On
each day post arrest, animals were evaluated using a validated neurologic deficit score (NDS),
as has been described in previous studies (Fries 2012). In brief, the test consisted of four items
representing the level of consciousness, respiration, posture, and feeding behavior. Each of the
items was graded by severity and given a score. A score of 100 represented no neurologic
impairment, while 0 signified brain death. Five days after successful resuscitation, animals
were re-anesthetized as described above. After surgical exposure, large-bore catheters were
introduced into both carotid arteries and external jugular veins. A buffered 4%
paraformaldehyde solution was then anterogradely injected into the carotid arteries until the
effluent from the external jugular veins cleared. The brains were then carefully removed from
the skulls and placed in identical fixatives for 14 days. Standardized coronal slices were taken
at a thickness of 4-5 mm, resulting in a total of 14-15 slices. The anterior and posterior CA I
sectors, respectively, of the hippocampus and occipital neocortex were chosen as the regions
of interest, and were then paraffin embedded. In addition to conventional hematoxylin and
eosin staining, immunohistochemical reactions were used to visualize reactive astrogliosis
(polyclonal rabbit anti-glial fibrillary acidic protein). An experienced neuropathologist, who
was blinded to the treatment of the animals, graded the degrees of histopathological alteration
(Fries 2012). Briefly, for each region of interest, the proportion of neurons with
hypereosinophilia, shrunken cytoplasm, and pyknotic nuclei (which are indicative of
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ischemically induced necrotic damage) was graded into five categories (l = 00/0-10%; 2 =
100/0-20%; 3 = 200/0-50%; 4 = 500/0-80%; and 5 = 800/0-100%). Reactive astrogliosis was
graded on a semiquantitative, 4-point scale (0 = absent; I = mild; 2 = moderate; and 3 =
severe). The results of these scales for each region of interest were then summed to yield an
overall neurohistopathological severity score.
Humans
Patients - Clinical validation of animal results was performed in plasma obtained from 5
patients resuscitated from non-traumatic out-of-hospital cardiac arrest. These patients were
prospectively studied in another trial that has been previously published and in which the
influence of TB on S-100b values after cardiac arrest has been studied (Derwall 2009, Stoppe
2012). Exclusion criteria were age less than 18 years, severe pre-existing conditions including
sepsis, stroke, previous CPR and cancer. Cardiac arrest was defined as the absence of
respiration, palpable pulse and responsiveness to stimuli. CPR was performed in accordance to
the European Resuscitation Council's (ERC) guidelines 2005. After recovery of blood
pressure and pulse for more than 1 hr after admission to the hospital, CPR was considered as
"successful" and patients were included in this study (Derwall 2009, Stoppe 2012). After
completion of CPR and admission to the hospital, all patients were transferred to the ICU and
received standardized intensive care treatment including mechanical ventilation, fluid
substitution, tight glucose control, sepsis and vasopressor treatment. The initiation of mild TH
was left at the discretion of the attending physicians since not being a standard
recommendation in the earlier ERC guidelines. TH was induced using ice bags and infusion of
cold fluids. Among the 5 cardiac arrest patients included in the study, 3 received hypothermia
treatment, while 2 did not. Tracheal extubation was performed when standard extubation
criteria were fulfilled. Patients were discharged from the ICU after fulfillment of standardized
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clinical discharge criteria. Three healthy volunteers served as control for plasma measurement
of KP metabolites.
Data collection - Clinical data were collected 1 hr after ICU admission and 3 days later, using
a web-based data entry system complying with the Utstein-Style, initiated by the German
Society of Anaesthesia and Intensive Care Medicine as part of a quality assurance system. A
standardized neurological assessment was performed by an independent physician, using the
CPC after 14 days. CPC 1 and 2 were considered as favorable neurological outcome, whereas
CPC 3 to 5 labeled adverse outcome (Derwa/l 2009. Stoppe 2012). Serum samples for the
determination of C-reactive protein (CRP), PCT, tumor necrosis factor alpha (TNF-a), IL-6
and 8, macrophage inhibitor factor (MIF), and KP metabolites, were taken at the same time
points. The inflammatory cytokines IL-6, IL-8, TNF-a and the biomarkers CRP, PCT were
quantified using commercially available automated systems (LIAison, DiaSorin, Dietzenbach,
Germany, and KRYPTOR, Brahms AG, Hennigsdorf, Berlin, Germany). The serum levels of
MIF were determined using an enzyme-linked immunosorbent assay (ELISA) (Stoppe 2012).
TRP and KP metabolites measurements
Absolute quantification of plasma TRP and KP metabolites was performed by LC-MRM
coupled with isotope-dilution MS. Metabolites assayed included: TRP; KYN; KYNA; 3-HAA.
Plasma samples (20 ul.) from rats, pigs and humans were spiked with 10 IlM of deuterated
standards (tryptophan-D8, L-kynurenine-D4, kynurenic acid-Do, 3-hydroxyanthranilic acid-
D2). Spiked plasma samples were then deproteinized by mixing with four volume of cold
methanol, vortexed, and incubated at -20°C for lh. Samples were centrifuged 10 min at 14.000
x g, the supernatant was collected, and the centrifugation was repeated. The supernatant was
dried in a SpeedVac and re-suspended in 20 ul, of 0.1% formic acid. Ten JlL of supernatant
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were analyzed directly by LC- tandem MS, with the Agilent 1200 series system for LC.
Separation was performed with a Synergy 4u Fusion-RP 80A column (50x2.00 mm,
Phenomenex) using as mobile phase A 0.1% formic acid in water and mobile phase B 100%
acetonitrile at a flow rate of 0.2 mLimin. Elution started with 99% of A and I% of B, followed
by a I3-min linear gradient to 99% of B, a 2-min isocratic elution and a I-min linear gradient
to 99% of A, which was maintained for 8 min to equilibrate the column. The mass
spectrometric analysis was performing using an Agilent 6410 triple quadrupole mass
spectrometer (Agilent Technologies) in positive ion mode for all the metabolites. Quantitative
analyses were processed with MassHunter workstation quantitative analysis software v
B.01.04 (Agilent Technologies). Assay performance in terms of linearity, sensitivity,
analytical recovery and instrumental repeatability was assessed in plasma samples for all the
tryptophan metabolites. The instrumental sensitivity was good and the IQLs ranged from
0.0015 to 0.25 pmoles/injected. LOQs in rat plasma ranged between 0.55 and 6 nM. The
recoveries in plasma were higher than 60% for all the metabolites. The analytical response
was linear for all the compounds in the range of concentrations measured in plasma and the
inter-day correlation factors (r2) were ~ 0.9994 with standard deviations (SD) ~ 0.0007.
Instrumental repeatability, assessed using replicate injections of standard mixtures and plasma,
was generally ~ 10%.
Statistical analysis
Normal distribution of the data was confirmed using the one sample Kolmogorov-Smirnov Z
test. For comparisons among time-based measurements within groups, one-way ANOYA with
Tukey Kramer's multiple comparisons was used. Linear correlations were calculated using the
Pearson correlation coefficient. All data are reported as mean ± SEM. A 2-tail p < 0.05 was
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considered as statistically significant. All analyses were performed by SPSS 16 (SPSS Inc,
Chicago, IL).
• STUDY 3: Validation of KP activation after cardiac arrest in a large cohort of out of
hospital cardiac arrest patients
Included patients - Patients included in the present study were part of the FINNRESUSCI
study, which was a prospective observational cohort study conducted at 21 hospitals in
Finland between March 1sI 2009 and February 29th 2010 (Vaahersalo 2013). The study was
approved by the ethic committees of each participating hospital. Informed consent from the
patient next of kin was obtained for data collection and blood sampling. For this study we
included patients with VF/VT as the initial rhythm, in whom blood samples were obtained at
ICU admission. Blood was drawn also from 10 healthy volunteers who were matched by age
and sex with patients.
Blood samples - Blood samples were collected into ethylenediaminetetraacetic acid (EDTA)
tubes, centrifuged and plasma stored at -70°C. Upon analysis. samples were thawed and
divided into aliquots. Plasma levels of TRP and its metabolites, KYN, KYNA and 3-HAA
were measured blinded to case identity using HPLC coupled MS. We used blood samples
from healthy subjects to serve as controls. Briefly. human plasma samples (100 J.1L)were
mixed with 10 J.1L of internal standard (IS, 5-HTRP, 1 ng/J.1L final concentration),
deproteinized by adding 400 J.1Lof cold methanol and incubating for 1h at -20°C. After
sample centrifugation for 10 min at 14.000xg, the supernatants were collected and centrifuged
again. Supernatants were dried under nitrogen flow, and residues were dissolved in 100 J.1Lof
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I% acetonitrile in 0.1% formic acid, transferred to autosampler vial insert and 40 J.lL of
supernatant were injected directly in tha HPLC system (Alliance separation module 2695,
Waters, Milford, MA, USA). The chromatographic separation was obtained with an Accucore
PFP column (150 x 2.1 mm; 2.6 urn particle size Thermo-Scientific), at a flow rate of 0.2
mLimin. Elution started with 99% of mobile phase A (0.1% formic acid in water) and 1%
mobile phase B (100% acetonitrile) for 2 min, followed by a 18-min linear gradient to 50% of
A, a l-rnin linear gradient to 30% of A and a l-rnin linear gradient to 99% of A which was
maintained for 12-min to equilibrate the column. The total run time was 35 min. The mass
spectrometric analysis was performing using a Micromass Quattro Micro API triple-
quadrupole (Waters, Milford, MA, USA) in positive ion mode and MRM mode, measuring the
fragmentation products of the deprotonated pseudo-molecular ions. The choice of
fragmentation products for all compounds and the optimization of collision-induced
dissociation energies (EC) were done in continuous-flow mode, using standard solutions at
concentrations of 10 ng/ul, for all compounds. Data were processed with the MassLynx
software (Waters, Milford, MA, USA). Plasma concentrations of TRP and KYN were
expressed in micromolar, and KYNA and 3-HAA in nanomolar.
Data collection - The participating hospitals were a part of the Finnish Intensive Care
Consortium (FICC) and all 21 ICUs used the same electronic data management systems and
data validation software (Web Validator, Tieto, Helsinki, Finland). Data of study patients were
prospectively collected using an Internet-based case report forms (CRF). Pre-hospital data was
collected by the paramedics in accordance with the Utstein Guidelines and included whether
the arrest was witnessed or not, the administration of bystander initiated life support (BLS),
time from call to the dispatch centre and to ROSC and the use of adrenaline (Langhelle 2005).
In-hospital care data were collected electronically and comprised the Simplified Acute
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Physiology Score (SAPS) II score and ICU and hospital mortality. For the present trial we
used SAPS II score derived systolic blood pressure (SAP) and bicarbonate to define the
severity of post cardiac arrest shock.
Survival and neurological outcome - Time of death was recorded for each patient. A specialist
in neurology blinded to management in the ICU contacted patients discharged from the
hospital by phone one year after cardiac arrest and determined neurological outcome
according to the CPC score (Langhelle 2005). We defined good neurological outcome as CPC (1-
2) and poor neurological outcome as CPC (3-5).
Statistical analysis - Descriptive statistics were calculated using counts and percentages for
categorical variables. Median values with interquartile range (lQR) were calculated for
continuous variables. Levels of KP metabolites across variables at admission were compared
by Chi-square,' Mann-Whitney V and the Kruskal- Wallis test and changes over time were
analysed using the Wilcoxon signed rank test for paired data. Multivariable linear regression
was used to identify the independent factors at resuscitation influencing metabolite levels on
ICU admission. Results of linear regression are reported in terms of beta coefficients with
95% confidence interval (Cl) and p-values. Multivariable logistic regression was used to
identify factors at resuscitation that were predictors of ICU mortality and poor neurological
outcome at 12 months from the arrest. All variables associated with the outcome in univariate
analysis (p<0.05) were included in the multivariable model. Each KP metabolite was included
separately in the model as continuous variables. Odds ratios (OR) with the corresponding 95%
Cl were calculated and p values were considered statistically significant if they were less than
0.05. The addition of new predictive variables into a model was assessed by comparing the
area under the curve (AVC) between models using a non-parametric method (DeLong /988). All
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statistical analyses were performed using IBM SPSS version 19.0 and Analyze-it® (Analyse-
it Software, Ltd. http://www.analyse-it.com/; 2009)
• ECG-DERIVED BIOMARKERS:
• STUDY 4: AMSA evaluation in 609 VF patients in the United States
Included ECGs - A database of ECG traces recorded during pre-hospital CPR, including 1410
DFs, obtained from 748 patients between 2005-2007, was available through the courtesy of
ZOLL Medical Corporation (Chelmsford, MA, USA). ECGs were recorded from defibrillation
pads using ZOLL AED PLUS and ZOLL AED PRO in multiple emergency medical systems
in the United States through a regular field case submission program. The electronic data did
not contain any patient identifiable information, accordingly to Health Insurance Portability
and Accountability Act (HIPAA) regulations.
ECG analyses - ECGs were recorded at a sample rate of 250 Hz. The AEDs provided a single
rectilinear biphasic waveform shock of 120 Joules for the first OF, and 150 or 200 Joules for
the subsequent DFs. The AMSA analysis has been previously described (Young 2004, Ristagno
2008b). Briefly, ECG signals were processed using a 2 Hz high-pass filter to minimize low
frequency artifacts produced by CC and a 48 Hz low-pass filter to remove interference of
ambient noise at higher frequencies. Analog ECG signals were digitized and converted from a
time to a frequency domain by FFT. AMSA was calculated as the sum of the products of
individual frequencies and their amplitudes (Figure 21):
AMSA = L Ai . Fi
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where Ai represented the amplitude at ;th frequency Fi.
The analysis was performed during hands off time on a 512 point window (2.05 sec) ending
0.5 sec prior to the DF.
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Figure 21. Fast Fourier Transformation with
AMSA calculation.
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A Tukey FFT window was used to reduce edge effects. More specifically, Tukey window
(r=0.2) was calculated as:
N
XOO =Lx(j)w2-1)(k-1.)
j=l
-2ui.
where xtj) is the ECG data points, (UN = e-;r is an Nth root of unity and X(K) is the FFT
coefficient of the associated frequency component. The absolute value of X(K) was then
obtained to represent the amplitude of the signal at the frequency domain.
A(f) = abs(X(K) ), [=0:0.488: 125, K= I: 1:257
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For the purpose of this study, the DF outcome was defined according to the following
established criteria (Ristagno 2008b): "successful defibrillation" or return of a potentially
perfusing rhythm, if DF restored an organized rhythm with heart rate 2: 40 beats/min
commencing within 60 sec post shock; and "unsuccessful defibrillation" or failure of return of
a potentially perfusing rhythm, if VF/VT, asystole, or pulseless electrical activity with pauses
> 5 sec occurred. Only ECG recordings with adequate pre- and post- DF durations and in
which DF outcome could be confirmed were included in the study: 1260 instances from 609
patients. In addition, subsequent DFs were classified as being for recurrent VF if the preceding
DF was successful, or for refractory VF if the preceding DF had failed to restore a potentially
perfusing rhythm (SIIannlllga,'Oullllaram 2012). A sub-group analysis was conducted on DFs
obtained from 303 patients, for whom CC depth data were available. Depth of CC was
measured from an accelerometer used for CPR feedback and registered by the AEDs. Changes
in AMSA between consecutive DFs were analyzed in relationship to the 2005 recommended
CC depth> 1.5 inches (in) (AHA guidelines 2005).
Statistical analysis - AMSA was computed using Matlab 7.2 (Math Works, Natick, MA). Two
independent readers reviewed the ECG recordings to confirm DF outcomes. Differences in
AMSA between DFs were analyzed by analysis of variance (ANOVA) with Scheffe's method
for multiple comparisons. A range of AMSA thresholds was evaluated. The sensitivity,
defined as the capability of AMSA to identify DFs that successfully reestablished a potentially
perfusing rhythm, was calculated as the number of correctly predicted successful DFs divided
by the total number of successful DFs. The specificity, which refers to the capability of
AMSA to identify failure of a DF, was calculated as the number of correctly predicted
unsuccessful DFs divided by total number of unsuccessful DFs. The PPV referred to the
proportion of DFs that were correctly predicted by AMSA to restore a potentially perfusing
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rhythm. The NPV represented the proportion of DFs that were correctly predicted by AMSA
to fail. The accuracy was calculated as the proportion of true results (both true positively
predicted successful DFs and true negatively predicted unsuccessful DFs) in the population.
Finally, ROC curve analysis was performed. SPSS 16.0 (SPSS Inc., Chicago, IL) was used. A
value ofp<0.05 was regarded as statistically significant. Data are presented as mean ± SEM.
•. STUDY 5: AMSA evaluation in 1.617 VF patients in Lombardia region, Italy
Included EeGs and patients - A database of ECG traces recorded during pre-hospital CPR,
including 2.442 DFs, obtained from 1.050 patients enrolled in 9 cities in Regione Lombardia,
Italy between 2008-2009, was used as derivation group. An additional database of ECG traces
recorded during pre-hospital CPR, including 1.386 DFs, obtained from 567 patients enrolled
in the same cities in Regione Lombardia, Italy in 2010, was used as validation group. ECG
traces were available through the courtesy of the EMS Regional Coordinating center "Azienda
Regionale Emergenze Urgenze" (AREU), Milan, Italy. The electronic data did not contain any
patient identifiable information. The study was approved by the ethic committee of
coordinating hospital, San Gerardo University hospital, Monza, Italy.
Data collection - The participating EMSs from the different cities were part of the AREU and
all used the same electronic data management system and data validation software
(EMMAweb, AREU, Milan, Italy). Data were prospectively collected using an Internet-based
CRF. Pre-hospital data were collected by the paramedics in accordance with the Utstein
Guidelines. In-hospital data, collected and stored electronically at the Regional database,
comprised: co-morbidities and drug treatment (over the last year prior to cardiac arrest),
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hospital survival, 6 month and I year survival. For the derivation group, data from the
Regional database were retrieved and linked to the EMMAweb database by the Department of
Clinical Medicine and Prevention CDIMEP), University of Milano-Bicocca, Italy.
ECG analyses - ECG parameters were computed using Matlab 7.2 (Math Works, Natick, MA).
ECGs were recorded from defibrillation pads using different AEDs: A. ZOLL Medical Corp.
(biphasic rectilinear DF waveform); B. Philips Health System (biphasic truncated DF
waveform); and C. PhysioControl Inc (biphasic truncated DF waveform), as reported in
Figure 22. The AEDs provided a single shock every 2 min of CC. ECGs were recorded at
different sample rates: 250 Hz for AEO A; 200 Hz for AED B; and 125 Hz for AED C.
Defibrillator-A: ZOll Med Corp.
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Figure 22. ECG traces and shock information recorded from the three different AEDs.
103
For each type of AED, the recorded waveforms were exported to a Matlab format for further
processing. The ECG traces were then re-sampled at 250 Hz using a polyphase filter
implementation. The re-sampling process was necessary due to different sample rates
employed by the different AEDs (Figure 23).
Figure 23. Converting ECG trace files into a
·.MAT(SI{~250) uniform .MAT format at a unique sample rate of
250 Hz.
Parsing Converting Resarnpllng
DefA(".ZOLl
I)cm(*.COl)l
After re-sampling, the analysis was performed during hands off time on a 512 point window
(2.05 sec) ending 0.5 sec prior to the OF (Figure 24). Each OF episode was then detrended by
subtracting the mean value. If the ECG in the selected window was corrupted by artifacts, the
ECG analysis was unreliable, and therefore the window was shifted backward until the ECG
was free from artifacts (Figures 25). A 512 points FFT was then computed from the 2.05 sec
data with a Tukey window, as reported in STUDY 4.
AMSA is calculated from ECGwaveform
extracted from window 1
15,----.--
Figure 24. Extracting a 2.05 sec ECG
waveform for VF features calculation
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Figure 25. On the left: Window I ECG corrupted by artifacts. On the right: Window I ECG shifted backward to
the artifact free ECG interval.
The root mean square (RMS) amplitude, which was defined as the square root of the average
of the squared values of the data points, was calculated as:
ffi1ARMS= N. 1l=
where xfi) denotes sample i in a detrended ECG episode of length N.
Peak frequency (PF), which denotes the frequency that corresponding to the maximum power,
was given by:
PF = arg max[A(f)]
Median frequency (MDF) represents the frequency that divides the signal in two regions
having the same amount of power:
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Mean frequency (MNF), which provides a smooth estimate of the concentration of spectral
power, is computed as:
where f1 and f2 (f2>f1) are the lower and higher frequency band limits.
AMSA, was calculated as reported in the STUDY 4.
DF outcome was defined according to the criteria reported above in STUDY 4 (Ristagno 2008
and 2013b): "successful defibrillation" or return of a potentially perfusing rhythm, if DF
restored an organized rhythm with heart rate 2: 40 beats/min commencing within 60 sec post
shock; and "unsuccessful defibrillation" or failure of return of a potentially perfusing rhythm,
if VF/VT, asystole, or pulseless electrical activity with pauses> 5 sec occurred. Only ECG
recordings with adequate pre- and post- DF durations and in which DF outcome could be
confirmed were included in the study (1.050 in the derivation group and 567 in the validation
one). In addition, for 860 patients in the derivation group, in-hospital and long-term outcome
were known arid additional analyses were performed.
Statistical analysis - Descriptive statistics were reported using counts and percentages for
categorical variables, mean with SD or median with IQR for continuous variables and
counting processes. Normal distribution of ECG-derived parameters was investigated. Linear
regression was used to investigate the association between relevant factors and ECG-derived
parameters values prior to DF. In the regression models, the natural logarithm of the ECG-
derived parameters was the dependent variable and age and gender were always introduced as
independent factors. All factors associated with the ECG-derived parameters in the univariate
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analysis (p<O.05) were included in the multivariate model. Results of linear regression were
reported including beta values and p-values. Comparisons of ECG-derived parameters mean
values between outcomes were performed using t-test or ANOVA, when adjusted for
confounding factors on the natural logarithm of the parameters. Logistic regression was used
to investigate the association between ECG-derived parameters and outcomes, i.e. OF
outcome, ROSC, and survival at hospital discharge, while Cox regression models were used
for survival at 6 months and 1 year. ECG-derived parameters were included separately in the
model as continuous variables. OR and Hazard Ratios (HR) with the corresponding 95% Cl
were reported for logistic models and Cox regression models respectively. We estimated both
unadjusted and adjusted relative risk (OR and HR). The estimates were adjusted for age and
gender and for factors that were predictors of outcomes in the multivariate models. The
discriminatory ability of ECG-derived parameters was measured as AVC using OF success
and ROSC as outcomes. AVC with 95% Cl and p-values for difference from chance were
reported. Differences among AVCs of ECG-derived parameters were tested assuming the
mathematical equivalence of the AVC to the Mann-Whitney If-statistic. Finally, sensitivity,
specificity, PPV, NPV and accuracy curves were computed to evaluate threshold values of
AMSA. All statistical analysis was performed using SAS version 9.2.
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• CIRCULATING BIOMARKERS:
• STUDY 1: Discovery of new circulating biomarkers with the aid of untargeted
metabolomics in a rat model of cardiac arrest
To initially explore the metabolome changes associated with the early post-resuscitation
phase, a plasma LC-MS/MS approach was used to discover unbiased small-molecule
metabolic profiles in rats not subjected to cardiac arrest (control, CTR) and in rats subjected to
cardiac arrest and CPR and sacrificed 2 hr after resuscitation. Mass-spectral data were subject
to peak alignment and data pre-processing by SIEVE 1.3. (Figure 26).
hroma Ol\ri!m iJlljlnmCnl..-~ Figure 26. Mass-. "._.1 spectral data were( .... subject to peak_
!. alignment and data" pre-proccesi ng by
SIEVE 1.3.
Data were then analyzed for global changes by using multivariate statistics to determine group
separation as well as univariate statistics to evaluate the number and percentage of features
that varied significantly between the 2 sample sets. As seen in Figure 27, PCA (principal
component I vs. principal component 2) revealed an excellent separation of the two
experimental groups under both positive and negative modes.
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Figure 27, PCA score plots of the
plasma profiling of rats not subjected to
cardiac arrest as control (CTR) and rats
subjected to cardiac arrest and
cardiopulmonary resuscitation,
euthanized 2 hr after resuscitauon
(CPR2h). Panel A. with the positive
ESI dataset. Panel B. with the negative
ESI dataset.
Up to 4.534 and 4.710 features respectively were detected in positive and negative ion mode.
1.306 features were detected in both sample sets, showing significant changes in their relative
signal intensity (defined as a 2::2-fold change with CV% ~10 and Welch's t-test p ~0.01)
(Supplementary Table S2, Appendix). Of these 1.306 features, 141 were related to molecular
species identified by database searches (METLfN and HMBO) and are listed III
Supplementary Table S3 (Appendix). It should be noted that a given molecule may be
represented by several different features, such as naturally occurring components of its
isotopic cluster or non-specific adduct ions. Several analytes were detected only in positive
mode, while others were observed only in the negative ion mode as already reported for
plasma samples. To further interpret the biological significance in the early post-resuscitation
phase, we used MetaboAnalyst tools to link these metabolites to metabolic pathways, as
described in Figure 28.
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Figure 28. Analysis of the metabolic pathways. Panel A gives the summary plot for the metabolite set
enrichment, panel B shows the difference in abundance of the metabolites, mapped into enrichment categories,
and panel C shows all metabolic pathways arranged according to the scores from enrichment analysis (y axis) and
topology analysis (x axis).
Analysis of the differences between the two datasets indicated that the beta-oxidation of fatty
acids, linolenic acid metabolism, tryptophan metabolisms and sphingolipid metabolism were
over-represented (Figure 28, panel A). The very early CPR phase (2h) showed plasma
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changes, although modest, in the composition of free fatty acids (FFA) compared to control.
For example there was a generally lower level of unsaturated FFA (e.g. linoleic, acid,
docosahexaenoic acid) and saturated acids (e.g. capric, myristic and dodecanoic acids). Rats
from the early CPR interval also had lower plasma levels for sphingoJipids such as sphiganine-
I-phosphate and sphingosine I-phosphate. Striking differences from controls were seen in
various intermediates of tryptophan catabolism through either kynurenine or a series of indoles
in the early post-resuscitation phase (Le. low level of indoxyl; higher levels of 5-
hydroxyindolacetic acid, formyl-5-hydroxykynurenamine, 4-(2-aminophenyl)-2,4-
dioxobutanoate, KYNA, indolelactic acids) (Figure 28, panel B). Pathway analysis (Figure
28, panel C) showed that the TRP metabolism was more likely to be significantly perturbed as
a consequence of early CPR and, depending on the location on the plot, changes in the
metabolites might have an impact on the pathway as inferred from pathway analysis reported
in Supplementary Table S4.
Absolute quantitation of circulating TRP metabolites
Because TRP metabolism was one of the most important pathways perturbed during the early
post-resuscitation phase, we explored whether the major route of TRP catabolism, the KP
played a role throughout a longer post-resuscitation observational period of prolonged
duration. We developed a highly sensitive and specific isotope dilution LC-MS/MS method
for accurately quantifying TRP, KYN, KYNA, and 3-HAA, in rat plasma at 2 hr after
resuscitation, compared to controls. Deuterated metabolites were added to plasma samples as
internal standards. We assessed the assay performance in terms of linearity, sensitivity and
analytical recovery. The instrumental sensitivity was good and the IQLs ranged from 0.0015
to 0.25 pmoles/injected. LOQs in rat plasma ranged between 0.55 and 6 nM (Table 7). The
recoveries in rat plasma were higher than 60% for all the metabolites (Table 7). The analytical
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response was linear for all the compounds in the range of concentrations measured in rat
plasma and the inter-day correlation factors (r) were ~ 0.9994 with standard deviations (SD) :s
0.0007 (Table 8). Instrumental repeatability, assessed using replicate injections of standard
mixtures and rat plasma, was generally :s 10% (Table 8).
Table 7. Tryptophan and its main metabolites (mean recovery ± SO), instrumental quantification limits (IQL),
and limits of quantification (LOQ) of the analytical method in plasma (5 replicates).
Chemicals Recovery % IQL LOQ
(mean ± SO) (pmoles/injected) (nM)
TRP 89±3.49 0.07 1
KYN 93±2.27 om 0.31
KYNA 93±2.17 0.0015 0.55
3-IIAA 65±2.36 0.02 5.43
Table 8. Linearity ranges and between-day correlation factors of the calibration curves (~± SO), intra- and inter-
day variability (relative standard deviation-RSO) in analytical standards and in plasma (5 replicates).
Chemicals Linearity Interday Intraday RSD Interday RSD Intraday
range correlation (%) (0/0) RSD(%)
(microM) factors (';%SD) Standard mixture Standard mixture Plasma
samples
I pmoles/inj I pmoles/inj
KYNA 0.025-16 0.9997±0.0002 2.17 1.21 1.67
3-HAA 0.025-16 0.9998±0.000 I 7.83 7.13 2.76
4 pmolcs/inj 4 pmoles/inj
KYN 4-64 0.999248±0.0005 6.47 10 5.30
0.5 nmoles/inj 0.5 nmoleslinj
TRP 12.5-500 0.9989±0.0007 4.49 4.17 9.04
Significant changes in plasma concentrations of TRP and the metabolites showed significant
differences from controls 2 hr after resuscitation (Figure 29). More specifically, TRP
decreased significantly, while KYN, KYNA and 3-HAA increased significantly compared to
control animals (Figure 29).
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TRP KYN
Figure 29. Rat plasma concentrations
of tryptophan (TRP) and its
metabolites at different
cardiopulmonary resuscitation phases
(CPR). Each bar represents the
metabolites' plasma concentration as
mean ± SD (n = 6 rats/group).
Asterisks mark significant
differences in expression (one-way
ANOVA, Tukey-Kramer HSD,
p<O.OS).
CrR, rats not subjected to cardiac
arrest, as control; CPR2h, rats
subjected to cardiac arrest and CPR,
euthanized at 2 hr after resuscitation;
KYN L-kynurenine; KYNA
kynurenic acid; 3-HAA 3-
hydroxyanthranilic acid.
*
• STUDY 2: Validation of KP activation after cardiac arrest with experimental models
in rats and pigs and in a small cohort of cardiac arrest patients
Rats. At 2 and 4 hr post-resuscitation resuscitation, plasma levels of TRP were significantly
KYNA
* 3-HAA,-L,
lower in cardiac arrest animals compared to healthy ones (p < 0.0 I, Figure 30). Plasma levels
80
of the TRP's metabolite KYN and its derivatives, KYNA and 3-HAA, significantly increased
60
:Ic
following resuscitation (p < 0.01 vs. healthy rats, Figure 30). Plasma levels ofTRP tended to
return to normal values 3 days after resuscitation (Figure 30). However, higher plasma
concentrations-of Kr'N, KYNA, and 3-HAA persisted (p < 0.01 vs. healthy rats, Figure 30).
Post-resuscitation LV systolic and diastolic dysfunction occurred in each rat, as evidenced by
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hemodynamic and echocardiographic data reported in Table 9.
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Figure 30. Kynurenine
pathway activation III rats
resuscitated from cardiac
arrest. Plasma concentrations
of trypthophan, L-
kynurenine, kynurenic acid
and 3-hydroxyanthrani Iic
acid in healthy rats and in
rats after 2 hours (h), 4 h,
and 3 days (d) post-
resuscitation (PR).
Data are reported as mean ±
SEM (n = 6 rats/group).
* p < 0.05 and ** p < 0.01
vs. healthy;
# p < 0.05 and ## p < 0.01
vs. PR 3 days;
§ p < 0.05 vs. PR 2 h.
Table 9. Hemodynamics, functional and histological outcome, and biomarkers in resuscitated rats.
Healthy PR 2 hr PR4 hr PR 3 days
MAP,rnmHg 136±2 105 ± 2** 105 ± 5** N.A.
CPP, mmHg 116±3 87 ± 2** 91±4** N.A.
EF,% 79±2 42 ± 5** 48 ± 6** 75 ± 3##§§
EDV, ilL 378 ± 24 446 ± 51 465 ± 57 280 ± 22*#§
SV,mL 0.34 ± 0.02 0.21 ± 0.02** 0.18 ± 0.02** 0.22 ± 0.02**
DT, msec 28.0 ± 3.9 18.8 ± 1.2 19.4±1.3 27.6 ± 2.8#§
hs-cTnT, ng/L 57 ± 18 4453 ± 615** 3874 ± 935** 669 ± 531##§
c-Isoprostanes,
7±2.2 57 ± 8** 47 ± 5** 14 ± 3.2##§§
pg/ug prot
MAP, mean arterial pressure; CPP, coronary perfusion pressure; EF, ejection fraction; SV, stroke volume; DT,
deceleration time; EDV, end diastolic volume; hs-cTnT, high sensitive cardiac troponin T; c-Isoprostanes, cardiac
isoprostane; PR, post-resuscitation, (n = 6 rats/group).
** p < 0.0 I and * p < 0.05 vs. Healthy or Baseline; ## p < 0.0 I and # p < 0.05 vs. PR 2 hrs;
§§ p < 0.01 and § p < 0.05 vs. PR 4 hrs.
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More specifically, marked decreases in MAP and CPP, LV EF, stroke volume, and
deceleration time of early mitral inflow, were observed at 2 and 4 hr post-resuscitation (p <
0.0 I vs. healthy rats, Table 9 and Figure 31). Changes in the echocardiographic parameters,
evaluating the severity of post-resuscitation LV dysfunction, were significantly and directly
related to changes in TRP and significantly inversely related to changes in KYNA and 3-HAA
(Table 10).
The severity of post-resuscitation myocardial injury was also reflected by the plasma levels of
hs-cTnT and cardiac isoprostanes, that significantly increased at 2 and 4 hr post-resuscitation
(p < 0.0 I vs. healthy rats, Table 9 and Figure 31). Changes in plasma levels of these
biomarkers of myocardial damage and oxidative stress were significantly inversely related to
the concurrent changes in TRP and significantly directly related to changes in KYNA and 3-
HAA (Table 10).
Figure 31. Left panel, post
resuscitanon LV ejection
fraction and right panel, high
sensitive troponin T, in control
rats (or baseline) and at 2, 4,
and 72 hr after resuscitation.
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Table 10. Correlation between KP metabolites and hemodynamics, myocardial function, and biomarkers in
resuscitated rats.
KP metabolite Variable r coefficient n value
EF 0.55 0.005
SV 0.53 0.011
TRP OT 0.699 0.000
hs-cTnT -0.501 0.017
c-Isoprostanes -0.516 0.014
EF -0.501 0.029
KYNA
SV -0.558 0.016
OT -0.523 0.026
hs-cTnT 0.641 0.004
EF -0.611 0.003
SV -0.598 0.004
3-HAA OT -0.470 0.031
hs-cTnT 0.581 0.006
c-Isoprostanes 0.523 o.ots
KP, kynurenine pathway; TRP, tryptophan; KYNA, kynurenic acid; 3-HAA, 3-hydroxyanthranilic acid; EF,
ejection fraction; CO, cardiac output; SV, stroke volume; OT, deceleration time; hs-cTnT, high sensitive cardiac
troponin T; c-Isoprostanes, cardiac isoprostanes.
Pigs. Similarly to rats, plasma levels ofTRP tended to decrease, while those ofKYN tended to
increase at 1 hr and 5 days post-resuscitation (p not significant, Figure 32). Plasma levels of
KYNA and 3-HAA significantly increased at 1 hr post-resuscitation compared to baseline
values (p < 0.01, Figure 32). These increased plasma concentrations of TRP's metabolites
persisted 5 days later (p < 0.05, Figure 32). Five days after cardiac arrest, animals that had
been subjected to hypothermia presented significantly higher plasma levels, approximately a
2-fold increase, of TRP, KYN, KYNA, and 3-HAA, compared to normothermic animals
(Figure 33).
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Figure 32. Kynurenine pathway
activation in 10 pigs
resuscitated from cardiac arrest.
Plasma concentrations of
trypthophan, L-kynurenine,
kynurenic acid and 3-
hydroxyanthranilic acid at
baseline (BL) and after I hour
(h), and 5 days (d) post-
resuscitation (PR),
Data are reported as mean ±
SEM,
* p < 0.05 and ** p < 0,01 vs.
BL;
# p < 0,05 vs, PR I h.
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Figure 33. Kynurenine pathway
activation and hypothermia in
pigs, 5 days after resuscitation
from cardiac arrest. Plasma
concentrations of trypthophan,
L-Kynurenine, kynurenic acid
and 3-hydroxyanthranilic in pigs
that had been subjected to
hypothermia or normothermia
after resuscitation,
Data are reported as mean ±
SEM, (n = 5 pigs/group),
*p<O,OI.
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Post-resuscitation myocardial dysfunction developed in each pig, as evidenced by the
hemodynamic measurements in Table 11. More specifically, lower MAP and LV CO were
observed at I and 4 hr post-resuscitation (p < 0.0 I vs. baseline, Table 11). These decreases in
MAP and CO were significantly inversely related to the increases in KYNA and 3-HAA
(Table 12). Neurological deficit score at day I, 3 and 5 post-resuscitation is reported in Table
11, together with cerebral histopathological scores, i.e. cortical and CA I hippocampal lesion,
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necrosis and astrogliosis. Early changes in 3-HAA were significantly directly related to the
severity of neurological deficit score (Figure 34) and to the histological alterations (Table
12). Overall changes in TRP were significantly inversely related to the severity of
hippocampal lesions (Table 12).
Table 11. Hemodynamics, functional and histological outcome, and biomarkers in resuscitated pigs.
Baseline PR I hr PR 4 hr
MAP, mmHg 121 ±4 76 ± 5** 86 ± 4**
CO, mLimin 5.8 ± 0.3 2.9 ± 0.3** 3.4 ± 0.2**
PR 1 day PR 3 days PR 5 days
(score) (score) (score)
NDS 66.5 ± 5.3 39.5 ± 10.3 41 ± 12.6
Brain lesion
Cortex 7.7± I
CAl 6.5 ± 0.7
Brain necrosis
Cortex 1.5 ± 0.2
CAl 2.4 ± 0.4
Brain astrogliosis
Cortex 1.4 ± 0.2
CAl 1.8 ± 0.25
MAP, mean arterial pressure; CO, cardiac output; NDS, neurological deficit score; CA I, CA I hippocampal
sector; PR, post-resuscitation; N.A., not available.
** p < 0.01 and * p < 0.05 vs. Healthy or Baseline.
Table 12. Correlation between KP metabolites and hemodynamics, myocardial function, and brain histology in
resuscitated pigs.
KP metabolite Variable r coefficient p value
TRP CAl lesions -0.728 0.017
MAP -0.799 0.000
KYNA CO -0.742 0.000
MAP -0.561 0.016
CO -0.729 0.001
3-HAA CA I necrosis 0.792 0.006
Cortical astrogliosis 0.778 0.008
NOS 0.744 0.014
KP, kynurenine pathway; TRP, tryptophan; KYNA, kynurenic acid; 3-HAA, 3-hydroxyanthranilic acid; CO,
cardiac output; MAP, mean arterial pressure; CA I, CA I hippocampal area; NDS, neurological deficit score.
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Figure 34. Correlation between early
changes in plasma level of 3-
hydroxyanthranilic acid and 3 day
neurological deficit score in pigs
resuscitated from cardiac arrest.
As expected animals treated with xenon showed a significantly better NOS through
postoperative days 1 to 3. On the first day following CPR, significantly more animals in the
control group were not able to stand up when compared with the animals treated with I hr of
xenon (7 of 8 vs. 1 of 8; p < 0.05). Strikingly, in animals subjected to this known
neuroprotective gas, post-resuscitation decreases in TRP and increases in 3-HAA were not
observed (p, not significant, Figure 35). On the contrary, KYNA significantly increased 5 day
post-resuscitation (p< 0.05 vs. baseline level, Figure 35).
Kynurenine pathway in xenon treated pigs after resuscitation
n=5
Figure 35. Kynurenine pathway
activation in pigs resuscitated from
cardiac arrest. Plasma concentrations of
trypthophan (TRP), kynurenic acid
(KYNA) and 3-hydroxyanthranilic acid
(3-HAA) at baseline (CTR) and after I
hr (PR 60), and 5 days (end) post-
resuscitation (PR).
Data are reported as mean ± SEM .
...P < 0.05 and vs. baseline (CRT).
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Humans. Similarly to rats and pigs, there was a trend towards lower plasma levels ofTRP and
higher levels of KYN, in resuscitated patients in comparison to healthy volunteers (p not
significant, Figure 36). Plasma levels of KYNA and 3-HAA were significantly higher at I hr
post-resuscitation, compared to plasma concentrations in healthy volunteers (p < 0.0 I, Figure
36), and tended to decrease during the following 3 days (Figure 36). However, higher plasma
levels of 3-HAA persisted 3 days later (p < 0.05 vs. healthy volunteers, Figure 36). Only 2 of
the 5 resuscitated patients survived till leu discharge and presented lower plasma levels of
KYNA and 3-HAA in comparison to those who died. Interestingly, plasma levels of 3-HAA
were approximately double in patients who died compared to those who survived (190 ± 12
nM vs. 102 ± 12 nM).
Post-resuscitation circulating levels of pro-inflammatory cytokines, PCT, and CRP are
reported in Table 13.
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Ftgure 36. Kynurenine
pathway activation in men
resuscitated from cardiac
arrest. Plasma concentrations
of trypthophan, L-kynurenine,
kynurenic acid and 3-
hydroxyanthranilic acid in
healthy volunteers and in men
after I hour (h), and 3 days (d)
post -resuscitation (PR).
Data are reported as mean ±
SEM.
II< P < 0.05 and "'''' p < 0.01 vs.
BL;
# p < 0.05 and ## p < 0.01 vs.
PR I h.
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Table 13. Pro-inflammatory biomarkers in men resuscitated from cardiac arrest.
PR I hr PR 3 days
Procalcitonin, mg/m L 0.6± 0.2 2.6±2.1
IL-6, ng/mL 92±39 63 ± 22
IL-8, ng/mL 51±18 18 ± 2
TNFa, ng/mL II ± I II ±3
MIF, ng/mL 549 ± 42 197 ± 63*
CRP, ng/mL 12±9 139 ± 21 *..
IL, interleukin; TNFa, tumor necrosis factor alpha; MIF, macrophage inhibitor factor;
CRP, C-reactive protein; PR, post resuscitation.
* p < 0.0 I vs. PR I hr.
• STUDY 3: Validation of KP activation after cardiac arrest in a large cohort of out-
of-hospital cardiac arrest patients
The FINNIRESUSCI study (Vaahersalo 2013) included 548 patients of which 311 had a
shockable initial rhythm. Among these patients, informed consent for blood sampling was
obtained at leu admission in 155 patients, and they were included in the study. Of these 155
patients, 139 (90%) survived to ICU discharge, 109 (70%) to hospital discharge, and 97 (63%)
of patients were alive at 12 months. Of the 97 patients, 92 (95%, or 59% of the 155 patients)
had favorable neurological outcome (Cl'C 1 or 2) at 12 months. Baseline characteristics and
factors influencing leu survival and good 12 month outcome are shown in Table 14. Pre-
hospital factors associated with 12-month outcome were age, witnessed arrest (yes/no) and
time to Rose (Table 14). Of these 155 patients, 134 patients also had blood samples drawn at
48 hr from the arrest.
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Table 14. Baseline characteristics and factors at resuscitation indexed by comparisons between leu survivors
and non-survivors and those with good and poor outcome at 12 months.
Characteristic leu ICU Poor outcome Good outcome
death survival at 12 months at 12 months
(n=16) (n=139) (n=63) (n=92)
Age, median (IQR) 68(63-76) 62(57-72)* 69(62-75) 61(55-67)§§
Gender (male), n(%) 14(88%) 118(85%) 57(90%) 75(82%)
Witnessed cardiac arrest, n(%) 13(81%) 131(94%)* 55(87%) 89(97%)§
Bystander initiated life support, n(%) 11(69%) 94(67%) 41(65%) 64(70%)
Adrenaline used, n(%) 16(100%) 78(56%)** 54(86%) 40(44%)§§
Time to ROSC, min median(IQR) 24(21-31) 20(13-28)** 25(21-32) 17(11-23)§§
Therapeutic hypothermia, n(%) 14(88%) 117(84%) 55(87%) 76(83%)
SAPS II score, median(lQR) 74(64-83) 55(37-66)** 66(57-72) 47(34-60)§§
SAPS II- Simplified acute physiology score; IQR=lnterquartile range.
* p < 0.05 and ** p< 0.01 vs.K'U death; § p < 0.05 and §§ p < 0.01 vs. Poor outcome at 12 months.
KP metabolites and factors related to resuscitation
The levels of TRP and KP metabolites in the 10 healthy volunteers, matched for age and
gender, were comparable to data reported in literature (TRP: 74.3 JlM [61.1-88.0], KYN: 2.4
JlM [2.2-3.0], KYNA: 49.0 nM [35.5-84.3] and 3-HAA: 25.0 nM [29-42]) (Darlington 2007,
Mackay 2006). At ICU admission, the levels of KYN and KYN/TRP were higher in older
patients (Table 15). All metabolites, but TRP, were also significantly higher in patients with
longer time to ROSC (Table 15). Patients awake at ICU admission had higher TRP levels, but
no difference was seen regarding the other metabolites (Table 15). In a linear regression
model, the inclusion of age, gender, whether the cardiac arrest was witnessed or not,
administration ofBLS, and time to ROSC was an independent predictor of admission levels of
KYN (P=0.028 95% Cl 0.008-0.047, p=0.005), KYNA (P 2.12 95% Cl 0.299·3.933, p=0.023),
3-HAA (P 0.541 95% Cl 0.125-0.956, p=O.Oll), KYNffRP ratio (P=O.OOI,95% Cl 0.000-
0.001, p=O.O15), but not TRP (P=-O.OOS95% Cl -0.26-0.15, p=0.617).
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Correlations between KP metabolites and severity of shock
Levels of all metabolites except 3-HAA at ICU admission were associated with the subsequent
24 hr SAPS II systolic blood pressure scores, with significantly higher levels in patients who
had lower systolic blood pressure (Table 15). Levels of all metabolites at ICU admission were
also associated with SAPS II bicarbonate scores during the following 24 hours (Table 15).
T bilK . d db d f h d f d' da e 5. Pin exe )y uration 0 .patient c aracteristics, uration 0 car lac arrest an Ipatient outcome.
Variable TRP KYN KYNn'RP KYNA J-IIAA
11M 11M ratio nM nM
Admission levels
Age, year
53 (18-59) 43.2 2.1 0.05 61.2 24.7
(34.5-57.9) (1.S-2.9) (0.04-0.07) (35.0-103.3) (18.1-41.8)
63 (60-68) 41.7 2.3 0.06 S3.9 24.2
(34.4-48.4) (1.8-3.1 ) (0.04-0.07) (38.4-90.6) (16.6-44.4)
75 (69-88) 43.2 2.8 0.06 68.9 26.7
(32.9-55.4) (2.1-3.8) (0.05-0.09) (48.3-113.0) ( 16.8-41.2)
p-value 0.620 0.005 0.001 0.412 0.874
Time to ROSC, min
1-16 43.7 2.2 0.05 53.0 20.9
(37.7-56.1) ( 1.5-2.9) (0.04-0.06) (35.1-77.9) (13.3-32.0)
17-24 40.8 2.6 0.06 64.6 28.6
(31.3-54.9) (I.7-3.3) (0.05-0.09) (38.5-120.5) (18.2-42.4)
25-57 41.7 2.6 0.07 66.7 28.1
(33.3-51.5) (1.9-3.2) (0.05-0.08) (49.8-129.7) (19.4-48.5)
p-value 0.339 0.066 0.0007 0.043 0.009
Lowest 24-hour systolic blood pressure, mmHg
>100 52.3 2.3 0.05 43.5 21.3
(33.2-63.7) (I.7-3.2) (0.04-0.07) (43.5-46.9) ( 14.6-44.0)
70-99 41.6 2.4 0.06 58.0 24.7
(33.9-50.9) ( 1.7-3.0) (0.04-0.07) (39.7-88.3) (17.3-39.7)
<70 47.9 3.4 0.07 141.6 44.6
(40.4-60.9) (2.9-4.8) (0.06-0.1) (58.4-478.1) ( 19.0-116.3)
p-value 0.144 0.004 0.025 0.03S 0.174
24-hour IICOJ, mEq/1
>20 43.0 2.1 O.OS 52.6 23.4
(34.S-SS.S) (1.6-2.9) (0.04-0.07) (38.1-77.6) ( 16.0-36.2)
15-19 41.3 2.6 0.06 64.6 24.5
(33.1-50.9) (1.9-3.4) (0.05-0.08) (39.9-117.6) (18.4-41.3)
<IS 44.8 3.2 0.07 191 77.5
(41.6-57.4) (2.3-4.3) (0.05-0.1) (85.3-471.4) (39.6-120.6)
p-value 0.288 0.003 0.001 0.001 0.001
Outcome at 12 months
Good 42.9 2.1 0.048 54.6 22.4
(34.7-55.3) (1.7-2.9) (0.040-0.073) (38.6-86.9) (16.3-36.9)
Poor 41.7 2.7 0.06S 67.6 29.9
(33.8-51.6) (2.2-3.5) (0.055-0.087) (43.1-160.4) ( 18.2-45.4)
p-value 0.956 <0.001 <0.001 0.043 0.047
WIlcoxon signed rank test for paired data, KP metabolites are reported as medlan(IQR).
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KP metabolites at ICU admission and outcome
All KP metabolites, but not TRP, correlated with ICU mortality (Figure 37) and outcome at
12-months (Table 15 and Figure 38). KP metabolite levels were significantly higher in
patients who died in the ICU or prior to hospital discharge compared to those who survived
(Figure 37 and Table 15), and in patients with a poor outcome at 12 months compared to
those with a good outcome (Table 15 and Figure 38). The AVC for the prediction of ICU
mortality was 0.813 (95% Cl 0.724-0.903, p<O.OOI) for KYN, 0.780 (95% Cl 0.660-0.899,
p<O.OOl) for KYNA, 0.757 (95% Cl 0.625-0.888, p<O.OOI) for 3-HAA and 0.766 (95% Cl
0.662-0.869, p<O.OOI)for KYN/TRP ratio.
Kynurenine pathway & leu survival
Kynurenine Kynurenine/tryptophan
5 * 0.12 o Alive
! * .Dead4 0.09 f~3 :!2 ::12 0.06
~
1 0.03
Kynurenine acid 3-Hydroxyanthranilie acid
400 * 120or- *
300 90 I~ 200 :! 60•• e100 30 [50 0"
0 0
Figure 37. KP and leu survival.Data are reported as median and IQR. • P < 0.001 vs. alive patients.
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Kynurenine pathway & mortality and CPC
Tryptophan Kynurenine KynlJ"enineltryptophan ratio
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Figure 38, KP and 12-month mortality and epe. Data are reported as scatter plot and median.
The AUC values for prediction of poor 12-month outcome based on metabolite levels on
admission were 0.665 (95% cr 0.578-0.752, p<O.OOl) for KYN, 0,598 (95% Cl 0.503-0.688,
p=0.043) for KYNA, 0.594 (0.502-0.686, p=0,047) for 3-HAA and 0.674 (95% Cl 0.590-
0,759, p<O.OOI)for the KYN/TRP ratio.
127
We developed multivariable models for the prediction of ICU mortality and for poor outcome
at 12 months from cardiac arrest. The (basic) clinical model for the prediction of ICU death
included age, time to ROSC, whether cardiac arrest was witnessed or not, and whether
adrenaline was used or not (Table 14). The AUC for the basic model was 0.79 (95% Cl 0.70-
0.88, p<O.OOOI). Each of the metabolites was independently associated with ICU mortality
when added to the basic model: KYN (OR 1.7 95% Cl 1.2-2.4 per JiM increase, p=0.005),
KYNA (OR 1.006 95% Cl 1.002-1.010 per nM increase, p=0.004), 3-HAA (OR 1.024 95% Cl
1.008-1.042 per nM increase, p=0.004), TRP (OR 1.04 95% Cl 1.004-1.08, per JiM decrease
p=0.032). The AUCs of the incremental models (basic clinical model and kynurenine
metabolite) were 0.89 (95% Cl 0.83-0.95) for KYN (p=0.025 for comparison with the basic
model), 0.9 (95% Cl 0.84-0.96) for KYNA (p=0.0191 for comparison with the basic model),
and 0.89 (95% Cl 0.83-0.94) for 3HAA (p=0.0339 for comparison with the basic model).
The model for the prediction of poor outcome at 12 months included age, whether cardiac
arrest was witnessed or not, time to ROSC, whether adrenaline was used or not, and admission
levels of KP metabolites, added separately. The AUe for prediction of poor 12-month
outcome was 0.84 (95% Cl 0.78-0.91) in the basic model. Higher levels of KYNA (OR 1.004
95% Cl 1.001-1.007 per nM increase, p=0.038) and 3-HAA (OR 1.015 95% Cl 1.010-1.030,
per nM increase, p=0.043) correlated with poor outcome at 12 months. The AUe for
prediction of poor outcome was 0.86 (95% Cl 0.79-0.92) with the addition of KYNA into the
model (p=0.18 for comparison with the basic model) and 0.86 with addition of 3-HAA
(p=0.13 for comparison with the basic model).
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• ECG-DERIVED BIOMARKERS:
• STUDY 4: AMSA evaluation in 609 VF patients in the United States
A total of 1260 OFs, including 578 first attempts and 682 subsequent ones from 609 patients,
were included in the analyses.
All DF attempts
Among all 1260 OFs, 316 were successful (25.1%), while 944 were unsuccessful (74.9%).
AMSA was significantly higher prior to a successful OF than prior to an unsuccessful one
(15.6 ± 0.6 vs. 7.97 ± 0.2 mY-Hz, p<O.OOOI,Figure 39).
Using the intersection of sensitivity, specificity, and accuracy curves (Figure 40A), an AMSA
threshold of 9.8 mY-Hz, provided a balanced sensitivity, specificity and accuracy of 78%,
with a NPV of 91% and a PPV of 54%. An AMSA threshold of 14 mY-Hz provided the
highest accuracy (80%) in predicting OF outcome, with a PPV of 61% and a specificity of
90%. Higher AMSA thresholds were associated with further increases in PPV and specificity.
An AMSA threshold of 17 mY-Hz resulted in the highest PPV (67%) in predicting OF
success.
For low AMSA thresholds, the majority of unsuccessful OFs were correctly predicted with
high sensitivity and NPV (Figure 40A). Using AMSA < 7 mY-Hz as cutoff, more than 42%
of unsuccessful OFs might have been avoided with a NPV > 97% (Figure 40A and Figure
41). Lower thresholds further improved NPV.
Area under the ROC curve was 0.84 (p<O.OOOI,Figure 408).
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Figure 39. AMSA
values for successful and
not successful DF for all,
first and subsequent
attempts. Number of
attempts are reported
inside bars.
* p<O.OOOI between
successful and not
successful DFs.
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Figure 40. A: Sensitivity, specificity, accuracy, and positive and negative predictive value (PPY and NPY)
curves for different AMSA values, in all DFs, first DFs, and subsequent DFs.
B: ROC curves for AMSA and DF outcome prediction for all, first, and subsequent DFs.
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Potentially Avoided Unnecessary Defibrillations, %
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Figu re 41. Percentage of
potentially avoided
unnecessary DFs for
different low AMSA
thresholds. Numbers on the
top of bars represent the
correctly predicted
unsuccessful DFs.
248
Among 578 first DFs, ] 56 were successful (27%), while 422 were unsuccessful (73%). AMSA
201
was significantly higher prior to a successful DF than prior to an unsuccessful one (15.7 ± 0.9
mY-Hz vs. 8.7 ± 0.3, p<O.OOOI, Figure 39).
163
Using the intersection of sensitivity, specificity, and accuracy curves (Figure 40A), an AMSA
threshold of ]0.2 mY-Hz provided a balanced sensitivity, specificity and accuracy of 73%,
with a NPV of 88% and a PPV of 50%. An AMSA threshold of 17 mV-Hz resulted in the
highest accuracy (76%) and PPV (60%) in predicting DF success, with a specificity of92%.
With an AMSA < 7 mY-Hz, more than 40% of unsuccessful DFs might have been avoided
with a NPY > 97% (Figure 40A and Figure 41). Lower thresholds further improved NPV.
Area under the ROC curve was 0.80 (p<O.OOOI, Figure 40B).
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Subsequent DF attempts
Among 682 subsequent OFs, 160 were successful (23.5%), while 522 were unsuccessful
(76.5%). AMSA was significantly higher prior to a successful OF than prior to an
unsuccessful one (15.5 ± 0.8 mY-Hz, p<O.OOOI,Figure 39).
Using the intersection of sensitivity, specificity, and accuracy curves (Figure 40A), an AMSA
threshold of9.2 mY-Hz provided a balanced sensitivity, specificity and accuracy of 79%, with
a NPV of 93% and a PPV of 54%. An AMSA threshold of 14 mV-Hz resulted in the highest
accuracy (84%) in predicting OF success, with a PPV of 72% and a specificity of 94%.
Further increases in AMSA threshold were associated with further increases in PPV and
specificity. An AMSA threshold of 18 mY-Hz resulted in the highest PPV (75%) in predicting
OF success.
With an AMSA < 7 mY-Hz, more than 46% of unsuccessful OFs might have been avoided
with a NPV > 97% (Figure 40A and Figure 41). Lower thresholds further improved NPV.
Area under the ROC curve was 0.87 (p<O.OOO1, Figure 40B).
DF attempts for recurrent and refractory VF
Among 682 subsequent OF attempts, 139 were delivered for recurrent VF, while 543 were for
refractory VFs. Among 139 OFs delivered for recurrent VF, 110 were successful (79.1%),
while of 543 OFs delivered for refractory VF, only 50 were successful (9.2%) (Table 16).
AMSA was significantly higher in recurrent VF than in refractory VF (16.2 ± 0.9 vs. 7.6 ± 0.2
mY-Hz, p<O.OOOI,Table 16). In the instance of recurrent VF, there was no significant
difference in AMSA prior to a successful OF compared to that prior to an unsuccessful one
(16.8 vs. 13.8 mY-Hz, Table 16). For refractory VFs, AMSA was significantly higher prior to
a successful OF than prior to an unsuccessful one (12.7 ± 1 vs. 7 ± 0.2 m'V-Hz, p<O.OOOI,
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Table 16). AMSA was accurate for predicting OF outcome only in the instance of refractory
YF (Figure 42).
In the instance of refractory YF, the intersection of sensitivity, specificity, and accuracy curves
provided an AMSA threshold of 8.5 mY-Hz accounting for a balanced sensitivity, specificity
and accuracy of 77% (Figure 42A). An AMSA threshold of 17 mY-Hz resulted in peak
accuracy (91%) and peak PPY (50%), with a specificity of97%.
Area under the ROC curve was 0.81 (p<O.OOOI) for refractory YF, and 0.65 for recurrent YF
(p=O.O12, Figure 42B).
Table 16. AMSA prior to defibrillation for refractory and recurrent YF
Refractory YF Recurrent YF
(n=S43) (n=139)
Mean AM SA, mY-Hz 7.6 ± 0.2 16.2 ± 0.9*
AMSA prior to successful DFs, mY-Hz 12.7± 1 16.8± 1
AMSA prior to failing DFs, mY-Hz 7.0 ±0.2# 13.8± 1.8
Successful DFs, % (n) 9.2 (50/543) 79.1 (110/139)
DFs, defibrillation attempts; YF, ventricular fibrillation.
Mean ± SEM; * p < 0.0001 vs. refractory YF; # p < 0.0001 vs. successful Drs
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Influence of CC depth and interruptions on AM SA
When CC depth was <1.75 in, AMSA decreased by 3.9 mY-Hz between the first and the
second DF and further decreased between the second and the third attempt (Table 17,
p<O.OOl). By contrast, when CC depth was >1.75 in, AM SA was equivalent for the first and
the second DF (p=0.47) and then increased by 1.7 mY-Hz between the second and the third
attempt. A similar but less pronounced trend was observed with a CC depth cutoff at 1.5 in
(Table 17).
AMSA significantly decreased during the 16 sec pre-DF CC interruption for AED rhythm
analyses and capacitor charge (p<O.OI, Figure 43). AMSA decreased even more during CC
interruptions prior to first OF (p<O.OI). In subsequent DFs, AMSA decrease during CC
interruptions was less pronounced (p<O.05 only after 12 sec CC interruption).
Table 17. AMSA value changes among the initial3 defibrillation attempts in relationship to chest compression
d hept .
AMSA AMSA AAMSA AMSA AMSA AAMSA
l"t DF 2ndDF rd_I't DF 2ndDF ydDF yd_lnd DF
mY-Hz mY-Hz mY-Hz mY-Hz
Depth> 1.75 in 11.2 ± 0.8 lOA ± 0.8 -0.7 8.1 ± 0.5 9.7± 0.8 +1.7
(n=155) (n=155) (n=81) (n=81)
Depth < 1.75 in 13.3 ± 0.9 9.4 ± 0.4## -3.9* 8.8± 0.5 8.4 ± 0.5 -004**
(n=148) (n=148) (n=80) (n=80)
Depth> 1.5 in 11.9 ± 0.8 10.1 ±0.7 -1.6 8.1 ± 004 9.5 ±0.7 +1.5
(n=192) (n=192) (n=96) (n=96)
Depth < 1.5 in 12.8 ± 1 9.5 ± 0.5# -3.3 9±0.6 8.5 ±0.6 -0.6··
(n=ll1) (n=lll) (n=65) (n=65)
DFs, defibrillation attempts; MMSA - difference ID AMSA value between DFs.
Mean ± SEM;*p < 0.02 and •• p < 0.01 vs. depth> 1.75 in;#p < 0.01 and ##p < 0.0001 vs. l" OF.
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AMSA during chest compression interruptions
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Figure 43. AMSA changes measured every 2 sec during the 16 sec pre-OF "hands off" period for all, first and
subsequent DFs.
* p < 0.05 and ** p < 0.01 vs. 2 sec;
# p < 0.01 vs. 4 sec;
t p < 0.05 and f+ p < 0.01 vs. 6 sec.
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• STUDY 5: AMSA evaluation in 1.617 VF patients in Lombardia Region, Italy
Population and outcome
A total of 2.447 DFs, including 1.050 first attempts, from 1.050 YF patients in the derivation
group (period 2008-2009), were included in the analyses. Of 860 patients among the 1.050,
baseline characteristics and outcome were known and are summarized in Table 18. Seventy-
three % of patients were male and the median age was 69.5 years. In more than 92% of cardiac
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arrests, the EMS was alerted for a medical cause. More than 50% of patients presented a
cardiac comorbidity and had more than 2 concurrent drug treatments, mainly represented by
renin-angiotensin system antagonist and anti-thrombotic agents (Table 18).
Median EMS arrival from the alert was 8 min and a median of 2 DFs were attempted for each
patient. ROSe was achieved almost in 36% of patients, while only 18% survived till hospital
discharge and 14.5% till one year after cardiac arrest (Table 18).
629 (73.14)
69.5 (59-78)
308(35.81)
160 (18.6)
139 (16.2)
125(14.5)
Table 18. Baseline population and
outcome
Patient. (total). N-- -- 1.050.----
860(81.9)
Age In y•• re, median (CIo,25-Q;).7~)
Cause EMS alert. N (%)
Medical
Traumatic
Tumoral
otner
EMS arrival time In minutes. median (CIo.25-Clo.7.)
N of d.nbrl~on ~ml't~ m~an (CIo.25-CIoo~L_. +
Outcome. N ('Yo)
ROSC
Hospital discl ..arge
Six-mon th SU rvival
One-year survival
Comorbldltl ... N (%)
Myocardiallnterction
Congestive heal1fallure
Peripheral vascu lar disease
Cerebrovascu lar disease
Chronic pulrnonerv disease
Diabetes
Liver disease
Renal disease
Cancer
Others
Drug Tr.atment. N ('Yo)
Cardiac therapy
An lith rornooti c dru gs
Antihypertensive drugs
Beta blocker dru9S
Calciu mchannel blockers
Renin-angiotensin system anteuon ists
Lipid modifying agents
Selective bet~ adrsn orecoptor agon ists
Concurrent drug treaflnent •. N ('Yo)o .
1
2
3
4
25 ( max 7)
259(30.12)
220(25.58)
88 (1023)
122(14.19)
10(1.16)
119(13.84)
51 (5.93)
21(2.44)
70(8.14)
__ 51(5.93)
229(26.63)
350(40.70)
37(4.30)
207 (24.07)
190(22.09)
444(51.63)
205(23.84)
15(1.74)
256(29.77)
133(15.47)
142(16.51)
144(16.74)
114(13.26)___ 71 (8.26)
AMSA and other ECG-derived parameters
Mean values of AMSA, RMS, PF, MDF, and MNF for all, first, subsequent and last DF
attempts are reported in Table 19. No differences in AMSA and RMS values were observed
between the first and the subsequent DFs. MDF and MNF, instead significantly increased
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between the first and the subsequent attempt (Table 19). More specifically, average AMSA
values were 8.39,8.27, and 8.48 mY-Hz, for all, first, and subsequent DFs respectively.
No differences were observed between values calculated in all 1.050 patients vs. those
calculated in the 860 ones with known outcome.
Table 19. ECG variables
I Deflb~lI;tl~n AMSA -l-~:~-I-PF MDF MNF
I attempt (mV-Hz) (Hz) (Hz) (Hz),
All 8.39::1:4.88 0.13::1:0.09 3.77:!: 1.709 , 4.48::1:1.421 7.S9:!: 1.568,
VI
~s I First 8.27 :!:4.95 0.14:!:0.09 3.58 ± 1.598' 4.30 ± 1.335' 7.30± 1.487*;:LOcao
Co .....= ~ Subsequent 8.48±4.83 0.13±0.08 3.90± 1.775 4.60± 1.469 7.80:!: 1.593c( ,
I Last 9.04±5.18 0.15± 0.09 3.88:!: 1.685 4.52± 1.435 7.43::1:1.439
i -- --
I: All 8.31 :!:4.81 0.13±0.09 3.75:!: 1.713 4.50± 1.429 7.62± 1.558
~--I
I
1:0
I F:st 4.31 ± 1.353' j~~ 8.16±4.89 0.14±0.09 3.54::1:1.593' 7.32 ± 1.495'oS'-._ 4>
~E I
~ ~ Subsequent 8.42:!:4.75 0.13±0.08 3.91 ± 1.779 4.64± 1.466 7.83± 1.566
;:0'
0.15± 0.09 I 3.83± 1.675 4.53 ± 1.43~ 17.45 ± 1.418:.JLast 9.01 ± 5.07
Mean ± SD; • p<O.001 vs. subseorent defibrillation attempts
Using linear regression models, age, gender, EMS arrival time, presence of a cardiac,
pulmonary, and renal disease, diabetes, anti-thrombotic, anti-hypertensive, beta-blocker,
calcium channel blocker, and renin-angiotensin system antagonist drugs, number of
comorbidities and number of concurrent drug treatments were significantly associated with the
value of the ECG-derived parameters (Table 20). Age and gender affected all the parameters.
EMS arrival time affected only AMSA and RMS, while the number ofDF attempts had effects
only for PF and MNF. As expected, beta-blocker treatment affected MOF and MNF.
Comorbidities and treatments had different effects among the various parameters (Table 20).
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More specifically, age, gender, EMS arrival, myocardial infarction, congestive heart failure,
diabetes, number of comorbidities, and anti-hypertensive drug, were the factors associated
with AMSA values.
Table 20. Relation between ECG parameters and baseline measurements. Univariate regression model.
Model AMSA RMS PF MDF MNF-_._----- ---,
p p value p p value p value p p value p value-- - ---
Age (years) -0.0037 <0.0001 10.0005 I 0.6221 -0.0051 <.0001 .-0.0042 <.0001 -0.00271 <.0001
-----
Gender (male) 0.1251 <0.0001 0.0866 0.0051 0.0788 0.0014 0.041 0.0132 0.0201 0.0495
Anlvilf time (minutes) '-0.0075, 0.01G8 '-0.0102 0.0025 0.0CXl2 0.9482 0.0022 0.2162 0.0007 0.5088
-- ------,--~ - --"
, Number of defibrillations -0.0056 0.4159 -0.0107 0.1484 0.0119 0.0433 10.0007 0.8608 0.0148 <.0001
~ ~
MYOCOlldl,'11lnfarctloll 0.252 <0.0001 0.2353 <.0001 0.0439 0.0621 0.0313 0.0474 .000741 0.4495
Congestive he'lI't failure 0.0749 0.0094 0.0865 0.0053 0.0109 0.6598 -0.0076 0.6479 -0.0269 0.0086.- - --
;.004251
---
Chronic Pulmonary DIsease 0.0005 0.99)2 0.3177 ,0.0529 I 0.1163 0.02 0.3003 0.03991 0.0045-- - --~- -~-- - ---- ---
'" Dlahetes -0.151 <0.0001 -0.0298 0.4564 -0.1226 0.0001 -0.1171 <.0001 -00691 <.0001'i!
'i .~ ----- _-_ ..<: RerHlI disease 1°·0137 0.7697 10.1097 0.0468 1-007551 0.0858 -0.0955 0.0012 1-0.05231 0.0041=::;,
t -
Number of comorbldltles 0.0359 0.0002 0.0474 <.0001 '-0.0013 0.B749 -0.0073 0.1809 -O.OI~t<.~1f- - --
Antlthrombotlc drugs :0.04131~1229 1008721 0.0024 ,-0.0493 0.0312 -0.0423 0.0059 -0.0507 < .0001--- - --,- - +-- .J,
Car,II.lC therapy 0.0331 0.2849 0.0972 0.0034 -0.0585 0.0271 -0.0737 <.0001 .0.064 <.0001- ~- . -
AntlhYflertenslve dnrgs 0.268 <0.0001 0.2706 <.0001 0.1045 I 0.052 '0.0854 0.018 \-0.0186 ~.4047
-!- I -Beta blocker dnrgs -0.0253 0.3824 0.0129 0.6785 '-0.037 0.1357 -0.0352 0.0348 -0.0275, 0.0075
Calclum channel blockers 1.00507 0.0925 I-oo~ 0.3645 1·00426! 0.0987 !·00055 0.7519 t·0.1ll39~4042 I
Renin.;lngiotensln system olntagonlsts .0.0463 0.0692 '-0.0791 0.0039 0.0128 0.5586 '0.0317 0.0304 0.0071 0.4328
Number of drugs 10.0241 0.1102 10.03811 0.0187 1.001981 0.125 ,.0.0151 0.0019 1.001971 0.0002
The analysis is adjusted for age and gender. The dependent variables are modeled as natural logarithm
Using a multivariate logistic regression model, including all variables individuated with the
univariate analysis (p<O.05), factors that were predictors of DF success were individuated for
each of the ECG-derived parameters (Table 21). More in details, factors to be considered for
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AMSA were: age, gender, myocardial infarction, diabetes, anti-hypertensive drugs and
calcium channel blocker agents (Table 21).
Table 21. Relation between ECG parameters and baseline measurements. Multivariate regression model
Model
AM SA
-- ~I-:oD032
0.129S
_jl _~~~~~0.2468
-00689
p value
0.0002
<0001
<0001
<0001
<0001
0.0213
- -
I
Age
Gender(male)
lMyocardialinfarctionDiabetesAntihypertensive dru gsCalciu m ch annel blockers_--
I RMS
Age 00000
Gender (male) 0.1139
Arrival time -0.0091
Myocardial infarction 0.2177
An tih yperten sive dru gs 0.2364
Antithromboticdrugs 0.1262
Re.n.l.!l-angiotensin system antagonists -0.111_9
PF
Age -~0043
Gender (male) 0.0749
Myocardial infarction 0.0594
Chronic Pulmonary Disease O.OS17
Diabetes -0.1219
liver disease -0.09859
~flcdiac therapy -OOq4?
MDF
Age -00032 <.0001
Gender(male) 0.0343 0.0367
Myocardial infarction 0.0541 0.0009
Congestive heartfailure 0.0429 0.0248
Diabetes -0.1227 <.0001
Renal disease -00753 0.0135
Cancer 0.07042 0.0092
Antithrombotic drugs -0.0358 0.044
Cardiac therapy -0.0767 0.0002
Beta blocker dru gs -0.0414 0.0201
Re':lin-angiotensi~stem antag>..;:oc:..;n.:.ois"'ts"--__ .,....l. _ _;o:::;..o~6~S~3~.'--..:;.<~.0;:::0::::.01:.,--
MNF _
Age -00019 ~001
Gender(male) 0.0167 0.0971
Defibrillation attempts 0.0125 <.0001
Chronic pulmonary disease 0.0549 <.0001
Diabetes -00652 <.0001
Antith rombotic dru gs -0.0343 0.0012
LCardiac therapy -0.0505 <.0001Ren il1:.1!n_giotensinsy_?j_e_rna ~g9..nist~_ 0~0273 _ 0.0039_
0.9914
0.0002
0.0063
<.0001
0.0004
<.0001
0.0001
<.0001
<0001
0.0132
0.0178
0.0002
0.0483
0·0.1_86
Cardiac therapy include: cardiac glycosides, anti-arrhythmics, inotropes, vasodilators.
The analysis is adjusted for age and gender. The dependent variables are modeled as naturallogarithlll
AMSA and other ECG-derived parameters and DF success
Among the 2.447 DF attempts, 26.2% were successful, while considering only the first DF
attempts (1.050), 26.5% were successful. AMSA was significantly higher prior to a successful
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DF than a failing one. Considering all DF attempts, AMSA values were 13 ± 5.2 and 6.8 ± 3.5
for successful and unsuccessful OFs respectively (p<O.OOOI, Figure 44). Considering only the
first OF attempts, AMSA values were 12.6 ± 5.5 and 6.7 ± 3.6 for successful and unsuccessful
OFs respectively (p<O.OOOI). All the other ECG-derived parameters, with the exception of
MNF, were also significantly higher prior to a successful OF compared to an unsuccessful one
(Figure 44).
ECGvariables and defibrillation outcome DSuccess • Failure
Figure 44. AMSA,
RMS, PF, MDF, and
MNF values for
successful and not
successful DF for all,
and first attempts. In
the bottom table: OR
of the different ECG-
derived parameters for
all and first DF
attempts.
Moreover, all the ECG-derived parameters, with the exception MNF, were independent
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specifically, AMSA presented an OR of 1.40 (95% Cl 1.36-1.44, p<O.OI) for all OFs, and 1.33
(95% Cl 1.28-1.38, p<O.O1) for only the first DF attempts (Figure 44).
The area under the ROe curve for the prediction of OF success based on ECG-derived
parameters are reported in Table 22. AMSA had the AUC significantly greater compared to
all the other parameters and thereby was a better OF success predictor. More specifically
AUCs for AMSA were 0.861 and 0.834 for all and first DF attempts (Table 22 and Figure
45). Considering the prediction of ROSe (based on ECG-derived parameters measured prior
to last DF), again AMSA was a better predictor compared to the other parameters, with an
AUC ofO.753 (Table 22 and Figure 43).
Table 22. ECG variables predictivity - Area under the ROC curve
AUCVariable Outcome(N)
OF success (All OFs, 2447) 0861 (0845-0877) <00001
AMSA OF success (First OFs, 1050) 0.834 (0.806-0861) <0.0001
ROSC(860) 0.753 (0.719-0.787) <0.0001
OF success (All OFs, 2.447) 0.810 (0.793-0.830) <00001
- -- - - --- ---1--
RMS OF success (First OFs, 1050) 0.795 (0765-0.824) <00001
ROSC(860) 0.705 (0668-0740) <0.0001
l--'~ - - - --
OFSUCC9SS(AIIOFs, 2447) 0.695 (0672-0.719) <00001
- -
PF OF success (FirstDFs, 1.050) 0.676 (0640-0.712) <0.0001
ROSC(860) 0.637 (0.598-0675) <0.0001-- -- -- - -
OF success (All OFs, 2447) 0.625 (0.600-0.650) <00001
- - - - -- --- - -
MDF OF success (First DFs, 1050) 0.616 (0578-0654) <0.0001
ROSC(860) 0.596 (0558-0637) <00001
OF success (All OFs, 2.447) 0.523 (0.500-0.550) 0.0825
MNF OFsuccess(FirstOFs,l.050) 0.505(0465-0.544) 0.8139
--- -1--
ROSC(860) 0.511 (0.470-0.551) 0.7661
Comparison between different AUCs are significantly different
p
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ROC Curves for AMSA
AIIDFs
(2.447)
FlrstDFs
(1.050)
LastDFs
vs.aosc
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AUC= 0.83
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AMSA and other ECG-derived parameters and outcome
Figu re 45. ROC curves for
AMSA and OF outcome
prediction for all and first
OFs, and for AMSA (last
OFs) and ROSC.
Relationship between ECG-derived parameters and ROSC and long-term outcomes were also
assessed (Table 21). All the ECG-derived parameters, with the exception of MNF, were
independently associated with ROSC (RRs are reported in Table 23). More specifically,
142
AMSA presented an adjusted OR for ROSC prediction of 1.21 (95% Cl 1.16-1.25, per mY-Hz
increase, p<O.OI, Table 23). Surprisingly, AMSA and all the other ECG-derived parameters,
with the exception of RMS, were also independent predictors for survival at hospital
discharge, 6-months, and I year after resuscitation (Table 23).
Table 23. ECG variables and outcome: ROSe and long term survival.
1.29 (1.18·1.45)
1.23(1.1 0-_1.3_9)_...J..-_~l
<0.0001
-
[- -
I AMSA,
f mV·Hz
I RR
~~S, I01~010 ~ O.I2.tO.0751<O~OI T 018i009 [018t012 Tom8 L018i0121 0~8 [ ~1269l018t008 ~ 018t012 ra1942
RR 1.09(1.07-1.11) _J__ ~,_ 100(09B-l02) _L I 100(O.98-~.:!_ j~ 100(098-102) 1
RR~'.' I 1.09(107-1.12) T 1 00(0.98-~1) I 100(0.98-101) 100(0.98-101) J__ -I
~F. 1 4.83tl.51 4.34t1.34 0.0003h·14il.47IUBil.49 0.0003- -l ____L______ - --- ----'-- - --~RR 1.27(1.15-1.41) 1.28(1.14-1.45)
RR'lI~.' I 1.21 (1.07-1.35) 1.22(1.06-1.39)
527i~.L~42
1.32(1.18-1.47)
1.25 (1.11-1.43)
.._ .~
7.86tl.3;T 7.20t1.46 0.0002___ ~l. __0.0051
1.23 (1.10-1.37)
~~tl.3417.24tl.49 _0.0004
1.22 (1.09-1.35)
RR~'.' I 1.00(0.90-1.13) 1.19(1.04-1.35) 1.20 (1.08-1.33) 1.19 (1.06-1.33)
'MJusted for age, gender end !actlJ'sldertited Inthemilti_e enalySs
Threshold AMSA values for DF outcome prediction
All DF attempts - Using the intersection of sensitivity, specificity, and accuracy curves
(Figure 46), an AMSA threshold of 8.9 mY-Hz, provided a balanced sensitivity, specificity
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and accuracy of 79%, with a NPY of 91% and a PPY of 56%. An AMSA threshold of 15.5
mY-Hz, instead, provided a balanced accuracy and PPY of 79% in predicting OF success,
with a specificity of 97%. Higher AMSA thresholds were associated with further increases in
PPY and specificity, Le. AMSA > 23 mY-HZ led to a PPY of 100% (Figure 46). For low
AMSA thresholds, the majority of unsuccessful DFs were correctly predicted with high
sensitivity and NPY (Figure 46). AMSA < 6.5 mY-Hz yielded a NPY > 95% (Figure 46).
Lower thresholds further improved NPY.
First DF attempts - Using the intersection of sensitivity, specificity, and accuracy curves
(Figure 46), an AMSA threshold of 8.6 rnV-Hz, provided a balanced sensitivity, specificity
and accuracy of 76%, with a NPY of 89% and a PPY of 54%. An AMSA threshold of 16 mY-
Hz, instead, provided a balanced accuracy and PPY of 77% in predicting OF success, with a
specificity of 97%. Higher AMSA thresholds were associated with further increases in PPY
and specificity, Le. AMSA > 23 mY-HZ led to a PPY of 100% (Figure 46). For low AMSA
thresholds, the majority of unsuccessful DFs were correctly predicted with high sensitivity and
NPY (Figure 46). AMSA < 5 mY-Hz yielded a NPY > 95% (Figure 46). Lower thresholds
further improved NPY.
Last DF attempts and ROSe - Using the intersection of sensitivity, specificity, and accuracy
curves (Figure 46), an AMSA threshold of 8.7 mY-Hz, provided a balanced sensitivity,
specificity and accuracy of 70%, with a NPY of 80% and a PPY of 56%. An AMSA threshold
of 13.2 mY-Hz, instead, provided a balanced accuracy and PPY of72% in predicting ROSe,
with a specificity of 92%. Higher AMSA thresholds were associated with further increases in
PPY and specificity, i.e. AMSA > 26 mY-HZ led to a PPY of 100% (Figure 46). For low
AMSA thresholds, the majority of unsuccessful DFs were correctly predicted with high
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sensitivity and NPY (Figure 46). AMSA < 3 mY-Hz yielded a NPY > 90% (Figure 46).
Lower thresholds further improved NPY.
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Validation of AMSA thresholds
AMSA thresholds for successful and unsuccessful OFs (all OFs and first OFs) defined in the
derivation group (Figure 46) were then validated in the validation group (Table 24). The
validation group included 1.386 OFs (with 567 first OF attempts) from 567 YF patients. The
AMSA thresholds for OF success, namely 15.5 (for all OFs) and 16 mY-HZ (for first OFs),
were confirmed to be able to predict OF success with a PPY > 80% and a specificity of 97%,
in the new YF database (Table 24). On the contrary, the AMSA thresholds for OF failure,
namely 6.5 (for all OFs) and 5 mY-HZ (for first OFs), were confirmed to be able to predict OF
failure with a NPY > 98% and a sensitivity> 97%, in the new YF database (Table 24).
Table 24. Validation of2008-2009 VF database-derived AMSA thresholds with the 2010 VF database
AMSA threshold 'Sensitivity Specificity I PPV NPV
I (mV-Hz) (%) (%) (%) (%)
I -
'0'0 ALLDFs ! 8.9 91 72 60 954)- (1.386) I(.)0I:J:
10 (I) -- t - - -- - 'T_ CD
FirstDFs I10 '-10£ (567) I 8.6 92 73 60 95Ir-
'- Io 1/1 ALLDFs I..... 1/1 15.5 35 97 82 76'0 CD (1.386)- (.) Io (.) - __L 1- -- ~'J: :l 1-
1/1 1/1 FirstDFs I~II.. 16 33 97 80 77J:o (567) i.... I
- _,
'-
ALLDFs I.gCD 6.5 97 50 47 98'0'- (1.386) I-:l
0::: _,_ ,_ - 1-- - - --J:IO
1/1 ..... I
4)11.. FirstDFs I 5 99 39 41 99,20 (567).... ____J
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DISCUSSION
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The mainjindings of our research can be summarized as follows:
1. Identification of a specific pathway, the kynurenine pathway, that is activated early in the
post-resuscitation period and that is associated with the severity of post-cardiac arrest
syndrome. Indeed, we have demonstrated that KP is activated in rats, pigs, and humans, after
ROSC and this activation persists during the initial days post-cardiac arrest. Moreover, in a
large cohort of cardiac arrest patients, we have furher demonstrated that ICU admission levels
of KP metabolites were associated with the duration of cardiac arrest, i.e. time to ROSC, and
with the severity of post-cardiac arrest shock during the first 24 hours. In addition, KP
metabolites predicted ICU mortality and 12 month outcome. KP therefore may play a
pathophysiological role in the severity of shock, early death and poor neurological outcome
after resuscitation. KP metabolites, and especially KYNA and 3-HAA, may have a clinical
utility for cardiac arrest outcome prognostication.
2. Confirmation and validation, in two large databases (one from US and one from Italy) of
out-of-hospital VFs, that AMSA is one of the best ECG-derived parameters to be used as
predictor of defibrillation outcome. Indeed, AMSA was capable of predicting DF outcome
with high accuracy. AMSA was significantly higher prior to a successful DF than prior to an
unsuccessful one. Thresholds for prediction of successful and unsuccessful DFs were similar
in both databases, i.e. 16-17 mY-Hz for success and < 7 mY-Hz for failure. AMSA also
showed additional promise for monitoring the effectiveness of chest compression. Finally, for
the first time, it has been showed association between AMSA and different factors, such as
age, gender, EMS arrival, heart disease, diabetes and cardiovascular drugs.
The Discussion is organized based on the two main topics of the researches described in the
previous pages: kynurenine pathway and amplitude spectrum area.
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Kynurenine pathway
Emerging metabolome profiling technologies offer the possibility of identifying novel
biomarkers and pathways activated in cardiovascular diseases; however, applications to post-
resuscitation myocardial dysfunction in the setting of cardiac arrest are still lacking. We used a
global LC-MS metabolomic approach to obtain a comprehensive view of changes in plasma
metabolites associated with CPR in an established and widely accepted rat model. The
application of metabolomic analysis in cardiovascular diseases is an emerging field and it is
not yet possible to depict any single metabolic picture responsible for the prediction and
progression of cardiovascular disease. However, the identification of clinically relevant
changes in circulating metabolites is opening exciting avenues in the cardiovascular field
(Alexander 2001, Barderas 2011, Lewis 2008, Mayr 2008 and 2009). For example, Shah and colleagues
(Shah 2010) showed that a signature composed of dicarboxyacylcarnitines was predictive of
further cardiovascular events in patients with coronary artery disease. An important role of
phospholipids as new key culprits in atherosclerosis was highlighted in patients with
cardiovascular disease and a pathological role of ketone bodies has been suggested for human
atrial fibrillation (Wang 2008). In acute ischemia and acute myocardial diseases many
intermediates of the citric acid cycle were found to be depressed as a direct consequence of
myocardial ischemia (Sabatine 2005, Zhao 2008).
Hence, we first adopted an unbiased strategy towards profiling as many plasma metabolites as
possible in the very early post-resuscitation phase (2 hr post-ROSC) in rats. The profiling data
was then used to detect altered biochemical processes using bioinformatics-based pathway
mapping. Indeed, statistically significant signatures could be obtained in rats' plasma in the
very early CPR period compared to control rats. Many biochemical alterations were in line
with those already reported in the literature about cardiovascular dysfunctions, supporting the
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feasibility and robustness of our explorative untargeted LC-MS strategy. For example, there
were changes in the plasma levels of some saturated and unsaturated fatty acids, with an
overall tendency to decrease in the early CPR phase. This de-regulation may have significant
energetic and functional consequences on the heart, affecting the delivery of free fatty acids to
the myocardium and their utilization during ischemia and following reperfusion. The
involvement of fatty acid beta-oxidation in rats in the early CPR phase is consistent with the
decrease in the myocardial capacity for this process in rodent models of heart failure (Lopaschuk
2010) and in clinical settings (Jaswal 201 I, Neglia 2007). Our findings are in accordance with a
general reduction in oxidative fuel metabolism and greater reliance on anaerobic metabolism
for energy revealed by metabolomic analysis in clinical settings of myocardial
ischemialreperfusion (furer 2009).
There is convincing body of the role of sphingolipids in cardiovascular dysfunction and in
particular for SIP, which has potent effects against acute ischemia-reperfusion injury
(Baranowski 201 I, Knapp 201 I). In line with these observations, in rat plasma from the early CPR
phase, we found a reduction in the level of SIP, which could reduce endogenous protective
action on cardiomyocyte viability (Knapp 2009).
Analysis of rat plasma using a comprehensive LC-MS platform also identified metabolites of
the essential aminoacid TRP catabolism that had not, to our knowledge, been previously
associated with any post-resuscitation syndrome. We identified what we believe to be novel
changes in plasma metabolites after CPR. The targeted LC-MRM-MS platform with stable-
isotope dilution method enabled us to unambiguously quantify the statistically meaningful
changes of TRP and KP metabolites throughout the post-resuscitation observational period.
Methodological refinements, including optimization of MS conditions, and deuterated
standards resulted in a sensitive, selective and accurate method for the simultaneous
151
measurements of TRP, KYN, KYNA, and 3-HAA in plasma. Baseline values were similar to
those reported in literature (Fukushima 2009, Midttun 2009, Pawlak 2001, Zheng 2012).
The subsequent study with targeted metabolomics confirmed that KP was activated following
resuscitation from cardiac arrest in three different species. Accordingly, KP activation was
initially observed in resuscitated rats, was then validated in pigs subjected to cardiac arrest and
CPR, and was ultimately confirmed in a small cohort of human patients. Indeed, increases in
plasma levels of KP metabolites, KYN, KYNA and 3-HAA, occurred during the initial hours
following resuscitation and persisted up to 3 to 5 days following cardiac arrest. KP activation
showed an equivalent time course in rats, pigs, and humans, and was significantly related to
the severity of post-cardiac arrest myocardial dysfunction, cerebral injury, functional outcome
and survival.
KP is a major pathway of the catabolism of the essential aminoacid TRP. Specifically, two
enzymes initiate the KP: tryptophan 2,3-dioxygenase (TDO), that is mainly present in the liver
and is stimulated by glucocorticoids; and indoleamine 2,3-dioxygenase (lOO), that is widely
expressed in a variety of human tissues, such as the brain, kidney, lung, spleen, and
duodenum, as well as in macrophages and dendritic cells and is stimulated by
proinflammatory cytokines, including interferon-y, TNFa, IL-I and 2, and by
Iipopolysaccharides and free radicals (Maes 201l. Wilson 2012). Indeed, upon inflammatory
stimulation, 100 is induced and consequently KP activated (Changsirivathanathamrong 201 I,
Wilson 2012). Similarly to a sepsis-like syndrome, a systemic inflammatory and immune
response is observed after CPR, and might be the trigger for IDO induction (Adrle 2004. Nolan
2008, Peberdy 2010, Stoppe 2012). In the present study, early KP activation has been consistently
observed in both small and large animals resuscitated from cardiac arrest, and ultimately
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confirmed in humans. In our study, systemic inflammation was present in the 5 resuscitated
patients, as demonstrated by circulating levels of TNFa, IL-8, MIF, and CRP, while
association between KP activation and myocardial oxydative stress, Le. isoprostanes, has been
observed in the rat model.
Altered TRP metabolism has been described as a hallmark of many stress related situations
(Clarke 2009, Maes 201/). In these settings of glucocorticoid overdrive, in fact, TDO is activated
together with a super induction of IDO in response to stress (Maes 201 I). Concurrently elevated
circulating catecholamines have been reported to contribute to reduction in total TRP
concentrations. Thus, rodents subjected to stressful conditions, Le. forced swimming or
immobilization, a low TRP diet increased adrenal weight, plasma corticosterone levels and
reactivity to stimuli; administration of TRP, instead, had acute antianxiety-like effects (Maes
201 I, Wong 2001). Indeed, cardiac arrest is characterized by increases in plasma cortisol level
and catecholamine release. A trend toward lower serum cortisol level in survivors than in non
survivors has been earlier reported (Hekimian 2004, Maes 2011). The stress of whole body
ischemialreperfusion that follows cardiac arrest might be therefore another component
affecting the described KP activation after CPR.
It has been proposed that TRP catabolism through the KP may contribute to oxidative stress
and brain damage following ischemia (Darlington 2007). Contributors to the development of
ischemia-induced cerebral injury are, in fact, post-ischemia neuroimmune and inflammatory
reactions (Neumar 2000, Nolan 2008). Accordingly, one component of this network is the KP
(Darlington 2007, Stone 1993). Indeed, KYN is the first KP metabolite, that is further metabolized
to the neurotoxic 3-HAA and its derivatives, quinolinic acid and picolinic acid (QA and PA).
3-HAA exerts its neurotoxic actions by inducing both cerebral oxidative stress and
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excitotoxicity through activation ofN-Methyl-D-Aspartate (NMDA)-receptors by QA and PA.
3-HAA's metabolites have not only neuroexcitatory effects, but also neurotoxic ones, causing
neuronal, astrocyte and microglial cell injury, destruction of postsynaptic elements, and
reductions in cerebral cholinergic circuits (Brouns 2010, Darlington 2007, Sas 2007, Stone 1993).
KYNA is another KYN metabolite, produced by astrocytes, in response to increased KYN
level. KYNA has neuroprotective properties related to its activity as NMDA antagonist (Nozaki
1992, Sas 2007, Stone 2002). KYNA generation might represent an adaptive response in order to
block the potentially harmful effects of excessive glutamate receptor stimulation that follows
an ischemic insult (Neumar 2000). The correlations between post-resuscitation 3-HAA plasma
levels and cortical and hippocampal histological lesions and neurological deficit scores in
pigs, suggest a possible role of KP metabolites in post-resuscitation cerebral injury and
neurological dysfunction also in the instance of cardiac arrest. Together with increases in
plasma 3-HAA, there were concurrent increases in plasma KYNA and these were consistently
seen in the 3 species.
In support of our results, KP activation, expressed as KYN to TRP ratio, has been shown to
correlate with stroke severity and long-term outcome in stroke patients (Brouns 2010, Darlington
2007). Patients with poor outcome had higher KYN/TRP ratio than patients with more
favorable outcome. Moreover, experimental blockade of the KP has been reported to reduce
cerebral infarct volume in a model of cerebral ischemia and reperfusion (Cozzi 1999).
It has been reported that in response to generation of KP's neuroprotective metabolite KYNA,
microglia and macrophages may produce even greater amounts of neurotoxic KP metabolites,
Le. 3-HAA (Sas 2007, Wilson 2012). This loop of events may explain TRP and KP metabolites
levels observed in our animals subjected to hypothermia. Therapeutic hypothermia is a well
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established protective intervention against brain ischemia/reperfusion injury after cardiac
arrest (Peberdy 2010, Polderman 2009). TH, in fact, suppresses many of the reactions associated
with reperfusion injury, i.e., inflammatory responses and intracellular injury pathways,
including activation of pro-apoptotic enzymes. Indeed, our pigs treated with TH presented
better neurological recoveries and lesser cerebral lesions compared to those that did not
receive TH. These hypothermia-treated animals also presented lesser TRP catabolism
compared to normothermic ones. The higher TRP plasma levels in these animals were
accompanied by higher levels of neuroprotective KYNA. However, hypothermic animals also
presented significant increases in plasma concentrations of neurotoxic 3-HAA, as an
hypothesized counteracting response to neuroprotection provided by TH (Nolan 2008, Peberdy
2010, Po/derman 2009). Nevertheless, a specific effect of TH on KP activation has to be
considered with caution. The levels of KP metabolites were, in fact, assessed at the 5th day
after cardiac arrest. Any direct and early effect played by TH on KP could not be investigated
due to the lack of an earlier blood sampling, as a limitation of the retrospective study design.
In further support of potential implications of KP in post-resuscitation brain injury and
outcome and in neuroprotective effects played by KYNA, are the additional investigation of
KP in pigs treated with a well-known neuroprotective intervention, namely inhalation of the
noble gas xenon. Although noble gases are traditionally believed to be 'inert', these
monoatomic colorless and odorless agents are indeed capable to interact with amino-acids in
the active sites of several enzymes and receptors, producing biological effects (Jawad 2009).
Especially, xenon has been widely explored in several neurological injury models, including
cardiac arrest and clinical phase II trials are currently underway to prove its benefits (Fries 2008
and 2012). Indeed, in our pigs, administration of xenon translated to improved early neurologic
and neurocognitive recovery and this was accompanied by no changes in post-resuscitation
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plasma levels of TRP and 3-HAA, and by a significant increase in post-resuscitation plasma
levels of the neuroprotective metabolite KYNA. This increase in KYNA after xenon treatment
may be related to a concurrent action as NMDA antagonist played by xenon itself, which may
lead to KYNA preservation.
More importantly, KP activation has been associated not only with brain injury but it may also
concur to the pathogenesis of systemic inflammatory response syndrome and sepsis
[Changsirivathanathamrong 2011, Huttunen 2010, Jung 2009, Sas 2007, Wang 2010). 100 activity was
markedly increased in 132 patients with bacteremia, in whom KP was significantly more
activated in non-survivors compared to survivors (Huttunen 2010). In 60 major trauma patients,
significantly increased KYN was detectable already within 24 hr after hospital admission in
blood from patients who later developed sepsis (Logters 2009). In those patients KP activation
predicted subsequent sepsis development, multiple organ failure, and survival. Most likely
early post-traumatic inflammation in conjunction with augmented circulating pro-
inflammatory cytokines and neutrophil activation resulted in IDO stimulation and consequent
KP activation. The above events may occur also in cardiac arrest patients (Adrie 2002 and 2004,
Nolan 2008, Peberdy 2010). Indeed, activation of the inflammatory cytokine cascade, chemokine
upregulation and ultimately recruitment of inflammatory leukocytes and reactive astrogliosis
have been reported after cardiac arrest and play major roles in the final outcome. From this
point of view, the reported anti-inflammatory effect of KYNA, through the inhibition of
TNFa, may provide an interesting feed-back mechanism in this post-cardiac arrest
inflammatory response (Wang 2006).
KP also concurs to the pathogenesis of vasoplegia and hypotension during septic shock
(Changsirivathanathamrong 2011, Jung 2009, Wang 2010).100 expression was, in fact, induced in the
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endothelial cells of small resistance vessels and contributed to the dysregulation of vascular
tone during systemic inflammation due to endotoxemia in mice (Wang 2010). This increased
100 activity accounted for a greater production of KYN, that directly mediated arterial
relaxation through soluble guanylate cyclase activation (Changsirivathanathamrong 2011). A clear
protection against hypotension due to septic shock and a reduced mortality has been reported
in 100 knockout mice or in mice treated with a specific 100 inhibitor, l-methyl-Dstryptophan
(Jung 2009). Those mice also presented decreased levels of the pro-inflammatory cytokines,
TNFa, IL-6, and IL-12, and enhanced levels of the anti-inflammatory IL-IO. A recent clinical
study confirmed the above experimental results on 16 septic shock patients, in which 100
activity increased up to 9-fold (Changsirivathanathamrong 2011). Moreover, inotrope requirements
were strongly correlated with 100 activity in those septic patients (Changsirivathanathamrong
2011).
The above events may occur also in the setting of cardiac arrest (Nolan 2010, Peberdy 2010). As
shown in our study, post-cardiac arrest myocardial dysfunction, with low ejection fraction,
cardiac output, stroke volume, together with profound arterial hypotension, were consistently
reported in rats and pigs. More importantly, in our rat model, plasma levels of KP metabolites,
KYNA and 3-HAA, increased concurrently to decreases in myocardial function and increases
in biomarkers of heart injury and oxidative stress. Similarly, the severity of post-resuscitation
arterial hypotension and reduction in cardiac output were significantly related to increases in
KYNA and 3-HAA in pigs.
The subsequent clinical study confirmed in a large cohort of patients that the TRP catabolism
through the KP is activated early after resuscitation from cardiac arrest. Patients who died
before leu discharge exhibited significantly higher levels of KP metabolites at leu admission
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suggesting a higher degree of KP activation and KP metabolites levels predicted early
outcome after resuscitation. More importantly, KP metabolites, KYNA and 3-HAA, were
associated with long term outcome.
Similarly to a sepsis-like syndrome, a systemic inflammatory and immune response is
observed after CPR and the magnitude of the inflammatory response correlates with outcome
as well as the severity of circulatory shock in cardiac arrest patients (Adrie 2002). The
inflammatory response commonly seen after cardiac arrest seems to be related to the duration
of ischemia (Adrie 2002). Adrie and colleagues (Adrie 2002) showed that after cardiac arrest an
inflammatory response is seen and its magnitude is similar to that of severe sepsis. In their
study, however, levels of various cytokines were not independent predictors of survival but
this may have been due to low study power. The KYN/TRP ratio, which is regarded as an
indicator of 100 activity, has been shown to predict case fatality and severity of shock in
bacteremic patients (Huttunen 2010). Huttunen et al. reported similar levels of TRP but higher
levels of KYN and KYN/TRP in patients with fatal bacteremia (Huttunen 2010). In our study,
patients exhibiting a high KP activation at hospital admission subsequently had a more severe
shock and were more likely to die in the ICU.
KP can be activated in the periphery as well as in the nervous system. Peripheral KYN readily
crosses the BSB and is taken up by glial cells, while KYNA, 3-HAA and QA do not (Fukui
1991. Speciale 1990). In the central nervous system further metabolism is segregated and under
physiologic conditions, after the influx of KYN into the brain equal amounts of KYNA and 3-
HAA are produced (Guidetti 1995). Indeed, KYN concentration within the central nervous
system is controlled by three main mechanisms: KYN movement from the peripheral
circulation, where peripheral 100 and TOO are induced, across the BBs through the large
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neutral amino acids transporter (Stone 1993); basolateral secretion of KYN from BBB cells such
as endothelial cells and pericytes (Owe-Young 2008); and KYN synthesis from TRP within the
central nervous system by astrocytes and microglia (Fukui 1991, Maes 2011, Owe-Young 2008, Wilson
2012). However, in the instance of cardiac arrest, post-resuscitation inflammatory and immune
system activation, might activate 100 both systemically and in the brain, and a larger amount
KP metabolites may cross BBB in regions where it has been made more permeable by local
ischemia-induced damage (Brouns 2010, Darlington 2007). As discussed above, the balance of
downstream KYN's metabolites, KYNA and 3-HAA, will modulate the resulting neurological
injury (Darlington 2007). Interestingly, also in our larger clinical study, both KYNA and 3-HAA
increased similarly after cardiac arrest to further remark the complex balance and relationship
between the generation of neuroprotective and neurotoxic KP metabolites after an ischemic
insult. More importantly, the KYNrrRP ratio was higher in those with a poor outcome at 12
months and the absolute levels were comparable to those seen in stroke patients by Brouns and
Darlington in stroke events, i.e. between 0.04 and 0.09 (Brouns 2010, Darlington 2007) Both
KYNA and 3-HAA were independent predictors of long-term outcome after resuscitation from
cardiac arrest.
Our large clinical study also confirmed the relationship between KP activation and the severity
of post-cardiac arrest shock, previously observed in the animals. Indeed, higher levels of
KYN, KYNA and KYN/TRP ratio were significantly associated with lower systolic blood
pressure. Nevertheless, the relationship between KP and blood pressure seems to be more
complex in the setting of cardiac arrest. In sepsis, in fact, high KYNrrRP activity was
associated with high vasopressor requirements (Darlington 2007). Absolute levels of KYNrrRP
in our study were comparable to septic patients (Changsirivathanathamrong 2011) with a fairly low
requirement of inotropes. Inotrope requirement during post-cardiac arrest is in general fairly
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low and high requirement correlates with poor outcome (Laurent 2002). In stroke patients on the
other hand it is intriguing that despite high activation of KP, hypotension is uncommon (Brott
1998). Thus, this finding contrasts the hypothesis that activation of the KP per se causes
vasodilatory shock and hypotension. Clearly the interplay between shock, neurological
damage and systemic inflammation seems to be complex. Further studies should look at where
organ specific activation of the KP occurs, especially measured in the cerebrospinal fluid.
We recognize limitations in the interpretations of our findings. First, the experimental design
was purely observational and focused on demonstration of post cardiac arrest activation ofKP,
thus it did not allow to identify causal relations: changes in circulating molecules may be the
consequence as well as the cause of the observed pathophysiologic alterations. In order to
investigate direct effects of KP activation on outcome of cardiac arrest, experiments that
include administration of specific 100 inhibitors are planned. Nevertheless, this is the first
evidence of consistent KP activation after cardiac arrest in animals and humans. Second, the
studies were performed in healthy animals and therefore effects of underlying coronary
disease in KP activation remain to be investigated. Third, animals were anesthetized and
general anesthesia might have influenced stress response and KP activation (Wilson 2012).
However, the consistency of the results further strengthens our findings. Furthermore, results
obtained from the 155 patients resuscitated from cardiac arrest provide exhaustive clinical
confirmation on activation of KP after resuscitation and its implication with the severity of
post-cardiac arrest syndrome and outcome. On the contrary, the strengths of the clinical study
include: 1. the sample size which makes it the largest biohumoral study in out-of-hospital
cardiac arrest to date; 2. robustness of clinical data; 3. representativeness of the population;
and 4. outcome determined prospectively by a qualified independent assessor.
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Amplitude spectrum area
Current OF algorithms are static in the sense that they do not consider the passage of time and
the pathophysiology of the arrested myocardium (Deakin 2010, Link 2010, Weisfeldt 2002). In our
setting, the standard DF approach led to a successful OF in only 25-26% of attempts. The
ability of AMSA to predict OF success is therefore of great importance, since this may allow
to optimize timing of OF delivery (Cal/away 2005). There is also a potential to reduce CC
interruptions and minimize myocardial damage by limiting repetitive and unnecessary OFs
(Cheskes 20 II, Snyder 2004, Steen 2003, Yu 2002, Xie 1997).
There is evidence that VF changes over time and that it is possible to predict the success of a
DF attempt by analysing the VF waveform features (Cal/away 2005, Eflestol2004, Endoh 2011, Li
2008b, Link 2010, Pernat 2001, Povoas 2002, Ristagno 2008b, Shanmugasundaram 2012, Sun 2011, Young
2004). Our studies are the first that investigated the ability of AMSA to predict OF success in
large databases of out-of-hospital VFs, from US (609 patients) and Italy (1.617 patients).
Beside the large number of patients enrolled, the studies have several additional strengths: I.
different defibrillators (ZOLL, Philips, and PhysioControl) have been used and thereby AMSA
was tested with different DF waveforms (biphasic truncated exponential (DTE) and rectilinear
biphasic (RLB», with different energy delivery algorithms (no lower than 150 J for DTE and
no lower than 120 J for RLB), and different trans-thoracic impedance compensation
techniques (time-based compensation or current-based compensation) (Kette 2013); 2. AMSA
was investigated as predictor for both short and long term outcome, to test a potentially new
use of AMSA as a prognosticator in cardiac arrest; 3. several factors, i.e. time of EMS arrival,
co-morbidities and drug treatment were known in the study conducted in Italy and their impact
on AMSA and other ECG-derived parameters was evaluated. Accordingly, the US study had as
main endpoint to individuate AMSA thresholds for DF outcome and to investigate
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relationships between AMSA and CC depth and between AMSA and resistant and recurrent
YFs. The Italian study, beside individuating and confirming AMSA thresholds in a different
population, through a consecutive derivation/validation approach, was also focused on
investigating relationships between AMSA and Rose and survival, and with potential
affecting factors, described above. These studies therefore provide a lot of information on the
use of AMSA and represent a valid basis for design a prospective intervention with a real time
AMSA analysis as a guide for ePR manoeuvres.
AMSA values and thresholds predictive of OF outcome were similar in the two different
databases. Indeed, we have confirmed AMSA to be significantly higher prior to a successful
OF than prior to a failing one. While an AMSA of approximately 9-10 mY-Hz was able to
predict OF outcome with a balanced sensitivity, specificity and accuracy of approximately
80%, higher AMSA values increased accuracy, specificity and PPY for predicting OF success.
An AMSA threshold of 16-17 mY-Hz, in fact, was associated with up to 80% OF success,
which could potentially be used to guide towards earlier OF as the likelihood of success is
high. AMSA values greater than 23 mY-Hz (which was found, however, in a minority of
patients) correctly predicted the success of OF with a PPY value of 100%, in the Italian
database.
Animal studies have consistently demonstrated accuracy of AMSA for predicting OF success,
yielding a balanced sensitivity and specificity of approximately 90%, with a NPY of 95% and
a PPY of 78% (Perna! 2001, Povoas 2002). Moreover, utility of AMSA as predictor of Rose has
been reported independent of myocardial substrate, i.e. in a swine model of ischemic YF (Indik
2011). Two small retrospective clinical studies, including 46 and 90 VF patients, subsequently
confirmed the above sensitivity and specificity (Ristagno 2008b, Young 2004). In the present
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investigations, although AMSA was able to predict with satisfactory accuracy OF outcome,
balanced sensitivities, specificities, and PPVs were lower compared to the earlier reports. We
believe, however, that current results are more realistic due to the large databases employed,
that were approximately 10 to 20-fold greater than earlier ones and represent the largest
studied to now for VF waveform analysis. Indeed, a good OF predictor should be both sensible
and specific. For this reason, a balanced sensitivity and specificity of 80%, as observed in our
results, makes AMSA a useful guide for OF decision.
Different approaches to VF analysis have been tested, resulting in variable accuracy for
predicting OF success (Callaham /993, Eftestol 2000 and 2005, Nakagawa 2012, Neurauter 2007, Watson
2006 Weaver 1985). Accordingly, a VF feature with at least a 50% specificity at a 95% sensitivity
has been suggested as a safe and useful predictor for OF decision (Eftestol 2005, Neurauter 2007).
Unlikely, results from relatively large clinical databases have demonstrated that only few of
the proposed methods achieved the above limit (Eftestol 2005, Nakagawa 2012, Watson 2006).
Indeed, the majority were considered with insufficient predictive power, having a high
sensitivity (> 90%), but a low specificity « 40%). Differently, AMSA, together with other VF
features, Le. median slope, power spectrum analysis, and the wavelet transform-derived
Cardioversion Outcome Predictor, achieved a sensitivity of approximately 95% with a
specificity between 56-66% (Eftestol 2005, Nakagawa 2012, Watson 2006). In our studies, AMSA, as
predictor of DF outcome, was confirmed to yield a specificity of more than 50% at a 95%
sensitivity. Moreover, different thresholds may be selected in order to maximize the OF
outcome prediction, such to achieve the best PPV and the best NPV. The present study
provided evidence that AMSA represents a clinically applicable tool, easily obtained from the
routinely available ECG Accordingly, the discussion attempts to suggest a potential AMSA·
based algorithm for first and subsequent OF attempts.
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Upon arrival at the cardiac arrest scene, rescuers need to determine the optimal first CPR
intervention, Le. a cycle of CC or an immediate OF (AHA guidelines 2005, Baker 2008, Iwami 2012,
Link 2010, Shanmugasundaram 2012, Wik 2005). Sun and colleagues (Sun 201l) have recently
optimized the timing of the first OF by applying real time AMSA analysis during CC in a rat
model ofVF. OF was attempted only when AMSA achieved a predefined threshold predictive
of successful shock. With that approach, 70% of animals were resuscitated after the first DF,
in contrast to 0% when OF was attempted following standard guidelines. AMSA-guidcd CPR
also significantly reduced CC interruptions and ultimately improved post-resuscitation
myocardial and neurologic function and survival. In our population, interrupting CC for
delivery of first DF at an AMSA of 16-17 mY-Hz could have raised first OF success up to
77% compared to 27% observed with the standard approach.
AMSA also has predictive ability for subsequent OF attempts, but is dependent upon the type
ofVF. Subsequent OFs may be due to either VF refractory to earlier DFs or to a recurrence of
VF after an initially successful OF. Similar to an earlier small retrospective study on 44
patients (Shanmugasundaram 2012), our study demonstrated that AMSA was accurate for OF
prediction only in the instance of refractory VF. The AMSA value to be considered as a
threshold for delivery of a OF with the highest likelihood of success was again 17 mV-liz.
AMSA therefore might be an useful decision tool for the treatment of refractory VF. Recurrent
VF, on the other hand, presented an overall high AMSA, with no differences between
successful and unsuccessful OFs, and an elevated OF success rate of almost 80%. Recurrent
VF will probably not benefit from an initial interval of CC, but rather should receive OF
immediately, similar to a witnessed arrest.
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The total electrical energy delivered with repetitive DFs might be an important determinant for
the severity of post resuscitation myocardial dysfunction and survival (Tang 1999 and 2004 and
2006, Tsai 2011, Xie 1997). Using AMSA lower than 7 mY-Hz as guidance, more than 45% of
unsuccessful and potentially detrimental DFs might have been avoided with a NPV > 97%.
This approach could also reduce unnecessary CC interruptions for the delivery of futile DFs.
Even minimal interruptions of less than 4 sec can generate declines in myocardial perfusion to
near 40% (Berg 2001). In our population, pre-OF pauses caused significant decreases in AMSA,
likely related to the reduced myocardial perfusion and ultimately anticipating decreases in OF
success (Ejtest(J/ T 2004, u 2008b). Limiting the frequency and duration of such CC interruptions
may improve clinically relevant outcomes in cardiac arrest (Cheskes 2011, Link 20/0, Steen 2003, Yu
2002).
Compared with other ECG-derived parameters, Le. VF amplitude (RMS), and frequencies (PF,
MDF, and MNF), whose characteristics have been described in depth in the introduction,
AMSA was a better predictor of OF outcome, with an AUC that resulted equivalent in both
the US and the Italian database, i.e. 0.86-0.87. Interestingly, although AMSA, au pair of other
VF features, has been ideated and recognized primarily as a predictor of OF success, our
results showed that it was also an independent predictor of ROSC and in patients who were
successfully resuscitated it was also associated with survival till hospital discharge, and 6
months and 1 year later. Based on these results, it can be extrapolated that, patients who had
higher AMSA during CPR, had probably a better myocardial perfusion and systemic
hemodynamic support, due to several factors, such as duration of untreated cardiac arrest,
quality of CPR, drugs, and this ultimately accounted for a better post-resuscitation survival.
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Little is known about effects of various drug treatments on ECG-derived parameters. Animal
models have shown that several cardiovascular drugs, i.e. beta-blockers and angiotensin
converting enzyme inhibitors may alter VF features, shortening its duration and favouring the
evolution towards asystole (Wang 2009). More recently, the effects of pretreatment with beta-
blockers on quantitative VF waveform measures have been investigated in a swine model of
cardiac arrest and CPR. Indeed, metoprolol and labetalol, administered prior to VF onset,
caused reduction in frequencies in the Fourier spectrum of VF and in AMSA, limiting their
ability to predict downtime or OF outcome (Sherman 2012). Our studies confirmed that several
treatments, including anti-hypertensive, angiotensin converting enzyme inhibitors, anti-
thrombotic drugs, cardiac drugs (glycosides, anti-arrhythmic drugs, inotropes), had different
effects among the various parameters. More specifically, anti-hypertensive drug prescription
was associated with higher AMSA values. As expected, beta-blocker treatment affected MOF
and MNF, but not AMSA.
Similarly, there are very limited investigations on the relationships between VF features and
co-morbidities, including and not only cardiac diseases. Swine models of cardiac arrest with
concurrent AMI revealed that VF spectral features, such as median, mean, or dominant
frequency and bandwidth were significantly reduced (lndik 2007). However, ECG predictors,
i.e. AMSA and its slope, maintained their capability to predict ROSC (Indik 2009).
Nevertheless, during CC, the VF waveform evolved differently, offering a means to
distinguish an AMI. Indeed, AMSA and slope were significantly lower for AMI swines
compared with controls, whereas in post AMI swines the waveform characteristics were
similar to controls (Indik 2011). Our clinical studies confirmed that cardiac disease, i.e.
myocardial infarction and congestive heart failure, had impact on AMSA values. Moreover,
AMSA was affected also by age, presence of diabetes, and EMS arrival time. These factors
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atTected in ditTerent way also the other ECG-derived parameters. Therefore, drug treatments
and co-morbidities need to be taken into account when the ECG predictors are used and
further studies are needed to better understand changes in AMSA thresholds in relation to
these factors.
AMSA appears to carry the additional promise of being able to monitor the etTectiveness of
CC. The present analyses have demonstrated that AMSA decreased between consecutive
shocks during shallow CC, while it increased when CC was of greater depth. We have
previously reported the possibility of assessing CC depth utilizing AMSA in a porcine model,
in which animals were randomized to optimal or suboptimal depth of CC tu 2008b). Similarly
to CPP, AMSA thresholds achieved were contingent on the depth of compressions such that
AMSA increased progressively during CC, and predicted the likelihood of successful OF.
Therefore, when future technology allows for real time AMSA analyses during CC, a rescuer
may be prompted to push harder if the AMSA value is too low (Aramendi 2012, Ruiz 2013).
Based on our results the following AMSA algorithm to guide CPR could be beneficial. In the
presence of a very low AMSA, i.e. below 7 mV-Hz, the likelihood to deliver a successful OF
is low. CC therefore should be performed until AMSA is deemed to be favourable for a OF,
minimizing interruptions in CC and delivery of unnecessary shocks. The decision of
interrupting CC to attempt a DF should be limited to when there is the highest probability of
success. DF may be delivered as initial intervention or during CC even before completion of a
regular 2 min cycle when AMSA reaches the threshold of 17 mV-Hz. If AMSA values fall in
the range between 7 and 17 mV-Hz, even though specificity and accuracy of shock success
prediction are high, CPR should be performed accordingly to guidelines. Finally, recurrent VF
should always receive an immediate DF.
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We recognize important limitations. First, these were retrospective analyses. Second, AMSA
was calculated only during the pre-OF hands off time and not in real time during CC.
Nevertheless, for the first time effects of different factors, i.e. EMS arrival time, drugs, co-
morbidities, etc. have been investigated. Moreover, we could use two large databases, that
allowed for estimation of robust thresholds to be tested in future prospective evaluations.
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CONCLUSIONS
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Our experimental studies demonstrated that KP is activated early in the post-resuscitation and
persists during the initial 3 to 5 days post-cardiac arrest, in rats, pigs, and humans. KP
activation is significantly related to the severity of post-resuscitation myocardial dysfunction,
cerebral injury, functional outcome and survival. The subsequent large clinical study showed
that the admission levels of KP metabolites are associated with the duration of ischemia and
the severity of shock during the first 24 hours in critically ill out-of-hospital cardiac arrest
patients. In addition, KYNA and 3-HAA, independently predict dismal neurological outcome.
Therefore, this pathway may be an important mechanism contributing to the severity of post-
cardiac arrest syndrome.
The two retrospective studies on AMSA as predictor of successful OF, the largest to now,
confirmed that AMSA is capable to predict DF outcome with high accuracy, for both initial
and subsequent attempts. Moreover, AMSA appears as a better predictor of OF outcome
compared to other ECG-derived parameters. Indeed, specific AMSA thresholds in order to
predict different OF outcomes, Le. success or failure, were identified during CPR. AMSA
shows also additional promise for monitoring the long-term (up to 12 months) effectiveness of
CC. An AMSA-based OF decision therefore would be an useful approach to guide the best
CPR intervention. Our results provide solid data for a future prospective study, adopting a real
time AMSA analysis during CPR.
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APPENDIX
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Supplemental Figure 1. Key elements of the tryptophan breakdown metabolic pathway
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Conversion of tryptophan to 5-hydroxytryptamine (5-HT) and to 5-hydroxyindolacetic acid and tryptophan
oxidation by the kynurenine pathway. IDO indoleamine 2,3-oxidase, TOO tryptophan 2,3-dioxygenase, MAO
monoamino-oxidase, KAT kynurenine aminotransferase, 3-HAO 3-hydroxyanthranilic acid oxidase, QPRT
quinolinic-acid phosphoribosyl transferase. From Stone and Darlington, Nature Reviews, 2002. The underlined
metabolites are those quantified by LC-MRM-MS in this study.
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Supplemental Table 1. Chromatographic retention times, MS source and analyzer conditions
for MRM analysis of tryptophan and its metabolites.
Product ion I Product ion II Internal
Fragmentor Dwell Precursor
RT 1111= /111= standards
Chemicals voltage time ion
min and collision energy and collision energy used for
V ms 111/=
cV cV quantiflcation
(Quantification ion) (Confirmation ion)
TRP 6.38 80 80 205 146(14) 118 (26) TRP-d,
TRP- (I, 6.32 80 80 213 151 (16) 123 (28) -
KYN 3.20 80 80 208 146(20) 94 (10) KYN-d,
KYN-{I, 3.08 80 80 213 150 (20) 98 (10) -
KYNA 7.56 80 80 190 144 (16) 89 (46) KYNA-d ..
KYNA-tlJ 7.53 80 80 195 149(16) 121(34) -
3-1-IAA 5.76 80 80 154 108(18) 80 (30) 3-HAA-dz
3-IIAA-tl1 5.75 80 80 156 82 (30) 110(18) -
..TRP, tryptophan; KYN, L-kynurenine; KYNA, kynurenic acid; 3-HAA, 3-hydroxyanthral1lllc
acid.
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Supplemental Table 2. Features detected in positive and negative ion mode showing
significant changes (two-fold increase or decrease In Ion intensity, coefficient of variation
(CV) < I0%, Welch's test p<O.O1) after cardiac arrest and cardiopulmonary resuscitation.
A: I'QSITIVE ION
pool I'al plasma control (CTR) pool rat plasma 2h p05frf'!UUfitalion afltr Fold change CV CV
cardiac arrest (CPR2) ("/oj (°/.)
MZ RT Replicate Replicate Replicate Replicate Replicate Replicate CPR2 v. SD p pool pool
I 2 J I 2 J CTR Value erR CPR2
368,12723 12,92 1142 956 1140 84505923 69679236 82218251 73009 14615,345 3,40E-03 0,099 10,1
520,34033 35,05 89304918 84028770 86886578 32474211 34537438 28906686 -2,71 0,044 1,80E-05 0,03 8.9
520,34045 35,24 21831105 23001899 22305057 71068146 68863809 69736478 3,12 0,132 6,80E-06 0,026 1,6
544,34009 35,09 66107602 60758979 66496529 11375210 11806095 13623338 -5,25 0,028 3,60E-04 0,05 9,7
544,33966 35,38 8252245 8598081 7616086 63751371 60850271 65387967 7,77 0,756 3,40E-04 0,061 3,6
1039,6731 35,02 21509691 20371245 20883174 2835552 3329329 3846467 -6,27 0,029 2,70E-06 0,027 15,1
114,066 2,84 4519863 3518009 1775512 12476557 11907185 8542713 3,36 2,074 9,4013-03 0,425 19,4
521,34332 J5,05 25962596 24441 J33 25116967 9402575 10124311 8407509 -2,70 0,045 2,10E-05 O,OJ 9,3
1063,67346 35,08 22041141 21707163 21391670 2686945 3053038 2105064 -8,30 0,024 2,3013-06 0,015 18,3
545,3432 35,09 20330294 18872909 20570530 3529864 3627559 4162940 -5,28 0,026 3,OOE-04 0,046 9
521,34344 35,24 6268270 6588812 6370807 20588468 19990562 20262835 3,16 0,128 4,60E-06 0,026 1,5
1039,67407 35,21 3154299 3986165 2515385 16061656 15471835 15704830 4,89 1,213 2,60E-04 0,229 1,9
545,34344 35,39 2636974 2725001 2427708 20747548 19718512 19858643 7,74 0,67 1,40E-04 0,059 2,8
520,3396 35,43 8577324 8386890 7524490 38679179 32920025 40332608 4,57 0,791 5,10E-03 0,069 10,4
544,33954 35,56 3845694 3718334 3308814 38174157 34553393 39063927 10,28 1,455 1,5013-03 0,077 6,4
1063,67151 35,3 2137205 2403945 2029115 16409544 14999500 16305388 7,26 0,999 6,10E-04 0,088 4,9
1087,67188 35,41 185127 215678 156097 15434344 13934613 15087965 79,83 17,042 9,40E-04 0,16 5,3
1087,67224 35,13 16487338 17022405 16502149 2169098 2316508 1681454 -8,11 0,022 6,60E-07 0,018 16,2
369,13 12,92 5515 6705 7538 15825955 13133408 15250774 2237,58 560,77 3,10E-03 0,154 9,6
1040,67627 35,02 12444112 11940956 12031190 1665450 1936205 2269427 -6,20 0,028 1,90Il-06 0,022 IS,S
699,22675 27,79 0 601 0 13235660 16876225 16056242 76818,85 142480,47 5,10E-03 1,732 12,4
350,11719 14,9 0 0 682 35801045 32229321 37398062 154587,14 279404,24 1,90E-03 1,732 7,5
1064,67627 35,09 13291742 12608419 12792717 1521128 1738212 2067686 -7,26 0,025 3,20E-06 0,027 15,5
1040,67712 J5,21 1706968 2198427 1382894 9374255 8885596 9143532 5,18 1,346 6,20E-05 0,233 2,7
1064.6748 35,3 1182838 1412625 1167388 9773250 8989500 9763081 7,58 1,189 4,OOE-04 0,11 4,7
1088,67517 35,41 112455 119662 94664 9421504 8587428 9229213 83,35 13,856 7,80E-04 0,118 4,8
1088,67664 35,09 10049063 9507526 9863954 527486 560788 686731 -16,57 0,01 9,60E-05 0,028 14,2
194,08133 15,97 1866 1832 2114 8485918 7126157 7880534 4042,09 672,769 2,50E-03 0,079 8,7
180,06546 14,38 768744 811276 1136766 6539850 5841396 5929574 6,74 1,918 2,20E-04 0,222 6,2
426,32166 29,09 2876 2366 2648 8585358 8759251 8284228 3248,27 406,331 2,60E-04 0,097 2,8
243,1344 15,69 1141476 893781 104188 5291981 5418197 4998251 7,34 5,879 1,70E-03 0,76 4,1
223,09692 29,43 5365309 5927263 6991032 113592 99946 81034 -62,07 0,005 6,20E-03 0,135 16,7
436,19287 14,93 276084 278114 393342 6695643 7034296 6668755 21,53 5,22 9,IOE-05 0,213 3
568,))966 35,05 7973664 7462650 7368047 1442478 1420630 1203635 -5,61 0,025 1,90E-04 0,043 9,7
223
494.32425 31.57 8038174 7910769 8070501 0 0 0 CTR only 0 3.70E·05 0.011 0
426.32175 25.56 6616199 5134227 5152919 0 0 1132 ·14932.28 0 7.50E·03 0.111 173.2
340.10321 15.28 383432 394458 196444 3642850 3716612 4237384 11.90 5.076 1.IOE·03 0.343 8.4
520.34003 35.61 4422871 4242681 3607998 11439106 10357484 10939843 2.67 0.411 9.80E·OI 0.105 5
102.96992 2.184 160746 125820 71581 3921162 3758807 4209214 33.20 14.404 8.00E·04 0.376 5.8
177,05478 29.43 3694414 4205510 4829589 71236 63732 49116 ·69.15 0.005 6,IOE·03 0,134 18.3
1063.67285 35.48 221337 170792 155878 10838588 8808034 10584795 55,17 16.418 4.IOE·03 0,188 II
521,34283 35.43 2452182 2426374 2146187 II II 1378 9439271 11568066 4,57 0,81 I, IOE·03 0.072 10.1
105,00314 2,217 57177 36771 23159 3056788 3209822 3624529 84,46 44,572 2,60E·03 0.439 8,9
544,33997 35,75 47930538 47255157 37493238 8298301 7514252 10325688 ·5,08 0.059 6,30E·03 0.132 16,7
854.35193 14.93 6909 8529 8858 3026732 3060789 2877497 368,99 59,591 3,60E·04 0.129 3,3
568,33984 35.34 858200 873119 789059 4975401 4721953 4808165 5,76 0.461 8,40E·05 0.053 2.7
1041,67932 35.02 383453 I 3606349 3622483 502709 576272 674234 ·6.31 0.029 1.40E·05 0,QJ5 14.7
496,33948 35,14 4137001 3291718 4435254 122591 124787 111504 ·32,69 0.006 7.90E-03 0,15 4
545.34351 31,18 1060843 1076903 930777 9703394 8741011 9931910 9,25 1.34 I.60E·03 0,078 6,7
310,11719 15,08 0 0 794 7695188 8875262 8031581 30984,93 56002.026 1,80E-03 1.732 7,4
125,98196 2,183 110720 90980 11329 3021296 2892183 2884618 34,77 13,38 3.70E·OI 0,359 2,6
225,12376 15.69 524325 438691 47075 2776616 2668080 2603617 7,97 6,281 1,70E·03 0.756 3,3
1061,67908 35,09 4112757 3896340 3849053 431191 113696 605369 ·7,65 0,027 1,90E·05 0,036 16,9
404,20688 28,94 3696319 3662151 3654663 0 0 0 only CTR 0 1,20E-05 0,006 0
522.34607 35.05 4084239 3950376 4015049 1555514 1665762 1386663 ·2,61 0.041 1,50E·04 0,017 9,2
388,60629 14.23 0 180 0 2686340 2712114 2689541 44933,31 78035 9,OOE·06 1,732 0.5
347,22183 26,72 591549 0 0 3328275 3232029 3329940 16,72 29,243 3,30E·03 1,732 1,7
110,00856 2.217 19928 13775 7486 2266392 2284166 2327429 166,99 77,951 3,40E·05 0,453 1,4
520.34039 35,79 21831105 20592598 19483800 511 1785 5346344 5309598 ·3,93 0,021 1,70E'()3 0,057 2.4
546,34515 35,09 342311 7 3060703 3439476 523652 528652 608308 ·5,98 0,025 1,30E·03 0,065 8,6
432,23877 28.95 3798696 3643869 3728066 225 350 0 ·19427,18 0 1.40E·04 0,021 92.5
130,96486 2,184 45211 40339 18034 2345870 211 7302 2490044 67,\3 33.615 2,IOE·03 0,42 8,1
1089.67944 35,09 3121391 2931977 3150260 151249 189589 216321 ·16,52 0,013 2,40E·04 0,039 17,6
1041,68005 35,21 492942 621273 361232 2834588 2636679 2721333 5,55 1,67 3,20E·05 0,264 3,6
494,32462 33.72 685498 688224 683490 4387576 5740267 5387868 7,54 1,049 8,IOE-03 0,003 13.6
1089,6781 35,41 3\304 33886 27972 2992903 2733153 2892454 92,51 13,05 7,OOE·04 0,095 4.6
243,13417 14,9 628602 619306 871592 2811046 2680025 2716190 3,87 0,88 2,80E-04 0,202 2,5
1065.67761 35,3 356156 416192 336787 2989398 2672985 2920927 7.74 1,317 8,40E-04 0.112 5.8
468.30832 30,77 3203352 3010396 3096461 0 0 0 onlyCTR 0 3.20E-04 0.031 0
404.20724 30,97 8536 10198 %57 2950601 2997698 2939470 313,05 31,301 3.60E·05 0,09 1
436.19287 13.91 110280 103684 110988 2371 007 2528131 23039% 22,17 1,886 8.30E·04 0,037 4,8
546,34619 35.39 398302 411324 357700 3438072 3368529 3360295 8,71 0,736 4,OOE·07 0,072 1,3
1064,67615 35.48 118759 98867 91522 6421122 5188432 6280180 57.87 14,461 4,40E-03 0,137 11,3
522,34558 35,28 799121 777606 610546 3291690 3063047 3127321 4,34 0.775 1.30E·OS 0,142 3,7
211,108 15,99 421 272 0 2055053 1997993 1848498 8515,94 8333,375 9,80E·04 0,924 5,4
214,08987 2.009 121532 655508 75062 35W183 4195277 4054177 13,86 16,913 1,70E-04 1.136 8,5
128.01924 2,217 36035 24589 14758 1709951 1755481 1795189 69,79 31,272 9,OOE·05 0,424 2,4
419.16629 14,93 70324 75913 95550 2394409 2314660 2256070 28,81 5,597 2,OOE-04 0,164 3
224
132.99818 2.217 12911 8781 4363 1680906 1541280 1846103 194.52 113.323 2.70E·03 0,492 9
370.12347 11.96 446 0 0 1%8786 2013049 1999403 13410.85 23399.352 4.30E-05 1.732 1.1
373.27405 29.09 474 402 673 2299380 2051052 2253902 4263.61 1414.493 1.2013-03 0.272 6
229.15498 4.398 126694. 151051 101025 2700895 2487265 2539120 20.40 4.925 4.00E-04 0.198 4.3
432.23834 31 5543 6383 7044 2281147 2233977 2282884 358.36 47.006 5.00E-05 0.119 1.2
1049,33911 25,41 0 0 424 1779847 1743227 1725654 12379.08 21664.577 8.30E-OS 1.732 1.6
427.32489 29.09 0 0 330 2255067 2304722 2162010 20369.09 35949.839 3.50E-04 1.732 3,2
569.34247 35.06 2404959 2229885 2256210 392201 408943 336580 -6.06 0.023 1.70E-04 0,041 10
524.67188 25.05 626 0 0 214313 I 2289644 2219464 10626.58 18758.549 3.6013-04 1.732 3.3
1111.67224 35.09 1956452 1877992 1910555 95443 104397 131127 -17.36 0.011 1.0013-05 0.021 16.8
148.97548 2.184 49333' 39910 21435 1581653 1389011 1634969 41.61 19.515 2.2013-03 0.385 8.4
338.08722 14.16 274185 282383 301817 1434157 1453236 1489506 5.10 0.351 9.4013-06 om 1.9
387.18082 28.96 1963785 1935670 1878275 0 0 0 onlyCTR 0 1.7013-04 0.023 0
834.60974 25,56 1417914 1136019 1123540 0 0 0 onlyCTR 0 6.IOE-03 0.136 0
1039.67407 35.39 286253 293017 212766 10018860 8502848 8308820 33.88 9.257 3.80E-03 0.169 10.5
420.19794 20.26 827 802 496 1702250 1641116 1682302 2365.02 658.542 1.20E-04 0.26 1,9
368.15536 15.27 4130 7899 6027 1455248 1594345 1603294 257.69 94.477 9.6013-04 0.313 5.4
401.15552 14.9 26284 28349 36343 1451512 1409000 1384673 46.66 9.291 1.40E-04 0,175 2.4
190.08635 20.47 1044516 1437437 1371570 13781 15317 15186 -87.02 0.003 9.00E-03 0.164 5,8
495.32782 33.8 519883 523192 569144 1572690 1908906 1835891 3.30 0,498 5.8010-03 0.051 10
518,32434 31.39 1914198 1881131 1797706 0 0 0 onlyCTR 0 3.5013-04 0.032 0
495.32745 31.57 2130141 2098017 2150851 0 0 148 -43101.41 0 5.2013-05 0.013 173.2
427.32495 25.56 1734329 1333099 1351240 0 0 0 onlyCTR 0 7.8013-03 0.154 0
241.11839 16.62 0 519 479 1037723 1259532 1292011 3596.46 3535.983 4.4013-03 0.868 11.6
380.25616 29.62 1230680 947176 1028342 0 0 0 only CTR 0 6.2013-03 0.137 0
268,15479 29,43 1748461 1794194 2017893 23952 22459 21051 -82.42 0.002 2.1013-03 0,Q78 6,5
874,28339 31.75 0 0 412 2741460 2749914 2518067 19440.39 34606.588 8.1013-04 1.732 4.9
350.11719 15.25 0 0 230 3268495 3441567 3194280 43062.36 763%.109 4.9013-04 1.732 3.8
478,29269 34.77 1712368 1646819 1593193 719316 705970 627912 -2.41 0.045 3,6013-05 0.036 7.2
52t.J4326 35.61 1238458 1194682 1010000 3221582 2979673 3088560 2.70 0,391 3,9013-05 0.106 3,9
373.27402 25.53 1475038 1511588 1637052 2567 340 20% -924.18 0.001 1.0013-03 0.055 70,4
568.33936 34.86 1943079 1767430 1665672 856671 861215 904721 -2,05 0.053 6.2013-03 0,Q78 3
120.98051 2.184 71731 57924 36080 1119732 1127987 1218154 20.91 7.793 2.80E-04 0.325 4.7
855.35529 14.93 3161 1920 2863 1130355 1102458 1049351 413.16 116.587 4.7013-04 0,245 3.8
387.18036 30.94 41250 49851 50512 1542483 1620389 1601340 33.64 4.543 1.901]-04 0.109 2.6
588.86029 27.94 0 0 169 1938226 2100454 2096215 36301.15 64385.175 6.80E-04 1.732 4.5
232.15448 10.38 74385 497667 11644 1766245 15%237 1285914 7,% 12.072 2.9013-03 1.359 15.7
548,37061 39.33 831853 665403 415797 2079512 1877241 1912965 3.07 1.177 2,401]-03 0.328 5.5
380.25635 30.52 1570238 1659378 1607545 0 1529 1405 -1648.66 0.001 2.6013-04 0,028 86.8
260,16086 15.69 236634 172885 26307 951346 1072340 889121 6.68 5.603 6.2013-04 0.742 9,6
214,09015 2.217 50510 28370 19986 2176765 1824628 1770424 58.38 34.631 4.30E-03 0,479 11.5
1111.67175 35.35 42633 47998 35061 1302433 1242798 1303342 30.62 5.578 1.70E-04 0.155 2.7
489.31436 18,97 10818 12785 10048 904875 899843 732700 75.40 18.223 4.60E-03 0.126 11.6
316.1395 19.54 0 0 222705 926218 975265 822083 12.23 22.236 1.6013-03 1.732 8.6
225
261.14478 12.23 318546 3 I0272 297339 1707053 1451624 1565187 5.10 0.591 3.20E·03 0.035 8.1
1048,33752 31.66 187 0 0 1918459 2070415 1834862 31142.97 55760.242 1.30E-03 1.732 6,2
437.19598 14.93 41629 47991 60120 1217806 1263434 1217605 24.70 5.178 3.20E·05 0.188 2.1
1112.67664 35.09 1176016 1160217 1189784 60118 63991 75668 -17,65 0,008 1.00E·06 O,Oll 12,2
569.34192 35.3 286001 298703 281676 1327684 1277342 1362584 4.58 0,289 3.6OE-04 0.OJ1 3.2
701,22235 14.57 0 0 268 I J72512 1309451 12J4527 14613,77 26109,086 9,30E-04 1,732 5,3
525,17261 25.1 275 0 0 12J9286 1039897 12702J8 12906,99 23711,9JJ 3.70E-OJ 1,7)2 10,6
542,l2111 l4.98 1425042 1347525 1397544 544928 633986 447070 -2,56 0,Q78 I,JOE-03 0,028 17,2
502.29309 J5.02 179147 214916 222J8J 1182920 1143767 1090477 5,54 0,849 8.50E-05 0,112 4.1
156,01428 2.217 6345 5160 2351 841953 864747 916320 189,31 92,329 6,20E-04 0,444 4,4
216,9511 2,217 22808 18014 11379 914317 831333 912898 50,93 19.528 8,60E-04 0,33 5,4
489,31427 17.01 15988 19083 16921 0 0 0 on1yeTR 0 2,80E-03 0,092 0
520,33893 36.49 1884186 1763071 1546908 931461 848171 753437 -2.05 0,1 4.10E-03 0,099 10,5
545.34351 35,79 10369)07 IOJ4)340 9611180 1774686 1960049 1047860 -5,24 0,022 ),30E-04 0,043 7,2
87),7818 29,02 0 209 0 1332324 1163105 1259993 17968,53 32344,24) 1,50E-0) 1,732 6.8
473,49094 25,72 0 0 223 901620 944941 961808 12593,58 22213,373 3,70E-04 1,732 3,3
542,32416 31,3 1173127 1167305 1128671 0 0 0 onlyeTR 0 1,50E-04 0,021 0
322,Il214 19,61 0 0 13015 846042 788829 893404 194,26 348,532 1,10E-03 1,732 6,2
874,28253 32.14 221 0 0 1682188 1751017 1903185 24146.56 4]]23,473 1,30Eo03 1,732 6,4
350.11734 15,47 322 0 0 1515943 1442203 1792643 14754,00 27285,121 4,50E-03 1,732 11,7
510,35532 39,36 783820 638582 335170 2221304 1659224 1686922 3,17 1,779 6,50Eo03 0,391 17,1
171,99159 2,183 28164 23981 12651 790139 761269 802085 36,32 14,469 4.30E-05 0,372 2,7
542.32178 35,21 605531 610118 571601 1307507 1281020 1231478 2,14 0,14 9,30Eo05 0,035 3
467,301l3 16,96 11675 15209 13207 0 0 0 onlyeTR 0 5,80E-03 0,133 0
341,10648 15,28 60375 59238 31611 605033 625433 712278 12,85 l,281 I.60E-03 0,323 8,8
874.28363 30,7 207 0 0 2258248 2672126 1968454 38158,59 71199,325 6,10Eo03 1,732 13,5
497,34274 35,54 1092475 861957 1172523 25479 23697 24992 -42,16 0.005 8,30E-03 0,155 3,7
1040,67529 35,41 129543 133265 96995 4457555 3513584 4704732 35,23 11,103 7,70E-03 0,166 14,9
835.61383 25.52 655355 719643 723484 0 0 0 onlyeTR 0 I,OOE-03 O,Ol5 0
327,00864 30.76 1477170 1418180 1501942 336901 277719 316125 -4.72 0,027 8,50E-06 0,029 9,7
511.32687 19,15 7905 7442 5280 588297 680007 582735 89,74 26,236 2,60E-03 0.204 8,9
313,17584 3,737 189750 283596 220085 507574 506658 510445 2,20 0,464 9,70E-03 0,107 0,4
368,15512 15,5 7929 9979 7464 1087976 1013891 909885 119,10 29,508 2,70Eo03 0,158 9
1112,67566 35,35 26068 33160 24093 840091 752640 797477 28,69 6,5 9,60E-04 0,172 5,5
395,1748 14,7 743 510 0 1383206 1136510 1075438 2869.24 3001,458 6,IOE-03 0.91 13,6
190.04996 13,17 3401 1443 2287 1017756 963811 959662 412,46 184,08 3,60Eo04 0,413 3,3
582,85693 31.22 155 0 0 1641859 1523577 1797105 32016.39 57963,998 2.30Eo03 1,732 8,3
329.00543 30,74 1363347 1278694 1388895 290144 286944 271217 -4,75 0,017 7,20Eo04 0,043 3,6
1063,67261 34,83 1018875 886709 793100 396768 346806 312551 -2,56 0,096 7,60Eo03 0,126 12
239,13925 15,97 325 0 524 979386 801282 887886 3143,17 3253,066 3,30Eo03 0,935 10
195,08461 15,99 407 0 0 917823 908799 853789 6585,78 11669,012 5,OOE-04 1,732 3,9
391,28482 29,07 363389 394583 405818 959096 886101 938892 2,39 0,233 1,40Eo04 0,057 4,1
224.10011 29,43 703365 773325 908169 9227 8687 7536 -93,71 0,002 5,80llo03 O,IlI 10,2
115.06929 2.84 145808 98729 56992 437347 435669 322812 3,97 2,406 4,40Eo03 0,442 16,5
226
464.30118 23,87 0 0 211 645895 710894 660766 9561,87 17050,065 8,50E-04 1,732 5,1
874,69891 24,84 389954 23264 430742 1222636 1390016 1172990 4,49 3.982 6,90E-03 0,798 9
244,13762 15,69 132454 99776 7094 616473 637903 607603 7,78 6,537 3,20E-03 0,815 2,5
521,34369 35,79 6268270 5886418 5576289 1447309 1527101 1504726 -3,96 0,022 1,80E-03 0,059 2,8
566,32104 35,45 321282 331647 282287 1083389 1139497 1066440 3,52 0,416 2,40E-05 0,083 3,5
874,6991 22,71 1227392 1064799 903972 0 0 0 only CTR 0 7,6OE-03 0,152 0
405,21085 28,95 889728 855848 884671 0 0 0 on1yCTR 0 1,40E-04 0,021 0
214,91762 2,184 37403 35573 20501 562270 518326 543932 17,38 5,882 I,OOE-04 0,298 4,1
874,44824 24,84 358302 25243 433736 1152245 1327690 1137449 4,43 3,91 7,6OE-03 0,798 8,8
1104,42688 28,79 105778 106413 112829 832593 1051773 1051586 9,03 1,493 6,90E·03 0,036 12,9
288,10809 13,44 10775 8383 5481 843465 936400 883268 108,09 40,571 9,OOE·04 0,323 5,3
410,32657 34,46 938938 833687 827023 108424 91345 84404 ·9,15 0,022 1,6OE-03 0,072 13,1
114,98752 2,217 1901 1394 617 562718 530055 617294 437,13 250,588 2,OOE-03 0,4% 7,7
181,06865 14,38 74083 79404 106026 610908 542577 541493 6,53 1,752 5,6OE·04 0,198 7
433,242 28,95 998471 966289 972391 0 0 0 only CTR 0 I,OOE·04 0,017 0
566,3208 35,12 1084213 968287 1055056 277121 275663 305573 ·3,62 0,032 1,10E-03 0,058 5,9
149,02325 29,43 645564 862628 860449 86187 78825 71486 ·10,02 0,025 9,90E-03 0,158 9,3
1066,68274 35,09 866665 837518 825545 97949 118922 139879 ·7,09 0,Q28 1,90E·06 0,Q25 17,6
1065,67908 35,48 37292 31103 26671 1%5)81 1511170 1887967 56,43 17,168 6,30E-03 0,168 13,6
874,44812 22,72 1245543 1032398 942961 0 382 0 ·8431,68 0 6,90E·03 0,145 173,2
348,22507 26,72 126515 0 0 746908 729300 753113 17,62 30,813 2,90E-03 1,732 1,7
874,28357 32,56 207 0 0 1158707 1351189 1320511 18504,38 33519,599 2,20E·03 1,732 8,1
468,30856 32.48 107660 91282 176339 2315747 2417467 2351057 18,88 7,223 7,30E-07 0,361 2,2
229,15486 3,613 78931 %384 103499 1388394 1242360 999604 13,02 3,884 9,90E·03 0,JJ6 16,2
260,16083 14,97 465560 , 422829 505342 72507 61095 54126 -7,42 0,032 2,40E-03 0,089 14,8
1%,06053 10,53 0 3005 0 789807 686350 608338 693,68 1292,252 5,70E-03 1,732 13,1
246,1701 14,07 127470 144415 194614 707254 712924 649607 4,44 1,222 4,80E-05 0,225 5,1
1042,68237 35,05 760367 77J 784 752229 263530 280977 217316 ·3,00 0,048 6,20E·04 0,013 13
206,08124 18,81 120651 0 0 555014 582585 492876 13,51 24,549 9,70E·04 1,732 8,5
502,28729 15,69 47322 27999 388 436274 483362 389389 17,29 18,023 9,50E·04 0,935 10,8
426.32138 28,91 3200 1647 2406 3584133 3970545 4757159 1697,48 792,595 7,OOE-03 0,321 14,6
157,06073 15,69 97470' 84267 5368 539185 538804 517696 8,53 7,007 2,40E-03 0,799 2,3
485,19897 3,396 149576 154907 136149 56450 46434 9327 ·3,93 0,186 9,10E-03 0,066 66,4
469,31158 30,77 773915 721052 735844 0 0 0 only CTR 0 4,50E·04 0,037 0
372,06668 30,77 1103021 1020242 1069678 72453 55479 66265 ·16,44 0,01 3,60E-04 0,039 13,3
531,24939 16,01 0 0 182 456875 430251 428652 7229,55 12818,27 4,40E-04 1,732 3,6
568,33972 35,52 306226 316216 269721 2451065 2180304 2019311 7,45 1,347 3,90E-03 0,082 9,8
405,21042 31 6% 1632 1426 672694 663095 681903 537,48 218,704 6,30E-05 0,393 1,4
1090,68237 35,09 699615 647680 695779 37333 44990 50192 ·15,42 0,012 4,OOIl-04 0,042 14,6
357,27887 34,S 735162 748734 687805 165554 108302 137097 ·5,28 0,048 2,10E·05 0,044 20,9
384,11508 10,46 0 9935 0 768407 878641 803547 246,66 444,252 1,40E·03 1,732 6,9
426,32132 26,36 7201 4283 4980 538704 512380 552541 97,40 30,769 4,60E·04 0.278 3.8
322.09238 16.08 0 0 250 423341 457529 488542 5477,65 9880.994 1.70E-03 1.732 7.1
943.97382 25,77 0 0 80 548508 490997 544473 19799.73 35674.945 1.201l·03 1.732 6,1
227
174,11238 15,66 11021 17267 11507 520370 58073 I 475168 39,61 14,368 3.40E-03 0,262 10,1
391,28445 25,53 756069 765970 805400 270600 253913 282815 -2,88 0,03 6,30E-05 0,034 5,4
699,56085 31,01 253 0 0 701352 725070 709366 8441,85 14758,325 9,60E-05 1,732 1,7
374,06339 30,76 1006126 913644 1059225 71430 54838 65589 -15,53 0,013 1,90E-03 0,074 13,2
295,12906 13,57 140435 136735 120555 630695 607207 576020 4,56 0,571 2,90E-04 0,08 4,5
485,2608 15,69 61121 34343 455 388909 387547 368962 11,94 11,704 8,90E-04 0,951 2,9
143,99655 2,183 32830 28063 16775 468405 496735 407464 17,67 7,39 2,9010-03 0,318 10
874,28369 30,52 428 0 0 1152056 1186216 1218691 8310,66 14615,73 2,60E-04 1,732 2,8
327,00824 30,93 1083958 1151671 1234896 310964 275755 280031 -4,00 0,033 1,50E-03 0,065 6,6
107,00066 2,217 7060 4178 2463 474020 455329 514166 105,36 60,175 1,20E-03 0.509 6,2
1090,68103 35.41 5193 8509 6280 638936 576473 623602 92,03 28,249 9,30E-04 0,254 5,3
174,11247 16,25 2838 374 2017 456967 506326 551486 289,69 235,688 2,90E-03 0,72 9,4
274,13995 15,77 429335 360476 325538 130381 162980 198343 -2,27 0,154 7,30E-03 0,142 20,7
245,07883 29,43 557707 654260 698561 2220 2277 621 -373,30 O,D02 4,lOE-03 0,113 55,1
218,98413 2,217 2488 1223 1012 416249 366354 407942 252,07 144,869 1,50E-03 0,507 6,7
546,34619 35,58 134652 137669 119869 1664551 15D0745 1711388 12,43 1,752 1,70E-03 0,013 6,8
329,00549 30,93 1150935 1132832 1105218 282116 282355 290884 -3,96 0,01 1.40E-04 0.D2 1,7
874,94946 24,84 268824 13268 304965 881359 971297 829234 4,57 4,079 7,80E-03 0,813 8
340,10312 15,47 656720 326943 557488 2249822 1777077 2570736 4,28 2,187 9,lOE-03 0,329 18,2
1066,68164 35,35 31703 36869 29044 693418 605349 651602 19,98 3,797 1,60E-03 0,122 6,8
489,81589 18,97 4964 3879 4181 443436 407573 334575 87,02 23,344 6,70E-03 0,128 14
518,32416 31,16 750778 716900 738905 0 ° 0 only CTR ° 1,80E-04 0,023 °
1087,67322 35,59 29292 28641 21697 5450533 4425041 5688370 195,45 56,291 5,60E-03 0,159 12,9
997,62531 34,77 513620 492134 408480 129844 109294 98783 -4,19 0,062 5,DOE-03 0,118 14
331,05408 4,095 241810 377164 168205 990242 8D0779 884096 3,40 1,735 I.60E-03 0,404 10,6
1104,30017 27,92 7525 12613 14227 839904 924169 751280 73,20 29,897 ),60E-OJ 0,305 10,3
372,23837 13,34 13614 13314 8785 402685 383361 388481 32,89 8,316 9,IOE-05 0,227 2,6
1104,42615 28,12 35533 92992 72862 996648 910987 725589 13,08 7,743 7,50E-03 0,434 15,8
2DO,9735 2,217 1740, 1352 923 401351 365069 404389 291,61 105,354 I,DOE-03 0,305 5,6
1042,68201 35,25 57497 56206 36455 615809 554801 583494 11,68 3,362 2,70E-04 0,236 5,2
1104,55078 27,82 9362 13970 15238 672046 897716 809909 61,70 23,689 7,DOE-OJ 0,241 14,3
274,16537 21,97 1627 485 855 433254 421807 389902 419,60 269,846 9,70E-04 0,589 5,4
571,35889 37,32 654497 636336 498824 129315 153045 112471 -4,53 0,066 8,IOE-03 0,143 15,5
445,28796 16,95 4801 5706 4647 0 ° 0 only CTR ° 4,20E-03 0,113 0
874,94952 22,71 863295 753760 668797 0 0 ° only CTR 0 5,40E-03 0,128 °
106,06187 14,55 2781 2697 3173 1276371 1301124 1004263 414,03 93,616 6,30E-03 0,088 13,8
514,28284 20,65 0 0 183 305754 345104 375867 5610,52 10315,217 3,50E-03 1,732 10,3
105,03313 14,38 61155 61453 88592 435614 332277 378732 5,43 1,95 5,50E-03 0,224 13,5
106,00391 2,217 5588 3811 2465 415647 407327 439488 106,41 46,367 4,80E-04 0,3% 4
511,35858 39,25 404277 330982 223925 918388 761562 748201 2,53 1,014 3,DOE-03 0,284 11,7
374,27747 29,09 ° 84 ° 572901 490258 560878 19333,77 35263,746 2,30E-03 1,732 8,2
533,32532 20,49 881 ° 345 42%63 385498 359319 957,98 1127,863 2,70E-03 1,087 9,1
1104,55139 28,88 91244 98573 89624 696232 816991 796712 8,27 1,117 2,90E-03 0,051 8,4
524,67181 25,23 311 0 0 4631552 3536837 3531889 37621,47 71n2,17 8,70E-03 1,732 16,2
228
1104,55127 28,13 35402 87710 194839 863244 790432 671755 7,31 6,521 9,OOE-04 0,767 12,5
874,69934 22,98 723849 796529 746171 0 0 0 only CTR 0 8,IOE-04 0,049 0
1104,30188 28,21 90925 196898 168669 837697 905972 728586 5,42 2,541 9,80E-04 0,361 10,9
503,J2971 18,97 1667 1897 2JOJ 340783 358092 312897 172,45 40,042 1,50E-03 0,165 6,8
1104,67651 28,76 74160 88410 82369 731497 668632 694818 8,55 1,136 5,20E-04 0,088 4,5
480,80099 18,97 3504 4115 5415 J49608 355578 J 10828 77,95 2J,105 1,70E-OJ 0,225 7,2
489,81573 17,01 7081 8394 6673 ° 0 0 onlyCTR 0 4,90E-OJ 0,122 0
433,24191 30,97 1451 1025 1663 559697 563731 561005 406,97 97,449 2,70E-06 0,236 0,4
1104,17554 27,97 9176 11753 26764 693210 732137 55J470 41,49 30,699 6,60E-OJ 0,597 14,2
243,13419 22,42 408662 44JJJ3 468086 ° 808 1589 -550,72 0,002 1,50E-OJ 0,068 99,S
370,13379 11,96 327 273 0 475997 430143 449702 2259,74 2099,495 8,60E-04 0,877 5, I
137,07057 2,942 20131 17080 15038 474911 413904 338761 23,49 7,374 9,90E-03 0,147 16,7
437,19608 13,91 14985 12869 12990 423490 448552 407200 31,32 4,264 8,20E-04 0,087 4,9
134,05984 13,52 524527 520516 559323 34678 961 0 only CTR 0,038 6,70E-06 0,04 166,2
511,82855 19,15 3843 3543 2479 282715 328911 286122 91,00 27,657 2,50E-03 0,218 8,6
503,32962 17 5313 6953 5980 0 0 0 only CTR 0 6,IOE-OJ 0,136 0
224,09525 13,82 19466 15301 20471 490828 556205 447597 27,06 6,998 4,20E-03 0,149 II
208,06059 13,9 7028 8371 5833 453662 326972 399265 55,57 18,95 8,90E-03 0,179 16,2
854,35187 13,91 0 945 0 342522 334241 318449 1053,13 1863,735 4,40E-04 1,732 3,7
387,18039 31,13 11174 11866 10701 1243814 978292 1366793 106,37 23,193 9,20E-03 0,052 16,6
151,03529 2,217 4216 3115 1663 345729 315827 320019 109,14 52,01 7,80E-04 0,427 4,9
246,16989 14,46 57719 55486 67335 337035 344453 353073 5,73 0,733 2,OOE·06 0,105 2,3
370,1235 13,1 889 330 0 1648882 1344128 1516715 3699,53 4464,647 3,40E-03 1,105 10,2
569,34277 34,86 571541 533361 492074 242095 241968 253884 -2,16 0,047 5,30E-03 0,075 2,8
178,05803 29,43 382335 437717 509473 2686 3247 1435 -180,45 0,003 6,90E-03 0,144 37,8
250,08018 3,401 150063 153039 141545 27660 28722 5842 -7,15 0,093 8,20E-04 0,04 62,3
519,32764 31,39 532845 519364 506554 0 0 0 onlyCTR 0 2,IOE-04 0,025 °
679,19824 15,32 3383 3536 4090 234578 207598 225003 60,60 9,869 1,30E-03 0,101 6,2
817,58258 25,53 332114 333312 347656 0 0 314 ·3226,38 0,001 2,20E·04 0,026 173,2
225,12337 14,38 50847 50075 83203 306285 238188 241237 4,27 1,941 4,40E-03 0,308 14,7
494,32364 31,21 562864 525889 559231 0 0 0 only CTR 0 4,60E-04 0,037 0
874,28345 29,64 221 0 0 1059135 1081708 1009710 14255,90 25171,64 4,IOE-04 1,732 3,5
232,92825 2,184 26629 22009 14789 296985 247553 309153 13,46 5,342 4,OOE·03 0,282 11,5
33 I ,05405 4,272 237047 264527 191564 834137 666021 765391 3,27 0,887 3,30E-03 0,159 11,2
261,14478 12,04 50574 56441 186714 984163 852445 994413 9,64 8,385 1,90E·04 0,786 8,4
478,29297 34,95 115499 205932 150120 760952 717065 741786 4,71 1,506 3,50E-04 0,29 3
388,18423 28,96 460907 442856 439428 0 0 0 only CTR 0 2,20E-04 0,026 0
263,19696 3,747 87739 98863 85832 297872 246704 286539 3,05 0,532 4,50E-03 0,077 9,7
701,22217 14,76 0 0 529 795171 711876 770798 4305,95 7694,854 1,IOE-03 1,732 5,6
355,26349 25,53 390346 399050 445552 1549 0 600 ·574,66 0,002 1,70E-03 0,072 109
502,29282 34,83 913253 760999 703620 364318 403060 233539 -2,38 0,17 5,30E-03 0,137 26,6
327,00894 31,14 863455 864766 818614 300421 290117 323307 -2,79 0,031 2,80E-05 0,031 5,6
652,41132 17,24 850 1141 0 277755 268536 236598 393,21 383,701 2,30E-03 0,893 8,3
574,19696 28,44 0 0 254 587592 513201 579150 6613,95 11943,772 1,80E·03 1,732 7,3
229
382,27176 33,09 175650 147757 165197 371029 451570 443490 2,59 0,497 5,601'·03 0,087 10,5
549,3739 39,33 238257 183795 106133 629959 564338 573323 3,35 1,464 2,301'·03 0,377 6
5JJ,32574 20,28 1454 0 1129 325122 324313 343116 384,26 352,83 3,201'·04 0,886 3,2
1189,15686 25,26 736701 642780 646339 0 596 2394 ·677,53 0,002 2, IDE-D) 0,079 125
1189,01392 25,36 729184 529930 650637 467 2513 2704 ·335,99 0,002 8,201'·03 0,158 65,5
226,12708 15,69 56990 46949 3168 308843 319294 309203 8,75 7,181 2,60E·03 0,802 1,9
374,06329 30,95 768691 756388 753824 47860 46209 42387 ·16,70 0,004 5,70E·06 0,01 6,2
387,18088 29,35 349059 375324 409140 137966 167902 175618 -2,35 0,086 9,70E·04 0,08 12.4
102,03347 2.183 31344 25132 13920 307390 345726 312913 13,72 6,048 3,50E·04 0,376 6,4
329,00534 31,11 759295 786626 806046 285511 292021 297961 ·2,69 0,019 3,60E·04 0,Q3 2,1
392,14883 11,1 0 6638 363 398680 308027 306839 144,77 254,064 7.90E·03 1,599 15,6
372,06641 30,96 779988 744371 745632 58496 45256 54162 ·14,37 0,011 7,OOE·05 0,027 12,8
1104,67603 28,13 21225 70064 129487 688542 620154 496679 8,18 7,346 3,20E·03 0,737 16,2
1189,01379 25,17 777317 609075 731891 621 896 1399 ·726,43 0,001 5,OOE·03 0,123 40,6
IJO,I5878 13,3 164451 138113 179746 349181 357010 318614 2,12 0,405 4,301'·04 0,131 5,9
376,12393 10,38 1922 20666 308 485557 494994 377982 59,33 96,499 5,80E·03 1,483 14,4
874,19806 22,71 606273 535922 447966 0 0 0 only CTR 0 7,40E·03 0,15 0
236,99837 3,023 269076 225419 204994 91351 97191 64657 ·2,76 0,125 5,801'·03 0,14 20,6
374,27722 25.53 359573 373854 402064 0 0 0 only CTR 0 1,10E·03 0,057 0
874,19781 24,84 159529 12290 196221 576804 671085 573729 4,95 4,378 4,IOE·03 0,793 9,1
516,30591 31.59 515985 501734 473715 210 355 0 ·2639,71 0 6,20E·04 0,043 94,8
570,35492 35.47 469496 432402 404709 0 0 0 onlyCTR 0 1,90E·03 0,075 0
112,00609 2,217 1646 1045 683 279919 230007 277962 233,52 126,203 3,90E·03 0,433 10,8
157,08588 17,47 35870 9228 9007 506713 424395 477874 26,04 24,619 I,OOE·03 0,856 8,9
175.09656 17.47 42347 8803 8715 511518 448959 489864 24,23 25,135 1,10[·04 0,972 6,6
1104,17688 28,21 61186 156314 123561 652790 668152 547982 5,48 2,905 6,30E·04 0,425 10,5
1119,40247 20,18 0 452 0 249516 263))9 256075 1701,17 2990,098 2,40E·04 1,732 2,7
479,29602 34,77 395618 375629 351444 147264 144070 129889 ·2,67 0,047 8,50E·04 0,059 6,6
1104,17627 28,92 59474 69090 65166 581879 470103 633767 8,70 1,947 9,10E·03 0,075 14,9
245,16106 3,808 9265 : 8144 2021 308838 322247 290173 47,41 31,029 5,30E·04 0,602 5,2
1113,67944 35,08 380755 359917 388927 21205 20472 15027 ·19,92 0,011 3,30E·04 0,Q4 17,9
1189,30017 25,31 650541 487879 515137 240 223 567 ·1605,40 0 8,20E·03 0,158 56,4
1048,33691 25,05 169 0 0 383260 342656 351894 6377,57 11443,18 1,20E·03 1,732 5,9
748.4115 22,79 404 0 0 272457 267507 248612 1951,92 3471,6 7,60E·04 1,732 4,8
106,06184 14,72 3218 2948 1831 984811 885470 963203 354,32 117,297 I,OOE·03 0,276 5,5
522,34644 35,48 272605 246552 242428 1007605 857737 1027834 3,80 0,611 4,60E·03 0,064 9,6
388,22342 31,42 409960 416697 435734 0 0 0 onlyCTR 0 3,40E-04 0,032 0
874,94989 22,98 500732 589925 529750 0 326 0 ·4970,57 0 2,40E·03 0,084 173,2
378,2402 29,96 189780 154219 134956 330478 373483 368672 2,24 0,538 8,IOE·04 0,174 6,6
241,11855 15,97 288084 283853 299483 0 S73 0 ·1520,80 0,001 2,50E-04 0,028 173,2
1189,15674 25,44 616838 477832 508161 1086 1587 2742 ·296,00 0,002 6,20E·03 0,137 47
520,33881 36,66 1018401 875796 802365 433661 391869 321912 ·2,35 0,115 5,SOE·03 0,122 14,8
526,17102 32,92 167 0 0 565578 515084 540802 9709,37 17260,243 7,30E-04 1,732 4,7
482,36105 38,11 108335 171314 189893 559249 734404 633565 4,10 1,683 3,80E-03 0,273 13,7
230
375,28937 34,S 407191 422099 386346 84106 56154 72025 -5,73 0,042 2,30E-05 0,044 19,8
564,35895 r 5,98 204618 220046 215178 0 0 0 only CTR 0 4,6OE-04 0,037 0
1104,42725 28,97 87038 90916 82349 708485 703983 751313 8,31 0,712 4,20E-04 0,049 3,6
198,93996 2,184 4486 4172 2417 275710 228504 275676 70,42 28,657 3,70E-03 0,302 10,5
377,14581 15,03 15774 16069 19679 226738 222818 207782 12,76 2,198 5,OOE-04 0,127 4,6
700,22876 29,88 93 0 0 372614 400100 383498 12432,39 22054,479 4,30E-04 1,732 3,6
420,16956 14,93 9394 9627 13082 379578 365909 352183 34,19 7,879 3,80E-04 0,193 3,7
329,00571 31,31 715670 670406 656739 294807 269761 295125 -2,38 0,04 3,70E-04 0,045 5,1
1104,80127 28,85 49402 49628 45398 464564 434113 505808 9,72 1.228 2.30E-03 0,049 7,7
443,29095 19,78 258538 292671 312713 0 0 0 onlyCTR 0 3,OOE-03 0,095 0
525,67255 25,1 502 293 0 294903 278738 289684 1085,94 1065,262 2,70E-04 0,952 2,9
874,44867 22,53 626222 593115 510601 0 0 0 onlyeTR 0 3,50E-03 0,103 0
508,33966 35,81 106657 108560 180906 483051 482978 443339 3,56 1,314 1,IOE-03 0,321 4,9
259,12915 11,56 1078 42032 3708 236929 317042 333512 18,96 31,155 4,50E-03 1,469 17,5
502,8136 19,15 2713 2151 2161 186403 248334 228291 94,38 26,447 6,90E-03 0,137 14,3
327,00861 31,41 681339 649132 649932 316607 282451 345348 -2,10 0,061 3,30E-04 0,028 10
508,33951 35,42 510957 479564 480820 9674 9722 11451 -47,70 0,003 4,40E-04 0,036 9,8
1104,42676 25,34 570548 566457 692084 0 2355 1302 -500,16 0,002 4,50E-03 0,117 96,8
1165,5946 22,69 493307 456676 384022 0 0 0 only CTR 0 5,20E-03 0,125 0
441,14804 14,92 23586 25376 35634 375814 375186 362891 13,17 3,294 5,10E-07 0,231 2
343,16559 31,43 383520 388316 391147 0 0 0 onlyeTR 0 3,30E-05 0,01 0
1165,9292 22,72 559375 487576 411992 0 0 282 -5173,56 0 7,6OE-03 0,152 173,2
1188,87085 25,21 609320 504712 542917 0 223 1067 -1284,46 0,001 3,OOE-03 0,096 130,9
464,22382 14,93 7391 6735 8752 33053 I 283500 256441 38,05 10,05 5,80E-OJ o.ns 12,9
202,04738 14,38 75120 74222 112083 223139 182055 215172 2,J7 0,838 2,50E-03 0,248 10,5
387,18042 31,75 12643 12872 12232 327647 322513 323267 25,79 0,885 2,IOE-05 0,026 0,9
520,32275 35,05 524440 410742 436906 198502 173854 161562 -2,57 0,092 9,50E-03 0,11 10,6
944,30792 26,04 0 0 173 247215 222203 225964 4019,55 7202,221 1,IOE-03 1,732 5,8
331,05414 4,495 201091 182262 135626 570570 564766 602396 ),35 0,769 2,20E-04 0,195 1,5
1104,67627 28,96 53203 64324 56006 535588 501003 522210 8,98 1.2 1,40E-04 0,1 3,4
244,13748 14,9 70994 67585 103471 301683 281736 288246 ),60 1,01 5,IOE-Q4 0,246 3,5
699,72797 34,32 797 250 278 505140 495254 502721 1134,43 802,634 3,)OE-05 0,697 I
111,00934 2,217 1882 1231 763 277579 270184 262699 209,10 96,752 2,40E-04 0,415 2,8
1104,30151 25,26 558832 646451 649286 196 1746 170 -802,15 0,001 2,30E-03 0,083 110,1
611,95001 33,19 162 0 0 385491 414624 397546 7392,97 13083,701 4,50E-04 1,732 3,7
543,32739 31,) 343116 339741 326197 0 0 0 #D1V/0! 0 2,40E-04 0,027 0
1088,67627 35,59 15725 18097 11519 3313483 2723696 3412974 208,42 70,589 4,70E-03 0,22 11,8
1104,55188 25,43 478275 477164 553692 0 2892 1227 -366,38 0,003 2,50E-03 0,087 105,7
327,00824 31,67 593921 580156 593594 316506 277123 279930 -2,02 0,044 6,20E-04 0,013 7,5
1104,8009 27,77 2756 8713 3944 369559 516890 489231 89,25 70,018 9,70E-03 0,614 17,1
856,35712 14,9 451 392 661 226703 248323 217183 460,25 161,844 1,60E-03 0,282 6,9
591,67102 19,05 0 552 0 254024 254026 235078 1346,25 2389,461 6,40E-04 1,732 4,4
209,09203 11,96 0 889 301 234307 225060 273816 616,12 767,36 3,70E-03 1,14 10,6
510,35513 39,54 3449032 3358251 2876641 720402 529986 521600 -5,47 0,052 1,90E-03 0,095 19
231
373,2738 26,36 34])2 849 1442 27953 I 236255 278445 21,69 36,063 2,20£-04 1,57 9,3
874,69897 22,52 636489 588508 514104 0 0 0 only CTR 0 3,80E-03 0,106 0
388,18396 31 3975 5294 5965 344719 363082 361758 70,21 16,013 2,50E-04 0,199 2,9
875,20001 22,71 466349 406387 347872 288 0 317 -2017,53 0,001 7,OOE-03 0,146 86,9
874,69873 23,16 484913 486156 471271 0 0 0 onlyeTR 0 9,80E-05 0,017 0
267,13419 3,852 2876 1714 2667 223908 205148 21764) 89,11 26,757 6,40E-04 0,256 4,4
874,44812 23.16 493174 466277 480271 0 1915 0 -751,81 0,002 2,40E-04 0,028 173,2
558,29541 35,2 94077 90771 94658 390332 371859 387231 4,11 0,199 2,30£-04 0,023 2,6
259,14771 2,009 5870 41135 3380 455084 397123 544564 27,72 39,276 5,80E-03 1,257 16
381,25949 29,62 232011 175394 198744 0 0 0 onlyeTR 0 6,50E-03 0,141 0
875,19965 24.81 130640 8647 126246 652104 521019 520787 6,38 5,843 1,30E-03 0,782 13,4
503,29605 35,01 37780 49964 47222 283837 286024 253332 6,10 1.273 7,80£-04 0,142 6,7
293,09854 19,92 159712 173692 190128 442810 500297 459198 2,68 0,403 6.30£-04 0,087 6,3
1021,62598 35,09 2124 8554 11448 278739 269281 283385 37,58 25,288 3,30E-06 0,647 2,6
569,34265 35,48 103524 86366 8803 I 831648 744778 852317 8,74 1,509 1,70E-03 0,102 7
1104,55164 25,21 504291 626448 682481 0 898 624 -1191,34 0.001 7,50£-03 0,151 90,7
239,96715 2,217 4116 3616 2408 226702 189585 198511 60,63 21,485 3,OOE-03 0,26 9,5
1189,1571 28,79 109641 101509 89000 470134 530518 435016 4,78 0,98 4,OOE-03 0,104 10,1
520,33252 15,8 160J80 157282 194260 0 0 0 onlyeTR 0 4,80E-03 0,12 0
411,17801 20,62 495 0 0 225105 204317 212917 1297,65 2309,545 7,90E-04 1,732 4,9
293,09848 20,36 158761 167610 187588 428745 520788 531140 2,88 0,577 7,OOE-03 0,086 11,4
293,0983 18,97 178512 179602 176490 510207 570841 489994 2,94 0,262 4,90£-03 0,009 8
392,19171 15,09 2215 2446 3693 219680 228696 216777 79,62 24,956 2,20E-04 0,285 2,8
431,27667 25,55 329858 276326 315804 0 0 0 onlyeTR 0 2,70E-03 0,Q9 0
508,3765 39,65 54085 105676 196236 521158 416425 439170 3,87 2,809 3,60E-03 0,606 12
160,09674 11,84 4740 14210 14455 254526 269316 329149 25,49 16,238 6,IOE-03 0,498 13,9
275,14349 16,01 495 0 0 233710 208923 226182 1351,14 2417,533 1,IOE-03 1,732 5,7
1041,67847 35,41 37621 39343 30410 1321352 994128 1372943 34,35 10,289 9,70E-03 0,132 16,7
1189,01282 28,86 103169 93997 73751 379776 400936 420787 4,43 0,966 5,70E-05 0,161 5,1
520,35333 35,25 78538 74027 65895 323341 275630 282806 4,04 0,708 2,90E-03 0,088 8,8
339,09058 14,15 36366 38819 38540 205917 226559 220212 5,74 0,482 9,80E-04 0,Q35 4,9
521,34216 36,46 525171 495340 426913 234260 216058 197594 -2,23 0,085 6,20E-03 0,104 8,5
261,0528 29,43 235736 274949 305077 1031 1114 716 -285,13 0,001 5.40E-03 0,128 22
279,13431 15,69 7082 5307 3456 190903 18%52 192111 36,14 12,637 8,60E-08 0,343 0,6
512,33472 31.08 297491 299022 296675 0 354 0 -2523,13 0,001 2,90E-06 0,004 173,2
293,09839 20,54 153248 167610 187588 429204 500515 505658 2,82 0.539 2,50E-03 0,102 8,9
661,29266 14,9 3432 2329 3235 201523 181118 161237 60,46 18,578 4,20E-03 0,1% 11,1
1113,6792 35,34 10874 12035 11560 287477 264564 261182 23,59 2.444 9,90E-04 0,051 5,3
413,14133 13,04 3396 9942 9965 164130 139715 139%1 19,05 11,089 1,90E-03 0,487 9,5
248,09546 14,82 1497 1731 3088 281980 267985 261998 128,56 57,329 4,50E-04 0,408 3,8
432,23804 25,69 218293 250983 263808 0 0 0 onlyeTR 0 3,IOE-03 0,0% 0
1104,427 25,62 406945 431096 450742 0 4998 1582 -195,86 0,006 7,60E-04 0,051 116,5
1021,62549 34,84 283377 308913 294358 147000 145155 144669 -2,03 0,026 2,20E-03 0,043 0,8
134,99568 2,217 834 801 382 201191 161987 194904 276,69 135,022 4,30E-03 0,375 11,3
232
100,07542 3,082 284885 215849 240879 41878 53665 41315 -5,42 0,054 7,90E-03 0,141 15,3
525,34259 17 4204 5005 4853 0 0 0 only em 0 2,70E-03 0,091 0
520,32556 35,25 122264 123541 110498 304118 285514 244471 2,34 0,399 9,IOE-03 0,061 II
1104,677 25,34 392714 400401 500255 1118 1892 1309 -299,46 0,001 6,40E-03 0,139 28
570,34619 35,08 301703 316745 331345 66486 67046 53993 -5,06 0,033 1,40E-04 0,047 11,8
1104,80212 28,18 50735 50767 89535 486350 469267 356618 6,87 3,522 7,IOE-03 0,352 16,1
325,17615 15,09 368 424 0 184786 181044 182380 692,18 611,491 2,80E-05 0,873 I
666,229 13,91 711 1804 1328 201143 264520 237073 182,86 103,02 6,IOE-03 0,428 13,6
518,32361 33,76 1959207 1897226 1768007 909146 416203 636112 -2,87 0,15 6,70E-03 0,052 37,8
790,38062 28,96 189128 198178 194502 0 0 0 only CTR 0 1,80£-04 0,023 0
547,34857 35,11 314650 301848 300840 58120 65292 52233 -5,22 0,026 2,40E-06 0,025 11,2
817,26495 33,12 0 186 0 359600 370072 382120 5977,38 10559,08 3,IOE-04 1,732 3
700,22809 31,01 0 160 81 302112 324699 333382 3984,20 4170,89 8,50E-04 0,996 5
331,00241 30,74 424063 404672 427768 78656 75704 73652 -5,51 0,011 2,70E-04 0,03 3,3
188,07069 22,71 5354 " 0 579 215987 218055 219197 110,10 164,433 I,OOE-06 1,486 0,7
503,83127 18,97 603 1246 663 162873 165486 135790 184,77 97,929 3,80E-03 0,424 10,6
160,04243 19,77 165 0 0 214807 256706 279779 4553,28 8511,969 5,70£-03 1,732 13,2
1104,05042 28,15 11109 42202 72451 367664 313072 308666 7,87 6,54 3,90E-04 0,732 10
566,32129 35,64 111034 109998 104473 606687 580475 711820 5,83 0,83 5,70E-03 0,033 II
583,1908 29,97 0 0 208 502709 498300 493348 7184,41 12531,812 2,90E-05 1,732 0,9
478,29236 31.78 262022 279023 232407 0 0 0 o"lyCTI! 0 2,80E-03 0,092 0
875,45093 24_63 22786 13786 18726 417539 563439 488969 26,58 10,458 7,70E-03 0,245 14,9
1104.30188 25,62 380966 390914 429241 521 4301 1096 -202,96 0,005 1_30E-03 0,064 103,3
197,07849 17,65 7167 0 331 220092 240337 261600 96,30 164,152 1,80E-03 1,619 8,6
520,36206 35_24 116401 105688 88420 284050 273615 257015 2,62 0,49 1,20E-04 0,136 5
525,34296 19,21 680 1477 467 196379 174241 179305 209,58 140,842 I,JOE-03 0,609 6,3
1188,87024 28,78 89439 87927 76593 389582 417351 350596 4,56 0,774 3,ooE-03 0,083 8,7
468,30881 30_95 672458 790784 674749 0 0 0 only CTR 0 3,ooE-OJ 0,095 0
998,62946 34_73 257537 237857 207015 62123 53216 47917 -4,30 0,056 4,IOE-03 0,109 13,2
1040,51343 25,41 407062 311192 336483 0 0 3283 -321,27 0,006 6,6013-03 0,141 173,2
586,35828 28,44 0 3427 1889 223630 209358 236271 125,90 129,54 1,IOE-03 0,969 6
132,10733 3,923 881385 1562074 1563401 2914939 3058706 2598977 2,14 0,806 8,20E-03 0,295 8,2
1189,29956 28,89 79223 70912 69852 317517 379350 319489 4,62 0,803 5,ooE-03 0,07 10,4
582,29462 35,41 61296 58215 49029 330172 344668 360870 6,15 0,971 1,9013-04 0,114 4,4
327,07843 38,78 396106 386576 356522 59352 38215 46523 -7,91 0,035 1,50E-04 0,054 22_2
465,30386 19,79 224944 182927 259469 0 0 0 o"lyCTR 0 9,80E-03 0,172 0
1040,76392 28,18 118677 94945 127471 325643 393920 424255 3,35 0,94 6,80E-03 0,148 13,2
374,06323 32,74 889490 889941 934374 316944 311358 366320 -2,73 0,044 1.9013-05 0,029 9,1
500,30405 22,23 20054 19268 19097 126285 140142 157522 7,26 0,994 5,40E-03 0,026 11,1
381.25964 30,52 295791 308941 309407 0 0 0 onlyeTR 0 2,IOE-04 0,025 0
293,09811 20,1 159712 172807 192744 411329 488340 533133 2,73 0,611 9,60E-03 0,095 12,9
1189,1571 25,62 447420 402457 399789 1086 4196 5742 -113,36 0,006 1,30E-03 0,064 64,5
311,16034 11,76 0 1494 1746 180660 188453 197954 175,02 160,935 6,20E-04 0,874 4,6
362,08484 15,28 31313 31551 16364 159052 167583 190893 6,53 2,776 8,IOE-04 0,329 9,6
233
1165,59558 24,84 73456 6763 79084 406562 445913 392940 7,82 6,441 4,30E-04 0,758 6,6
372,0658 32,77 985130 985188 1030734 351940 352016 384780 -2,76 0,028 I, JOE-05 0,026 5,2
678,31909 14,85 1847 2241 7768 149406 136150 141424 36,01 31,861 7,90E-05 0,838 4,7
\049,33923 30,4 0 243 0 40799] 420211 413208 5108,69 8930,]49 7,30E-05 1,7]2 1,5
394,22601 22,43 275810 286407 275303 0 0 0 only CTR 0 1,70E-04 0,022 0
369,15857 15,27 0 0 383 199162 214965 223838 1665,70 2980,658 I, JOE-03 1,732 5,9
1166,26257 22,69 347706 ]32503 247854 0 0 0 onlyCTR 0 9,90E·03 0.174 0
413.27988 22,91 154 0 0 146948 179369 198672 3409,02 6421,669 7,40E·03 1,732 14,9
1189,01416 25,61 449934 395404 354978 983 3688 5022 -123,83 0,006 4,70E-O] 0,119 63,7
699,72803 34,12 797 2138 623 477016 419202 392300 362,15 289,73 3,40E·03 0,699 10,1
402,15918 14,92 3541 4679 4782 236424 206376 218573 50,87 11,574 1,60E·03 0,159 6,9
1104,17676 25,38 376408, 387599 457115 324 0 818 -1069,28 0,001 3,80E-03 0,107 108,2
243,13402 24,79 449453 443]33 468086 200340 225481 227097 -2,08 0,047 3,90E·05 0,028 6,9
293,09845 21,88 155701 159838 185305 323060 399542 385799 2,21 0,457 6,70E-03 0,096 II
1040.51294 25,17 443583 374865 414647 0 1610 1380 -412.41 0,002 2,30E·03 0,084 87,4
1104,30078 25,44 461026 511803 531065 521 3518 0 -372.34 0,004 1,70E·03 0,072 141
192.06561 14,15 9224 86]8 10828 245873 231844 223765 24,45 4,069 7,40E·04 0,119 4,8
143,10652 17,04 67788 72618 68060 227651 249311 221334 3,35 0,342 2,OOE-03 0,039 6,3
1165,92981 24,87 71563' 10081 86185 420764 367186 3]6735 6,70 5,598 7,20E-04 0,722 11,3
293,09821 22,06 150020 158503 175206 408348 391747 382289 2,44 0,276 2,60E-05 0,079 3,3
1189,29932 25,5 484452 399936 417463 510 4058 3352 -164,38 0,005 3,50E-03 0,103 71,2
1104,55225 25,66 346561 368661 388250 0 6407 4913 ·97,48 0,01 8,50E-04 0,057 88,8
164,0706 12,93 217731 190894 220003 50454 61412 50599 -3,87 0,05 1,30E-03 0,077 11,6
372,06631 31,16 485147 449301 504686 62963 59728 60149 -7,87 0,011 1,40E-03 0,059 2,9
1104,04993 27,89 3216 6504 10904 348204 397005 319156 51,61 34,678 3,90E·03 0,561 11,1
547,34778 35,38 33657 38172 33996 288248 262542 301717 8,06 1,138 1,90E-03 0,071 7
409,16226 28.96 292257 294677 264905 0 0 0 onlyCTR 0 I,IOE·03 0,058 0
1040,6377 25,24 446217 382476 382769 ° 503 560 -1139,66 0,001 2,70E·03 0,091 87
543,32452 35,25 136628 146324 127039 313581 273274 285610 2,13 0,301 1,70E-03 0,071 7,1
374,06335 31,16 458934 429499 495428 60303 54481 54439 -8,18 0,016 2,OOE-03 0,072 6
132,10693 3,747 673091 615028 633002 1336864 1463898 1493309 2,24 0,234 1,50E-03 0,046 5,8
331.2269 32,6 36567 36143 32091 271457 253757 264912 7,54 0,79 2,20E-04 0,071 3,4
1104,427 29,18 72939 74554 65725 406257 411345 389677 5,66 0,534 5,80E-05 0,066 2.8
1078,92871 29,04 0 0 76 220500 230144 230036 8956,32 15681,584 2.00E-04 1,732 2,4
335,22278 17.24 3114 2502 2682 134962 156931 155806 53,95 10,609 2,40E-03 0,114 8,3
524,67175 34,34 219 0 0 484961 457079 454850 6378,49 11301,896 4,30E-04 1,732 3,6
181,06079 12,4 335 1618 1067 241851 223098 222913 227,77 156,556 7,30E-04 0,64 4,7
481,30264 18,97 1573 1936 1132 142692 155857 130366 92,42 32,266 2,70E·03 0,26 8,9
215,09305 2,009 13009 72238 7626 391400 456498 447068 13,94 17,284 1,60E-04 1,158 8,1
1040.76379 25,26 358770 318426 318210 0 1332 1626 -336,51 0,003 1,60E-03 0,07 87,9
543,3244 34,98 296703 313891 309672 141386 141574 105835 -2,37 0,079 1,40E-03 0,029 15,9
544,35938 35.41 29193 36616 27970 297387 320678 340720 10,22 2,224 I,JOE-OJ 0,15 6,8
508.37677 39,98 382805 421958 416156 148965 91930 96188 -3,62 0,092 4,lOE-04 0,052 28,3
134,10576 3,737 114802 118689 107186 250152 228244 222834 2,06 0,233 1,70E-03 0,052 6,2
234
368,15533 15,09 917 2799 2367 649513 631677 776635 338,29 203,438 4,40E·03 O.4S6 11,5
523,34851 35,05 ) 15337 312864 2%065 123183 126626 107599 ·2,59 0,046 2,40E·05 0,034 8,5
392,27985 26,7 51476 358 292 198153 199311 199695 11,46 19,518 8,70E-D] 1,7 0,4
148,07552 20,09 497 193 0 190910 177828 178413 792,97 896,575 5,40E-D4 1,09 4,1
190,04973 13,35 1247 0 0 602383 643569 527733 1422,36 2604,359 3,3OE·03 1,732 9,9
299,20081 29,52 222178 225636 233987 0 0 240 ·2840,84 0,001 2,40E-D4 0,027 173,2
874,94989 22,53 454889 428807 355261 0 0 0 onlyCTR 0 5,20E·03 0,125 0
293,09821 23,47 119100 128707 140772 356996 417390 450223 3,15 0,629 7,IOE·OJ 0,084 11,6
482,32407 31,68 255591 291051 306152 0 0 0 only CTR 0 2,80E·03 0,091 0
818,58679 25,52 146517 160284 167583 0 0 0 only CTR 0 1,50E·03 0,068 0
293,09821 23,76 98422 120007 130505 367528 396176 401115 3,34 0,625 4,60E·05 0,141 4,7
243,11313 16,16 0 360 0 138804 157618 154706 1253,13 2255,313 1,50E·OJ 1,732 6,7
699,56238 32,26 208 0 0 319238 286105 298114 4343,54 7771,868 I,OOE·03 1,732 5,6
1104,05017 28,89 37526 39516 43305 323972 351300 377784 8,75 1.311 2,30E·03 0,073 7,7
457,12192 14,92 5661 5465 7919 239114 237662 235484 37,40 8,323 2,20E·08 0,215 0,8
129,02 2,217 3711 2258 1528 195860 198092 194289 78,46 35,652 2,60E·07 0,445 I
130,01677 2,217 3436 2180 1317 172505 189440 192270 79,94 41,497 I,OOE-D3 0,461 5,8
496,33014 31,57 284184 266755 275563 0 0 0 #DIV/O! 0 3,30B·04 0,032 0
450,17184 13,64 6386 4711 4222 251143 231459 237141 46.98 12,429 5,40E·04 0,222 4,2
1050,33923 32,42 0 158 0 383458 341087 369515 6924,43 12380,542 1,20E·03 1,732 5,9
836,61591 25,53 173558 179402 180495 0 0 0 onlyeTR 0 1,50E·04 0,021 0
544,35883 35,1 330785 290568 379039 43727 64044 58103 ·6,03 0,053 6,IOE·03 0,133 18,9
240,12331 12,61 392 389 735 192590 164010 187478 358,89 171,301 2,40E·03 0,393 8,4
269,15768 29,42 267824 255699 300791 1189 1210 1645 ·203,84 0,001 2,40E-03 0,085 19,1
133,09857 3,882 103443 127806 154094 313947 253548 3324% 2,34 0,782 6,40E·03 0,197 13,8
465,30444 23,87 0 118 0 170844 191608 169916 4511,59 8119,609 1,60E-03 1,732 6,9
874,94928 23,16 328904 319893 346578 0 0 0 onlyCTR 0 5,60E-04 0,041 0
1104,30029 29,14 71437 72809 70907 409175 362000 380852 5,35 0,404 1,90E·03 0,014 6,2
1189,44263 25,17 460833 365415 427330 0 0 816 ·1536,25 0,001 4,406-03 0,116 173,2
293,09796 25,1 113950 128895 168949 313%8 315432 397869 2,49 0,867 6,IOE-03 0,207 14
520,36169 35,05 420567 426079 329781 156445 137172 106525 ·2,94 0,111 6,006·03 0,138 18,9
257,11343 15,77 162339 132591 137467 46607 51997 62216 ·2,69 0,0% 3,40E-03 0,111 14,8
438,29764 37,68 63683 73045 75649 275677 272953 240820 3,71 0,604 1,606·03 0,089 7,4
293,09821 26,16 104649 153747 107435 289994 393663 355920 2,84 1,073 7,006-03 0,226 15,1
1104,92639 27,89 4894 4614 7378 251849 308730 238787 47,34 19,406 6,606-03 0,27 14
293,09845 25,28 108062 136741 122321 329350 383544 372038 2,% 0,58 1,IOE·03 0,117 7,9
1104,67737 25,53 339354 319489 368030 494 1043 1346 ·356,18 0,001 1,70E-03 0,071 44,9
1104,42712 29,36 53399 63296 59807 369820 313521 291187 5,52 1,16 7,OOE-03 0,085 12,5
345,18436 3,786 63309 83399 105789 241342 177931 204952 2,47 1,002 7,40E·03 0,212 15,3
544,31604 35,1 282655 319133 307725 50310 57867 56859 ·5,51 0,025 1,20E-03 0,062 7,5
172,04022 3,179 56194 58928 57540 18825 15530 4032 -4,50 0,14 8,30E-03 0,024 60,7
524,67169 34,52 219 0 0 416084 374338 406045 5463,32 9782,167 9,90E-04 1,732 5,5
1040,38782 25,21 356025 293540 330917 0 0 303 ·3235,91 0,001 3,106-03 0,0% 173,2
230,15833 4,398 8715 13252 6260 281381 251930 266976 28,35 12,254 6,20E·04 0,377 5,5
235
1104,67639 29,14 40329 57305 51465 333052 316418 291832 6,31 1,513 5,20E-04 0,174 6,6
391,26703 22,83 574 522 442 190365 183808 185198 363,70 53,652 1,10[-04 0,129 1,9
404,15515 15,27 86027 87323 52732 144504 153459 163050 2,04 0,654 9,60[-OJ 0,26 6
252,12679 19,52 0 0 6755 130920 158854 132424 62,50 115,236 2,80E-03 1,732 11,2
293,09827 25,51 91908 103906 91249 294594 363908 349616 3,51 0,644 6,10E-03 0,074 10,9
1015,67139 36,24 290744 262811 237238 134739 97513 100088 -2,38 0,122 1,80E-03 0,102 18,8
157,08586 15,25 10360 10087 10671 185923 151130 177561 16,54 2,218 4,20E-03 0,028 10,6
160,04247 19,3 166 337 0 216395 226737 266527 1410,85 1572,499 4,20[-03 1,005 11,2
293,0979,1 25,93 117576 171324 125403 315229 377975 381851 2,59 0,816 1,70E-03 0,21 10,4
699,56122 30,38 208 0 0 279889 279022 285611 4060,20 7090,222 5,30E-05 1,732 1,3
143,10648 16,75 79188 75994 73606 190407 176638 213187 2,54 0,335 7,IOE-03 0,037 9,5
382,27176 ]1,06 234842 234489 232527 0 0 0 only CTR 0 9,50E-06 0,005 0
567,32465 35,18 30063 I 313215 300974 99114 104535 82646 -3,20 0,045 4,70E·05 0,024 11,9
523,34802 35,24 72686 76160 76167 247440 248440 258744 3,35 0,173 1,30[·04 0,027 2,5
509,32962 23,55 185 0 0 174042 170754 171860 2792,74 4861,159 2,90E-05 1,732 I
1188,87012 25,68 301370 312688 273304 0 2497 5316 -113,58 0,01 1,40E-03 0,069 102,1
1188,72729 25,17 382005 286287 362404 0 1607 1899 -293,98 0,003 7,20E-03 0,147 87,S
699,729 33,37 3029 2851 2961 275383 283341 259147 92,51 7,005 7,OOE-04 0,03 4,5
481,30258 17,01 2803 2444 2804 0 0 0 only CTR 0 2'OOE-03 0,077 0
227,07918 12,05 215674 295960 242379 40105 54826 61981 -4,81 0,078 9,70E-03 0,163 21,3
185,11725 17,7 24802 16797 12569 204975 190649 148487 10,04 5,083 8,30E-03 0,344 16,2
435,17642 19,74 2960 4696 3182 151199 169525 139839 42,50 15,262 3,20E-03 0,262 9,8
875,19952 22,9 353119 345566 312589 0 0 159 -6360,21 0 1,40E-03 0,064 173,2
567,32446 35,48 71380 64977 66931 268892 264238 280262 4,00 0,315 I,OOE-04 0,048 3
231,11635 2,009 17656 69267 13025 293626 345719 342397 9,82 10,08 2,90E-04 0,937 8,9
817,36591 12,1 143562 136163 131222 0 5791 6876 -32,44 0,028 3,50E-05 0,045 87,6
404,20737 29,41 65269 71742 80249 161315 177770 174138 2,36 0,364 J,]OE-04 0,104 5,1
1040,63721 25,S 322571 302345 302497 0 1708 1431 -295,45 0,003 4,40E·04 0,QJ8 87,6
279,15933 2,009 14892 87715 11280 305807 383675 364783 9,26 11,586 8,OOE·04 1,136 11,6
327,0083 2,009 9289 56764 6180 289126 311508 323537 12,79 15,79 3,80E·04 1,177 5,7
192,03255 11,82 3623 32881 17244 220389 228929 186143 11,82 10,925 5,70E·04 0,817 10,7
1104,17639 25,65 236408 284289 317158 673 3283 1128 ·164,80 0,006 7,OOE·03 0,145 82,3
392,28802 29,09 76572 77019 87456 221116 197271 212839 2,62 0,351 5,10E·04 0,077 5,8
411,32986 34,46 229937 196987 199474 24163 19853 17297 -10,22 0,025 2,40[·03 0,088 17
331,00247 30,93 356260 360812 340921 75252 79883 82548 -4,45 0,017 1,20E-04 0,03 4,7
1050,34192 32,23 0 158 0 344361 348124 323077 6427,61 11368,308 5,30E·04 1,732 4
425,1532 20,26 2057 1323 1085 198322 193226 197311 131,88 46,726 3,70E·05 0,341 1,4
376,06012 30,74 291675 265946 312133 20239 16721 17033 ·16,11 0,012 2,30E·03 0,08 10,8
372,06592 31,35 366468 360791 350728 72175 60303 71610 ·5,28 0,023 1,50E·06 0,022 9,8
526,29181 35,06 1213 9105 4288 219664 210865 204939 43,51 37,067 2,40E·05 0,817 3,5
570,35614 37,64 487625 629981 672605 320229 1909S2 246604 ·2,36 0,177 9,90E-03 0,162 2S,7
350,02243 14,74 201 0 0 317370 299498 381728 4968,14 9256,163 5,60E·03 1,732 JJ
1015,67175 36,65 247067 212049 200126 118397 100254 90704 ·2,13 0,116 4,50E-03 0,11 I 13,6
987,64142 31,59 177831 186043 163505 0 0 0 only CTR 0 1,40E·03 0,065 0
236
241,1548 3.51 19626 16022 20038 173026 153673 133531 8,26 2,048 6,50E-03 0,119 12,9
517,33044 24,96 18465 0 2J354 137708 126192 159650 10,13 10,169 7,40E-04 0,884 12
287,63303 34,98 192896 194259 173471 86426 89J13 73886 -2,25 0,072 4,20E-04 0,062 9,9
1040,5 I 306 25,59 294501 234982 246737 0 0 4214 -184,20 0,01 4,80E-OJ 0,122 173,2
520,31854 35,25 95048 101041 86245 277493 315006 360300 3,37 0,707 9,50E-03 0,079 13,1
242,1217 16,62 168 0 0 117955 140491 140365 2373,88 4337.022 3,20B-OJ 1,732 9,8
1104,17578 29,12 53283 58422 52750 339927 312532 291381 5,74 0,772 2,60E-03 0,057 7,7
468)0841 29,55 170755 176733 193751 338 346 0 -791,29 0.001 1,50E-03 0,066 86,6
374,0629 31.35 377253 371216 342735 74232 59476 64313 -5,51 0,03 2,90E-04 0,051 11,4
317,1427 19,53 0 0 26405 138375 142391 131788 15,62 27,67 2.IOB-03 1,732 3,9
424.19232 3.967 7994 39229 52032 146711 127268 163561 4.41 3,567 3,OOE-03 0,685 12,5
1104,30042 29.39 42614 51624 60965 328375 298424 262063 5.73 1,658 3,80E-03 0,177 11,2
171,14909 21,19 5494 5614 5492 223612 209508 216838 39,15 1,767 3,70E-04 0,013 3,3
1022,62927 35,09 1486 747 3009 156966 136379 156515 85.82 63,395 1,90E-03 0,66 7,8
419,16602 14,75 1018 1656 4816 925620 1159463 1092857 424,29 393,847 4,JOE-OJ 0,815 11,4
276,15561 11,56 0 15320 981 105152 148442 140072 24,15 42,34 5,50E-03 1,578 17,5
411,1698 13,9 1421 1730 385 153726 1256J4 116425 111,93 8J,376 7,20E-03 0,598 14,7
293,09811 27,06 117455 128707 133072 251128 280769 252271 2,07 0,265 UOE-03 0,064 6,4
311,12573 19,2 0 549 0 150145 140754 137371 780,09 1387,611 7,OOE-04 1,732 4,6
329,0054 2,097 7256 8727 3684 221982 252721 270993 37,92 18,777 3,20E-03 0,396 10
424,30606 23,57 5131 5214 6415 193 175 281 -25,82 0,015 1,70E-03 0,129 26,2
1104,55115 29,32 57447 50307 59484 332138 278098 312078 5,51 0,967 3,10E-03 0,086 8,9
288,1922 22,36 137928 103553 121238 0 370 898 -286,06 0,004 6,70E-OJ 0,142 106,7
218,02136 14,38 13 156 11178 18219 100520 94050 90233 6,69 2,08 6,OOE-05 0,256 5,5
432,28033 15,18 26931 32189 48560 116284 113034 95238 3,01 1,263 1,40E-03 0,314 10,5
293,09827 27,29 109498 119825 126631 243636 217948 265054 2,04 0,347 6,30E-03 0,073 9,7
354,28485 35,33 221619 207018 200528 0 670 1653 -270,84 0,004 8,40E-04 0,052 107,4
425,13583 30,94 519 949 1918 176085 194312 181544 163,01 111,832 8,20E-04 0,635 5,1
1104,42615 25,79 359524 320032 333801 1580 9121 3044 -73,73 0,013 8,20E-04 0,059 87,3
503,31525 19,15 0 1543 983 89478 113809 95037 118,10 124,725 5,40E-03 0,928 12,8
227,07909 12,25 263322 242070 267707 68988 93930 98130 -2,96 0,079 1,60E-04 0,053 18,1
611,94867 32,99 162 0 0 298192 294850 303237 5532,59 9666,535 6,60E-05 1,732 1.4
348,21732 31,81 20763 32138 34089 161816 151082 154366 5,37 1,523 3,OOE-05 0,248 3,5
1189,15759 28,97 85205 73976 69431 323819 304242 271079 3,93 0,769 2,50E-03 0,107 8,9
1040,76379 25.44 302461 256371 257452 0 2392 871 -250,16 0,005 3,10E-03 0,097 111,3
874,19763 23,13 244046 282475 266404 0 0 532 -1490.46 0,001 1,80E-03 0,073 173,2
175,0965 15,25 5287 6651 7807 148759 135927 148938 21,96 5,344 7,30E-04 0,192 5,2
289,15106 3,638 5374 8978 10353 96950 90072 79624 10,79 4,43 2,IOE-03 0,312 9,8
1061,65454 35 145320 158221 156130 69488 65425 45143 -2,55 0,103 1,50E-03 0,045 21,7
700,22809 30,08 193 0 0 377501 320592 275839 5046,28 9557,082 8,10E-OJ 1,732 15,7
1189,58667 25,21 311094 246268 277986 0 582 922 -555,42 0,002 4,50E-03 0,116 93
1048,33691 33,99 187 0 0 310020 334853 309655 5104,43 9057,123 6,90E-04 1,732 4,5
243,12308 17,29 509 176 0 150163 165284 148550 677,37 808,413 1,20E-03 1,133 6
420,19791 20,44 498 802 496 689750 673740 670269 1132,38 349,968 7,80E-OS 0,294 1,5
237
293,09808 26,36 94611 146126 124188 277013 270344 318429 2,37 0,718 1,40E,03 0.213 9
520,33984 38,25 290133 268563 253464 133678 146841 115725 ,2,05 0,091 6,60E,04 0,068 11.8
469,31192 32.48 21678 17328 33084 553167 556398 551782 23,05 7,902 2,20E,05 0,339 0,4
293,09824 28.15 104248 146951 120439 232555 244887 301732 2,10 0,663 9,70E,03 0,174 14,2
192,12315 17,47 18385 850 1072 211155 177403 203488 29,15 45,951 3,70E,04 1.486 9
311.1239 8,715 10312 28792 25943 232108 180057 211534 9,59 5,601 2.80E,03 0.458 12.6
372.0657 31.54 300558 316745 292198 78087 66024 73024 '4.19 Om 1.20E,04 0.041 8.4
1043.68457 35.05 141042 137827 125132 49047 46701 37203 ,3.04 0.067 1.90E,04 0.062 14.2
1067.13245 34.99 100119 108564 88546 9252 13534 14973 ,7.87 0.043 2.50E,03 0.101 23.6
1189.58557 25,44 234002 176261 209572 0 2431 865 ,188.06 0.007 6.50E,03 0,14 112,1
1067.68433 35.09 157686 150925 146284 14737 17733 20317 ,8.62 0.023 6.00E,05 0.038 15.9
1104.80139 25,44 240517 245136 269555 0 0 691 -1092,92 0,002 1.30E,03 0,062 173.2
875,4505 24.84 55521 3573 66800 185976 219519 190246 4.73 4.238 5.30E,03 0.804 9.2
1040,88916 25.31 268700 213049 234185 0 450 619 ,669.72 0.002 4,60E,03 0,118 89,8
1022.62823 34.83 159136 163090 163912 83101 73969 80671 ,2,04 0.037 9,70E,05 0,016 6
1040,38733 25,44 277730 232102 267548 473 1796 1318 ,216,72 0,003 2,80E,OJ 0,092 56
699.72821 33.65 1818 2455 1692 278379 298)57 277477 143,20 )5.412 5,70E,04 0.206 4.1
320,07687 15.2 373 0 0 112832 107180 104825 870,88 1543,354 4,70E·04 1.732 3.8
B: NEGATIVE ION ,
n .;_.., ,
pool rat plasma eentrel (C'I'R} pool rat plasmA lh postresII8cilRtion erter Fold CV CV
cardia, arresl (CPR2) rhanae ('!o) ('!o)
MZ RT Replicate Replicate Replicate Replicate Replkate Replicate CPR2 ve SO p pool pool
I 1 3 I 1 3 CTR V"IIII: CTR CPRl
348, I0306 11.81 2427 262 1946 27158746 24033276 23354333 16083,36 13143,97 2.20E,D03 73.6 8.2
241.11969 15,51 0 347400 263395 16741165 18007758 19222338 88,36 84,759 I,JOE·D03 89 6.9
322,12354 4,623 469 0 4635 8634990 8824199 8886613 5161,80 7819.006 7.40E,D05 150 1,5
313,06549 2.356 4334971 )859101 3888211 10763680 10595456 10032767 2,60 0,267 4.50E,D05 6,6 3,7
697,21295 15.45 0 1882 0 9164013 9238368 9607148 14882,85 26161.16 2,20E,D04 173,2 2.5
241.11975 14,66 0 488304 334 9153942 9435939 8098817 54.62 98,833 6.20E,D04 173 7,9
348,10263 14,9 0 988 0 8449280 8779152 1712894 25244,26 45384.32 1,40E,D03 173,2 6.6
164,07199 5,742 4203177 4033509 3959711 14087 6725 6572 ,445.38 0,001 3.IOE,D04 3.1 47,1
697.71454 15,45 0 1356 0 6741608 7086724 7145230 15467,23 27282,38 3.20E,D04 173.2 3,1
239,104 16,J5 25026 3809 27436 7093588 7474004 6174197 379.27 281,573 8.00E,004 69,3 4.9
178.05125 4,615 ID05465 674814 2248 4867470 5251560 5223113 9,12 8,693 1,30E,D03 91.2 4.2
164.07204 5,537 4203177 4174634 4519886 37247 20341 32169 ,143.70 0.002 6.60[·D04 4.5 29
514.28516 20 593931 608121 617501 4884802 5023818 4634039 7,99 0,482 6,90[,004 2 4,1
277,2178 46.29 7699107 7389022 7279582 1090572 809929 840673 ,8,16 0,024 5.40E,006 2.9 16.8
329.03958 2,339 422160 430753 419021 3804789 3949719 3578507 8.91 0.569 1.00E,D03 1,4 5
164.07204 4.976 0 141125 394 3308743 4252836 3698532 79.57 147.295 4.40E,003 172.5 12,6
697.21332 14,88 0 8009 0 4192444 3955613 5027518 IG45.10 3060,273 5,40E,D03 173,2 12,8
512.26959 18.54 623830 643124 615093 3498316 3733202 3539101 5.72 0.331 5,20E,D04 2.3 3,5
522,6582 15.4 3243 0 346 3198868 3059070 2768687 2515.08 3927,197 1,80E,D03 148,9 7,3
349,10596 11.81 1730 0 1363 4705603 4113454 3978374 4137.55 4032.711 2.70E-D03 88,4 9,1
464.47299 15,45 0 415 0 3604618 3623332 3515927 25888.86 45274,16 8,GOE,D05 173.2 1.6
238
129,05615 4,535 744368 787959 1079594 2251172 2929965 2343975 2,88 1,026 6,70E·003 20,9 14,7
172,99152 5,669 4392 622036 0 4354152 5135921 3976421 21,50 39,676 1,IDE·OO3 171,4 13,2
227,20198 47,27 4728938 5313641 3918454 926953 924790 683411 ·5,51 0,057 9,OOE·003 15,1 16,6
322,12354 3,582 0 0 2625 2401861 2749553 2508387 2918,02 5257.493 1,60E·003 113,2 1
253,21773 48,3 3893758 3714815 4607091 1287676 1169916 1062534 ·3,47 0,061 6,30E·003 11,6 9,6
523,15973 15,4 0 0 352 1900395 1738100 1558230 14163,42 27066,83 3,20E·003 173,2 9,9
351,02142 2,356 404740 380363 364986 2040055 2029906 1847133 5,14 0,552 1,IOE·003 5,2 5,5
401,15701 14.46 0 80691 0 2906929 2808816 3163026 110,03 197,385 1,OOE·004 113,2 6,2
201,02289 15,36 3311 201709 3154 1850057 2190849 2586363 31,84 57,882 5,80E·003 165,1 16,7
697,2135 16 10156 1848 6321 2164445 2194064 1986769 346,26 254,076 9,30£·004 68,1 5,3
327,23343 47,27 2820524 3199440 2547276 1241015 966784 637448 ·3,01 0,144 1,80E·003 11,5 31,9
167,02132 2,816 125406 54416 175087 2028888 2208924 2082247 17,81 9,911 2.40E·005 51,3 4,4
697,71527 15,07 0 5562 0 1422041 1904827 1611011 887,79 1669,049 7,20E·003 173,2 14,8
269,08813 2,663 396244 434117 466115 1767957 1614978 1436193 3,12 0,685 5,OOE·003 8,1 10,3
242,12302 15,52 908 41504 33425 2278785 2147867 2387244 89,85 81,121 6,80E·004 85 5,3
698,21649 14,88 0 693 0 1487950 1399271 1722629 6652,02 12244,75 3,90E·003 173,2 10,9
255,09882 6,152 994632 20113 909265 3071115 2118025 3059136 4,29 4,461 9,00£·003 84,2 19.9
255,08052 14,34 0 5133 0 1377754 1616766 1494968 874,63 1584,827 2.IOE·003 173,2 8
291,08371 2.189 729300 809993 623921 2432682 2410169 2444445 3,37 0,46 7,IOE·004 12,9 0,7
483,24713 15,52 0 1356 1773 1514409 1414730 1471454 1406,39 1297,66 3,90E·004 88,9 3,4
515,28845 20 150084 162910 156810 1366785 1417905 1313606 8,72 0,69 5,20E·004 4,1 3,8
339,20016 31.81 2943396 2537092 2406540 645573 597449 646230 ·4,17 0,036 6,IOE·003 10,6 4,4
228,00998 13,2 1584 1431 2256 1089731 1024345 1055673 601,36 168,892 3,20E·OO4 25 3,1
314,06879 2,356 433940 419291 403764 1189735 1133261 1108049 2,73 0,198 3,30£·004 3,6 3,7
698,21515 16 2427 0 890 1202226 1182036 1044689 1033,75 1225,719 1,90E·003 111 7,5
225,12471 24,99 3794252 2920729 3063161 1320848 963711 939853 ·3,03 0,113 6,60E·003 14,4 19,9
239,10393 16,86 1373986 1475114 1402625 90630 91249 45474 ·18,70 0,02 4,OOE·005 3,7 34,6
579,3913 40,83 2497586 2689616 2324720 1336645 1099498 995311 ·2,19 0,103 7,40E·004 7,3 15,3
115,04044 3,492 72936 35307 39368 719872 612784 655272 13,47 6,749 8,40£·004 42 8,1
325,18463 30,43 2324614 1794859 2126628 613552 1010188 907524 ·2,47 0,151 3,90E·003 12,9 24,4
225,11957 24,47 1352863 1431632 1128948 595743 506947 337760 ·2,72 0,145 2,50E·003 12 27,3
357,10797 11,23 0 2424 0 899127 1206095 1157623 1346,06 2535,566 7,60E·003 173,2 15,2
157,03693 2,737 119470 102514 95906 1407628 1499676 1140487 12,73 3,221 7,20E·003 11,5 13,8
513,27289 18,54 169475 167204 163150 978054 1045003 980687 6,01 0,343 6,40E·004 1,9 3,8
465,2865 21,8 400198 422828 412650 1179163 1402636 1209902 3,07 0,379 6,30E·003 2,8 9,6
329,03058 2,285 1187242 1289008 1363950 328751 170613 257370 ·5,07 0,076 l,lOE·004 6,9 31,4
311,16882 28,7 1695570 2237839 1727199 502330 760044 793990 ·2,75 0,143 8,90E·003 16,1 23,3
464,47348 15,07 0 895 0 791774 975426 768605 2833,30 5287,811 5,90E·003 173,2 1l,4
582,37903 41.69 1940236 1784401 2233864 1129277 913395 843342 ·2,06 O,IlI 4,80E·003 11,5 15,5
473,23862 24,47 1711149 1331660 1387793 624127 474239 445699 ·2,87 0,113 6,20E·003 13,9 18,6
329,15109 5,537 667679 627244 524120 0 0 0 only CTR 0 4,90£·003 12,2 0
172,99158 6,26 872696 748432 925511 63527 99873 76430 ·10,62 0,032 3,50E·003 10,7 23
514,28571 18,21 346502 297910 367035 1316088 1308451 1175986 3,76 0,629 5,30E·004 10,5 6,2
278,22098 46,29 1505933 1415395 1423960 203831 152759 163590 ·8,35 0,023 3,10E·005 3,5 15,5
239
253.21764 48.51 1428601 1736879 1515380 555505 528700 452294 -3.05 0.068 4.00E·003 10.2 10.s
254.98195 2.789 4806 6386 0 556675 541093 600216 151.12 143.482 8.80E·004 89,2 5.4
242.12299 14.66 0 56730 0 1104096 1141911 980826 56.88 102.974 6)OE·OO4 173.2 1.8
498.29041 19.92 119566 141331 139963 819648 881810 785647 6.35 0.991 I.JOE-003 9.1 6.5
172.99146 6.077 679663 933402 864710 451102 3633 II 245694 -2.34 0.193 9.20E-003 15.9 29.2
579.39136 40.47 1767576 2359442 2302715 718751 524771 442531 -3.81 0.106 6.30E-003 15.2 25.2
464.80777 15.07 0 287 0 598167 761564 575478 6742,89 12725,15 8,20E·OO3 173,2 15,7
580.39459 40.71 1214653 1222425 1076972 660156 527910 477650 -2.11 0.114 1,IOE·003 7 17
522.65851 15,07 0 0 346 638139 838286 735580 6393,08 11936.49 6.IOE-003 173,2 13,6
329.03055 2.081 1200614 1199307 1240318 401761 373567 398753 ·3,10 0.019 4.00E-006 1,9 4
262.01382 5.207 321190 376270 458682 0 40943 12651 -21,57 0,063 7,40E·003 18 117,3
269.06686 .1.881 0 318 0 634012 741394 708411 6552,88 11885,02 2,IOE-003 173,2 7,9
273.20746 47.27 1078083 1161718 872445 198585 193653 154345 -5,69 0.049 8,60E-003 14,3 13,3
465,3053 40,4 1567404 1222594 1258660 306882 254948 194541 -5,35 0.068 6.10E-003 14 22,3
283.10388 2.712 125146 69836 86254 636926 772388 573137 7,05 3,221 7.00E·003 30.3 15,4
165.07516 5,742 413889 410262 407266 1625 0 861 -495,34 0,002 7,60E-006 0,8 98,1
301.21774 45,33 909283 870981 836095 277486 203997 206711 -3,80 0,059 4,10E-005 4,2 18,2
405,26511 21,8 211508 221632 229805 651421 781723 678464 3,19 0,443 6.00E-003 4,1 9,8
609,51105 49,36 887112 862733 759771 171053 191685 180990 -4,51 0,034 2,60E-003 8.1 7,3
483.24698 14.66 0 7433 0 591976 531251 459517 212,93 395,581 5,IOE-003 173,2 12,6
351,10178 14,8 1115 0 275 489128 448368 461842 189,36 318,247 4,40E-004 163.6 4,5
299,22348 48,3 891606. 821293 1005749 262917 248816 238576 -3,62 0.042 6,OOE-003 10,3 4,9
179,05449 4,615 142442 145590 90806 475306 572254 570025 4,27 1,478 1,20E-003 24,4 10,3
173.08203 3.728 2657 4948 1580 743568 778611 768867 249,43 146,056 1,70E-004 56.2 2,4
291,08356 3,166 354944 280588 414277 1016298 995253 1240091 3,10 0,981 3,90E·OO3 19,1 12,5
165,07524 5.537 414381 423799 468111 1212 440 2329 -328,13 0,002 1,40E·003 6,6 71,6
199,17049 40.49 909796 886744 743696 330822 276070 284220 ·2,85 0,072 4,90E·003 10.6 9,9
389.05109 2,211 646802 656037 722490 225731 259486 207655 ·2,92 0,06 2,70E·004 6,1 11,4
389.06064 2,285 334287 367450 397524 163504 122330 112866 ·2,76 0,105 7,00E·004 8.6 20,3
330,04276 2,339 40933 39225 38030 360784 400981 360139 9,49 0.946 1,60E·003 3,7 6,3
451,30737 30.03 767515 755649 687842 276054 220503 224108 ·3.07 0.061 1,60E·004 5,8 12,9
165.07524 4.976 492 13537 0 344804 429982 368446 81,49 143,206 3,60E·003 164,2 11,5
401,1572 14,28 0 3487 0 1253125 1406057 1000976 1049,66 1994,336 9,30E·003 173,2 16,8
476,27905 34,86 803882 801647 754788 224382 217819 180089 ·3,79 0,04 1.30E·005 3,5 11.5
225.13498 24,47 1288565 1008903 1181930 336658 252311 495161 ·3,21 0,144 1,90E·003 12,2 34,1
254,22104 48,3 677133 637796 795154 216530 198138 180876 ·3,54 0.058 6,60E·003 11,6 9
328,23666 47,27 647932 766661 601025 298901 236277 154543 ·2,92 0,151 2,60E·003 12,7 31,5
351,01285 2,362 352941 372367 382133 185131 162684 160700 -2,18 0,055 7,IOE·005 4 8
141,01714 6,368 564392 707273 742166 190199 244424 292320 ·2,77 0,127 5.60E·003 14 21,1
225,11412 24,47 525959 541776 521485 214708 174378 130379 -3.06 0,086 3,OOE·003 2 24,4
241,11955 15,32 0 93958 767 4612342 6053566 5908734 174,98 324,531 6.70E·OO3 171,1 14,4
451,27087 21.8 167277 175163 168818 470656 553578 467156 2,92 0,359 7,10E·003 2,5 9,8
279.24081 49,36 876637 774812 712341 202999 163754 171215 ·4,39 0,05 4,IOE·003 10,5 11,6
255,08034 13,52 9484 7733 0 351922 306605 317655 56,70 53,976 1,20E·003 87,9 7,3
240
351, I3287 5,742 256210 257044 241696 0 0 0 only CTR 0 ],90E·004 ),4 0
557.45856 48.13 684177 553325 479420 150394 56107 116782 ·5,31 0,118 7,20E·OO3 18.1 44,]
564.33179 35.9 647639 640805 635520 269883 259367 270800 -2,40 0,014 2.IOE·007 0,9 2,4
225,12459 25,97 789432 806510 762795 246241 228794 249383 ·3,26 0,023 4,50E·005 2.8 4,6
402,16028 14.46 0 12473 0 526781 502659 573234 128,49 231,185 1,10£·00] 173,2 6,7
580,39459 40,49 627420 840210 785278 251698 183280 161408 ·3,78 0,102 6,00£·003 14.7 23.7
]51,13297 5.537 256210 259523 295452 0 0 0 onlyCTR 0 2,20E·003 8 0
225,12463 26.2 688877 686238 611693 214000 214109 211361 ·3.11 0,024 3, IOE·003 6,6 0,7
241.11407 15,51 0 6105 6066 461242 447928 520297 117,45 111.208 2,IOE·003 86,6 8, I
523,15985 15,12 0 0 703 436257 399471 405497 1765,61 3142,168 7,50E·004 173.2 4,8
588,33167 35.9 605075 598271 575389 263084 263606 272325 ·2,23 0,021 2,40E·004 2,6 1,9
554.3476 39.16 665017 705937 658188 317821 289122 248534 ·2,37 0,068 1,70E·004 3,8 12,2
141,01715 6.819 670455 831003 614407 216173 268674 363159 ·2.50 0,169 8.30E·003 15.9 26.4
567.3186 19.37 5163 3755 2982 347086 312125 353929 85.14 29.381 1.50E·003 27.9 6.6
213.97603 13,44 1874 3J7 855 322291 277785 246736 276,19 248.55 6.00E·003 76.5 13.5
605.15656 2.286 195495 181193 142541 41724 8040 72940 ·4.23 0.225 6.20E·003 15.8 79.4
565.30249 17.51 5860 3738 6544 285168 276034 333566 55.43 20.819 3.60£·003 27.2 10.4
480.31058 41.7 564163 654661 717304 202551 156653 176182 ·3.62 0.069 5.50E·003 11.9 12,9
496.27481 20 86103 83137 90588 421959 413873 366571 4.63 0.546 2.70E·003 4,3 7.5
1105,7422 42.19 622789 569268 524786 298074 215437 251049 ·2.25 0.111 1.20E·003 8.6 16.3
391.28589 30.03 599482 579881 517056 219681 169750 170934 ·3.03 0.076 5.00E·004 7.6 15.3
193.01353 2,749 39078 37986 50186 508928 489241 397207 10.97 3,151 6,IOE·003 15.9 12.8
288.61972 17,25 11581 7056 8325 258306 264255 279835 29,76 8.967 3.80E·004 26 4,2
143.10806 20.54 88567 67095 84936 478954 507089 411007 5.81 1.448 3.80E·003 14.3 10.6
283.16422 3.636 176374 237681 217860 81104 122130 85906 ·2.19 0.174 8.80E·003 14.9 23.3
310.12573 2.749 66309 ' 71590 88582 358461 342911 304102 4.44 1.055 1.20E·003 15.4 8.4
583.38245 41.69 610702 566364 709030 352693 281778 263790 ·2.10 0.13 4.80E·003 11.6 15,7
255.08055 14.13 0 7039 0 661104 497039 612574 251,56 471.664 6,70E·003 173.2 14.3
331.03751 2.339 21491 38015 32153 245122 258642 229712 8.00 2.668 1.30E·004 27,4 5.9
554.34747 38.98 416266 537236 445447 242597 196410 170366 ·2.10 0.137 6.80E·003 13.5 18
484.25037 15.52 0 728 522 337339 29993 I 348175 788.36 770.636 2.00E·003 90.1 7,7
684.72498 15.62 0 375 343 308206 335758 278205 1284.36 1236.713 2.90E·003 86.9 9,4
255.58221 14.34 0 390 0 307906 31783 I 331042 2453.28 4334.889 4,40E·004 173.2 3,6
373.00317 2.356 58809 54749 53116 226998 210229 192565 3.78 0.509 3.30£·003 5.3 8.2
466.28983 21.84 145679 140258 110327 429795 396061 347578 2.% 0.74 2.90E·003 14.4 10.6
223.17067 38.58 531255 439122 481154 283899 220685 177150 ·2.13 0.156 3.50E·OOJ 9.5 23.6
248.03462 5,41 193884 153097 213180 326 1329 1077 ·205,04 0.004 8.90E·003 16,4 57,3
291.08359 3.345 195496 162085 175736 849848 820216 846975 4.72 0,538 1.IOE·006 9.4 1.9
225.12453 27 528494 590887 572718 183614 180554 185918 ·3.08 0.023 2.20E·003 5.7 1.5
178.04721 14.78 4117 0 472 264399 271154 284624 178,73 270.072 2.80E·Q04 147.3 3.8
310.0567 2.211 403422 400588 454770 131852 109636 99543 ·3.69 0.059 5.30E·004 7,3 14.5
341.60776 14.53 0 270 0 214712 193289 232601 2372.60 4336.277 2.80E·003 173.2 9.2
3 I3.07364 2.3 73372 62863 69124 206486 235313 213150 3.19 0,467 1.40E·003 7.7 6.9
186.02647 13.86 247 0 485 269281 250999 3068% 1130.02 1241.625 3.50E·003 99.4 10.3
241
437.29153 30.03 435045 434229 387433 168655 133172 139787 -2,85 0,068 2,90E-004 6.5 12,8
211,07253 4,699 43891 2519 0 254588 215755 238045 15,26 25.577 3,50E-004 159.3 8,3
405.22867 25.11 37447 36328 43478 421037 395001 331563 9,79 2,141 5,70E-003 9,8 12
498.29004 22,06 62052 48667 46276 288059 262545 223019 4,93 1.427 5.70E-003 16.2 12,7
241.21758 49.9 482943 546087 624424 108099 87726 55605 -6,58 0.068 3,50E-003 12.9 31,6
225.12456 27,86 435583 469519 407541 119680 129044 126815 -3,50 0.031 2.70E-OOJ 7,1 3,9
340.20352 31.74 397077 401032 404538 110782 114143 78742 -3.96 0,051 1.00E-003 0,9 19,3
151.06136 3,26 93756 87635 73956 550140 494539 482854 5,98 1.135 1.30E-003 11.9 7.1
329,0307 1.879 384606 321210 376997 143982 \71\37 154350 -2,31 0,08 4,30E-003 9,6 8,8
297.24368 37,97 467857 386355 405878 120754 111505 77068 -4,07 0.08 1.30E-003 10,1 22.3
555.44299 46.29 345340 301549 311592 5586 1841 2%8 -92,21 0,007 1,60E-003 7.2 55,4
145.03825 3,26 178571 142285 119985 386245 389506 353682 2,56 0,65 7,40E-004 20,1 5,3
141,01717 8,078 428654 526789 416880 207481 JJ8783 208364 -2,47 0,141 4.60E-003 13,2 21,6
515,28888 18,21 89516 76772 91889 358280 356946 321332 4,01 0,623 6,60E-004 9,4 6,1
335,04959 2,855 55530 65925 73247 210480 208912 226619 3,32 0,606 4,20E-005 13,7 4,6
205,97871 12,11 353 525 697 401178 388664 325380 708,08 309,617 4,OOE-003 32,8 10,9
172,99156 5,483 0 184970 0 1377433 1212375 1787408 23.66 45,79 8,30E-DOl 173,2 20,3
130,05933 4.535 44287 50832 73331 166074 213385 172685 3,28 1,346 3,80E-003 27,1 13,9
171,13924 32,4 464011 389833 510256 229188 181715 180670 -2,31 0,119 850B-D03 13,4 14,1
1101,7106 38,08 378256 293884 356564 188876 132448 120263 -2,33 0,162 4,50E-003 12,8 24,9
311,04984 2.356 74184 82440 66650 214202 211839 204590 2,82 0,367 5,70E-005 10,6 2,4
246,07503 5,596 189142 232437 195842 1050 461 876 -258,66 O,OD2 4,30E-D03 11,3 38,1
499,29364 19,92 27682 33289 33708 236884 230358 200648 7,05 1,364 2,70E-OOJ 10,7 8,7
189.04073 2.712 83DO 6061 5991 148354 174629 175240 24,48 7,002 2,90B-OD3 19,4 9,2
583,31299 17,94 10268 12122 6906 180327 210946 180509 19,52 7,09 2,60B-D03 27,1 9,2
576,33142 33,37 332783 403798 299578 67624 147979 14OD78 -2,91 0,181 5,30E-D03 15,4 37,4
141.0172 6,577 727401 707273 665741 150397 266162 275220 -3,04 0,114 2,40E-003 4,5 30,2
299,22336 48,51 342208 422083 363015 134251 126%4 121635 -2,94 0,054 8,OOE-D03 11 5
516,28094 20 24919 21584 22640 190460 217812 189475 8,65 1,337 2,50B-OD3 7,4 8.1
228,51152 13,2 0 386 237 215081 197532 182714 955,58 974,26 2,20E-D03 93,8 8,2
326,18793 30,43 450614 342119 404939 109610 192664 176573 -2,50 0,165 4,70B-OD3 13,6 27,6
291,0835 3.793 77119 84510 68830 546304 498900 446886 6,47 1.308 3,90E-D03 10,2 10
491,2298 18,91 11391 13579 12825 259389 244376 244246 19,79 2,437 3,70E-004 8,8 3.5
227,12912 24,47 438112 402142 344253 118758 134862 115425 -3,21 0,064 7,70E-D03 12 8,4
476,27878 34,67 591166 512439 452901 147674 72531 105211 -4,78 0,101 2,60B-D03 13,4 34,7
319,22815 37,32 2895 9179 10640 305405 275847 228451 35,65 24,504 6,70B-D03 54,4 14,4
239,5648 17,02 176501 164964 166580 0 0 802 -633,47 0,003 4,30E-004 3,7 173,2
321,08063 2.764 277390 243249 290151 70424 59620 81959 -3,82 0,065 1.40E-OD3 9 15,8
348,10269 15,4 0 1332 0 264372 313841 267290 634,76 1162,263 3,20B-OD3 173,2 9,8
1106,7455 42,19 360964 319525 298859 177045 119094 141242 -2,24 0,133 2,OOE-D03 9,7 20,1
199,03807 2,804 289315 272851 274131 155655 146687 105179 -2,05 0,113 6,60E-D03 3,3 19,8
324.22641 46,29 310583 294465 286008 33490 21879 26293 -10,91 0,024 8,GOB-OD5 4,2 21,5
225.1246 28,9 413360. 539816 510186 137064 143029 176806 -3,20 0,086 7,70B-D03 13,6 14,1
225,18633 42,28 351296 344820 311621 84709 66718 82366 -4,31 0,044 4,70E-D04 6,3 12,6
242
151,06145 3,496 65988 67278 93510 345434 355336 415404 4,92 1,512 1,90E-003 20,5 10,2
141,01715 14.42 327199 293862 282088 124575 91419 103572 -2,83 0,083 5,20E-004 7,8 15,7
1021,3087 2,23 67229 52096 35685 168376 154430 \30799 2,93 1,261 2.50E-003 30,5 12,6
562,31573 33,37 296529 380496 283512 62494 140163 129732 -2,89 0,189 6,60E-003 16.4 38
607,42242 44,49 338072 333586 26293 I 132797 103296 95718 -2,82 0,111 6,00E-003 13,5
17,7
505,229 15,52 ° 3895 3114 243434 181324 200499 89.21 92,301
7,60E-003 88,2 15,3
186,05629 15.7 870 644 2113 228035 287595 241415 208,72 162,418 5,IOE-003 65.4
12,4
301,10428 5,715 121181 161838 159138 ° 3703 1950 -78,22 0,015 7,70E-003 15.4 98.3
352,02463 2,356 37556 37429 39292 172781 179210 179141 4,65 0,224 8,60E-005 2,7 2,1
171,03941 13.89 11082 2692 5022 227716 290149 290309 43,00 35,482 5,70E-003 69,1 13.4
621,1214 2.211 276204 281217 275995 79435 57799 65911 -4,10 0.042 4,30E-004 1,1 16,1
474,24167 24.47 329859 281959 276974 127542 97685 94680 -2,78 0,097 1,50E-003 9.9 17
151.04036 3,8 40745 46853 58677 332885 279583 337756 6,50 1,876 2,80E-003 18,7 10,2
143,10797 23,42 82980 98842 91973 266673 342492 298055 3.31 0.706 8,50E-003 8,7 12,6
256,10214 6,152 116124 1835 98479 360598 252960 347734 4,44 4,602 7,30E-003 85,3 18,3
214,02776 4,623 9567 4111 3023 179234 200695 2223J3 36,06 26,586 3,30B-003 63 10,7
241,11411 14,66 0 9334 0 211320 247870 180869 68,57 129,548 7.20E-003 173,2 15,7
366,99509 2,356 18456 12036 13333 167426 171453 145422 11,05 3,527 1,90E·003 23,2 8,7
267,07245 2,661 63617 54721 54829 182917 182470 168350 3,08 0.416 1,IOE-004 8,8 4,7
173,99486 5,716 5911 49201 18086 368012 309299 348674 14,02 14,051 2,OOE-004 91,5 8,7
291,0835 9,536 34420 40746 43383 281996 333145 358700 8.21 1,946 5,70E-003 11,7 12
330,15427 5,537 133938 118798 99081 0 0 0 onlyCTR 0 7,30E-003 14,9 0
516,29095 19,97 13391 10460 17932 163493 160207 179560 12,04 3,999 4,80E-004 27 6,2
291.08368 11.28 24751 18784 49856 325198 435132 422328 12,66 8,639 5,90E-003 53 \S,2
141,01717 14,23 288818 312228 300967 53587 91382 67381 -4,25 0,073 2,IOE-004 3,9 27
604,36255 36.83 260366 261180 269620 121757 95456 92363 -2,56 0,069 1,60E-003 1.9 15,7
391,28589 30,21 470926 ' 374790 459581 244327 149885 155280 -2,38 0,173 4,30E-003 12,1 29
141,01717 13,93 422154 337524 417541 183197 164783 236106 -2,02 0,155 5,70E-003 12,1 19
291,08347 10,36 39085 32198 56980 300889 337859 362937 7,81 3,067 1,20E-003 29,9 9,3
478,29483 37.68 306432 386658 377997 159837 129131 123241 -2,60 0,103 5,60E-003 12,3 14,3
567,31824 17,9 ° 557 ° 180958 172336 170140 939,74 1658,724 3,50E-004 173,2 3.3
606,37823 39,35 380551 301808 299414 170729 100931 82141 -2,77 0,193 5,3013-003 14,1 39,6
250,1451 42.42 268036 268888 280292 87118 85458 65025 -3.44 0,052 1,20E-004 2,5 IS,S
225,12465 30,72 327692 333837 324827 112022 121797 100226 -2,95 0,038 1,40E-004 1.4 9.7
466,30869 40,4 436586 349856 374382 81673 70536 49917 -5,74 0,062 3,OOE-003 11,6 23,9
377,07062 17,77 13848 7285 14399 260078 223734 199751 19,24 8,993 5,90E-003 33,4 13,3
339,2002 32.48 444116 461045 499464 107235 174525 193018 -2,96 0,117 1,30E-003 6,1 28,5
270,09137 2.663 36690 39262 35794 173186 147827 133582 4,07 0,735 9,70E-003 4.8 13,2
298,15649 26,78 252371 317522 274055 57820 58098 66254 -4,63 0,042 6,60E-003
11,8 7,9
399,2757 45,92 54054 51006 31376 215785 211475 211397 4,68 1,322
1,20E-003 27,1 1,2
353,01956 2,339 24100 22560 27124 123406 131922 140923 5,37 0,863
1,20E-003 9,4 6,6
202,02618 15.36 0 16404 ° 170327 176073 207278 33,75 62,099 9,90E-004
173,2 10,8
522.65802 14,88 0 348 0 340006 340343 335135 2918.06 5073,978 2,3013-005
173,2 0,9
291,08377 11,6 23841 52506 49495 261603 290742 366256 7,30 4,029 9,20E-OOJ
37,6 17,6
243
897.24799 2.285 76369 85066 92507 0 0 7256 -35.00 0.052 5_60E-004 9.5 173.2
200.04843 5.742 114721 108907 107947 0 0 0 onlyCTR 0 3.70E-004 3,3 0
225,12459 32,39 381423 299724 366713 98722 85798 84944 -3,89 0,054 7,70E-003 12,5 8,6
225,12459 31,81 425193 394009 323345 108716 108509 88137 -3,74 0,068 8,80E-003 13,7 11,6
826.5611 43,7 44014 55168 91745 329157 278429 232785 4.40 2,484 6,20E-003 39,2 17,2
594,71527 15,68 0 399 0 129922 93751 116204 851,82 1614,215 8,60E-003 173,2 16,1
310,05698 2,018 252517 257891 287330 132807 134640 121015 -2,05 0,062 2,50E-003 7 5_7
564.3313 36.1 287508 283916 297105 81954 127428 127941 -2,57 0,1 4,90E-003 2,4 23,5
254,220% 48,51 250317 297632 269395 96850 88869 77602 -3,10 0.064 2.00E-003 8.7 II
179.05638 2,575 275107 459173 247355 900584 856790 681277 2,48 1,229 6,80E-003 35,2 14,3
871,53497 46,21 271733 253103 213706 158510 110798 91067 -2,05 0,2 9.30E-003 12 28,9
324,05643 2,339 25035 39024 42416 93477 106146 123891 3,04 1,219 4,40£-003 26 14,2
220,9682 16,59 1035 5% 688 213048 210076 180953 260,49 100.876 2.60E-003 29,9 8.8
166,03903 2,737 39831 26140 36028 206295 198170 150548 5,44 2,017 9,90E-003 20,8 16,3
451.30725 30,21 459934 372659 447051 204424 140726 149408 -2,59 0,124 2,IOE-003 II 21
146,04599 2,356 7011 11518 0 104321 100406 71590 14,91 16,908 8,80E-003 94 19,4
320,1076 3,644 6765 9459 11704 144722 161118 158910 16,64 5,376 6,OOE-004 26,6 5,7
246,07498 5,911 178049 146580 134189 0 0 0 onlyCTR 0 7,20E-003 14,8 0
354.02515 2,356 24550 16898 18340 85949 83199 76128 4,10 1,091 1,IOE-004 20,4 6,2
621,12134 2,008 260457 233448 248462 104056 %508 99167 -2,48 0,038 1,50E-003 5.5 3,8
337.10031 2,749 14038 13448 19213 160272 142092 133676 9,34 2,776 2,40E-003 20.4 9,4
276,12769 18,89 2079 3500 2998 128719 142332 126270 46,32 14,701 1,40£-003 25,2 6,5
1046,6027 19,97 2692 1122 1786 113061 109081 122450 61.53 29,667 1,IOE-003 42,2 6
609,4895 49,28 179752 178106 151608 29859 11447 12341 -9,50 0,071 3,70E-004 9,3 58,1
826,56097 42,% 45970 50032 86478 282571 258520 202913 4,08 2,167 5.50E-003 36.7 16,5
826,56097 45,65 44054 70136 104033 300383 266402 217816 3,60 2,057 4,20£-003 41,3 15,9
301,10434 5.933 121181 149371 163263 686 433 429 -280,24 0,002 7,30E·003 14,8 28,S
283,15533 19,37 2139 2244 2274 136432 108639 147937 59,04 10,996 8,IOE-003 3,2 15,4
406,26825 21,89 61339 60035 62875 219890 235331 184865 3,47 0,501 9,40E-003 2,3 12,1
321,08063 3,046 280399 266185 236760 116836 119500 95711 -2,36 0,086 1,50E-003 8,5 11,8
329,06033 2,3 49351 36706 30018 135003 122371 123335 3,28 1,014 4,OOE-004 25,4 5.5
292,08701 2,816 67026 75217 63264 239315 249120 203564 3,37 0,65 4,90E·003 8,9 10.4
214,0722 5,742 103502 101898 79163 9368 9370 10379 -9,77 0,021 8,30E-003 14.4 6
200,04852 5,537 114721 110759 121126 0 0 0 onlyCTR 0 6,80E-004 4,5 0
347,08478 2,827 16913 25220 25830 179278 152196 161987 7,26 2,202 1,20E·003 22 8,3
581,39752 40,65 235659 278160 204239 117271 89018 77638 -2,53 0,147 8,70E-003 15,5 21,6
291,08353 7,364 39744 12642 19644 388008 362720 284332 14,37 10,671 6,40£-003 58,6 15,7
826,56104 46,78 34217 64512 108861 277357 256451 207892 3,57 2,453 4,OOE-003 54,3 14,4
826,56122 43,16 44734 S2322 88087 295159 26208S 204776 4,12 2,285 7,70E-003 37,S 18
826,56104 44,04 38695 54295 88029 202557 277846 228174 3,91 2,27 4.40E-003 41,8 16,2
155,04655 2,816 14193 6922 7661 96724 10933S 102559 10,72 5,132 9,SOE-005 41,7 6,1
225,12466 33,86 263276 261878 268892 77861 77991 76624 -3,42 0,007 7,30E·005 1,4 I
514,26538 18,56 24153 19351 20602 149841 124846 131653 6,34 1.344 3,30E-003 11,7 9,5
188,98643 5,596 103705. 82484 98418 47108 46789 34985 -2,21 0,126 4,30E-003 11,6 16,1
244
1167.856 2.219 19731 32428 33212 133917 118336 115883 4.31 1.49 2.70E·OO4 26.6 8
826,56122 46.01 29410 61912 102286 288658 258053 209208 3.90 2.83 4.00E-003 56.6 15.9
417.11975 13.97 0 12115 0 150120 147191 135392 35.72 63.794 2.30E-005 173.2 5.4
291.0835 8.342 13873 11711 21055 281093 393412 350368 21.97 10.559 9.50E-003 31.5 16.6
476,27905 35.05 201935 231534 258585 102370 53902 78623 -2,95 0,147 2,30E-003 12.3 31
221.03047 2.892 29962 32348 30353 151072 146026 116186 4,46 0.795 1.00E-002 4.1 13.7
225,12459 34.28 23923 I 252976 261928 75774 74886 82920 -3,23 0,032 4,OOE-004 4,5 5,7
826.56116 46.43 37848 . 74676 90239 287375 251163 203339 3,66 2,08 5.70E-003 39.8 17
225.12466 34.75 213247 238488 216562 71410 69127 60983 -3,32 0,043 7,80E-004 6,2 8.2
594.3786 42,71 263584 227365 239203 42632 21480 23578 -8,33 0.057 2.20E-004 7.6 39.9
514,27551 18,54 12894 15017 17024 114221 121427 118158 7,87 1,327 1,70E-005 13.8 3.1
881,51868 44.49 224039 228372 199063 65859 33868 72982 -3,77 0.115 6.50E-004 7.3 36,2
199.01105 2,892 4660 1581 3409 158465 159209 118847 45,24 28,952 8,40E-003 48,1 15,9
256,07837 14.34 0 317 0 146008 143733 118653 1288,31 2373,908 4.IOE-003 173.2 11.2
616,36285 38.66 235177 226854 222719 77975 63372 51805 -3,55 0,065 3,70E·004 2,8 20,4
200,04854 4,976 0 1852 0 85476 108910 90414 153,78 286,447 5.40E·OO3 173,2 13
315,0693 I 2,339 54471 49954 52326 149708 146724 147753 2.83 0.152 2,00E·006 4,3 I
174,98714 5.669 0 24343 0 199380 242342 191617 26,02 48,431 1.50E-003 173,2 12,9
157,01216 2,629 57277 79934 68848 195848 214261 211217 3,02 0,641 I,OOE-OO4 16.5 4.8
226,12799 24,99 435866 326378 363792 146445 104771 105086 ·3,16 0,111 7,30E·OO3 14,8 20,2
397.01849 2.429 202863 210560 200514 87485 97056 90955 ·2,23 0,035 1.IOE·005 2.6 5.3
307.06482 2,715 152649 149404 147781 45193 62366 44395 ·2,96 0,073 2,20E'003 1.7 20
327.02365 2.356 6940 8570 7155 92495 106182 85066 12,52 2.885 4,80E·003 11,7 II ,3
484.25021 14.66 0 D37 0 1288% 129387 104429 271,29 501,921 4.50E·003 173,2 11,8
481.09314 2.3 10172 20016 16916 61692 71563 54339 3,98 1,827 3,OOE-003 32,1 13,8
253.21761 49,11 255454 195684 189797 65600 44578 33268 ·4,47 0,115 7.00E·OO3 17 34,3
239.16544 26.82 233210 201179 232770 24210 21877 20428 ·10,03 0,017 2.60E-003 8.3 8,6
282.1473 I 17,51 1692 1039 1178 105561 110906 142644 91,87 39,621 9,40E·OO3 26,4 16,7
225.12471 34,46 222672 245451 247973 67440 66227 73174 ·3,46 0,032 1,20E·OO3 5,8 5,4
452,) 1046 30,03 211628 210006 184983 68984 57725 61599 ·3,22 0,051 1,40E·003 7,4 9,1
588.33 IJ )6,1 242169 238241 255636 71650 114734 119030 ·2,41 0,122 6,OOE·OO3 3,7 25,7
288,10635 2.749 1702 2605 3159 152999 150668 140557 59,50 20,241 6,OOE·OO4 29.6 4,5
826,56104 46,% 34217 76799 108360 284576 239697 201984 3,31 2,25 6,40E·OO3 50,9 17.1
240,10722 16.86 164944 166833 164984 9398 8591 4876 ·21,73 0,015 4.70E·OO6 0.7 31.6
312.22626 32,25 202160 202462 242519 40825 25545 22431 .7,29 0,06 1,70E·003 10.8 33,3
291,08344 12.61 18993 28868 32858 203120 259100 242738 8,73 3,387 4,30E·OO3 26,5 12,2
913.21112 2.211 169578 163857 190493 60957 51485 41062 ·3,41 0,081 4.30E·OO4 8 19.4
158.08241 3,881 588 2327 6883 129088 152744 152768 44,36 48,336 2,OOE·003 99,5 9,4
291,0835) 6,471 12901 17934 25390 246244 219480 225827 12,30 4,87 2,70E·OO4 33,5 6,1
826,56134 45,8) 42619 71322 104723 188261 261762 217532 3,05 1,81 6,30E-003 42,6 16,6
)02.22104 45,33 192954 183322 178704 57271 42387 42246 ·3,91 0,057 3,70E·005 3,9 18,3
223,01999 4.349 235016 281873 274001 91450 61551 66736 ·3,60 0,087 8,80E·004 9,5 21,8
368,10907 3,582 9212 983) 22692 105902 121119 106646 7,99 4,99 1,40E·004 54,7 7,7
226.05084 14.14 3195 3205 3466 84204 96006 73632 25,73 4,604 6,20E·003 4,7 13,2
245
249,18626 41,77 194326 230955 176396 24724 19885 13692 -10,32 0,041 6,10E-D03 Il,9 28,S
826,56116 44,29 32251 42150 71821 252872 250281 203130 4,83 2,615 1,10E-D03 42,2 11,9
214,07225 5,537 108215 107253 93603 13770 7378 9344 -10,14 0,04 7,70E-D04 7,9 32,2
225,12474 35,61 180546 233468 216685 59822 80926 59115 -3,16 0,1 4,60E-D03 12,9 18,6
826,5611 41,22 33545 34024 54950 238534 240119 194325 5,49 2,28 2,OOE-D03 29,9 11,6
207,07758 6,105 98624 102116 116103 674 330 0 -315,58 0,003 2,50E-003 8,8 IDO,7
876,2677 2,219 48209 52640 43806 116304 113959 93039 2,23 0,47 9,OOE-003 9,2 11,9
225,1246 34,09 256176 262768 268476 77748 85667 74468 -3,31 0,029 3,10E-D06 2,3 7,3
223,02017 5,207 286484 214509 284426 26181 21942 17684 -11,94 0,029 9,OOE-D03 15,7 19,4
351,10129 11,81 0 613 0 177579 162071 158125 812,03 1456,59l 1,30E-D03 173,2 6,2
630,37848 38,66 212724 210318 203849 72696 56601 44112 -3,62 0,075 1,40E-D03 2,2 24,8
388,97745 2,339 1793 7134 0 89595 81178 92564 29,50 38,781 1,10E-D04 124,7 6,7
386,99817 2,415 54\39 49645 58223 \34097 142711 \36681 2,55 0,285 1,90E·D05 7,9 3,2
225,12473 35,85 221194 216899 227801 66711 66071 64472 -3,38 O,Oll 2,40E·D04 2,5 1,8
223,02023 5,41 248875 208912 229238 27215 33887 37763 -6,95 0,036 2,OOE·D03 8,7 16,2
350,11765 3,107 3011 0 1549 73708 84838 60104 47,95 55,648 9,10E·D03 99,1 17
697,21246 16,41 0 1379 0 223689 255000 258393 534,50 967,738 2,OOE·003 173,2 7,8
1102,7139 38,08 203447 170175 204747 109437 83817 74981 -2,16 0,14 2,60E·D03 10,2 20
586,31549 33,21 187849 183857 173166 27690 43505 50552 -4,48 0,074 1,80E-004 4,2 28,8
320,99741 3,434 256492 192325 210340 65103 99858 74536 ·2,75 0,137 7,OOE·003 15,1 22,S
241,13124 15,52 0 3761 2260 167538 148292 184022 83,02 87,215 3,60E·003 94,3 10,7
237,02278 17,7 105193 1087% 79869 13218 12978 2054 -10,40 0,081 4,70E-003 16,1 67,7
600,33142 33,23 192207 190701 173084 26134 46994 50013 -4,52 0,083 1,50E-004 5,7 31,7
367,10687 5,537 75355 80909 95373 0 0 0 onlyCfR 0 5,OOE-OOJ 12,3 0
367,10672 5,742 75355 80582 76548 0 0 0 only CTR 0 4,20E-004 3,5 0
348,00879 11,77 \308 1388 664 140313 190093 155500 144,61 74,083 8,30E-003 35,S 15,8
567,31805 18,89 2483 2475 915 108553 104573 91276 51,83 28,518 2,50E-D03 46,1 8,9
614,3468 37,62 234D02 182047 173257 16571 27439 28366 -8,14 0,054 9,70E-D03 16,7 27,2
250,145 42,61 28011 23300 40102 1%332 182576 184484 6,16 1,998 2,20E·005 28,4 4
300,12051 5,128 79321 60900 76888 0 0 0 only CTR 0 6,30E·003 13,8 0
3 \3,05304 2,827 66802 61425 67391 204307 193779 164243 2,87 0,463 8,20E-D03 5 11,1
207,07764 5,902 98624 99572 106259 647 360 424 -212,76 0,002 5,60E-004 4,1 31,6
687,07623 2,339 41138 58943 34046 155725 169233 134927 3,43 1,37 1,30E-D03 28,7 11,3
223,0202 5,019 221127 224119 229109 25237 10626 18390 -12,43 0,034 2,DOE-D05 1,8 40,4
826,56\34 41.65 23257 31690 41690 213061 207462 170686 6,12 2,467 2,50E-003 28,6 11,7
225,12465 36,1 219162 235073 223865 66421 58352 68870 -3,50 0,QJ5 2,90E-D05 3,6 8,5
389,05127 2,018 294212 278244 295856 128214 174281 127335 -2,02 0,109 5,80E-D03 3,4 18,7
225,12474 34,93 252358 226708 200401 63497 79938 81103 -3,03 0,081 4,60E-003 II,S \3,2
291.08359 6,23 19468 25026 35480 223476 197928 241826 8,29 3,356 1,70E·D03 JO,~ 10
449,2916 24,72 33208 26272 30120 130910 131351 138968 4,48 0,673 1,10E-DOS 11,6 3,4
247,08276 16,86 95901 98030 86823 6932 40S8 4382 -18,26 0,Q2 8,OOE-D04 6,4 30,7
3\3,0817 2,3 33664 20291 28692 72286 92S64 79478 2,% 1,099 2,80E-D03 24,S 12,6
225,12469 39,31 161937 204388 197350 52860 51971 51365 -3,61 0,Q38 9,20E·003 12,1 1,4
225,12476 35,12 232774 209114 194186 59827 74958 63938 -3,20 0,066 2,30E-DOl 9,2 11,8
,
'I
I
246
399,27588 46,52 214018 210416 161018 80404 73366 44359 -2,95 0,149 5,30E-003 15,2 28,9
373.23886 47.27 171035 194804 156129 76101 58820 37030 -3,04 0,149 1,90E-003 11,2 34.2
241,17407 15,51 0 2223 2110 134874 148923 155738 101,44 95,309 1,60E-003 86,7 7,3
329,04749 2,356 5421 4960 5124 93171 R4254 715n 16,06 2.831 6.40E·003 4.5 13,1
391,21323 25,06 14208 14581 12816 131497 133412 125239 9,38 0,937 2,60E·004 6,7 3,3
826,56128 47,18 21301 34719 64733 217745 214359 162714 4,93 3,488 2,80E·003 55,2 15,6
291,08353 5,978 23511 21729 35091 259695 199953 260870 8,97 3,731 6,80[·003 27,1 14,5
268,08072 2,022 72372 %130 94242 197185 192229 190236 2,21 0,373 3,20E·003 15,1 1,9
568,36285 43,93 205902 207886 189515 109261 85352 89446 ·2,12 0,087 4,60E·004 5 13,5
594,37854 42,91 162595 194187 217713 106197 90118 53007 -2,30 0,205 8,40£-003 14,4 32,8
358,10587 11,23 0 14198 0 127613 130067 110711 25,95 47,168 1,60E-004 173,2 8,6
171,13921 30,57 188504 23283 I 194995 82106 72799 77330 -2,65 0,067 9,40E-003 11,7 6
442,16037 5,759 58449 66244 70958 0 0 0 onlyCTR 0 3,IOE·003 9,7 0
223,02008 4,642 221428 224851 221588 21503 8920 10687 -16,25 0,031 1,40E-004 0,9 49,7
514,28485 17,59 6738 8326 5947 96168 89492 %851 13,45 2,906 2,90E-004 17,3 4,3
568,32123 19,4 879 490 572 103508 107674 94661 157,57 60,289 1,40E-003 31,7 6,5
214,0723 4,976 15074 13464 13431 113479 93665 98567 7,28 1,227 4,30£-003 6,7 10,1
183,01613 2,892 5305 2271 5107 128423 141199 118104 30,57 15,013 2,40E-003 40,2 9
325,2478 49,45 113272 146189 115761 59854 42660 33998 -2,75 0,159 5,OOE-003 14,7 28,9
709,05847 2,356 45080 35752 31564 108819 112924 99808 2,86 0,707 2,30E·004 18,5 6,3
549,30725 19,54 0 672 0 94380 94114 100962 430,74 763,584 4,80E·004 173,2 4
1167,3546 2,021 104445 87104 91372 202518 209010 198775 2,16 0,262 2,50E·004 9,6 2,5
241,06555 15,52 0 2131 2024 152131 148133 158900 110,51 99,739 2,40[·004 86,7 3,6
510,25381 19,04 22560 20519 21933 99481 89801 98591 4,43 0,461 1,20E·003 4,8 5,6
225,12471 38,75 189062 201320 198455 61442 55025 53187 ·3,47 0,031 2,00[·005 3,3 7,7
349,00281 17,09 3955 3741 2906 95912 88172 87577 25,62 5,336 8,20E·004 15,7 5,1
145,03828 3,492 76874 60383 74017 165305 201183 218061 2,78 0,734 9,70E·003 12,5 13,9
195,01051 2,737 11724 14732 7274 140856 147229 110874 11,83 5,674 6,70[·003 ll,4 14,6
288,61975 16,86 9033 4959 6334 107049 97308 89092 14.44 5,743 2,20[·003 30,6 9,2
225,12473 36,62 188932 164988 195855 48749 52517 54884 ·3,52 0,042 3,90E'003 8,8 5,9
697,21222 18,08 0 1234 0 171946 16%79 204335 442,43 813,666 3,70[·003 173,2 10,7
225,12459 36,41 180236 211368 180533 59665 56850 52976 ·3,38 0,045 4,70E·003 9,4 5,9
218,87421 2,604 130393 145061 151877 19292 23723 17204 ·7,10 0,034 1,30E·003 7,7 16,6
589,33484 35,82 253858 227229 228518 111118 110191 113789 ·2,12 0,038 4,30E·003 6,3 1,7
329,03961 2,546 234924 78720 270699 712116 670451 789863 3,72 2,26 3,40[·003 52,4 8,4
555,35065 39,09 179503 179575 146344 99816 56738 51597 ·2,43 0,204 8,IOE-003 11,4 38,2
246,07503 4,976 0 20535 0 122173 121607 108157 17,14 30,844 4,OOE'()()4 173,2 6,8
329,17599 21,89 19425 11063 12591 154740 129965 121842 9,44 4,12 4,40E-003 31 12,6
130,08762 3,166 6710 28358 17148 61540 59000 82605 3,89 3,165 7,30[·003 62,2 19,1
450,96548 2,429 86213 81%3 96630 32126 30667 28306 ·2,91 0,051 3,70E,003 8,5 6,3
608,3941 42,71 191580 170194 168921 28866 16811 16843 ·8,49 0,048 2,80E·OO4 7,2 ll,4
188,98637 5,359 90510 81173 98418 0 9972 7569 ·15,40 0,064 4,40[·004 9,6 89
225,12459 39,9 158954 174239 201098 56495 46906 51944 ·3,44 0,062 7,IOE-003 12 9,3
274,21072 47,27 179531 190059 140441 29145 26120 20921 ·6,69 0,047 9,30E·003 15,4 16,4
247
442.16006 5.537 58449 66244 68531 0 0 0 only CTR 0 2.20E-003 8.2 0
291.08353 5.799 24765 25345 34470 247044 201241 267883 8.47 2.844 7.40E-003 19.3 14.3
452.2738 21.8 38712 47040 43998 115198 140968 118319 2.89 0.606 6.IOE-003 9.7 11.3
387.02661 3.272 241538 182293 238392 31208 31193 24578 -7.61 0.037 9.20E-003 15.1 13.2
325.22971 49.36 206779 155013 201122 56166 44422 35357 -4.14 0.092 7.00E-003 15.1 23
566.30554 17.51 1856 281 1970 82325 79156 101070 63.93 52.714 6.00E-003 68.9 13.5
225,12457 41.17 162922 176462 187741 50871 47070 50038 -3.56 0.031 2.60E-003 7.1 4.1
826.5614 47,4 17727 28498 60050 199544 182285 152921 5.03 3.79 1.60E-003 62.1 13.2
225.12457 39.04 171577 186444 201305 52122 58855 46140 -3.56 0.057 1.20E-003 8 12.1
697.21204 18,46 0 212 0 152893 175824 153070 2272,58 4128,461 2.20E-003 173,2 8.2
559,45416 49.36 167076 138130 155852 16433 9557 9332 -13.05 0,034 2.00E-003 9.5 34,3
477.2821 34.86 183770 175809 164414 48969 46226 39786 -3,88 0,041 3.IOE-004 5.6 10.5
300.22668 48.21 256095 224695 273913 50570 41195 45940 -5.48 0,037 3,80E-003 9,9 10.2
574.26971 18.51 21229 20503 20116 81353 83519 98884 4.26 0,58 6.50E-003 2,7 10,9
315.19672 18.12 3198 888 3864 97875 120695 101859 40,31 28,351 4,ooE-003 58,9 11,4
826.56116 46.61 38698 66231 108861 278199 241489 207774 3,40 2,182 4,ooE-003 49.6 14,5
151,06148 5,003 46183 35356 45106 155609 168104 183602 4,01 0,898 1.20E-003 14,1 8,3
498,28973 20.41 6842 7163 8440 106478 100072 84068 12.95 3.005 5.30E-003 11.3 11,9
582.37823 43.61 201570 198914 177073 113513 86659 84026 -2,03 0,119 1,50E-003 7 17,2
322.03976 4.623 0 0 275 59134 59369 62840 659,43 1162,958 3,70E-004 173.2 3.4
582.37842 43.92 191086 180733 160503 94650 80355 68347 -2,19 0,114 1,40E-003 8,8 16,2
405,1243 13.2 0 0 912 108945 98626 106018 343.85 613,153 7.80E-004 173,2 5,1
277.21011 46.29 152529 159695 152716 23350 15740 19134 -7,99 0.D28 2,OOE-006 2,6 19,6
840,57654 40.24 26433 24827 40500 188030 193334 151389 5.81 2,383 3,70E-003 28,2 12.9
204.06674 6.152 61592 33425 80645 193068 152714 191693 3,06 1.633 3.20E-003 40.6 12.8
835,53534 47,13 148004 146873 111994 64428 60213 25798 -2,70 0,212 7.40E-003 15.1 42,3
288,61963 18.12 2979 3899 5239 71028 87717 63825 18,37 8.203 9.50E-003 28.1 16.5
826,56042 40.86 14375 26239 25130 176168 213978 165662 8,45 3.688 5,40E-003 29,9 13.7
291,0835 13.46 8839 17450 17657 145704 18M45 176454 11,58 5.429 4,40E-003 34.4 12.5
225.1246 26.38 642642 655709 613836 198623 251896 179880 -3,03 0,07 3,ooE-004 3,4 17,8
225,12477 42.54 133814 161109 152828 55988 44495 56664 -2,85 0,079 2.00E-003 9,4 13.1
365,24686 49,36 178656 152476 174255 65898 97492 76439 -2,11 0,135 2,IOE-003 8,3 20,1
530.04022 2,356 3956 0 10733 48068 48792 47091 9.80 11,039 4.40E-003 110.9 1.8
330.03372 2.285 113218 118062 115496 14022 16821 36962 -5,11 0,112 4,70E-003 2.1 55.4
243,06235 3.166 2857 4251 4861 53653 49219 62544 13,82 5,259 5,ooE-003 25,7 12.3
697.2121 18.28 0 785 0 154063 169749 174018 634.18 1138,863 1.30E-003 173,2 6.3
359.11975 2,715 81930 85882 75632 43748 39186 37326 -2,02 0.072 7,50E-004 6,4 8.2
452.27896 35.59 131691 150987 120991 72656 50725 42774 -2,43 0.162 3,20E-003 11,3 27.9
840.57635 42.87 27268 32975 51036 175053 159676 134721 4,22 1,96 2,20E-003 3J.5 13
313,16461 28,37 175070 153442 193806 43257 52813 38773 -3,87 0.071 4.ooE-003 11.6 16
840,57629 43.61 26311 33700 49354 123550 149947 132771 3,71 1,566 7,IOE-004 32,3 9,9
164.07188 6.278 190099 154102 137467 5011 1780 2377 -52.54 0,014 9,40E-003 16,8 56,3
362,01221 2.356 7748 6970 6186 44691 46504 38961 6,23 1,263 2,90E-003 11.2 9.1
1047.6062 19,97 1490 647 0 61583 64542 70239 91,89 102,539 1,20E-003 104,9 6,7
248
830,49829 44.45 17435 20282 31888 150392 148346 143580 6,35 2,248 2,IOE·D04 33 2,4
389,26981 24,77 14604 5478 10609 102144 129755 96067 10,69 6,533 7.70E·D03 44.7 16.4
315,63379 19,08 1220 1290 10)2 74891 5828) 60581 54,70 13,809 6,60E·00) 11,3 13,9
535,38641 44,85 166599 164794 188656 89447 63236 94700 ·2,10 0,134 2,10E·Q03 7,7 20.4
191,0199 2,661 20431 23037 16005 107308 111365 92006 5,22 1.452 2,20E·D03 17,9 9,9
168,02458 2,816 4369 0 6687 105199 114381 103554 29,23 28,511 6,90E·D05 92,1 5,4
220,87128 2,604 115937 128299 128315 21491 27181 24469 ·5,09 0,034 4,50E·D04 5,8 11,7
226,12796 25,21 166733 207073 226396 43762 50827 67022 ·3,71 0,101 7,30E·D03 15,2 22,1
840,57623 43,78 26960 34853 51130 120672 156753 126671 3,58 1,685 1,40E·D03 32,7 14,4
358,10495 14,8 702 0 0 79823 69327 72892 316,30 570,843 1,70B·003 173,2 7.2
697,21222 20,86 1045 0 0 147978 166128 153704 447,67 802,101 1,IOE·D03 173,2 6
225,12474 42,35 134434 150959 176802 42397 42137 55778 ·3,29 0,093 7,OOE·D03 13,9 16,7
497,27798 20 25770 21402 22469 105378 95753 9209) 4,21 0,709 1,20E·D03 9,8 7
826,56091 44,49 24480 43115 62128 196361 204594 175308 4,44 2,287 5,70E·D04 43,7 7,9
255,58189 13,53 1927 781 0 61869 73302 69283 75,50 87.526 2,OOE·OO3 107,4 8.5
890,7439 15,78 0 0 791 109686 140647 116829 464,17 865,043 5,80E·D03 173,2 13,2
289,12128 17,25 2635 1491 1570 67108 80116 70386 38,20 16,417 2,80E·OO3 33,6 9,3
840,5766 37,73 29463 28842 33797 166899 164825 128776 5,00 1,138 9,20E·D03 8,8 14
725,03235 2,356 8254 0 7284 85111 84242 63514 14,99 15,414 4,60E·D03 87,1 15,7
277,21762 46,96 251273 253022 218430 25525 16032 16684 ·12,41 0,029 1.40E·D03 8,1 27,3
262,04886 4,976 0 7891 0 ID0891 92720 82387 34,98 64,104 7,60E·D04 173,2 10,1
225,12463 40,78 149320 155691 176885 50295 54420 46574 ·3,19 0,053 3,50E·OO3 9 7,8
265,21762 47,18 130361 132827 125761 18057 13171 9418 ·9,57 0,036 5,IOE·D06 2,8 J2
697,21252 19,04 0 319 0 136725 160295 159745 1431,87 2604,747 2,60E·OO3 173,2 8,8
260,0235 3,166 9493 2733 10320 95839 84432 90070 11,99 7,399 6,80E·D05 55,4 6,3
249,02428 2,892 9314 3473 6440 87070 91599 77950 13,35 7,167 6,90E·D04 45,6 8,1
270,0701 3,881 778 1574 0 76899 87093 87217 106,81 114,809 1.40E·DO) 100.4 7,1
697,2121 19,66 0 609 788 146525 159692 149393 326,13 304,218 6,70E·OO4 88,7 4,6
523,66296 15,07 0 0 222 74902 802DO 83684 1075,61 1923,879 I,OOE·D03 173,2 5,6
413,29138 45,92 25654 , 24282 12897 104896 96541 104412 4,87 1,851 1,90E·OO4 33,4 4,6
840,57605 43,06 27508 )2975 51974 120268 163555 135444 3,73 1,863 4,80E·D03 34,3 15,7
481,31384 41,6 160243 145189 185536 67550 55733 59716 ·2,68 0,083 8,50E·003 12,5 9,9
592,36267 39,09 160536 152979 123915 65629 36435 28355 ·3,35 0,174 3,OOE·D03 13,3 45,1
317,21234 31,34 146747 138175 151276 46707 59479 58232 ·2,65 0,066 8,70E·D05 4,6 12,8
240,95708 15,52 0 2697 1246 116163 108268 125606 88,77 97,76 1,50e·D03 102,7 7,4
826,56042 37,51 15713 22676 26942 156620 170648 122394 6,88 2,931 9,40E·003 26 16,6
279,22415 46,29 125113 113229 117369 16216 11762 14333 ·8.41 0,025 3,10E·004 5,1 15,9
840,57587 40,93 14869 15072 24290 144368 112228 109104 6,74 3,087 7,90e·OO3 29,8 16
697,21191 18,71 0 872 434 154821 169136 162441 372.43 389,526 6,30E·D04 100,2 4.4
392,28915 30,03 142864 137740 120764 53246 37020 36924 ·3,16 0,098 5,50E·0Q4 8,6 22,2
840,57623 43,25 25322 36947 50042 176047 158913 135991 4,19 1,922 2,IOE·OO3 33 12,8
408,9718 2,429 106462 115116 123058 40347 42418 27451 ·3,13 0,094 3,10E·004 7,2 22,1
697,21179 21,37 0 969 741 126814 146544 136686 239,79 230,466 1,70e·003 88,9 7,2
225,12466 41,51 208630 170843 166162 44668 48417 44149 ·3,98 0,045 9,10E·D03 12,8 5,1
249
465,28632 20.87 35860 52437 46380 107763 92198 88111 2.14 0.631 3.IOE-003 18.7 10.8
283.15518 17.9 328 316 0 85541 77268 77741 373.52 345.663 I. IOE-003 86,6 5.8
402,16031 14,28 0 763 0 211802 245046 185256 841.55 1575.106 6,50E-D03 173,2 14
297.03619 2.71 79214 76674 87198 21834 17840 15465 -4,41 0,D55 2,80E-D04 6,8 17,5
228.90311 2.601 96821 109820 109470 22038 24910 25277 -4,38 0,033 1,70E-D03 7 7.4
188.D0232 4,453 900 10741 19847 56335 86447 76756 6.97 7,759 6.80E-D03 90,3 21
606,37842 39.09 135923 136316 106363 54745 27273 27078 -3.47 0,165 2.70E-003 13.6 43,8
697.2124 21.55 0 969 741 122463 109404 141252 218,20 222.051 5,50E-D03 88,9 12,9
212,9794 15.82 140970 168908 148767 71074 73311 69819 -2,14 0,056 9,50E-003 9,4 2,5
213.14966 23,71 107054 128165 121970 13865 8508 13726 -9,89 0,DJ5 1,90E-D03 9,1 25,4
840,57635 42_61 23637 30762 44553 154939 148590 120129 4,28 1,942 2,50E-D03 32_2 13,1
287.22308 49.9 131123 150607 179229 30262 24078 16862 -6,47 0,068 7,70E-D03 15,7 28,3
165_03075 3,496 365 0 0 38080 46813 53000 377,79 715,248 8,80E-D03 173,2 16,3
141,12883 16.63 0 0 310 88374 100493 109817 963,50 1770,712 3,90E-D03 173,2 10,8
292_08688 3,005 52886 49152 69747 163313 147914 185830 2,89 0,887 2,70E-D03 19,2 11,5
225,12466 42,84 135642 144324 154043 37962 40356 44182 -3,54 0,04 1,IOE-D03 6,4 7,7
1021_3095 2.021 43234 38489 35198 94860 91820 106978 2,ll 0,466 1,60E-D03 10,4 8,2
697,21234 17,9 0 914 279 162355 151697 157056 394,89 478,404 3,50E-D04 117,8 3,4
331.19147 21 3209 8609 6901 104355 102646 117749 17.35 9,001 8,80E-D04 44,2 7,6
626,34692 35,61 124629 150742 147183 47197 71074 42674 -2,63 0,147 2,00E-D03 10,1 28,4
181,062 5,902 62031 69049 76188 14389 12109 10806 -5,50 0,045 3,40E-D03 10,2 14,3
262.04886 5,596 67102 82168 65552 ° 342 0 -628,13 0,D03 5,40E-D03 12,8 173,2
565,3349 35,95 180967 180945 173452 73699 68429 41953 -2,91 0,104 4,70E-D03 2,4 27,7
241,10828 4.203 705 0 0 48840 49770 56386 219,85 398.073 2,00E-D03 173,2 8
244,15915 34,26 117146 14D002 142366 41482 33029 36208 -3,61 0,061 3,90E-D03 10,5 11,6
310,55869 2_149 106129 80317 96210 18983 9026 19865 -5,90 0,087 3,20E-D03 13,8 37,7
697,21191 21,17 789 284 297 138257 144443 183429 340.24 268,248 8,20E-D03 63,1 15,8
840,57635 36,54 15419 4396 2D065 124498 180374 142601 11,22 8,938 9,90E-D03 60,5 19,1
608_3941 42,91 112926 141108 143028 77020 59326 38915 -2,27 0,2 7,60E-D03 12,7 32,6
405,22885 25,3 14836 20085 28113 183464 153452 138771 7,55 3,486 5,60E-D03 31,8 14,4
826,56018 33.83 17179 20233 25034 146686 124647 116410 6.21 1,933 4.70E-D03 19 12,1
476.2789 34.35 211360 204505 204886 109251 89739 102577 -2,06 0,057 9,50E-D04 1,9 9,9
115,07671 9,693 12101 13208 15436 141968 171087 159342 11,59 2,529 3,10E-D03 12,5 9,3
212,97925 15,51 145140 138891 152854 44496 50962 78622 -2,51 0,144 7,30E-D03 4,8 31,2
197,04326 3,496 26711 13219 15873 44230 42316 50881 2,46 1,188 8,30E-D03 38,4 9,8
303.08353 3,706 29827 34308 36380 73398 66620 75509 2,14 0,353 5,30E-D04 10 6,5
271,07068 4.286 0 512 0 110173 118564 125395 691,66 1241,733 1,40E-D03 173,2 6,5
697,21271 17,68 521 0 1884 173107 140224 145856 190,93 253,741 4,30E-D03 121,4 11,5
199,99678 12,88 2158 1745 3608 61861 61150 56361 23,88 10.525 3,20E-D04 39,1 5
840,57611 35,97 19971 22437 289DO 156071 160295 129828 6,26 1,908 3,50E-D03 19,4 11,1
826,56091 47,61 19845 21265 53216 139209 143807 130824 4,39 2,843 5,60E-D03 60 4,8
231_99229 2.892 1127 2371 1189 85435 85805 74933 52,52 27,529 1,70E-D03 44,9 7,5
241,28282 15,52 0 1478 1406 103603 %381 110251 107,57 100,463 1,30E-D03 86,7 6,7
697,21228 17,07 390 639 0 142516 151488 130875 412,90 417,859 1,80E-OD3 93,9 7,3
250
521,20313 15,52 0 1097 605 104663 80179 87907 160,25 177,288 6,JOE·D03 %.8 13.8
280,2442 49,36 163174 142719 ])3067 36346 27286 29774 -4.70 0,054 3,30E·D03 10,5 15
643,10315 2.293 34088 37867 34441 0 0 0 only CTR 0 1.20E·D03 5,9 0
350,10941 3,025 5030 5510 5569 70398 74797 71676 13,46 1,163 3.IOE·D04 5.5 3,1
697,21301 17.47 0 0 787 121269 143257 145530 521,04 953,6 3,20E·D03 173,2 9,8
697,21216 21,73 0 0 370 141436 131761 124974 1076.14 1929,128 1,30E·D03 173,2 6,2
580,84283 16.63 0 480 0 104448 135783 127095 765,26 1426,695 5,80E·D03 173,2 13,2
419,00012 2.436 96D05 107538 109020 35681 36274 33473 ·2,96 0,037 2,60E·D03 6,8 4,2
215,05382 2,663 15461 17499 10478 63530 58108 46670 3,87 1,561 6,60E·D03 24,9 15,3
513,27271 18,25 16102 17977 21244 76757 70258 70377 3,93 0,756 7,50E·D05 14,1 5,1
210,07724 5,742 49254 517% 44753 0 0 0 only CTR 0 1,80E-D03 7,3 0
657,10724 2,298 0 0 7999 37823 29652 27604 11,89 22,615 2,30E·D03 173,2 17,1
295,228 40 130560 127267 120595 12478 8866 9065 ·12,44 0,019 1,20E·004 4 20
352,13596 5,742 46916 45756 36390 0 0 0 only CTR 0 5,90E·003 11,4 0
3]),1459 2,339 29114 25336 19510 73254 64369 68181 2,78 0,727 3,30E·004 19,6 6,5
318,19431 33,05 106062 91139 99295 50184 55359 39357 ·2,05 0,12 1,40E·003 7,6 16,9
312,9852 2,339 30484 18371 19654 74944 69431 68761 3,11 1,055 1,60E·003 29,1 4,8
261,00754 3,041 1843 0 0 83458 80348 83507 134,19 235,359 3,30B·006 173,2 2,2
840,57648 46,01 20825 35163 53243 139348 120510 99940 3,29 2,011 5,JOE·DOl 44,6 16,4
840,57654 44,29 21301 29049 43184 139555 141611 102666 4,10 2,163 6,70E·003 35,6 17,1
567,31793 19,66 4455 4607 4282 78119 72711 67602 16,37 1,781 2,00[·003 3,7 7,2
451,30719 25,62 89077 88442 106294 26389 38131 28537 .3,05 0,101 1,70B·003 10,7 20,2
JJ9,20001 31,16 156573 193951 166463 39260 44651 68356 ·3,40 0,123 1,30E·003 11,2 30,5
280,22952 49,36 152821 109800 135327 41080 35994 24069 ·3,93 0,107 8,OOE·003 16,3 25,9
210.84265 2,601 90697 98368 101219 11958 12005 13632 ·7,72 0,017 I,OOE·003 5,6 7,6
352,13623 5,537 46916 46101 47783 0 0 0 onlyCTR 0 1,IOE·004 1,8 0
279,2114 49,36 141702 133309 124805 41316 339% 36463 ·3,58 0,046 6,20[;·004 6,3 10
225,12459 44,8 104282 132149 137246 44747 33903 34315 -3,31 0,092 7,90E·003 14,2 16,3
225,12463 44,07 122634 140105 145125 36077 35154 40227 ·3,66 0,044 3,30E·003 8,7 7,3
473,14578 15,77 0 671 0 91134 800% 98995 402,72 739,837 3,70E·003 173,2 10,5
424,95395 2.414 14664 12265 12764 71499 63826 57434 4,86 0,997 5,IOE·003 9,6 11
330,03394 2,081 113006 111617 104003 29454 31248 47561 ·3,04 0,106 1,70E·003 4.4 27,6
882,52179 44,49 109960 113784 93507 32519 18649 34910 ·3,69 0,111 8,OOE·004 10,2 30,6
325,19205 30 120174 95081 105430 31333 28345 42399 -3,14 0,107 2,40E·003 11,8 21,8
827.56433 45,65 21013 28562 50257 132529 117863 98084 3,49 2,112 3,60E·003 45,6 14,9
697,21228 17,25 0 1327 258 128131 143205 ]]D090 253,39 352,645 1,10E·OOl 133,1 6.1
180,06668 5.742 48009 36812 36622 2679 3475 1305 ·16,28 0,037 8,30E·003 16,1 44.2
162,95731 2.575 6603 13690 10788 90251 90532 79211 8,37 J.5 3,OOE·OO4 34,4 7,5
498,29034 18.91 4994 6924 6241 65652 66310 61705 10,67 2,136 1,20E·OO4 16,2 3,9
331,04291 2,356 4622 2325 7895 54508 55283 48365 10,66 6.795 1,IOE·004 56,6 7,2
608,42554 44.49 116959 117551 96381 43458 34222 31648 ·3,03 0.092 2,60B·003 10,9 17
437,13364 14,46 0 3272 0 92462 88515 105742 87,63 160,06 2,20E·003 173,2 9,4
581.39709 40,83 162871 176031 155075 83140 62952 59346 -2,40 0,105 6,60E·004 6,4 18,7
697,21204 22,28 0 448 0 119937 132315 125834 843,94 1501,839 7.90E·004 173,2 4,9
251
241,10829 14,66 0 2999 0 88274 88792 71489 82,88 153,415 3,90E-003 173,2 11,9
512,25287 18,54 8950 9617 9047 55422 70275 60153 6,73 1.088 6,70E-003 3,9 12.2
584,3161 17,94 4086 4394 2791 59389 66233 59389 16,41 4,768 I,OOE-003 22,6 6,4
1159,7874 40,71 104202 101439 82636 28647 20908 16089 -4,39 0,094 2,IOE-003 12,2 29
840,57629 45,74 22234 38798 52084 141250 134532 107370 3,39 1,819 2,90E-003 39,7 14
826,56073 41,84 29580 36023 37512 147811 144104 124946 4,04 0,853 2,IOE-003 12.3 8,8
827,56433 43,52 22977 23606 39565 95429 120690 97225 3,64 1,682 2,60E-003 32,7 13,5
582,3783 44,49 122908 136626 109952 57160 47500 49621 -2,39 0,086 5,70E-003 10,8 9,9
840,57611 33,35 14273 16606 18661 129445 119721 99496 7,04 1,861 6,80E-003 13,3 13,1
871,76733 18,69 0 289 0 145547 125187 128847 1382,63 2510,926 2,20E-003 173.2 8,1
397,22668 28,44 66499 83053 85828 11247 8541 9812 -7,95 0,034 6,90E-003 13,3 13,7
840,57599 34,34 23044 23152 26363 138551 129009 107345 5,17 1,064 7,60E-003 7,8 12,8
827,56451 39,96 17864 18780 29817 135142 128672 96952 5,43 2,553 8,80E-003 30 17
210,07732 5,537 49254 53616 51707 2020 1165 3207 -24,18 0,022 7,60E-005 4,2 48,1
222,99187 5,631 834 2369 0 107101 88722 100975 92,66 113,017 2,70E-003 112,5 9,5
281,0882 2,712 26471 17168 12796 59384 67324 56692 3,25 1,5 1,50E-003 37,1 9
697,2121 22,66 1721 0 0 106305 127147 129109 210,67 387,021 3,50E-003 173,2 10.5
345,22864 17,42 3560 309 0 64967 65081 64362 50,25 77,156 2,OOE-004 152,9 0,6
225,12465 45,57 105795 121272 130218 34039 31263 30942 -3,71 0,042 5,90E-003 10,4 5,3
241,11937 18,93 92743 80502 75200 24819 29674 28363 -3,00 0,067 5,70E-003 10,9 9,1
452,96252 2,429 60113 53029 57625 19503 19831 18806 -2,94 0,031 2,60E-003 6,3 2.7
225,1246 43,79 130866 140946 147042 40980 40299 426)2 -3,38 0,026 1,90E-OO,1 5,9 2,9
200,1738 40,49 118210 113428 91803 39173 26228 31268 -3,35 0,1 4,40[-003 13,1 20,3
438,29462 30,03 107312 105949 93946 40987 31236 31770 -2,95 0,Q78 3,40E-004 7,2 15,8
283,15512 18,89 1766 0 795 51659 56055 47087 60,45 67,885 1,90E-003 103,6 8,7
225,06178 3,244 69615 52602 46157 151258 122415 157654 2,56 0,888 4,20E-003 21,6 13,1
581,297 18,17 14833 14101 11349 50908 57715 56249 4,09 0,827 4,OOE-004 13,7 6,5
840,57617 37,12 23645 28842 27044 137608 162262 126940 5,37 1,218 7,IOE-003 10 12,7
291,08334 25,38 2207 523 I 8109 99007 120214 87408 19,72 14,444 8,IOE-003 57 16,3
593,36615 39,31 94199 104389 99978 45509 34181 18554 -3,04 0,153 7,10[·003 5,1 41,3
151,06145 5,483 44052 46471 37834 126560 140913 161899 3,35 0,764 7,40E·003 10,4 12,4
406,23196 25,16 6725 6168 7286 109716 93988 84838 14,30 3,06 6,40E-003 8,3 13,1
697,21222 23,33 0 0 273 98357 128002 125715 1289,65 2413,214 6,50E-003 173,2 14,1
826,56049 37,96 16729 13656 21207 114524 124717 92217 6,42 2,385 7,90E-003 22,1 15
467,15677 ,18,73 4338 3217 3363 57842 57682 48405 15,01 4 3,40E-003 16,7 9,9
208,8456 2,601 73924 76735 81683 10284 10715 11911 .7,06 0,018 7,40E-004 5,1 7,7
1107,7482 42,19 115107 91082 98243 56412 42044 49373 -2,06 0,13 6,40E-003 12,2 14,6
610,49304 49,28 69044 67162 62057 13037 4237 5410 ·8,74 0,079 1,20E-004 5,5 63,2
840,57635 46,78 19315 34950 51282 121074 116591 89605 3,10 1,893 5,50E-003 45,4 15,6
827,56421 40,15 18883 17020 27151 130176 120718 97803 5,53 2,211 5,80E-003 25,7 14,3
319,14005 15,14 0 2710 0 70412 67311 57538 72,05 132,227 2,40E-003 173,2 10,3
241,13126 14,66 0 4538 0 88446 97524 74043 57,30 107,065 4,70E-003 173,2 13,7
213,14955 23,89 108872 132490 122385 22219 22323 17964 -5,82 0,037 3,40E-003 9,8 11,9
225,12469 45,28 107493 117723 117825 33164 31828 42892 -],18 0,069 8,90E-005 5,2 16,8
252
Table S2 reports: quantitated ion (rn/z), retention time (RT), ion intensity in each replicates,
fold change, standard deviation (SO), p<O.O1 (welch's test), coefficient of variation (CV).
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Supplemental Table 3. Features detected 111 positive and negative Ion mode showing
significant changes (two-fold increase or decrease 111 Ion intensity, coefficient of variation
(CV) <10%, Welch's test p<O.OI) after cardiac arrest and cardiopulmonary resuscitation.
Metabolite
Measured neU. Adduct MW FCCI'R2 Chemical Taxonomy IIMIID kegg merlin
Mass I'pm vs CTI{' formula class 11) id ID
I-{beta-D- CIII·116N20
Ribofuranosylj-La- 255.09882 0.656 -11-1 256.255 4.29 5 I-IMDB11648
dihydronicot inamide
l lbeta-
331.2269 0.425 +11-1
330.219 7.54 C21113003 Not Available HMDBI3594 C05498
H),droxyprogcstcroue 5
12-KETE 317.21234 0.425 -IH
318.219
-2.65 C20113003 IIMDBI3633 C 14807
5
I-Methyliuosine 281,0882 3,308 -III
282.096 3.25 CIIII14N40 Nucleoside IIMDB0272I 37804 5 Analogues
2-Methyl-3- 129,05615 3,386 -IH 130,063 2,88 C61-11003 Keto-Acids HMDB00408 c03467
kctovalcr!c acid
2-Piperidinonc 100,07542 2,750 +11-1
99,0684 -5.42 C51-19NO HMDBI1749I
:1 -Ketolactose 341,10648 3,985 +IH
340.100 12.85 C121-120011 Carbohydrates IIMDBOI030 C054036
3b-Hydroxy-5- 375.28937 0.033 +111
374.282 -5,73 C24113803 Bile Acids IIMDB00308 5297
cholenoic acid I
3-Chlorotyrosinc 214,02776 0.487 -III
2 I 5.034 36.06 C91-IIOCINO Amino Acids IIMDBOl885 63699 3
3-Dehydroquinatc 189.04073 1,351 -11-1
190.047 24.48 C71-11006 HMDBI2710 C009447
3-Deoxy-D-glycero-D- 268.079
galacto-z-nonulosonic 267.07245 1.073 -IH 4
3.08 C91-11609 Carbohydrates I-IMD1300425 5414
acid
3-lndole carboxylic 338,08722 0,505 +11·1
337.079 5,10 CI5HI5N08 HMDBI3189acid rlucuronide 8
Indoles and
3-lndolcpropionic acid 190,08635 0,500 +11-1 189,079 -87.02 Cl 11-11I N02 Indole I-IMDI302302 6602
Derivatives
163.063 Indoles and
3-Methyldioxyindole 164,0706 0.015 +111 3
-3,87 C9H9N02 Indole HMDB04186 C05834 7024
Derivatives
3-0-fueopyranosyl-2- 367,147 C141·125NOI
acctamido-2- 368.15512 0.036 +111 9
119,10
0 Carbohydrates HMDB06700deoxyglucopyranose
3-0xocholic acid 405,265 I I I, I 57 -IH
406.271 3.19 C24113805 Bile Acids HMDB00502 54889
3-0xodoclccanoic acid 213,14966 0.202 -IH
214,156 -9,89 CI2I·I2203 Fatty Acids HMDBI0727 C023679
4-(2-Aminophenyl)- Amino acids208,06059 0,739 +IH 207,183 55,57 C)OH.NO, and Amino HMDB00978 cOl2522.4-dioxobutanoic acid
Acid conjugates
4-lIydroxy-3- 151.04036 1.891 -IH 152.047 6,50 C8H803 Aromatic Acids IIMDB04815mcthylbenzoic acid 3
4-0xoretinal 299,2008 I 0,877 +111
298.193 -2840,84 C20112602 HMDBI27943
5.8- Tetradecadienoic 223.17067 1.427 -IH 224,339 -2,13 CI4H2402 Fatty Acids HMDB00560acid
159.089 Amino acids5-Acetamidovalerate 158.0824 I 0.941 -IH 44,36 C7HI3N03 and Amino HMDBI21755
Acid conjugates
5-Acetylamino-6-
226.070fonnylamino-3- 225,06178 5,074 -II-J
2
2.56 C8HION404 HMDBI I 105 cl6365
methyluracil
5-Hydroxy-6- 339.095methoxyindole 340,10312 1.224 +IH 4
4,28 CI51-117N08 Glucuronidcs HMDBI0363 C03033
glucuronide
5-Hydroxyindoleacetic 191,058
Indoles and
192_06561 0.491 +11·1 24.45 CIOH9N03 Indole J-IMDB00763 C05635 2975acid 2 Derivatives
5-1·lydroxymethyl-4-
Nucleosides
157,06073 0,276 +11-1 156,139 8.53 C6H8N203 and Nucleoside HMDB00544methyluracil conjugates
7a- Hydroxy- 3-oxo- 5b-
391,28482 1,375 +II-J 390.277 2,39 C24H3804 Bile Acids HMDB00503 5489cholanoic acid
9-HODE 295.228 0,455 -IH 296,235 -12,44 CI8H3203 Fatty Acids HMDBI0223I
Allanloin 157.03693 1.337 -II-J 158.044 12,73 C4H6N403 Amino Ketones I-IMDB00462 COl551 89
254
all-trans-IB-
315,19672 0,428 -IH
316,203
40,31 C20112803 IIMDBI2452 CI6679
Hydroxvrennoic acid 9
Alpha- Amino acids196,06053 0,480 +IH 195,172 693,68 C9H9N04 and Amino IIMDB02404lIydrolyhil)puric acid
Acid cOl'Jilgates
AII·h.-keloisovaleric 115,04044 3,270 -11-1
116,047
13,47 C5H803 Keto-Acids 1-IMD1300019 cOOl41acid 3
Alpha-Linolenic acid 277,2178 1,801 -III 278,224 -8,16 C18H3002 Fatty Acids IIMD1301388 c064276
Aspartame 295_12906 0,683 +111 294,121 4,56 CI4H 18N20 Polypeptides IIMD1301894 CII045 63776 5
Benzocaine 164,07204 2,022 -11-1 165,079 79,57 C9HIIN02 1-IMD1306044
IJ1,094 Amino acidsBeta-Leucine 130,08762 1,960 -IH 6 3,89 C6HI3N02 and Amino HMD1303640 C02486
Acid conjugates
Calcitroic acid 373,23886 1.176 -IH 374,245 -3,04 C23113404 Alcohols and HMDB06472 CI82307 Polyols
Capric acid 171,13921 0,871 -11-1 172.146 -2,65 CI01l2002 Fatly Acids I-IMDB00511 COl571 3363
Caproic acid 115,07671 2,210 -11-1 116,083 11,59 C6111202 Fatly Acids IIMD1300535 CO15857
Caprylic acid 143,10797 1,465 -11-1 144,115 3,31 C8H1602 Fatty Acids HMDB00482 C06423
Carnosol 329,17599 0,502 -11-1 330,183 9,44 C20H2604 Polyphenols 1-IMD1J02121 C09069I
Ccrvonoyl 373,27405 0,867 +111 372.266 4263,61 C241-13603 HMDBI3627 CI3828cthanolamidc 4
Cervonoyl 373,2738 0,211 + II-I 372,266 21,69 C24H3603 HMD1313627 CI3828ethanolamide 4
466,311 Steroids and
Cholesterol sulfate 465.3053 1,925 -IH 7 -5,35 C271-14604S Steroid 1-IMD1300653 cl8043 5625
Derivatives
Cholic acid 583,31299 1,067 -IH 584,319 19,52 C30H48011 Glucuronidcs HMDB02577 C03033 6714glucuronide 6
Corticosterone 347,22183 0,402 +11i 346,461 16,72 C211i3004 Cholesterols 1-IMDBOI547 c02140and derivat ives
Creatinine 114,066 1,664 +IH
113,058 3,36 C4H7N30 Amino Ketones HMDB00562 C0079 I 89
V-Arabitol 151,06136 0,990 -III
152,068 5,98 C5H 1205 Alcohols and HMDB00568 C003795 Po_!yols
Deoxycholic acid 3-
567,31793 0,774 -III
568,324
16.37 C301-148010 Glucuronides HMDB02596 C03033 6721glucuronide 8
Docosahcxaenoic acid 327,23343 1,435 -IH 328,240 -3,01 C22H3202 Fatty Acids I-IMDB02183 c06429 34572
Dodecanoic acid 199,17049 0,672 -11-1 200,177 -2,85 CI2112402 Fatly Acids 1-IMDB00638 C02679 56116
dUDP 386,99817 4,766 -11-1 388,007 2,55 C9HI4N201 Nucleorides I-IMDBOIOOO COIJ46 59313 IP2
Ethyladipic acid 175,0965 0,101 +11-1
174,089 21,96 C81-11404 Dicarboxylic HMDB02023 64442 Acids
Fexofenadine 502,29309 4,166 +11-1 501.287 5,54 C321139N04 Diphenylmetha IIMDB05030 C06999 27669 nes
Formyl-5- 209,09203 0,208 +IH 208,084 616,12 C101l12N20 HMD1312948 C05647hydroxykynurenamine 8 3
Fonnyl-5- 207,07764 0,575 -ru 208,084 -212,76 CI01-l12N20 IIMDBI2948 C05647hvdroxvkvnurenamine 8 3
Gamma- 311.1239 0,449 +11-1 310,116 9,59 CI41-118N20 I-IMDBI1741Glutamvltvrosine 5 6
Gamma-Linolenic acid 277,21762 1.142 -IH
278,224
-12.41 C18H3002 Fatty Acids HMDB03073 C06426 3866
Amino acids
Ile •• noylglycine 174,11247 0,015 +IH 173,21 289,69 C8HI5N03 and Amino HMD1300701 C02710
Acid conjugates
179,058 Amino acids
Hippuric acid 178,05125 1,604 -III 9,12 C91-l9N03 and Amino I-IMDB00714 cOl5862
Acidco~tcs
Amino acids
Hippuric acid 180,06546 0,328 +IH 179,173 6,74 C9H9N03 and Amino IIMDBI2884 cOl586
Acidco~tes
Homovanillic acid
261,00754 0,400 -III
262,014 134,19 C91-11007S HMDBI1719 C05582sulfate 7
Hyodeoxycholic acid 391,28589 1,244 -IH 392,572 -3,03 C24H4004 Bile Acids HMDB00733
Imidazole lactic acid 155,04655 2,138 -III
156,053 10,72 C6H8N203 Hydroxy Acids HMDB02320 C05132 6617
5
147,068
Indoles and
Indole-3-carbinol 148,07552 1,226 +111 792,97 C9H9NO Indole IIMDB05785
4 Derivatives
Indeleacrylic acid 187,063 208,72 CII1I9N02
Indoles and
HMDB00734 C00331 5702186,05629 1,292 -III
3 Indole
255
Derivatives
187,063 Indoles andIndoleacrylic acid 188,07069 0.502 +111 110.10 CII H9N02 Indole HMDIJ00734 C00331 57023 Derivatives
Indoles and
lndolclactic acid 206,08124 0,311 +IH 205.21 13.51 CIIIIIIN03 Indole HMDIJ00671
Derivatives
205.073 Indoles andIndulelacric acid 204,06674 0.585 ·IH 3,06 CIIHIIN03 Indole IIMDIJ0067I C020439
Derivatives
133.052 Indoles andlndoxyl 134,05984 1.473 +IH 8 ·45.02 C8H7NO Indole HMDB04094 C05658 7014
Derivatives
lsobutyryl-L, Amino acids232,15448 0.606 +111 231.289 7.96 CIII121N04 and Amino HMDIJOO736carnitine
Acid coniu rates
Isocitric acid 191.0199 0.875 ·111 192.027 5.22 C6H807
Tricarboxylic
HMDBOOl93 C00311Acids
Amino acids
lsovalerylcarnitine 246.1701 0,510 +IH 245.315 4,44 CI21-!23N04 and Amino IIMDB00688
Acid con'lIgates
Amino acids
lsovalerylgfycfne 160.09674 0.467 +II-! 159.183 25.49 C7HI3N03 and Amino HMDIJ00678
Acid co".iugales
Kynurenic acid 190.04973 0.712 +IH 189.042 1422,36 C101l7N03 Aromatic Acids I-!MDIJ00715 COl717 56836
Lanrhioninc ketimine 188.00232 0.065 ·IH 189.009 6,97 C61-!7N04S Amino Acids HMDIJ04823 70856
Leukotricne 135 335,22278 3.247 +111 334,214 53.95 C20H3004 Eicosanoids IIMD13050734
L·Gnlose + 13 altri 180.063mctaboliti ad uguale 179.05638 1,512 ·111
4
2,48 C61-11206 Carbohydrates HMD1312326 C15923
delta
Lvphenylafanyl-l> 279.13431 1.380 +11-1 278.126 36,14 CI41-118N20 Polypeptides 1-IMDB11176hydroxyproline 6 4
LysoPC( 14:0) 468.30832 0.289 +11-1 467,301 only CTR C22H46N07 Phospholipids IIMDBI0379 C042302 P
LysoPC(16:0) 496,33948 0.580 +11-1
495.332
·32,69 C24H50N07 Phospholipids 1-IMDB10382 C042305 P
LysoPC( 16: 1(9Z» 494.32425 0.284 +11-1
493.316
only CTR
C241-148N07
Phospholipids IIMDBI0383 C042308 P
LysoPC(17:0) 510.35513 0,565 +11-1 509,348 ·5,47 C251-152N07 Phospholipids HM01312108 C04230I P
lysoPC(18:2(9Z.12Z» 520.34033 1.057 +IH 519.332 ·2,71 C261-150N07 Phospholipids I-IMDBI0386 C042305 P
LysoPC( 182(9Z.12Z» 520.33984 0,117 +IH 519.651 ·2,Q5 C26H50N07 Phospholipids I-IMDIJI0386 C04230P
LysoPC(18:3(9Z.12Z.1 518.32416 0,118 +IH 517.316 only CTR C261-148N07 Phospholipids 1-IMDBI0388 C042305Z)) 8 P
LysoPC( 18A( 6Z,9Z, 12 520,33881 4,454 +11-1 515,62 ·2,35 C26H46N07 Phospholipids HMD1310389 C04230Z,15Z» P
lysoPC(20:2( II Z, 14Z» 548,37061 0,780 +111 547.677 3,07 C281-154N07 Phospholipids HMBDI0392 C04230P
lysoPC(20:4(8Z.11 Z, I 544.33997 0.337 +IH 543.332 ·5.08 C28H50N07 Phospholipids J-IMDB10396 C042304Z.I7Z) 5 P
lysoPC(20:5(5Z.8Z, II
542.32416 1,127 +IH
541,316
only CTR C281-148N07 Phospholipids 1-IMOB10397 C04230Z.14Z,17Z») 8 P
LysoPC(22 :5(7Z, IOZ,I
570.35492 0.857 +11-1
569.348
onlyeTR C30H52N07 Phospholipids J-IMOB10403 C042303Z.16Z,I9Z» I P
lysoPC(22:6(4Z,7Z,10 404.20688 0.215 +IH 567,332 .5.61 C30J-l50N07 Phospholipids HMDBI0404 C04230Z,13Z,16Z,I9Z» 5 I'
LysoPE( 16:0/0:0) 452.27896 1.509 ·IH 453,285 ·2.43 C21J-144N07 Phospholipids 1-IMDB115036 I'
LysoPE( 18:0/0:0) 482.32407 0.089 +111 481.316 only CTR C23H48N07 Phospholipids 1-IMDB111308 P
LysoPE( 18: 1(9Z)/0:0) 478,29483 1,937 -11-1 479.301 ·2.60 C23J-146N07 Phospholipids I-IMDBI15062 P
LysoPE( 18:2(9Z.12Z)/
478,29269 0,256 +lIi 477.285 ·2,41 C231144N07 Phospholipids J-IMDB115070:0) 6 P
LysoPE( 18:2(9Z, 12Z)/
476,27878 1,022 -IH
477.285 ·4,78 C23H44N07 Phospholipids HMDBI1507
0:0) 6 P
Lysol'E( 18:2(9Z, 12Z)/
478,29297 0,321 +11-1
477,285 4,71 C23H44N07 Phospholipids HMDBI1507
0:0) 6 P
LysoPE( 18:2(9Z.I2Z)/
476.2789 1,278 ·IH
477,285 ·2,Q6
C231-144N07 Phospholipids HMDBI15070:0) 6 P
LysoPE(20: I (II Z)/O:O) 508,33951 0.506 +11-1 507.332 ·47,70
C251150N07 Phospholipids IIMDBI1512
5 P
LysoPE(22:6(4Z,7Z.10
526.29181 1.006 +IH 525.285 43,51 C27H44N07 Phospholipids HMDBI1526Z.13Z,16Z.19Z)/0:0) 5 P
256
Methyldopa 210,07732 0,641 -IH 211,084 -24,18 CI01-l13N04 I-!MDB 11754 C07194
5
MG( 141 (9Z)/0:0/0:0) 299,22336 1,872 -II-!
300,230 -2,94 CI71-!3204 Glycerolipids I-IMDBI1562I
Monocthylhexyl 279,15933 0,943 +II-! 278,151 9,26 CI61-!2204 I-!MDBI3248 C03343phthalic acid 8
Myristic acid 227,20198 1,472 -II-! 228,371 -5,51 CI4H2802 Fatly Acids HMDB00806 c06424
N-Acetyl-4-0- 350,10941 0,383 -11-1 351,116 13,46 C131-121 NOI Carbohydrates 1-IMDB00796 C040 15 5761acetylneuraminic acid 5 0
N-
304,090 CIII-!16N20Acctylaspartylglutamic 303,08353 0,443 -11-1 2,14 Polypeptides I-IMDBOI067 CI2270
acid .'
7 8
147,053
Amino acids
Ne Acetylserine 146,04599 0,728 -II-! 14,91 C51-19N04 and Amino I-!MD130293I2
Acid conjugates
N icotinuric acid 181,06079 0,100 +II-! 180,053 227,77 C81-!8N203 Cyclic Amines I-IMD1303269 C05380 14995
N-Methylnicotinamide 137,07057 2,676 +11-1 136,063 23,49 C7I-!8N20 Cyclic Amines I-IMDB031527
Norsalsolinol 164,07188 1,097 -11-1 165,079 -52,54 C91-111N02 I-IMDB06044
Nutriacholic acid 389,26981 0,189 -11-1 390,277 10,69 C24H3804 Bile Acids 1-IMDB00467
Octanoy [glucuronide 319,14005 0,613 -II-!
320,147 72,05 C141-12408 Glucuronidcs I-IMDB10347 C03033I
o-Tyrosine 180,06668 0,325 -11-1
181,073 -16,28 C9HIIN03 Amino Acids HMDB060509
Palmitelaidic acid 253,21761 1,190 -11-1
254,224 -4,47 C16H3002 Fatty Acids I-IMDB123286
PE(p-16:0e/0:0) 438,29764 0,588 +11-1
437,290 3,72 C211-144N06 I-IMDB111526 I'
Pentadccanoic acid 241,21758 1,123 -11-1 242,224 -6,58 C151-13002 Fatty Acids HMDB00826 cl6537 57896
Amino acids
Phenylacelylglycine 194,08133 0,805 +IH 193,199 4042,09 CIOI-! IIN03 and Amino I-IMDB0082I c05596
Acid conjugates
1'1(18: 1(9Z)/16:0) 835,53534 1.329 -II-!
836,541 -2,70 C431-181013 Phospholipids I-IMDB09834 C006265 P
PS(22:6(4Z,7Z,IOZ,13
C461-!74NOIZ,16Z,19Z)/18:2(9Z,12 830,49829 0,660 -11-1 831,505 6,35 or Phospholipids I-IMDBI2446Z))
Pseudouridinc 243,06235 0,366 -11-1
244,069
13,82 C9HI2N206 Nucleoside I-!MDB00767 C02067 57345 Analogues
Pteroyltriglutamic acid 698,21515 1,572 -11-1 699,625 1033,75 C291-!33N90 Heterocyclic I-!MDBOl90212 molecules
Retinyl ester )01,21774 1,456 -II-!
302,224 -3,80 C201-!3002 Retinoids HMDB03598 C02075 69666
Riboflavin 3~7,14581 0,697 +II-!
376,138 12,76 CI7H20N40 Pterins I-IMDB00244 C00255 52493 6
Sphingosine 1- 380,25635 0,851 +11-1 379,248 -1648,66 CI81-138N05 Sphingolipids I-IMDB00277 C06124 5272phosphate 7 I'
Suberic acid 173,08203 0,599 -11-1
174,089
249,43 C81-11404 Dicarboxylic HMDB00893 c082782 Acids
Suberic acid 175,09656 0,452 +11-1 174,194 24,23 C8HI404 Dicarboxylic 1-IMDB00893 c08278Acids
Succinyladenosine 384,11508 0,206 +IH
383,107 246,66 CI4HI7N50 Nucleoside HMDB00912 58677 8 Analogues
Sulfolithocholylglycine 512,26959 1,690 -IH 513,276 5,72 C261-143N07 Acyl Glycine. I-!MDB02639 CI1301 6725
S
Sulfolithocholylglycine 51,4,28284 0,857 +IH 513,276 5610,52 C261-!43N07 Acyl Glycines I-!MDB02639 CI1301 6725
S
Ta urochenod esox ych 500,30405 0,Q35 +11-1 499,296 7,26 C261-!45N06 Bile Acids I-IMDB0095I C05465 5897olic acid 8 S
Taurocholic acid 514,28485 0,854 -11-1 515,291 13,45 C261-!45N07 Bile Acids HMDBOO036 CI55167 S
Taurodeoxycholic
498,28973 0,514 -IH
499,296 12,95 C261-!45N06 Bile Acids I-IMDB00896 C05465acid 8 S
Tetracosahexaenoic
357,27887 0,221 +IH 356,271 -5,28 C241-!3602 Fatty Acids HMDB02007 6430acid 5
trans-2-0ctenoic acid 143,10652 0,946 +IH
142,099 3,35 C8HI402 Fatly Acids HMDBOl568 63284
trans-3-
CI61-!20N20Hydroxycotininc 369,13 2,037 +II-! 368,122 2237,58 Glucuronides HMDBOl204 C03033 6080
glucuronide 8
trans- Tetra-dec- 2 -enoic
225,18633 1,406 -11-1
226,193 -4,31 CI41-!2602 Fatty Acids I-!MDBI0732acid 3
Traumatic acid 227,12912 1,060 -IH
228,136 -3,21 CI2H2004
Dicarboxylic
HMDB00933 CI6308 5882
2 Acids
Uric acid 167,02132 1,527 168,028 17,81 C51-!4N403
Purines and
I-IMDBOO289 C00366 88-11-1
3 Purine
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Derivatives
Valerylcarnitine 246.16989 0,362 +IH
245,162
5,73 C121123N04 HMDD13128
7
• fold change 2h post-resuscitation after cardiac
arrest vs control
Bold metabolites: metabolites whose identification was based on MSn spectra matching with
authentic standard present in HMBO metabolomic database
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Supplemental Table 4. Metabolic pathway analysis by MetaboAnalyst's tools
Total Ilits Raw p ncgLog(p) lIolm adjust FOR Impact
Tryptophan metabolism 79 8 0,0002883 8,1517 0,02306 0,02306 0,02286
Fatty acid biosynthesis 49 4 0,022723 3,7844 I 0,90891 0
Retinol metabolism 22 2 0,08576 2,4562 I I 0
Sphingolipid metabolism 25 2 0,10679 2,2369 I I 0,04292
Valine, leucine and isoleucine degradation 40 2 0,22572 1,4885 I I 0,02803
Primary bile acid biosynthesis 47 2 0,28457 1,2568 I I 0,01838
Linoleic acid metabol ism 15 I 0,28919 1,2407 I I 0
Penrose and glucuronate interconversions 53 2 0,33484 1,0941 I I 0,009
Taurine and hypotaurine metabolism 20 I 0,36595 1,0053 I I 0
Citrate cycle (TCA cycle) 20 I 0,36595 1,0053 I I 0,05826
Riboflavin metabolism 21 I 0,38029 0,96682 I I 0,14504
Pantothenate and CoA biosynthesis 27 I 0,4599 0,77674 I I 0,07366
Valine, leucine and isoleucine biosynthesis 27 I 0,4599 0,77674 I I 0,0885
Phenylalanine, tyrosine and tryptophan biosynthesis 27 I 0,4599 0,77674 I I 0,09102
alpha-Linolenic acid metabolism 29 I 0,48414 0,72539 I I 0,20335
Tyrosine metabolism 76 2 0,51423 0,66508 I I 0,05093
Vitamin B6 metabolism 32 I 0,5185 0,65681 I I 0,02697
Glycerophospholipid metabolism 39 I 0,59019 0,52732 I I 0,00317
Inositol phosphate metabolism 39 I 0,59019 0,52732 I I 0,0499
Nicotinate and nicotinamide metabolism 44 I 0,63487 0,45434 I I 0
Phenylalanine metabolism 45 I 0,64321 0,44128 I I 0,0315
Steroid hormone biosynthesis 99 2 0,65998 0,41554 I I 0,0457
Starch and sucrose metabolism 50 1 0,6822 0,38243 1 1 0,01265
Glyoxylate and dicarboxylate metabolism 50 I 0,6822 0,38243 I I 0,02494
Pyrimidine metabolism 60 I 0,74806 0,29027 I I 0
Arginine and proline metabolism 77 I 0,83063 0,18558 I I 0,00645
Purine metabolism 92 I 0,88098 0,12672 I I 0,00969
Total: total number of compounds in the pathway
Bits: matched number of metabolites from the uploaded list
Raw p: p-value from enrichemnt analysis
Holm adjust: p value adjusted by Holm-Bonferroni method
FDR: p value adjusted using False Discovery Rate
Impact: pathway impact calculated from topology analysis
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ARTICLE INFO ABSTRACT
Aim of tile study: Kynurenine pathway (KP) is a major route of the tryptophan (TRP) catabolism. In the
present study. TRP and KP metabolites concentrations were measured in plasma from rats. pigs and
humans after cardiac arrest(CA) in order to assess KPactivation and its potential role in post-resuscitation
outcome.
Metllods: Plasma was obtained from: (A) 24 rats. subjected to 6 min CA and 6 min of cardiopulmonary
resuscitation(CPR); (B) 10 pigs. subjected to 10 min CAand 5min CPR;and (C)3 healthy human volunteers
and 5 patients resuscitated from CA.KPmetabolites were quantified by liquid chromatography multiple
reaction monitoring mass spectrometry. Assessments were available at baseline. and 1-4 h. and 3-5 days
post-CA.
Results: KP was activated after CA in rats. pigs. and humans. Decreases in TRP occurred during the
post-resuscitation period and were accompanied by significant increases in its major metabolites. 3-
hydroxyanthranilic acid (3-HAA) and kynurenic acid in each species. that persisted up to 3-5 days post-CA
(p < 0.01 ).In rats. changes in KPmetabolites reflected changes in post-resuscitation myocardial Function.
In pigs. changes in TRP and increases in 3-HM were significanlty related to the severity of cerebral
histopathogical injuries. In humans. KP activation was observed. together with systemic inflammation.
Post-CA increases in 3-HAAwere greater in patients that did not survive.
Conclusion: In this fully translational investigation. the KPwas activated early following resuscitation
from CAin rats. pigs. and humans. and might have contributed to post-resuscitation outcome.
~ 2013 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
After the initial success of cardiopulmonary resuscitation (CPR),
the majority of resuscitated patients die within 72 h, due to what is
now termed "post-cardiac arrest syndrorne't.l= ' Most prominent
are post-resuscitation myocardial failure, ischemic brain dam-
age and processes related to the systemic ischernia/reperfusion
response.Jrf
)'r ASpanish translated version of the abstract of this article appears as Appendix
in the finalonline version at hllp://dx.cioi.org/I0.10 IG/j.resllscitation.2013.0G.002.
• Corresponding author at: IRCCS- Istituto di Ricerche Farmacologiche"Mario
Negri".ViaLa Masa 19.20156 Milan. Italy.
E-mail address:gristag@gmail.com(G.Ristagno).
0300-9572/5 - see front matter © 2013Elsevier Ireland Ltd.Allrights reserved.
http://dx.doi.org/IO.I0 I6/j.resuscitation.20 I3.06.002
Due to the complexity and interplay of events occurring during
the post-cardiac arrest syndrorne.V' predicting survival and func-
tional outcome in patients resuscitated from cardiac arrest remains
a difficult task, especially in the early post-resuscitation phase.ID.II
In earlier investigations in a rat model of cardiac arrest and CPR. we
adopted an untargeted metabolomics approach to identify pertur-
bations in post-resuscitation circulating rnetabolites.F Following
resuscitation. we identified alterations in a major route of the tryp-
tophan (TRP) catabolism. namely kynurenine pathway (KP, rig. 1).
KP is mainly activated upon inflammatory stimulation and is impli-
cated in the pathogenesis of numerous central nervous system
disorders, as well as in sepsis development and profound hypoten-
sion during septic shock.P'!" KP activation has been also described
in various clinical conditions, including infection, autoimmune syn-
dromes, malignancies, depression, and pregnancy.15.1 G
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Fig. 1. Tryptophan degradation through the kynurenine pathway. In black are the
metabolites assayed in the present study. TOO. tryptophan 2.3-dioxygenase; 100.
indoleamine 2.3-dioxygenase.
The present study aimed to investigate KP activation after car-
diac arrest and its relationship with the severity of post-cardiac
arrest syndrome. by a fully translational approach. More specifi-
cally. I<Pwas assessed during the initial hours and days following
resuscitation from cardiac arrest in rats. pigs, and humans. We
hypothesized that the KP would be activated following cardiac
arrest and this activation would be associated with the severity
of post-resuscitation organ dysfunctions and outcome.
2. Methods
Detailed methods on experimental procedures, clinical studies,
and metabolite measurements, are reported in the "Supplementary
Material".
Procedures involving animals and their care were in compli-
ance with national (D.L. n. 116, G.V., suppl. 40, 18 February 1992,
Circolare no. 8, G.V., 14 luglio 1994) and international laws and
policies (EEC Council Directive 86/609, OJl 358, 1, December 12,
1987; Guidefor the Care and Use of Laboratory Animals, USNational
Research Council, 1996). Approvals of the studies were obtained by
the local institutional review board committees and governmen-
tal institutions. KP activation was initially investigated in rats, at
the Mario Negri Institute, Milan, Italy. Results were then validated
in plasma obtained from earlier experiments in pigs performed at
Aachen University.!? Clinical validation of animal results was fur-
ther performed in plasma obtained from 3 healthy volunteers and
5 patients resuscitated from cardiac arrest of non-traumatic ori-
gin. These patients were prospectively studied in another trial that
has been previously published and in which the influence of thera-
peutic hypothermia on S-l OOBvalues after cardiac arrest has been
studied.18.19
2.1.1. Rats
2.1.1.1. Animal preparation. Twenty four male Sprague-Dawley
rats were used for the study. Animals were anesthetized and
instrumented for hemodynamic measurements and induction of
cardiac arrest, as previously described.i"
2.1.1.2. Experimental procedures. An established model of electri-
cally induced cardiac arrest and CPR has been used.2o Briefly,
animals were subjected to 6 min of untreated cardiac arrest and
6 min of mechanical chest compression and ventilations prior to
defibrillation. After resuscitation, rats were sacrificed at different
time points: 2 h post-resuscitation (n ~6); 4 h post-resuscitation
(n = 6); and 3 days post-resuscitation (n - 5). Additional rats were
sacrified at baseline, prior to inducing cardiac arrest, and served as
healthy rats (n -7).
2.1.1.3. Measurements. Hemodynamics and echocardiography
were performed as described previously.2o.21 Plasma high sensitiv-
ity cardiac troponin T (hs-cTnT) concentration was assessed with
an electrochemiluminescence assay (ECLlA,Elecsys 2010 analyzer,
Roche Diagnostics, Germany). Cardiac isoprostanes were assessed
by ELISAmethod.
2.1.2. Pigs
2.1.2.1. Animal preparation. Ten male domestic pigs were used for
this study. Pigs were anesthetized and surgically prepared as pre-
viously described."?
2.1.2.2. Experimental procedures. An established model of electri-
cally induced cardiac arrest and CPR has been used.'? Briefly,
animals were subjected to 10 min of untreated cardiac arrest and
5 mins of mechanical chest compression and ventilations prior to
defibrillation. After resuscitation, pigs were observed up to 5 days
post-resuscitation.
2.1.2.3. Measurements. Hemodynamics, neurological recovery,
and cerebral histology were measured and recorded as described
previously.!?
2.2. Human studies
2.2.1. Patients
Five adult non traumatic out-of-hospital cardiac arrest patients
were included. CPRand post-resuscitation treatments were based
on standardized protocols, as previously reported. 18.19 Among the
5 cardiac arrest patients included in the study, 3 received hypother-
mia treatment, while 2 did not. Three healthy volunteers served as
control for plasma KPmetabolites.
2.2.2. Data collection
Clinical data were collected 1 h after intensive care unit (ICU)
admission and 3 days later, using a web-based data entry sys-
tem complying with the Utstein-Style,,8.19 Blood samples for the
determination of C-reactive protein (CRP), procalcitonin (PCT),
tumor necrosis factor alpha (TNF-a), interleukin 6 and 8 (ll-6,ll-8),
macrophage inhibitor factor (MIF), and KPmetabolites, were taken
at the same time points.
2.3. TRPand KP metabolites measurements
Plasma samples (20 u.L) from rats, pigs and humans were used.
Absolute quantification of plasma TRPand KPmetabolites was per-
formed by liquid chromatography-multiple reaction monitoring
coupled with isotope-dilution mass spectrometry (lC-MRM-MS).
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Fig.2. Kynurenine pathway activation in rats resuscitated from cardiac arrest. Plasma concentrations of trypthophan, L-kynurenine, kynurenic acid and 3-hydroxyanthr;milic
acid in healthy rats and in rats after 2 h (h), 4 h, ,1I1d3 days (d) post-resuscitation (PR). Data are reported as mean ± SEM. 'p < 0.05 and "p < 0.0 1 vs. hea] thy; 'p < 0.05 and
•• p <0.01 vs. PR 3 days; ip < 0.05 vs. PR 2 h.
Metabolites assayed included: TRP; t-kynurenine (KYN); kynurenic
acid (KYNAl; and 3-hydroxyanthranilic acid (3-HM).
reported as mean ± SEM. A 2-tail p < 0.05 was considered as statis-
tically significant. All analyses were performed by SPSS 16 (SPSS
Inc, Chicago, ILl.
2.4. Statistical al1alysis
3. Results
Normal distribution of the data was confirmed using the one
sample Kolmogorov-Smirnov Z test. For comparisons among time-
based measurements within groups one-way ANOVAwith Tukey
Kramer's multiple comparisons was used. Linear correlations were
calculated using the Pearson correlation coefficient. All data are
3.1. Rats
At 2 and 4 h post-resuscitation resuscitation, plasma levels of
TRPwere significantly lower in cardiac arrest animals compared to
Table 1
Hemodynamics, functional and histological outcome, and biomarkers in resuscitated rats and pigs.
Rats Healthy PR2h PR4h PR 3 days
MAl'. mmHg
CPI', mmHg
EF, %
EDV.JJ.L
SV. mL
DT, msec
hs-cTnT, ng/L
c-Isoprostanes, pg/JJ.g prot
136 ± 2
116 ± 3
79 ± 2
378 ± 24
0.34 ± 0.02
28.0 ± 3.9
57 ± 18
7 ± 2.2
105 ± 2"
87 ± 2"
42 ± 5"
446 ± 51
0.21 ± 0.02"
18.8 ± 1.2
4453 ± 615"
57 ± 8"
105 ± 5"
91 ±4"
48 ±6"
465 ± 57
0.18 ± 0.02"
19.4±1.3
3874 ± 935"
47 ±S"
N.A.
N.A.
75±3#i'iI
2BO±22'i'i
0.22±0.02'·
27.6±2.8itfi
669±53Iillt!
14± 3.211#11
Pigs Baseline PR I h PR4h
MAP, mmHg
CO, mL/min
121 ±4
s.8±0.3
76±5"
2.9±0.3"
86±4"
3.4 ±0.2"
Pigs PR 1 day (score) PR 3 days (score) PR 5 days (score)
NDS
Brain lesion
Cortex
CAl
Brain necrosis
Cortex
CAl
Brain astrogliosis
Cortex
CAl
66.5 ±s.3 39.5 ± 10.3 41 ± 12.6
7.7 ± I
6.5 ± 0.7
1.5 ± 0.2
2.4 ± 0.4
1.4 ± 0.2
1.8 ± 0.25
MAP, mean arterial pressure; CI'I', coronary perfusion pressure; EF, ejection fraction; SV, stroke volume; Dr, deceleration time; EDV, end diastolic volume; hs-cTnT, high
sensitive cardiac troponin T; c-Isoprostanes. cardiac isoprostane; CO. cardiac output; NDS. neurological deficit score; CAI, CA I hippocampal sector; PR, post-resuscitation;
N.A.. not available.
"p < 0.01 and 'p < 0.05 vs. Healthy or Baseline; .# p < 0.0 I and • p < 0.05 vs. PR 2 h: §i P < 0.0 I and I p < 0.05 vs. PR 4 h.
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TableZ
Correlation between KP metabolites and hemodynamics, myocardial function,
biomarkers, and brain histology in resuscitated rats and pigs.
KP metabolite Variable rcoefficient p value
Rats
EF 0.55 0.005
SV 0.53 0.011
TRP OT 0.699 0.000
hs-cTnT -0.501 0.017
c-Isoprostanes -0.516 0.014
EF -0.501 0.029
SV -0.558 0,016
KYNA OT -0.523 0.026
hs-clnT 0.641 0.004
EF -0.611 0.003
SV -0.598 0.004
3-HAA OT -0.470 0.031
hs-cTnT 0.581 0.006
c-Isoprostanes 0.523 0,015
Pigs
TRI' CAl lesions -0.728 0.017
MAP -0.799 0.000
KYNA CO -0.742 0.000
MAP -0.561 0,016
CO -0.729 0.001
3-HAA CA1 necrosis 0.792 0.006
Cortical astrogliosis 0.778 0.008
NOS 0.744 0.014
KI', kynurenine pathway; 1RI', tryptophan; KYNA, kynurenic acid; 3-HAA. 3-
hydroxyanthranilic acid; EF,ejection fraction; CO, cardiac output; sv. stroke volume;
01. deceleration time; hs-cTnT, high sensitive cardiac troponin T; c-lsoprostanes,
cardiac Isoprostanes; MAl', mean arterial pressure; CAI, CA1 hippocampal area;
NOS, neurological deficit score.
healthy ones (p <0.01, Fig. 2). Plasma levels of the TRP's metabolite
KYNand its derivatives. KYNAand 3-HM significantly increased
following resuscitation (p <0.01 vs. healthy rats. Fig. 2). Plasma
levels of TRP tended to return to normal values 3 days after
resuscitation (Fig. 2). However. higher plasma concentrations of
KYN,KYNA,and 3-HM persisted (p <0.01 vs. healthy rats. Fig. 2).
Post-resuscitation left ventricle (LV) systolic and diastolic dys-
function occurred in each rat. as evidenced by hemodynamic and
echocardiographic data reported in Table 1. More specifically,
marked decreases in mean arterial pressure (MAP) and coronary
perfusion pressure. LVejection fraction. stroke volume. and decel-
eration time of early mitral inflow. were observed at 2 and 4 h
post-resuscitation (p <0.01 vs. healthy rats, Table 1). Changes in
the echocardiographic parameters, evaluating the severity of post-
resuscitation LVdysfunction. were significantly and directly related
to changes in TRP and significantly inversely related to changes in
KYNAand 3-HM (Table 2).
The severity of post-resuscitation myocardial injury was also
reflected by the plasma levels ofhs-cTnT and cardiac isoprostanes,
that significantly increased at 2 and 4 h post-resuscitation (p <0.01
vs. healthy rats, Table 1). Changes in plasma levels of these biomark-
ers of myocardial damage and oxidative stress were significantly
inversely related to the concurrent changes in TRPand significantly
directly related to changes in KYNAand 3-HM (Table 2).
3.2. Pigs
Similarly to rats, plasma levels ofTRP tended to decrease, while
those ofKYN tended to increase at 1 hand 5 days post-resuscitation
(p not significant, fig. 3). Plasma levels of KYNAand 3-HM sig-
nificantly increased at 1 h post-resuscitation compared to baseline
values (p<O.Ot, Fig. 3). These increased plasma concentrations of
TRP's metabolites persisted 5 days later (p <0.05, Fig. 3).
Post-resuscitation myocardial dysfunction developed in each
pig, as evidenced by the hemodynamic measurements in Table 2.
More specifically, lower MAP and LV cardiac output (CO) were
observed at 1 and 4 h post-resuscitation (p <O.Ot vs, baseline,
Table 1), These decreases in MAP and CO were significantly
inversely related to the increases in KYNAand 3-HM (Table 2).
Neurological deficit score at day I, 3 and 5 post-resuscitation is
reported in Table 2, together with cerebral histopathological scores,
i.e. cortical and CAt hippocampal lesion, necrosis and astrogliosis.
Early changes in 3-HM were significantly directly related to the
severity of neurological deficit score (supplemental Fig.) and to the
histological alterations (Table 2). Overall changes in TRPwere sig-
nificantly inversely related to the severity of hippocampal lesions
(Table 2).
3.3. Humans
Similarly to rats and pigs, there was a trend toward lower plasma
levels of TRP and higher levels of KYN. in resuscitated patients
in comparison to healthy volunteers (p not significant. Fig. 4).
Plasma levels of KYNAand 3-HM were significantly higher at 1 h
post-resuscitation. compared to plasma concentrations in healthy
volunteers (p <0.01, Fig. 4). and tended to decrease during the fol-
lowing 3 days (Fig. 4). However. higher plasma levels of 3-HM
persisted 3 days later (p <0.05 vs. healthy volunteers. Fig. 4). Only
2 of the 5 resuscitated patients survived till ICU discharge and
presented lower plasma levels of KYNA and 3-HM in compari-
son to those who died. Interestingly, plasma levels of 3-HM were
approximately double in patients who died compared to those who
survived (190± 12 nM vs. 102 ± 12nM).
Post-resuscitation circulating levels of proinflammatory
cytokines, procalcitonin. and CRPare reported in the supplemental
Table.
4. Discussion
This study demonstrates that kynurenine ~athway ~s acti-
vated following resuscitation from cardiac arrest In three different
species. Accordingly, KPactivation was initially observed. in resus-
citated rats, was then validated in pigs subjected to cardiac arrest
and CPR,and was ultimately confirmed in a small cohort of hu,:"an
patients. Indeed, increases in plasma levels of KP metabolites,
KYN, KYNAand 3-HM, occurred during the initial hours follow-
ing resuscitation and persisted up to 3-5 days following cardiac
arrest. KPactivation showed an equivalent time course in rats, pigs.
and humans. and was significantly related to the severity of post-
resuscitation myocardial dysfunction, cerebral injury. functional
outcome and survival.
KP is a major pathway of the catabolism of the essential
aminoacid TRP. Specifically. two enzymes initiate the KP: trypto-
phan 2.3-dioxygenase (TOO), that is mainly present in the liver and
is stimulated by glucocorticoids; and indoleamine 2,3-dioxygenase
(100), that is widely expressed in a variety of human tissues. such
as the brain, kidney, lung, spleen, and duodenum. as well as in
macrophages and dendritic cells and is stimulated by proinflarn-
matory cytokines, including interferon-v, TNFa, IL-t and 2. and by
Jipopolysaccharides and free radicals.I).ls Indeed, upon inflamma-
tory stimulation, IDa is induced and consequently KPactivated.I).14
Similarly to a sepsis-like syndrome, a systemic inflammatory and
immune response is observed after CPR,and might be the trigger for
100 induction.3.9.10.18 In the present study, early KP activation has
been consistently observed in both small and large animals resus-
citated from cardiac arrest. and ultimately confirmed in humans.
In our study, systemic inflammation was present in the 5 resusci-
tated patients, as demonstrated by circulating levels ofTNFa, IL-8,
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Fig.3. Kynurenine pathway activation in pigs resuscitated from cardiac arrest. Plasma concentrations oftrypthophan. L-kynurenine. kynurenic acid ancl3-hydroxY,1I1thranilic
acid at baseline (BL) and after 1 h (h). and 5 clays (d) post-resuscitation (PR). Data are reported as mean ± SEM. 'p < 0.05 and "p <0.01 vs. BL; • fl <0.05 vs. PR I h.
MIF,and CRP,while association between I<Pactivation and myocar-
dial oxydative stress, i.e. isoprostanes. has been observed in the rat
model.
Altered TRP metabolism has been described as a hallmark of
many stress related situations.15.22 In these settings of glucocor-
ticoid overdrive, in fact, TDO is activated together with a super
induction of IDa in response to stress. IS Concurrently elevated
circulating catecholamines induce an enhanced uptake of free
TRP contributing to reduction in total TRP concentrations. ISThus,
rodents subjected to stressful conditions, i.e. forced swimming or
immobilization, a low TRP diet increased adrenal weight, plasma
corticosterone levels and reactivity to stimuli; administration of
TRP, instead, had acute antianxiety-like effects.IS.23 Indeed, car-
diac arrest is characterized by increases in plasma cortisol level and
catecholamine release. A trend toward lower serum cortisol level
in survivors than in non survivors has been earlier reported.15.24
The stress of whole body ischemia/reperfusion that follows car-
diac arrest might be therefore another component affecting the
described KP activation after CPR.
It has been proposed that TRP catabolism through the KP
may contribute to oxidative stress and brain damage following
ischernia.I? Contributors to the development of ischemia-induced
cerebral injury are, in fact, post-ischemia neuroimmune and
inflammatory reactions.J·2G Accordingly, one component of this
network is the KP,2S.27 Indeed, KYN is the first KP metabo-
lite, that is further metabolized to the neurotoxic 3-HAA and
its derivatives, quinolinic acid and picolinic acid (QA and PAl·
3-HAA exerts its neurotoxic actions by inducing both cerebral
oxidative stress and excitotoxicity through activation of N-Methyl-
n-Aspartate (NMDA)-receptors by QAand PA.3-HAA's metabolites
have not only neuroexcitatory effects, but also neurotoxic ones,
causing neuronal, astrocyte and microglial cell injury, destruction
120
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Fig.4. Kynurenine pathway activation in men resuscitated from cardiac arrest. Plasma concentrations oftrypthophan. t-kynurenine, kynurenic acid and 3-hydroxyanthranilic
acid in healthy volunteers and in men after 1 h(h). and 3 days(d) post-resuscitation (PR). Data are reported as mean ± SEM. 'p < 0.05 and "p < 0.01 vs. BL; • P < 0.05 and" p < 0.0 I
vs. PR I h.
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of postsynaptic elements, and reductions in cerebral choliner-
gic circuits.25.27-29 KYNA is another KYN metabolite, produced
by astrocytes, in response to increased KYN level. KYNA has
neuroprotective properties related to its activity as NMDA
antagonist.29-31 KYNA generation might represent an adap-
tive response in order to block the potentially harmful effects
of excessive glutamate receptor stimulation that follows an
ischemic insult." The correlations between post-resuscitation 3-
HAA plasma levels and cortical and hippocampal histological
lesions and neurological deficit scores in pigs, suggest a possible
role ofKP metabolites in post-resuscitation cerebral injury and neu-
rogical dysfunction also in the instance of cardiac arrest. Together
with increases in plasma 3-HAA, there were concurrent increases
in plasma KYNAand these were consistently in the 3 species.
In support of our results, KP activation, expressed as KYN to
TRP ratio, has been shown to correlate with stroke severity and
long-term outcome in stroke patients.25.28 Patients with poor out-
come had higher KYN/TRPratio than patients with more favorable
outcome. Moreover, experimental blockade of the KP has been
reported to reduce cerebral infarct volume in a model of cerebral
ischemia and reperfusion.F
More importantly, KP activation has been associated not only
with brain injury but it may also concur to the pathogenesis ofsys-
temic inflammatory response syndrome and sepsis.'4.16.29.33.34100
activity was markedly increased in 132 patients with bacteremia,
in whom KP was significantly more activated in non-survivors
compared to survivors.!" In 60 major trauma patients, signifi-
cantly increased KYN was detectable already within 24 h after
hospital admission in blood from patients who later developed
sepsis." In those patients KPactivation predicted subsequent sep-
sis development, multiple organ failure, and survival. Most likely
early post-traumatic inflammation in conjunction with augmented
circulating pro-inflammatory cytokines and neutrophil activation
resulted in IDO stimulation and consequent KP activation. The
above events may occur also in cardiac arrest patients.3.9.ID
. KPalso concurs to the pathogenesis ofvasoplegia and hypoten-
sion during septic shock.'4.33.34 100 expression was, in fact, induced
in the endothelial cells of small resistance vessels and contributed
to the dysregulation of vascular tone during systemic inflamma-
tion due to endotoxemia in mice.33 This increased IDO activity
accounted for a greater production of KYN,that directly mediated
arterial relaxation through soluble guanylate cyclase actlvanon.':'
A clear protection against hypotension due to septic shock and
a reduced mortality has been reported in 100 knockout mice
or in mice treated with a specific 100 inhibitor, I-rnethyl-n-
tryptophan.>' Those mice also presented decreased levels of the
pro-inflammatory cytokines, TNFa, IL-6, and IL-12, and enhanced
levels of the anti-inflammatory IL-1O. A recent clinical study con-
firmed the above experimental results on 16 septic shock patients,
in which IDO activity increased up to 9-fold.14 Moreover, inotrope
requirements were strongly correlated with IDO activity in those
septic patients."
The above events may occur also in the setting of cardiac
arrest.t'" As shown in our study, post-resuscitation myocardial
dysfunction, with low ejection fraction, cardiac output, stroke
volume, together with profound arterial hypotension, were con-
sistently reported in rats and pigs. More importantly, in our rat
model, plasma levels ofKP metabolites, KYNAand 3-HAA, increased
concurrently to decreases in myocardial function and increases
in biomarkers of heart injury and oxidative stress. Similarly, the
severity of post-resuscitation arterial hypotension and reduction
in cardiac output were significantly related to increases in KYNA
and 3-HAA in pigs.
We recognize limitations in the interpretations of our find-
ings. First, the experimental design was purely observational and
focused on demonstration of post cardiac arrest activation of
1609
KP, thus it did not allow to identify causal relations: changes
in circulating molecules may be the consequence as well as the
cause of the observed pathophysiologic alterations. In order to
investigate direct effects of KP activation on outcome of cardiac
arrest, experiments that include administration of specific IDO
inhibitors are planned. Nevertheless, this is the first evidence of
consistent KPactivation after cardiac arrest in animals and humans.
Second, the results obtained from the 5 patients resuscitated from
cardiac arrest have to be considered as a "proof of concept" and
not as an exahustive clinical confirmation, due to the small num-
ber of subjects. Future studies on a larger number of patients are
underway. Third, the studies were performed in healthy animals
and therefore effects of underlying coronary disease in KP activa-
tion remain to be investigated" Fourth, animals were anesthetized
and general anesthesia might have influenced stress response and
KPactivatlon.U Nevertheless, implications of the above factors on
KP have been already adressed.13.36 Last, the studies on the differ-
ent species were performed at different Institutions with different
study designs, i.e. duration of cardiac arrest. However, the consis-
tency of the results further strengthens our findings.
5. Conclusions
This study demonstrates that KP is activated early in the post-
resuscitation and persists during the initial 3-5 days post-cardiac
arrest, in rats, pigs, and humans. KP activation is significantly
related to the severity of post-resuscitation myocardial dysfunc-
tion, cerebral injury, functional outcome and survival.
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ARTICLE INFO ABSTRACT
Introduction: The capability of amplitude spectrum area (AMSA) to predict the success of defibrillation
(OF) was retrospectively evaluated in a large database of out-of-hospital cardiac arrests.
Methods: Electrocardiographic data. including 1260 DFs. were obtained from 609 cardiac arrest patients
due to ventricular fibrillation. AMSA sensitivity. specificity. accuracy, and positive and negative pre-
dictive values (PPV. NPV) for predicting OF success were calculated, together with receiver operating
characteristic (ROC) curves. Successful OF was defined as the presence of spontaneous rhythm ~40 bpm
starting within 60 s from the OF. In 303 patients with chest compression (CC) depth data collected with
an accelerometer, changes in AMSA were analyzed in relationship to CC depth.
Results: AMSAwas significantly higher prior to a successful OF than prior to an unsuccessful OF(15.6 ± 0.6
vs. 7.97 ± 0.2 mY-Hz, p <0.0001). Intersection of sensitivity, specificity and accuracy curves identified a
threshold AMSAof 10 mY-Hz to predict OF success with a balanced sensitivity, specificity and accuracy of
almost 80%. Higher AMsA thresholds were associated with further increases in accuracy, specificity and
PPV. AMSA of 17 mY-Hz predicted OF success in two third of instances (PPV of67%). Low AMsA, instead.
predicted unsuccessful OFs with high sensitivity and NPV >97%. Area under the ROC curve was 0.84. CC
depth affected AMSA value. When depth was <1.75 in .. AMSA decreased for consecutive OFs. while it
increased when the depth was >1.75 in. (p <0.05).
Conclusions: AMsA could be a useful tool to guide CPR interventions and predict the optimal timing of
OF.
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1. Introduction
Cardiopulmonary resuscitation (CPR) in conjunction with elec-
trical defibrillation (OF) can re-establish spontaneous circulation
(ROSC) after cardiac arrest from ventricular fibrillation (VF) and
pulseless ventricular tachycardia (Vf).1.2 However, despite major
efforts to improve outcomes from cardiac arrest. survival rates
remains disrnal.v" Major factors contributing to poor outcomes
include delays in CPR, ineffective and frequently interrupted chest
compressions (CC), and limited access to. or delayed OF.2.G.7
,'r ASpanish translated version of the abstract of this article appears as Appendix
in the final online version at htlp://dx.doi.org/I 0.10 16/j.resuscitation.20 13.08.017.
• Corresponding author at: Department of Cardiovascular Research, IRCCS- Isti-
tuto di Ricerche Farmacologiche "Mario Negri", via La Masa 19.20156 Milan. Italy.
E-mail address: gristag@glllail.colll (G. Ristagno).
0300-9572/$ - see front matter © 2013 Elsevier Ireland ltd. All rights reserved.
http://dx.doi.org/10.1016/j.resllscit.ltion.20 13.08.017
Timing of OF in relationship to CC has been a subject of major
interest. Based on available evidence, the 2005 guidelines rec-
ommended an initial interval of CC prior to OF, especially when
the duration of untreated cardiac arrest exceeded 4 mins.L" Nev-
ertheless, the recent 2010 guidelines highlighted the insufficient
evidence to support or refute CPR before OF and called again
for early OF.9-11 Subsequent OF has been recommended to be
attempted on a time based protocol, i.e. after every 2 min cycle
of CC,9 which may lead to futile OF attempts and unnecessary CC
interruptions. potentially creating worse outcomep-16 The tim-
ing of OF is even more difficult in the instance of recurrence of
VF.17
The onset time of VF is rarely known, especially in the out-of-
hospital setting, making it difficult to determine the priority of CPR
intervention based on the duration of the untreated cardiac arrest.
There is also insufficient knowledge about the optimal duration
of the CC interval prior to OF. The decision whether to interrupt
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AMSA and Success of DefibrillationCCto deliver a OF is therefore difficult. Electrocardiographic (ECG)
analysis of the VFwaveform might represent the best non-invasive
decision guide.
The "Amplitude Spectrum Area" (AMSA)has been demonstrated
to be one of the most accurate predictors for successful OF, in both
animal and small retrospective clinical studies.IR-22 In the present
study, we retrospectively evaluated the ability of AMSAto predict
OFsuccess in a large database of out-of-hospital VFs.We hypothe-
sized that AMSA,derived from conventional AEDpads, would be an
useful indicator to predict OFsuccess and guide CPR interventions.
We further hypothesized that AMSAcould serve as a monitor of CC
quality.
2. Methods
A database of ECG traces recorded during pre-hospital CPR,
including 1410 DFs, obtained from 748 patients between 2005 and
2007, was available through the courtesy ofZOll Medical Corpora-
tion (Chelmsford, MA,USA).ECGswere recorded from defibrillation
pads using ZOLl AED PLUSand ZOLl AED PRO in multiple emer-
gency medical systems in the United States through a regular field
case submission program. The electronic data did not contain any
patient identifiable information, accordingly to Health Insurance
Portability and Accountability Act (HIPAA) regulations.
ECGswere recorded at a sample rate of 250 Hz. The AEDs pro-
vided a single rectilinear biphasic waveform shock of 120J for the
first OF,and 150 or 200J for the subsequent DFs. The AMSAanaly-
sis has been previously described.18-21.23 Briefly, ECGsignals were
processed using a 2 Hz high-pass filter to minimize low frequency
artifacts produced by CC and a 48 Hz low-pass filter to remove
interference of ambient noise at higher frequencies. Analog ECG
signals were digitized and converted from a time to a frequency
domain by fast Fourier transformation. AMSAwas calculated as the
sum of the products of individual frequencies and their amplitudes
(Supplemental Fig. 1), i.e. AMSA= 2::AiFi, where Ai represented the
amplitude at ith frequency Fi•
Supplementary material related to this article can be
found, in the online version, at http://dx.doi.org/1 0.1016/j.
resuscitation.2013.08.017.
The analysis was performed during hands off time on a 512
point window (2.05 s) ending 0.5 s prior to the OF. A Tukey FFT
window was used to reduce edge effects. For the purpose of this
study, the OF outcome was defined according to the following
established critertar'! "successful defibrillation" or return of a
potentially perfusing rhythm, if OF restored an organized rhythm
with heart rate > 40 beats/min commencing within 60 s post shock:
and "unsuccessful defibrillation" or failure of return of a poten-
tially perfusing rhythm, if VF/VT, asystole, or pulseless electrical
activity with pauses> 5 s occurred. Only ECGrecordings with ade-
quate pre- and post-OF durations and in which OF outcome could
be confirmed were included in the study: 1260 instances from 609
patients. In addition, subsequent DFs were classified as being for
recurrent VF if the preceding OF was successful. or for refractory
VF if the preceding OF had failed to restore a potentially perfusing
rhythm.'? A sub-group analysis was conducted on DFs obtained
from 303 patients, for whom CCdepth data were available. Depth
of CCwas measured from an accelerometer used for CPR feedback
and registered by the AEDs. Changes in AMSA between consecu-
tive DFs were analyzed in relationship to the 2005 recommended
CCdepth> 1.5 in.8
2.1. Statistical analysis
AMSA was computed using Matlab 7.2 (MathWorks, Natick,
MA). Two independent readers reviewed the ECG recordings to
o Successful OF
• NotSuccessful OF
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Fig. 1. AMSA values for successful and not successful DF for all. first and subse-
quent attempts. Number of attempts are reported inside bars. 'p < 0.0001 between
successful and not successful DFs.
confirm OFoutcomes. Differences in AMSAbetween DFswere ana-
lyzed by analysis of variance (ANOVA) with Scheffe's method for
multiple comparisons. A range of AMSA thresholds was evalu-
ated. The sensitivity, defined as the capability of AMSAto identify
DFs that successfully reestablished a potentially perfusing rhythm,
was calculated as the number of correctly predicted successful DFs
divided by the total number of successful DFs.The specificity, which
refers to the capability of AMSA to identify failure of a OF, was
calculated as the number of correctly predicted unsuccessful DFs
divided by total number of unsuccessful DFs.The positive predictive
value (PPV) referred to the proportion of DFs that were correctly
predicted by AMSA to restore a potentially perfusing rhythm. The
negative predictive value (NPV) represented the proportion of DFs
that were correctly predicted by AMSA to fail. The accurac.y was
calculated as the proportion of true results (both true positively
predicted successful DFs and true negatively predicted unsucc~s~-
ful DFs) in the population. Finally, receiver operator charact~nstlc
(ROC) curve analysis was performed. SPSS 16.0 (SPS~ I~C.,Chl.ca~o,
IL)was used. Avalue of p < 0.05 was regarded as statIstically signif-
icant. Data are presented as mean ± SEM.
3. Results
Atotal of 1260 DFs, including 578 first attempts and 682 subse-
quent ones from 609 patients, were included in the analyses.
3.1. All DF attempts
Among all 1260 DFs, 316 were successful (25.1%), while 944
were unsuccessful (74.9%). AMSAwas significantly higher prior to
a successful OF than prior to an unsuccessful one (15.6 ± 0.6 vs.
7.97 ± 0.2 rnv-Hz, p < 0.0001, Fig. 1).
Using the intersection of sensitivity, specificity. and accuracy
curves (Fig. 2A), an AMSA threshold of 9.8 rnv-Hz, provided a bal-
anced sensitivity, specificity and accuracy of 78%, with a NPV of
91%and a PPVof54%. An AMSAthreshold of14 mv-Hz provided the
highest accuracy (80%) in predicting OFoutcome, with a PPVof61 %
and a specificity of 90%. Higher AMSA thresholds were associated
with further increases in PPV and specificity. An AMSA threshold
of 17 mY-Hz resulted in the highest PPV (67%) in predicting OF
success.
For low AMSAthresholds, the majority of unsuccessful DFswere
correctly predicted with high sensitivity and NPV (rig. 2A). Using
AMSA< 7 mY-Hz as cutoff, more than 42%of unsuccessful DFsmight
have been avoided with a NPV> 97% (Fig. 2A and Supplemental Fig.
2). Lower thresholds further improved NPV.
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Supplementary material related to this article can be
found. in the online version. at http://dx.doi.org/10.1016/j.
resuscitation.2013.08.017.
Area under the ROCcurve was 0.84 (p <0.0001, Fig. 2B).
3.2. First DF attempts
Among 578 first OFs. 156 were successful (27%),while 422 were
unsuccessful (73%). AMSAwas significantly higher prior to a suc-
cessful DF than prior to an unsuccessful one (15.7 ± 0.9 mY-Hz vs.
8.7±0.3,p<0.0001,fig.1).
Using the intersection of sensitivity, specificity, and accuracy
curves (Fig. 2A), an AMSA threshold of 10.2 mY-Hz provided a bal-
anced sensitivity. specificity and accuracy of73%. with a NPV of88%
and a PPV of 50%.An AMSA threshold of 17 mY-Hz resulted in the
highest accuracy (76%) and PPV(60%) in predicting OFsuccess, with
a specificity of92%.
With an AMSA<7 mY-Hz, more than 40% of unsuccessful OFs
might have been avoided with a NPV>97% (Fig. 2A and Supple-
mental Fig. 2). Lower thresholds further improved NPV.
Area under the ROCcurve was 0.80 (p <0.0001. Fig. 2B).
3.3. Subsequent DF attempts
Among 682 subsequent OFs. 160 were successful (23.5%). while
522 were unsuccessful (76.5%). AMSAwas significantly higher prior
to a successful DF than prior to an unsuccessful one (15.5 ± 0.8 mV-
Hz, p <0.0001, Fig. 1).
Using the intersection of sensitivity, specificity. and accuracy
curves (Fig. 2A), an AMSA threshold of 9.2 mY-Hz provided a bal-
anced sensitivity. specificity and accuracy of 79%. with a NPV of
93%and a PPVof 54%.An AMSA threshold of 14 mY-Hz resulted in
the highest accuracy (84%) in predicting OF success, with a PPVof
72% and a specificity of 94%. Further increases in AMSA threshold
were associated with further increases in PPV and specificity. An
AMSA threshold of 18 mY-Hz resulted in the highest PPV (75%) in
predicting OF success.
With an AMSA<7 mY-Hz. more than 46% of unsuccessful OFs
might have been avoided with a NPV>97% (Fig. 2A and Supple-
mental Fig. 2). Lower thresholds further improved NPV.
Area under the ROCcurve was 0.87 (p <0.0001. Fig. 2B).
3.4. DF attempts for recurrent and refractory VF
Among 682 subsequent OF attempts. 139 were delivered for
recurrent VF. while 543 were for refractory VFs. Among 139 OFs
delivered for recurrent VF. 110 were successful (79.1 %), while of
543 OFs delivered for refractory VF, only 50 were successful (9.2%)
(Table 1). AMSA was significantly higher in recurrent VF than in
refractory VF(16.2 ± 0.9 vs. 7.6 ± 0.2 mY-Hz, p < 0.0001. Table 1).In
the instance of recurrent VF, there was no significant difference in
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AMSA prior to a successful OF compared to that prior to an unsuc-
cessful one (16.8 vs. 13.8 mY-Hz, Table 1). For refractory VFs,AMSA
was significantly higher prior to a successful OF than prior to an
unsuccessful one (12.7 ± 1 vs. 7 ± 0.2 mY-Hz, p <0.0001, Table 1).
AMSAwas accurate for predicting OFoutcome only in the instance
of refractory VF (Fig. 3).
In the instance of refractory VF, the intersection of sensitiv-
ity, specificity, and accuracy curves provided an AMSA threshold
of 8.5 mY-Hz accounting for a balanced sensitivity. specificity and
accuracy of77% (Fig. 3A). An AMSA threshold of17 mY-Hz resulted
in peak accuracy (91 %) and peak PPV (50%), with a specificity of
97%.
Table 1
AMSA prior defibrillation For reFractory and recurrent VF.
ReFractory VF
(n-543)
Recurrent VF
(11-139)
Mean AMSA. mV-Hz
AMSA prior to successful OFs.mV-Hz
AMSA prior to Failing OFs.mV-Hz
Successful OFs.% (n)
16.2±0.9·
16.8± 1
13.8± 1.8
79.1 (110/139)
7.6±0.2
12.7± 1
7.0±0.2·
9.2 (50/543)
DFs,defibrillation attempts; VF, ventricular fibrillation; and mean ± SEM.
• P < 0.000 I vs. refractory VF.
• P < 0.000 I vs. successful DFs.
Area under the ROC curve was 0.81 (p <0.0001) for refractory
VF,and 0.65 for recurrent VF (p =0.012, Fig. 3B).
3.5. Influence of cc depth and interruptions on AMSA
When CC depth was <1.75 in., AMSA decreased by 3.9 mY-Hz
between the first and the second OFand further decreased between
the second and the third attempt (Table 2, p <0.001 ). By contrast,
when CCdepth was >1.75 in., AMSAwas equivalent for the first and
the second OF (p= 0.47) and then increased by 1.7 mY-Hz between
the second and the third attempt. A similar but less pronounced
trend was observed with a CCdepth cutoff at 1.5 in. (Table 2).
AMSA significantly decreased during the 16s pre-DF CC inter-
ruption for AEO rhythm analyses and capacitor charge (p <0.01,
Fig. 4). AMSA decreased even more during CC interruptions prior
to first OF (p <0.01). In subsequent OFs, AMSAdecrease during CC
interruptions was less pronounced (p <0.05 only after 12 s CCinter-
ruption).
4. Discussion
Current OF algorithms are static in the sense that they do
not consider the passage of time and the pathophysiology of the
arrested rnyocardiurn.V" In our data, the standard OF approach
led to a successful OF in only 25%of attempts. The ability of AMSA
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Table 2
AMSA value changes among the initial3 defibrillation attempts in relationship to chest compression depth.
AMSA 1st DF (rnv-Hz) AMSA 2nd DF (rnv-Hz) t:.AMSA 2nd-I st DF AMSA 2nd DF (mV-Hz) AMSA 3rd OF (mV-Hz) t:.AMSA 3rd-2nd OF
Depth> 1.75 in. 11.2 ±O.S (n = 155) 1O.4± O.S (11c ISS) -0.7 8. I ± 0.5 (n - 8 I ) 9.7±0.8(11-81) +1.7
Depth < 1.75 in. 13.3±0.9(n=148) 9.4±0.4 (n-148)'" -3.9' 8.8 ± 0.5 (n - 80) 8.4 ± 0.5 (11- 80) -0.4"
Depth> 1.5 in. 11.9±0.8 (n - 192) 10.1 ±0.7(11-192) -1.6 8.1 ± 0.4 (11-96) 9.5±0.7 (11-96) +1.5
Depth < 1.5 in. 12.8± I (11=111) 9.5 ±O.s (n-111)# -3.3 9±0.6(n-65) 8.5 ±0.6 (11- 65) -0.6"'
DFs, defibrillation attempts: 6.AMsA. difference in AM SA value between OFs: and mean ± sEM.
p<0.02.
P <0.0 I vs. depth> 1.75 in .
• p<O.OI.
•• p<O.OOOI vs. lst OF.
to predict DF success is therefore of great importance, since this
may allow to optimize timing of DF delivery. There is also a poten-
tial to reduce CC interruptions and minimize myocardial damage
by limiting repetitive and unnecessary DFs.12-16
There is evidence that VF changes over time and that it is pos-
sible to predict the success of a DF attempt by analysing the VF
waveform features.9.17-23.25.2fiOur study is the first that investi-
gated the ability of AMSAto predict DFsuccess on a large database.
We have shown AMSAto be significantly higher prior to a success-
ful DF than prior to a failing one. While an AMSAof 10 mV-Hz was
able to predict DF success with a balanced sensitivity, specificity
and accuracy of approximately 80%. higher AMSAvalues increased
accuracy, specificity and PPV for predicting OF success. An AMSA
threshold of 17 mV-Hz was associated with up to 67% DF success,
which could potentially be used to guide toward earlier OF as the
likelihood of success is high.
Animal studies have consistently demonstrated accuracy of
AMSAfor predicting OFsuccess, yielding a balanced sensitivity and
specificity of approximately 90%, with a NPV of 95% and a PPV of
78%.18.19Moreover, utility of AMSA as predictor of ROSChas been
reported independent of myocardial substrate, i.e. in a swine model
ofischemicVF.27 Two small retrospective clinical studies, including
46 and 90 VFpatients, subsequently confirmed the above sensitiv-
ity and specificity.20.21 In the present investigation, although AMSA
was able to predict with satisfactory accuracy OFoutcome, sensitiv-
ity, specificity, and PPVwere lower compared to the earlier reports.
We believe, however, that current results are more realistic due to
the large database employed, that is approximately 1O-fold greater
than earlier ones and represents one of the largest studied to now
for VF waveform analysis. Indeed, a good OF predictor should be
both sensible and specific. For this reason, a balanced sensitivity
and specificity of 80%, as observed in our results, makes AMSA a
useful guide for OF decision.
AMSA during chest compression interruptions
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Different approaches to VF analysis have been tested, resulting
in variable accuracy for predicting DF success.28-3~ Accordingly, a
VF feature with at least a 50% specificity at a 95% sensitivity has
been suggested as a safe and useful predictor for DF decision.29.30
Unlikely, results from relatively large clinical databases have
demonstrated that only few of the proposed methods achieved
the above limit.29.34.35 Indeed, the majority were considered with
insufficient predictive power, having a high sensitivity (>90%),
but a low specificity «40%).30-33 Differently, AMSA, together with
other VF features, i.e. median slope, power spectrum analysis.
and the wavelet transform-derived Cardioversion Outcome Predic-
tor, achieved a sensitivity of approximately 95% with a specificity
between 56 and 66%.29.34.35In our study, AMSA,as predictor of OF
outcome, was confirmed to yield a specificity of 55% at a 95% sen-
sitivity. Moreover, different thresholds may be selected in order to
maximize the OFoutcome prediction, such to achieve the best PPV
(67%) and the best NPV (>95%). The present study therefore pro-
vided evidence that AMSA represents a clinically applicable tool,
easily obtained from the routinely available ECG.Accordingly, the
following discussion attempts to suggest a potential AMSA-based
algorithm for first and subsequent DF attempts.
Upon arrival at the cardiac arrest scene, rescuers need to deter-
mine the optimal first CPR intervention, i.e. a cycle of CC or an
immediate DF.I.7-11.17Sun and colleagues have recently optimized
the timing of the first OF by applying real time AMSAanalysis dur-
ing CC in a rat model ofVF.26 DFwas attempted only when AMSA
achieved a predefined threshold predictive of successful shock.
With that approach, 70%of animals were resuscitated after the first
DF, in contrast to 0%when DF was attempted following standard
guidelines. AMSA-guided CPR also significantly reduced CC inter-
ruptions and ultimately improved post resuscitation myocardial
and neurologic function and survival. In our population, interrupt-
ing CCfor delivery of OFat an AMSAof 17 mY-Hz could have raised
first DF success up to 60% compared to 27% observed with the
standard approach.
AMSA also has predictive ability for subsequent OF attempts,
but is dependent upon the type ofVF. Subsequent DFs may be due
to either VF refractory to earlier DFs or to a recurrence of VF after
an initially successful OF. Similar to an earlier small retrospective
study on 44 patients.'? our study demonstrated that AMSA was
accurate for DFprediction only in the instance of refractory VF.The
AMSAvalue to be considered as a threshold fordelivery ofa OFwith
the highest likelihood of success was again 17 mV-Hz. AMSAthere-
fore might be an useful decision tool for the treatment of refractory
VF. Recurrent VF, on the other hand, presented an overall high
AMSA, with no differences between successful and unsuccessful
DFs, and an elevated DF success of almost 80%. Recurrent VF will
probably not benefit from an initial interval ofeC, but rather should
receive DF immediately, similar to a witnessed arrest.
The total electrical energy delivered with repetitive DFs might
be an important determinant for the severity of post resuscitation
myocardial dysfunction and survival.12.36 Using AMSA lower than
7 mV-Hz as guidance, more than 45% of unsuccessful and poten-
tially detrimental DFs might have been avoided. This approach
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Acknowledgementscould also reduce unnecessary CC interruptions for the delivery of
futile OFs. Even minimal interruptions of less than 4 s can generate
declines in myocardial perfusion to near 40%.37 In our population,
pre-OF pauses caused significant decreases in AMSA, likely related
to the reduced myocardial perfusion and ultimately anticipating
decreases in OF success.22.23 limiting the frequency and duration
of such CCinterruptions may improve clinically relevant outcomes
in cardiac arrest.9,13.15,lG
AMSA appears to carry the additional promise of being able to
monitor the effectiveness of Cf', The present analyses have demon-
strated that AMSA decreased between consecutive shocks during
shallow CC,while it increased when CCwas of greater depth. We
have previously reported the possibility of assessing CCdepth uti-
lizing AMSAin a porcine model, in which animals were randomized
to optimal or suboptimal depth of ce2J Similarly to CPP, AMSA
thresholds achieved were contingent on the depth of compressions
such that AMSA increased progressively during CC, and predicted
the likelihood of successful OF.23Therefore, when future technol-
ogy allows for real time AMSA analyses during Cc, a rescuer may
be prompted to push harder if the AMSAvalue is too 10w.38
Based on our results the following OF decision, based on a con-
tinuous real-time AMSAanalyses during uninterrupted CC,could be
beneficial. In the presence of a very low AMSA, i.e. below 7 mY-Hz,
the likelihood to deliver a successful OF is low. CCtherefore should
be performed until AMSAis deemed to be favorable for a OF,mini-
mizing interruptions in CCand delivery of unnecessary shocks. The
decision of interrupting CC to attempt a OF should be limited to
when there is the highest probability of success. OFmay be deliv-
ered as initial intervention or during CC even before completion
of a regular 2 min cycle only when AMSA reaches the thresh-
old of 17mY-Hz. If AMSA values fall in the range between 7 and
17 mY-Hz, even though specificity and accuracy of shock success
prediction are high, CPRshould be performed accordingly to guide-
lines. Finally, recurrent VFshould always receive an immediate OF.
We recognize important limitations. First, this was a retrospec-
tive analysis. Second, the study was performed on AEO records
and thereby data on duration of untreated VF, period of CC prior
to first OF, patients' characteristics, co-morbidities, outcome and
survival were not available. Nevertheless, earlier investigations
have shown that peri-arrest factors, i.e. patients' age, sex and
presenting rhythm, ambulance response time and presence of
bystander CPR,did not significantly improve prediction accuracy.t?
Although, patients' age was not known in our database, since all the
OF attempts had energy ~ 120J, all the patients might be consid-
ered as adult patients. Third, AMSAwas calculated only during the
pre-OF hands off time. Nevertheless, a large database was avail-
able, allowing for estimation of robust thresholds to be tested in
future prospective evaluations. Finally, AMSA values might have
been affected by different conditions, i.e. an underlying myocardial
ischemia and/or the presence of medications interfering with VF
features.27.40 However, these hypotheses could not be investigated
due to the retrospective design of the study.
5. Conclusions
In this retrospective study, AMSA was capable to predict OF
outcome with high accuracy. A specific AMSA threshold could
be identified in order to predict OF outcome for both initial and
subsequent attempts. AMSA showed also additional promise for
monitoring the effectiveness ofCe
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Abstract: High quality cardiopulmonary resuscitation (CPR, i.e. chest compressions and ventilations) and
prompt defibrillation when appropriate (i.e. ill ventricular fibrillation and pulseless ventricular tachycardia,
VFNT) are cunently the best early treatment for cardiac arrest (CA). In cases of prolonged CA due to
shockable rhythms, it is reasonable to presume that a period of CPR before defibrillation could partially revert
the metabolic and hemodynamic deteriorations imposed to the heart by the no flow state, thus increasing the
chances of successful defibrillation. Despite supporting early evidences in CA cases in which Emergency
Medical System response time was longer than 5 minutes, recent studies have failed to confirm a survival
benefit of routine CPR before defibrillation. These data have imposed a change ill guidelines from 2005 to
2010. To take in account all the variables encountered when treating CA (heart condition before CA, time
elapsed, metabolic and hemodynamic changes, efficacy of CPR, responsiveness to defibrillation attempt), it
would be very helpful to have a real-time and non invasive tool able to predict the chances of defibrillation
success. Recent evidences have suggested that ECG waveform analysis of VF, such as the derived Amplitude
Spectrum Area, can fit the purpose of monitoring the CPR effectiveness and predicting the responsiveness to
defibrillation. While awaiting clinical studies confirming this promising approach, CPR performed according to
high quality standard and with minimal interruptions together with early defibrillation are the best immediate
way to achieve resuscitation in CA due to shochable rhythms.
Keywords: cardiac arrest, cardiopulmonary resuscitation, ventricular fibrillation, defibrillation, waveform
analysis
Main abbreviations: CPR, Cardiopulmonary Resuscitation; CA, cardiac arrest; VF, ventricular fibrillation; VT
pulseless ventricular tachycardia; EMS, emergency medical system; ROSC, rerum to spontaneous circulation;
StHD, survival to hospital discharge, AMSA, amplitude spectnun area.
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Introduction
Treatment of cardiac arrest (CA) is a difficult challenge. Once CA has occurred, whether in- or out- of-hospital
setting, chances of survival are still low despite efforts in research and implementation 1.2. Options for effective
treatment are substantially restricted to and conditioned by a few early interventions: immediate high quality
cardiopulmonary resuscitation (CPR, i.e. chest compressions and ventilatious) and, if appropriate, rapid
defibrillation). Progress has been made in defining the importance of what makes the quality of CPR "good"
enough to improve survival. On the other hand, the teclmical elements of "good defibrillation" have also been
established 3. However, it is possible that a better integration of these two interventions, with some grade of
flexibility to suit each specific CA instance, might improve resuscitation success.
Initial rhythm is a major determinant of outcome since CA sustained by shockable rhythms, i.e. Ventricular
Fibrillation and pulseless Ventricular Tachycardia (VFNT), has a far better outcome in tenus of survival to
hospital discharge (StHD) when compared with not shockable rhytms, i.e. Asystole and Pulse less Electrical
Activity (PEA) 4.
Therefore, even if a decline in the prevalence of VFNT in out-of-hospital CA has been observed over the last
20 years 5,6, it seems important to optimize strategies to improve defibrillation effectiveness.
The aim of this article is to present the background of current guidelines together with recent studies about the
best timing for defibrillation during CA; secondly, we will offer the reader an update about possible
developments in the field.
"You are here": the background of current recommendations.
Best practice in resuscitation is regularly reviewed every five years by the International Liaison Committee on
Resuscitation (!LCOR, a world-wide expert.s' network) 7 and translated into guidelines adapted to local needs
(here we will refer to the European Resuscitation Council Guidelines for Resuscitation) 8. For each topic of
interest, a standardized systematic review is performed providing the basis for consensus on treatment.
A major effort in writing resuscitation guidelines has always been to keep them simple. "Time is life" when CA
occurs, bystanders can widely vary in their role and experience and wasting minutes trying to follow
complicated flow charts can be extremely deleterious. However exceptions can be admitted if the context can
be easily delimited.
In the last two guidelines editions (2005 and 20 I0), a specific question focused on the possibility to improve
defibrillation success ill patients with prolonged CA found with a shockable rhythm. In these cases, the concern
is that immediate defibrillation can filld the heart in a state of poor "responsiveness" due to hypoxia, acidosis,
metabolic derangement and hemodynamic modifications imposed to the heart by the no-flow state. It was
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reasonable therefore to consider that a period of "restoring" CPR before attempting defibrillation could revert
some of those processes that make the fibrillating heart refractory to shock.
Accordingly, a modification in the basic life support (BLS) protocol was introduced in the 2005 guidelines
acknowledging that "recent evidence has suggested that a period of CPR before defibrillation may be beneficial
after prolonged collapse" 9. This evidence came from two clinical studies (one "before-after" study 10 and one
randomized trial, RCT ") in which a period of 1.5-3 min of CPR before defibrillation improved outcome in the
patients subgroup where emergency medical system (EMS) response time exceeded 4-5 min. Other
experimental and predictive studies supported a positive role of CPR before defibrillation in long lasting VF
(>5 min). However another RCT failed to prove benefit 12 . On this basis, it seemed reasonable to recommend
"a period of about 2 min of CPR before defibrillation in patients with prolonged collapse (> 5 mill)", but
limiting this suggestion only to out-of-hospital CA and EMS protocols. No specific evidence was available for
in-hospital CA.
More data were available to the 2010 !LCOR reviewers 13. Another RCT 14 and other studies 15. 16. 17 did not
show improvement in StHD, shifting the balance of evidence supporting CPR before defibrillation to a neutral
equilibrium. Therefore, currently the "routine delivery of a specified period of CPR (e.g., 2-3 min) before
rhythm analysis and shock is delivered, is no longer recommended". However if the protocol has already been
implemented in local EMS following previous recommendations, "it is reasonable for them to continue tins
practice" 18 since it is not harmful.
Together with new guidelines, in 2010 two meta-analyses of available RCTs concluded that CPR before
defibrillation did not demonstrate an improvement in terms of StHD and sUPP0l1ed the equivalence of both
approaches 19,20, highlighting RCTs limitations (e.g., only the study of Baker et a1. was sufficiently powered to
detect difference in StHD). As shown in Table 1, RCTs were performed under different CPR protocols due to
current guidelines (e.g., compression/ventilation ratio and number of consecutive shocks administered) and
with local variations in response time. No clear data are available about quality of CPR administered from both
bystanders and EMS personnel. Thus, studies with a larger number of patient.s and an univocal protocol were
called for.
Recent clinical evidence: different designs, similar results.
In 2011, the Resuscitation Outcome Consortium (ROC) published the results of the "Early versus Delayed
Analysis" (ROC PRIMED) trial 21. The study had a large population sample (9933 patients), CPR protocol was
standardized (30/2 ratio and single shock), EMS performances were carefully optimized by frequent retraining
(every 6 months) and CPR quality was monitored. Furthermore, a more realistic protocol was designed instead
of a difficult to define "defibrillation-first" versus "CPR-fn·st" comparison. Indeed, it is common practice to
Thisdocument is protected by internationat copyright laws. No additional reproduction is authorized. It is permitled for personal use 10 download and save only
one hie and prinl only one copy of fhis Article. It is not permifted to make additional co,pies (either sporadically or systematically. either printed or electronic,) at the
Artlc:le for any purpose. It is not permitled to distribute the electronic copy of the arlicle through online ,internet andlor intranet file shoring systems. electronic
mOIling or any other means which may allow access 10 the Article. The use of all or any part of Ihe Arlicle for ony Commerciot Uso is no! pe,milled. The 'creation of
derivative works from the Article IS not permitted. The production of reprints for personal or commercial use is not permitled. 'It is not ,permitted to remove, cover.
~:erlay, obscure. block, or change any copyright notices. or terms of us.ewhich Ihe Publisher may post on the Article. r:t is not permi:Ued to frame or use framing
chnlques to enclose any trademark. logo. or other propnetary inforrnction of fhe Publisher.
COPVRIGHT© 2012 EDIZIONI MINERVA MEDICA
start CPR while the defibrillator is being retrieved even ill patients in which shock is administered as S0011 as
possible. In the ROC study, patients assigned to the "early-analysis" group received 30 to 60 seconds of CPR
while the defibrillator was connected (i.e., before rhythm analysis); patients in the "late-analysis" group
received 3 minutes of CPR before rhythm analysis. The StHD was exactly the same ill the two groups
(5.9%).Interestingly, in patients with the ideal situation of VTNF as first recorded rhythm who had received
bystander CPR, there was a tendency to decline in survival with delaying the rhythm analysis.
Another very recent RCT was performed in Taipei (Taiwan), where incidence of shockable rhythm as first-
recorded rhythm is traditionally low (8%). A group of patients with out-of-hospital CA receiving a period of 10
cycles of 30:2 RCP (about 4 minutes) before rhythm analysis was compared with another group in which CPR
and rhythm analysis were started together immediately after CA confirmation and defibrillation delivered as
soon as VFNT was detected. There were no differences in return of spontaneous circulation (ROSe) as
primary outcome nor in StHD as secondary outcome. In a post-hoc analysis of ROSC patients, those receiving
CPR before rhythm check had an higher rate ofStHD 22.
To complete the picture, in a recent retrospective nationwide Japanese study, CPR before defibrillation did not
show an improvement in long term outcomes compared with early defibrillation 23.
So far, in large human clinical studies CPR before defibrillation protocols have failed to demonstrate clear
benefits in survival independently from the study design, local context, presumed CA interval, current
compression/ventilation ratio and duration of CPR before shock. Is this the end of the road?
Table I. Characteristics of the main RCTs on Cardiopulmonary Resuscitation (CPR) before Defibrillation
(Modified from: Meier et a1. BMC Medicine 2010;8:52; and from: Simpson PM et a1. Resuscitation
2010;81 :925-931)
Rhythm analysis and defibrillation: the "depth bomb" model.As mentioned above, the rationale behind
delaying the shock in favor of a period of compressions before defibrillation is to partially revert the processes
imposed to the heart by the no-flow state. As described in Weisfeldt and Becker's 3-phase model 24, once VF
has started, the heart passes through an immediate electrical phase lasting about 4 minutes in which
defibrillation can be the sole intervention needed to restart the pump function, followed by about 10 minutes of
circulatory phase in which compressions are required to increase the chance of successful defibrillation.
Afterwards, the metabolic phase represents the time of in-eversible changes with no effective treatment
currently available (Figure 1).
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Figure 1. The 3-phase model of Cardiac Arrest (CA). After ventricular fibrillation (VF) onset, the heart passes
through three phases that require different treatments; VF waveform changes with passing of time (Adapted
from: Weisfeldt ML, Becker LB. JAMA. 2002 Dec 18;288(23):3035-8).
Changes to the heart during this VF are multifactorial. Energy-substrate depletion induced by ischemia plays a
role in the low response of the myocardium to defibrillation 25. Hypoxia and acidosis increase the minimum
defibrillation voltage (MOV) needed to convert VF in sinus rhythm highlighting the importance of recovering
perfusion and oxygenation during CA 26. The concept that VF is a high energy demanding condition is wen
established in cardiac surgery: during VF, oxygen consumption is 75% that of the beating working heart while
subendocardial perfusion falls due to chambers distension that increases coronary resistance 27. Indeed, as well
as metabolic derangement, hemodynamic modifications must be taken into account. Elegant studies have
described shape and volume changes in cardiac chambers during VF: the light heart overload leads to a bulging
into the hollow left sections, decreasing the normal pressure gradient that drives coronary perfusion from aortic
root toward coronary sinus. These seem early changes compared with metabolic alterations and could promptly
be reversed by good compressions 28.
Currently, the extent of these modifications at the moment of rhythm analysis is impossible to be detect: when
rescuers arrive at the victim's side, they can only confinu CA, start CPR and analyze the underlying rhythm .. In
a setting in which even estimating CA onset interval can be difficult, they cannot understand the heart condition
before CA nor which theoretical phase the heart is facing at the moment of their arrival, Furthermore, shockable
rhythms are not all the same varying with underlying conditions and onset mechanisms 29. Therefore,
administering a shock can resemble dropping a depth bomb under a wavy surface while ignoring the actual
characteristics of the target. Might we look for a specific radar?
Detecting signals of Ventricular Fibrillation: possible methods to identify the best timing for
defibrillation.
The development of a non-invasive and real time monitoring that allows prediction of whether or not a shock
would achieve ROSC would be important to prioritize rescuers' intervention (compressions or defibrillations),
reducing the number of failed defibrillation attempts and CPR interruptions. In fact, CPR pauses are mandatory
for rhythm analysis prior to attempting defibrillation since compressions create artefacts on the ECG signal 30.
Evellminimal interruptions «4 secs) decreases myocardial perfusion to near 40% 31. During pre-hospital CPR,
pauses for rhythm analysis and defibrillation have been of more than 20 and 24 sees, respectively 32.
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Established predictors of good quality CPR, i.e. coronary perfusion pressure and end-tidal C02 (EtC02),can
predict defibrillation success 33. Corollary perfusion press lire (the difference between minimal aortic pressure
and right atrial pressure during compression diastole) is currently recognized as the best single indicator of the
likelihood of successful defibrillation and ROSC 34. However its invasive measurement during CPR is feasible
in a very small minority of patients. EtC02 is determined by body's CO~ production and relationship between
minute ventilation and pulmonary perfusion. Cardiac output produced by compressions is usually less than one-
third of normal, reducing dramatically pulmonary flow and EtC02 35. EtC02 is highly correlated with coronary
perfusion pressure during CPR, and may therefore serve as a tool for monitoring the effectiveness of
compressions. When EtC02 exceeds the threshold level of approximately 10-15 1I1l11Hg,greater likelihood of
successful ROSC has been reported 36. However, practical measurements of EtC02 are currently limited by the
need of endotracheal intubation.
ECG wwavefortn analysis to predict defibrillation success
In contrast with Cl'P and EtC02, electrocardiogram (ECG) registered by external defibrillators is routinely
available during CA. Therefore, ECG analysis of VF waveform waveformmight represent a non-invasive and
real time approach to guide the priority of interventions and to predict the best timing for defibrillation delivery.
There is evidence that VF waveform change over time. Several retrospective case series, animal studies, and
theoretical models have suggested the possibility to predict the success of defibrillation by analyzing waveform.
Indeed, VF features reflect vital organ blood flow and specifically myocardial blood flow and energy
metabolism 37. The story of this search began more than 25 years ago and included measurements of VF
amplitude, first, and frequency, later.
'VF voltage', or signal amplitude, is defmed as the maximum peak-to-trough VF amplitude in a given time
window of the ECG signal 38. Mean VF voltage is the average ofVF voltage over the same time interval. It was
observed that VF amplitude declines over time and greater amplitudes were associated with correspondingly
greater defibrillation success. Weaver et al observed that, if VF amplitude was greater than 0.2 mV, likelihood
of resuscitation was significantly greater 37. VF voltage appeared not only as a predictor of ROSC but also as an
indicator for timing the duration ofVF following collapse.
Subsequently, it was realized that other parameters could be computed utilising the Fast Fourier transformation
in a selected ECG interval. Brown et al developed a VF voltage and frequency analysis such as to obtain the so
called 'median frequency' (MF) which served as a predictor of successful defibrillation 39. In a porcine model, a
MF of more than 9.14 Hz had 100% sensitivity and 92% specificity in predicting the defibrillation success. MF
was also correlated with coronary perfusion pressure in animal models as well as human victims and therefore
it became the preferred ECG predictor of outcome 40. In addition, MF appeared as a more accurate indicator for
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estimating the duration of untreated VF, compared to the earlier VF amplitude. To improve sensitivity and
specificity, more sophisticated methods ofVF waveform analysis were investigated.
Amplitude Spectrum Area (AJ\1SA)
Among different approaches, the Amplitude Spectrum Area (AMSA) is one of the 1110stefficient ECG-derived
defibrillation predictors in which mean amplitude and dominant frequency are combined. The amplitude
spectrum is obtained by fast Fourier transform of the ECG scalar signal (Figure 2).
Figure 2. Fast Fourier Transformation with AMSA calculation.
In a porcine model, threshold values of AMSA for defibrillation success have been established and AMSA has
confirmed its capability to optimize the defibrillation timing 41. It was highly correlated with coronary perfusion
pressure levels during CPR and significantly greater values were observed in animals that were resuscitated
compared to those that were not 42. AMSA demonstrated a negative predictive value for resuscitation of 96%
and a positive predictive value of 78% both higher than other predictors, offering a guide to minimize
ineffective shocks.
In clinical scenario AMSA values were significantly greater ill successful defibrillation: a threshold value of 12
mV -Hz was able to predict the success of each defibrillation attempt with sensitivity and specificity of 1I1Ore
than 91% 43.
The optimal duration of CPR before defibrillation may be difficult to define without an objective feedback
measurement. It depends on the duration of VF and the quality of CPR, since poor myocardial perfusion is
associated with decreased VF frequency spectrum. On the other band, the increased VF amplitude and
frequency indicate a positive effect of CPR with improved myocardial perfusion resulting in increased ROSe.
The ECG and ill turn AMSA analyses has the advantages of detecting changes in the electrical status of the
myocardium during CPR 44. More importantly, AMSA is not invalidated by artifacts resulting from
compressions allowing for uninterrupted compressions during ECG analyses. Recently, Sun and colleagues 45,
in a rat model of prolonged CA, optimized the duration of CPR and defibrillation timing by adopting a real time
AMSA analyses during compressions. Shock was attempted only when AM SA achieved a predefined threshold
level predictor of successful defibrillation: 70% of animals were resuscitated after the first shock in contrast to
0% when defibrillation was attempted following standard guidelines. The AMSA-guided CPR significantly
improved ROSC success, reducingcompressions interruptions and shock number prior to achieve ROSC and
ultimately survival.
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Recently we have investigated the accuracy of an AMSA-based defibrillation decision algorithm to guide CPR
interventions in 1291 defibrillation events from 609 out-of-hospital VF patients 46. AMSA value was
significantly higher in successful defibrillation compared to unsuccessful ones (16.8 mV-Hz vs. 11.4,
p<O.OOOI). More interestingly, with an AMSA threshold of 7.5 mV-Hz, a large amount of unnecessary
defibrillations (35% for the first shocks and 50% for the subsequent shocks) were avoided with extremely high
accuracy (Table II). Decreasing the threshold value, accuracy of AMSA in guiding shock decision further
improved. An AMSA-based algoritlun therefore clearly appeared as a useful approach to avoid many
unnecessary and potentially harmful defibrillation ill the clinical scenario.
Table II. Prediction of non successful defibrillation (defibrillation) attempts with all AM SA-based
defibrillation decision algorithm.
Detecting different kind of VF
To improve prognostication, several studies have been focused on waveform changes in relationship to CA
physiopathology, with more attention OIl CA as resultant of ischemic VF (i.e. the main cause of sudden death
compared to experimental electrical~v-induced VF). It was unknown, in fact, whether waveform predictive
utility differed in acute myocardial infarction (MQ or normal myocardium. AMSA changes and other VF
features (i.e. AMSA slope), measured in animals with CA overlapping AMI or chronic ischemia, predicted
ROSC independently of myocardial substrate. Furthermore, with compressions, the waveform evolved
differently in the healthy or ischemic heart 47. Thus, ECG predictors were, at least in part, related to the
mechanism by which VF evolves and may distinguish an AMI-related CA.
Waveform analyses during CPR may also help in guiding the best treatment for recurrent VF and shock-
resistant VF, the optimal treatment of which is still unknown. In out-of-hospital CA patients, AMSA and slope
were higher ill recurrent VF compared to shock-resistant VF, and recurrent VF was more likely to be
defibrillated than shock-resistant VF. However, when VF was shock-resistant, AMSA and slope were highly
predictive of defibrillation outcome 48.
Conclusions
Despite sensible background, the routinely application of CPR before defibrillation in clinical settings seems to
not add the expected benefit in survival, Variables such as CA duration, underlying ischemic heart conditions,
progressive hemodynamic changes, metabolic deterioration and quality of CPR affect the likelihood of
defibrillation success. Currently, there are no simple instruction nor tools able to take in account all these
variables while guiding CPR interventions. Promising evidence on ECG analysis have now emerged as a
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clinically applicable method to provide a real-time indicator for compressions effectiveness and predictor of
defibrillation success. The validity of VF feature analyses has been proven in animal studies and retrospective
human trials. We therefore anticipate that these algorithms, incorporated into conventional defibrillators, will
minimize interruptions in compressions and delivery of futile defibrillation, guiding to a more optimal timing of
defibrillation. However, guidelines statements for clinical practice must be based all solid evidence. Unlikely,
there are no prospective studies that have identified optimal VF waveform analyses algorithm as well as effects
of medications and interventions (i.e. adrenergic blockade and hypothermia) on VF features. While awaiting for
future diffusion of these promising smart technologies, early defibrillation in conjunction with high quality
CPR, are the determinant weapons in the difficult battle to achieve resuscitation from CA.
Key messages
1. So far, clinical studies failed to clearly prove that an interval of CPR performed before attempting
defibrillation can improve survival of cardiac arrest victims. Therefore, a specific period of CPR before
defibrillation is no more recommended in current guidelines and defibrillation should be attempt as soon
as possible with minimal interruptions in chest compressions.
2. Metabolic and hemodynamic cardiac changes OCCUlTing during ventricular fibrillation affect the
possibility of successful defibrillation and may be reversed by chest compressions. Therefore, a real-
time and non invasive tool able to detect heart responsiveness to defibrillation could be very useful to
prioritize rescuers' intervention (compressions first or defibrillation first).
3. The ECG analysis and particularly the Amplitude Spectrum Area (AMSA) analysis has been proven to
be a valid predictor of successful defibrillation ill animal studies and retrospective luunan trials, AMSA
can detect changes in the electrical status of the myocardium during CPR and it is not invalidated by
artifacts resulting from compressions.
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~abl£' I.Characterlsncs of the main RCTs on Cardiopulmonary Resuscitaticu (CPR) be/ore Deflbrillatlou (DF)
f4l1lhors Country IPllbficatiOl 'Sampling Comparison CPRjirst Ipts iplHD (n, %) CIV ~hocks !EMS mean response
(Year) (Yem) (sec) (11) OR (95%CJ) 'atio 1/) time (mill)
IP m/lie
~ik et al. lNonvay 12003 1995- !oF first vs 196 14 (15%) 5:1 l3 11.42
'001 jePR first 180 104 ~3 (22%) 12.00
1.66 (0.80 to
p.46)
II> = 0.20
lTacobs et ~ustralia 12005 '000- IDF first vs 137 7 (5.1%) 5:1 l3 19.00
al. Q002 !cPR first &0 119 5 (4.2%) 19.20
~.SI (0.25 to
~.64)
II> 110t provided
!Baker et ~ustralia 1200s ~005- !oF first vs 105 18 (17.1%) 15:2 l3 8.14
al. 2007 CPR first 180 197 10 (10.3%) land 1 7.41
p.56 (0.25 to ~0:2
1.25)
1P=0.16
lIost et France 2010 2005- IOF first vs 1424 ft5 (10.6) !CP* l3 vs 1 10.54
~1.49 200S !cPR first 60 1421 56 (13.3) 10.30
1.27 (0.78-
~.07)
P = 0.34
Stiell et ~SACanada ~01O 2007- !Early vs 30-60 5290 ~27 (8.1) 30:2 1 ~.OO
~l. ~009 lLate vs 180 ~643 ~72 (8.0) ~.OO
analysis 0.1 (-1.2 to
1.1)
P=0.92
~A et al Taipei 2012 'OOS- IOF first vs 14S 11 (7.4) 30:2 I ~.70
(Taiwan) 2009 jePR first 240 141 16(11.3) ~.70
1.59 (0.71 to
3.57)
J.= 0.31
CN ratio: Compression to Ventilation ratio. EMS: Emergency Medical System. StHD: Survival to Hospital DIscharge.
"Cardio-pump (Ambu, Denmark).
Modified from: Meier et al.(BMC Medicine 2010;8:52) and Simpson PM et al. (Resuscitation 2010;81 :925-931).
T able II. Prediction of non successful defibrillation (DF) attempts with an AMSA -based defibrillation decision
algorithm.
Selected AMSA thresholds Events of correct predtctien of 'DOD % of correct prt'dirtioD overall
successful" DF 'DOD successful" DFs
First DF (n=609)
5.5 124 (N~126) 98.4
6.5 175 (N=184) 95.1
7.5 213 (N~229) 93
Subsequent DFs (11=662)
5.5 205 (N=210) 97.6
6.5 272 (N~283) 96.1
7.5 328 (N=346) 95
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A combination of un targeted and targeted metabolomics
approaches unveils changes in the kynurenine pathway following
cardiopulmonary resuscitation
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Abstract The mechanisms responsible for post-resuscita-
tion myocardial and cerebral dysfunction are not well under-
stood, especially in the early post-resuscitation phases. In this
investigation, we first adopted unbiased mass spectrometry-
based metabolomic profiling to identify perturbations in
circulating metabolites in a rat model of cardiac arrest and
cardiopulmonary resuscitation. Our findings strongly indi-
cated early alterations in a major route of the tryptophan
catabolism, namely the kynurenines pathway, after resusci-
tation. Specific metabolites involved in the tryptophan
catabolism were quantified absolutely using liquid chroma-
tography-multiple reaction monitoring-mass spectrometry.
Tryptophan plasma concentration fell significantly very early
in the post-resuscitation phase,while its metabolites, L-kyn-
urenine, kynurenic acid, 3-hydroxyanthranilic acid and
5-hydroxyindoleacetic acid, rose significantly. Changes in
their concentration reflected changes in rat post-resuscitation
myocardial dysfunction. Elevated plasma level of kynurenic
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acid. 3-hydroxyanthranilic acid were associated with signifi-
cant decrease in ejection fraction and stroke volume. It is well
known that kynurenines pathway is involved in the patho-
genesis of numerous central nervous system disorders. By
implication, altered levels of tryptophan metabolites in the
early post resuscitation phase might contribute to the degree of
cognitive recovery. Our results suggest that kynurenine
pathway is activated early following resuscitation from car-
diac arrest and might account for the severity of post-resus-
citation syndrome. Our explorative investigation indicate that
metabolomics can help to clarify unexplored biochemical
pathways in cardiopulmonary resuscitation.
Keywords Cardiac arrest - Resuscitation· Plasma
metabolomics • Kynurenines pathway • LC-MS •
LC-MRM-MS
Abbreviations
3-HAA 3-Hydroxyanthranilic acid
5-HAA 5-Hydroxyanthranilic acid
5-HIAA 5-Hydroxyindoleacetic acid
CA Cardiac arrest
CPR Cardiopulmonary resuscitation
FFA Free fatty acids
IDO Indoleamine-2,3-dioxygenase
KYN L-kynurenine
KYNA Kynurenic acid
SIP Sphingosine I phosphate
TRP Tryptophan
1 Introduction
Novel metabolomics technologies have made it easier to
acquire high-throughput snapshots of a whole organism's
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metabolic status and it is now possible to establish meta-
bolic signatures in many relevant human diseases (Griffin
et al. 20 II; Locasale et al. 2012; Nordstrom and Lewen-
sohn 2010). Knowing which metabolites are altered in a
disease helps define its pathophysiology better. Metabolic
profiling also facilitates high-throughput patient screening
to diagnose the disease state or for risk assessment (Sab-
atine et al. 2005).
The application of metabolomic analysis in cardiovas-
cular diseases is an emerging field and it is not yet possible
to depict any single metabolic picture responsible for the
prediction and progression of cardiovascular disease.
However, the identification of clinically relevant changes
in circulating metabolites is opening exciting avenues in
the cardiovascular field (Abramson 1991; Alexander et al.
20 II; Barderas et al. 20 II; Lewis et al. 2008; Mayr et al.
2009; Rhee and Gerszten 2012; Turer et al. 2009; Wang
et al. 20 II b). For example, Shah and colleagues showed
that a signature composed of dicarboxyacylcarnitines was
predictive of further cardiovascular events in patients with
coronary artery disease (CAD) and most significant dif-
ferences persisted after adjustment for CAD risk factors
(Shah et al. 2010). An important role of phospholipids as
new key culprits in atherosclerosis was highlighted in
patients with cardiovascular disease (Wang et al.
201la)and a pathological role of ketone bodies has been
suggested for human atrial fibrillation (Mayr et aJ. 2008).
In acute ischemia and acute myocardial diseases many
intermediates of the citric acid cycle were found to be
depressed as a direct consequence of myocardial ischemia
(Sabatine et al. 2005; Zhao et al. 2008).
Cardiovascular disease remains the main cause of death in
developed nations and in Europe cardiac arrest (CA) is the
leading cause of death (Chugh et al. 2004; Sans et al. 1997).
The treatment for CA is cardiopulmonary resuscitation
(CPR) to provide circulatory support, followed by defibril-
lation if a shockable rhythm is present. Morbidity and mor-
tality after successful CPR largely depend on recovery of
neurologic function. As many as 30 % of survivors of cardiac
arrest, in fact, suffer permanent brain damage (Brown et al.
1992; Krause et aJ. 1986). The mechanisms responsible for
post-resuscitation myocardial and cerebral injury are not
well understood, although several events have been descri-
bed. The reintroduction of oxygenated blood after the return
of spontaneous circulation (ROSC) stimulates a sequence of
complex actions that lead to acute inflammatory responses
and release of reactive oxygen species (ROS), causing oxi-
dative damage, cellular edema, cell membrane damage and
apoptosis (Dezfulian et al. 2007; Lebuffe et al. 2003; Levraut
et al. 2003; Ouyang et al. 1999). Several other processes,
including interactions between pleiotropic mediators,
coagulation abnormalities, activation of the inflammatory
cytokine cascade, chemokine upregulation and ultimately
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recruitment of inflammatory leukocytes and reactive
astrogliosis have also been reported after CA and are major
players in the final outcome (Frangogiannis et al. 1998;
Meybohm et al. 2009; Vakeva et al. 1998). There is still
controversy about how much current biomarkers contribute
to the information provided by conventional risk factors, and
the clinical use of specific biomarkers (e.g. troponins, neu-
ron-specific enolase, protein S-I 00 beta) to predict outcome
ofCA is still debated (Nolan et al. 20 I0). Predicting survival,
myocardial and neurological outcome is therefore a difficult
issue, especially in the early post-resuscitation phase.
The comprehensive quantitative assessment of plasma
metabolites might help fill this information gap as metab-
olite differences in plasma provide the closest link to cel-
lular metabolism in the whole body and its response to
resuscitation. Thus, we hypothesized that extensive char-
acterization of the largest possible number of metabolites
from relevant or potentially affected metabolic pathways
might help in identifying mechanisms explaining the out-
come of CA and CPR and might serve as early prognos-
ticator biomarkers and ultimately as targets for therapeutic
intervention.
The aim of this study was to examine plasma metabo-
lites in a rat model of CA in post-resuscitation observa-
tional periods to identify perturbation in circulating
metabolites and thus potential mechanisms accounting for
outcome of cardiac arrest. We used a well-known rat model
of CA and CPR (Sun et al. 20 I0). Changes in plasma
metabolites in the early post-resuscitation phase were
identified using an untargeted metabolomics approach
by liquid chromatography/tandem mass-spectrometry
(LC-MSIMS). On the basic of the findings, specific
metabolites involved in the tryptophan metabolism were
then targeted, using LC-multiple reaction monitoring
(MRM)-mass spectrometry.
2 Materials and methods
2.1 Standards and chemicals for metabolomic analysis
HPLC-grade acetonitrile, ammonium acetate (>99 % dry
matter) and formic acid (98 %) were purchased from F1uka
(Buchs, Switzerland). HPLC grade MilliQ water was
obtained with a MILU-RO PLUS 90 apparatus (Millipore,
Molsheim, France). Analytical standards t-tryptophan
(TRP), L-kynurenine (KYN), kynurenic acid (KYNA),
3-hydroxyanthranilic acid (3-HAA), 5-hydroxyanthranilic
acid (5-HAA), 5-hydroxyindoleacetic acid (5-HIAA) were
from Sigma-Aldrich (Italy). Deuterated standards D8-L-
tryptophan, De-kynurenic and 05-5-hydroxyindoleacetic
acid were from CON Isotopes (Chemical Research 2000
S.r.1., Italy). D4-L-kynurenine and D2-3-hydroxyanthranilic
Kynurenine pathway activation folJowing resuscitation from cardiac arrest
acid were from Buchem BV (Netherlands). Individual
stock solutions were prepared in MilliQ water and stored at
-20°C. Working solutions containing all the metabolites
and their internal standards were prepared freshly before
analysis.
2.2 Rat model of cardiac arrest
Procedures involving animals and their care conformed
to institutional guidelines in compliance with national
(4D.L. N.1l6, G.U., supplement 40, 18-2-1992) and
international (EEC Council Directive 86/609, OJ L 358,
I, 12-12-1987, National Institutes of Health's Guide
for the Care and Use of Laboratory Animals, and US
National Research Council 1996) law and policies. All
efforts were made to minimize the number of animals
used and their suffering.
An established rat model of CA and CPR was used.
Eighteen male Sprague-Dawley rats weighing 470 ± 25 g
were anesthetized with pentobarbital, endotracheally intu-
bated and surgically instrumented, as previously described
(Sun et al. 2010). Ventricular fibrillation (VF) was induced
in 12 rats by delivering up to 4 rnA AC current into the
right ventricle. CPR, including mechanical chest com-
pression, ventilation with oxygen, and epinephrine
(0.02 mg/kg), was then started and continued for a 6 min
before defibrillation. Chest compression was maintained at
a rate of 200/min with equal compression-relaxation and
ventilation at 50/min. Resuscitation was attempted with up
to three two-joule counter-shocks. Animals were consid-
ered successfully resuscitated if supra-ventricular rhythm
returned with mean aortic pressure above 50 mmHg. Two
(n = 6) and 4 h (n = 6) after resuscitation, animals were
anesthetized and surgically prepared for femoral artery
cannulation for blood withdrawal. Animals were then
euthanized. Blood was collected into EDTA-tubes and
centrifuged for 10 min at 2,000xg at room temperature.
Plasma samples from each animal were immediately stored
at -80°C. Six other rats were not subjected to CA and
served as controls (CTR). Body temperature was held at
37 ± 0.5 °C throughout the experiment.
2.3 Metabolomic profiling by LTQ-Orbitrap mass
spectrometry
Discovery pilot metabolomics analysis began with an
unbiased search for plasma analytes linked to post-resus-
citation using two experimental groups from the rat model.
The control group (CTR, n = 3) was selected from rats not
subjected to CA, while the case group was selected from
rats subjected to CA and CPR and sacrificed 2 h after
resuscitation (CAlCPR2, n = 3, early post-resuscitation
phase). To reduce biological variation that might mask
important changes in metabolite abundances, we prepared
metabolite samples by pooling plasma (5 ~Uanimal) from
individual rats in the experimental groups. Every specimen
made an equal contribution to the pool and two composite
groups (CTR and CAlCPR2) were then created.
Metabolites were extracted by adding four volumes of
cold methanol to the plasma sample; samples were vor-
texed and incubated at -20°C for 1 h. They were then
centrifuged 10 min at 14,OOOxg, and the supernatant (rich
in small-molecules analytes) was collected, dried in a
SpeedVac and resuspended in 20 ~L of 0.1 % formic acid.
A portion (2 ~L) of metabolite extract from the CTR
and CAlCPR2 groups was directly analysed by LC-MS!
™ ScientifiMS, using an LTQ Orbitrap XL (Thermo c,
Waltham, MA, US), interfaced with a 1,200 series capillary
pump (Agilent, Santa Clara, CA, US). The MS instrument
was operated in positive (POS) and negative (NEG) ioni-
zation modes. Analyses were run in triplicate.
Metabolites were separated on an Agilent Technologies
Zorbax CI8 SB column (150 x 0.5 mm ID, particle size
5 11m).Flow rate 10 ~min with mobile phases: water
containing 0.1 % formic acid (A) and acetonitrile (B) for
the positive ion. For negative ion mode, 2 mM of ammo-
nium acetate was substituted for the 0.1 % formic acid. The
gradient consisted of 5 % B for 5 min, followed by a Iin~ar
gradient to 95 % B over 45 min, hold at 95 % B for 5 mm,
and re-equilibration at 5 % for 2 min.
MS conditions were: source DESI Omni Spray (Proso-
lia, Indianapolis, IN) used in nanospray mode with positive
and negative ion modes; ion spray voltage 2,100 V; cap-
illary temperature 220°C; capillary voltage, 42 V. MS
spectra (mlz 100-1,000) were acquired in the Orbitrap
analyzer at 60,000 resolution, 'in parallel with the low-
resolution MSIMS scans of the four most abundant pre-
cursor ions being acquired in the LTQ. The lock-mass
option was used to obtain the most accurate mass mea-
surements in MS mode. The polydimethylcyclosoloxane
ion generated in the electrospray process from the ambient
air (protonated (Si(CH3hO)6, mlz 445.120025) was used
for internal recalibration in real time. MSIMS analysis was
done in data-dependent mode (DTA) using Xcalibur soft-
ware (Thermo Scientific, Waltham, MA, US) with target
ions previously selected for the MSIMS dynamically
excluded for 30 s.
To ensure the stability and repeatability of the LC-MS
systems, ten runs of pooled samples were done on the
system before the sample run sequence. Samples were run
in an order that alternated the CTR and CAlCPR2 groups to
reduce any systematic error associated with instrumental
drift.
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2.4 Untargeted metabolomics data processing
and statistical analysis
AIl LC-MS files were analyzed using the MS label free
differential analysis software SIEVE v1.3 (ThermoFisher,
Cambridge, MA, US). SIEVE was run on all the LC-MS
full-scan chromatograms using the small molecule setting.
The chromatograms were time-aligned, referencing the
CNCPR2 sample acquired in the middle of the sequence. The
framing parameters were set at 0.01 Da for the m/z window
and 0.35 min for the retention time (RT) window; 500,000
was used as the intensity threshold. Prior to performing any
statistical analysis, an additional filtering criteria was applied
to include in the dataset only frames with an intensity coef-
ficient of variation (CV%) <10. The preprocessed results
were then fed into the SIMCA-P 13 (Umetrics, Umea, Swe-
den) platform for multivariate analysis. Principal component
analysis (PCA) was performed on intensity data, preprocessed
using the Pareto scaling, to examine cluster and outliers
within the observations. All analyses were performed on data
from both ion modes separately. Univariate analysis
was performed using a 2-tailed Welch t test (p < 0.0 I; Prism
v. 5.0; GraphPad Software Inc, USA) to identify metabolites
presenting intensities significantly different in the two
experimental groups.
2.5 Identification of plasma metabolites
For metabolite identification, the frame mlz values were
used for batch searches on the METLIN database (http://
metlin.scrpss.edu) and Human Metabolome Database
(HMDB, http://www.hmdb.cal). Both sites allow the user
to search by ionization mode, either positive or negative.
Accurate mass data and isotopic distribution for the pre-
cursor and product ion were compared to spectral data of
the reference compounds in the databases. Definite iden-
tifications were reported only for metabolites with accurate
mass match <5 ppm.
2.6 Mapping metabolic pathways
For biological interpretation of the metabolite dataset by our
untargeted strategy, we mapped the identified metabolites to
the KEGG pathway database (Kyoto Encyclopedia of Genes
and Genomes; (www.genome.jplkeggl).using MetaboAna-
Iyst 2.0, a comprehensive online tool suite for metabolomic
data analysis and interpretation (www.metaboanalyst.ca).
Metabolite sets were analyzed to identify biologically
meaningful patterns that were significantly enriched in our
metabolomic data. The OverRepresentation Analysis (ORA)
algorithm was applied and the hypergeometric test was used
to see whether a particular metabolite set was represented
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more than expected by chance in the given compounds list.
Then the Pathway Analysis Module was used to combine
the enrichment analysis results with the pathway topology
analysis (centrality measures to estimate node importance)
to identify the most important pathways involved in early
CPR (Xia and Wishart 2011).
2.7 Absolute quantification of plasma tryptophan
metabolites by LC-multiple reaction monitoring
(MRM) coupled with isotope-dilution mass
spectrometry
Plasma (20 JlL) from each animal (n = 6) in each experi-
mental group (CTR and CNCPR2, CAlCPR4,: respec-
tively 2 and 4 h after resuscitation, respectively) was
spiked with 10 JlM of deuterated standards (tryptophan-D8,
L-kynurenine-D4, kynurenic acid-Dfi, 3-hydroxyanthranilic
acid-D2, S-hydroxyindoleacetic acid-Do). Spiked plasma
samples were then deproteinized by mixing with four
volume of cold methanol, vortexed, and incubated at
-20 DC for 1 h. Samples were centrifuged 10 min at
14,OOOxg, the supernatant was collected, and the centri-
fugation was repeated. The supernatant was dried in a
SpeedVac and resuspended in 20 JlL of 0.1 % formic
acid. 10 JlL of supernatant were analysed directly by
LC-MSIMS with the Agilent 1200 series system for LC.
Separation was with a Synergy 4u Fusion-RP 80A column
(50 x 2.00 mm, Phenomenex) using as mobile phase A
0.1 % formic acid in water and mobile phase B 100 %
acetonitrile at a flow rate of 0.2 mUmin. Elution started
with 99 % of A and 1 % of B, followed by a 13-min linear
gradient to 99 % of B, a 2-min isocratic elution and a
l-min linear gradient to 99 % of A, which was maintained
for 8 min to equilibrate the column.
The mass spectrometric analysis was done using an
Agilent 6410 triple quadrupole mass spectrometer (Agilent
Technologies) in positive ion mode for all the metabolites.
Typical chromatograms from the analysis of rat plasma are
presented in supplementary Fig. S l. Instrumental condi-
tions optimized for each compound are summarized in
supplementary Table SI. Quantitative analyses were pro-
cessed with MassHunter workstation quantitative analysis
software v B.01.04 (Agilent Technologies).
2.8 Performance of the quantification method
The performance of the method was assessed in rot plasma
samples for all the TRP metabolites. Recoveries and
repeatability were assessed by analyzing rat plasma samples
in five replicates. Since plasma already contained substantial
amounts of metabolites, the samples were spiked with I JlM
of KYN, KYNA, 3-HAA, S-HAA, S-HIAA and 180 JlM of
Kynurenine pathway activation following resuscitation from cardiac arrest
TRP before extraction and processed as previously men-
tioned. Known amounts of isotopologues (ID pM) were then
added to samples before LC-MS/MS analysis. Blank sam-
ples (water + 0.1 % formic acid) were analyzed in each
analytical run to test and correct bias. Instrumental quan-
tification limits (IQL) were determined by directly inject-
ing standard solutions with increasing amounts of each
metabolite. The limits of quantification (LOQ) for the
whole method were calculated directly from extracted
samples as the concentrations giving peaks with a signal-
to-noise ratio of 10. The linearity of the calibration curves
was tested in the concentration ranges normally measured
in rat plasma and a calibration curve was injected during
each analytical run to check the linearity (correlation fac-
tors) and the instrumental repeatability. Intra- and inter-
day instrumental repeatability and precision were also
assessed by replicated injections of standard mixtures and
rat plasma samples. '
2.9 Correlation with hemodynamic and myocardial
functions
We assessed whether the relative levels of individuals
TRP's metabolites correlated with post resuscitation myo-
cardial dysfunction developed in each rat, following ROSC
by using the Pearson correlation coefficient (r) (SPSS
16.0).
2.10 Targeted metabolomics statistical analysis
Physiological parameters in the rat model and metabolite
concentrations in different experimental groups were
compared by one-way ANOVA followed by a multiple
comparison test (Tukey-Kramer HSD test) computed using
Prism v. 5.04 (GraphPad Software Inc, USA). The limit of
statistical significance was set at p < 0.05.
3 Results
3.1 Rat model of cardiac arrest and experimental
measurements
Some key measurements of the rat model of CA used are
summarized in Table I. There was no differences in the
body weight of the animals and in their heart rate values. 2
and 4 h after CPR, there was a significant decrease in value
of mean arterial pressure, coronary perfusion, ejection
fraction, cardiac output and stroke volume compared to
controls. More details are reported in Ristagno et al. 2012,
in preparation.
Table 1 Experimental measurements. hemodynamics and myocar-
dial functions in the rat model of cardiac arrest
CTR CPR2h CPR4h
Body weight (g) 468 ± 35 480 ± 24 471 ± 16
Heart rate (beats/min) 387 ± 35 357 ± 19 377 ± 16
Mean arterial pressure 136 ± 2 105 ± 2* 105 ± 5*
(mmHg)
Coronary perfusion 116 ± 3 87 ± 2* 91 ± 4*
pressure (mmHg)
Ejection fraction (%) 79 ± 2 42 ± 2* 48 ± 4*
Cardiac output 122 ± 10 74 ± 7* 66± 5*
(mUmin)
Stroke volume (mL) 0.34 ± 0.02 0.21 ± 0.02* 0.18 ± 0.02*
Declaration time (ms) 28 ± 4 18.8 ± 1.2 19.4 ± 1.3
End diastolic volume 378 ± 24 446 ± 51 465 ± 57
(mL)
Data are mean ± SD (n = 6). Asterisks mark significant expression
differences from CTR (one-way ANOVA. Tukey-Kramer HSD,
*p<O.OI)
CfR rats not subjected to cardiac arrest as control. CPR2h and CPR4h
rats subjected to cardiac arrest and cardiopulmonary resuscitation.
euthanized respectively 2 and 4 h after resuscitation
3.2 Plasma metabolome profiles in the early
post-resuscitation phase
To initially explore the metabolome changes associated
with the early post-resuscitation phase, a plasma LC-MS/
MS approach was used to discover unbiased small-mole-
cule metabolic profiles in rats not subjected to CA (CTR)
and in rats subjected to CA and CPR and sacrificed 2 h
after resuscitation as described in Methods. Mass-spectral
data were subject to peak alignment and data pre-pro-
cessing by SIEVE 1.3. Then, data were analyzed for global
changes by using multivariate statistics to determine group
separation as well as univariate statistics to evaluate the
number and percentage of features that vary significantly
between the two sample sets. As seen in Fig. I, peA
(principal component 1 vs principal component 2) revealed
an excellent separation of the two experimental groups
under both positive and negative modes.
Up to 4,534 and 4,710 features respectively were
detected in positive and negative ion mode. 1.306 features
were detected in both sample sets, showing significant
changes in their relative signal intensity (defined as a
~twofold change with CV% =:;10 and Welch's I test
p =:: o.oi.; (Supplementary Table S2). Of these 1,306 fea-
tures, 141 were related to molecular species identified by
database searches (METLIN and HMBD) and are listed in
Supplementary Table 53. It should be noted that a given
molecule may be represented by several different features,
such as naturally occurring components of its isotopic
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Table 2 Significant correlation among plasmatic levels of tryptophan
and its metabolites witb hemodynamic and myocardial functions
Pearson r-coefficient p Value
Tryptophan vs
Ejection fraction 0.546 0.016
Cardiac output 0.492 0.032
Stroke volume 0.596 0.009
Kynurenic acid vs
Ejection fraction -0.771 0.0001
Stroke volume -0.625 0.013
3-Hydroxyanthranilic acid vs
Ejection fraction -0.641 0.004
Cardiac output -0.632 0.005
Stroke volume -0.639 0.006
5-Hydroxyindolacetic acid vs
Ejection fraction -0.691 0.002
Pearson correlation coefficient (r) was assessed by SPSS 16.0
cluster or non-specific adduct ions. Several analytes were
detected only in positive mode, while others were observed
only in the negative ion mode as already reported for
plasma samples (Nordstrom et al. 2008). To further inter-
pret the biological significance in the early post-resuscita-
tion phase, we used MetaboAnalyst tools to link these
metabolites to metabolic pathways.
Figure 2 shows the results of the metabolic pathway'
analyses. Panel A gives the summary plot for the metab-
olite set enrichment, panel B shows the difference in
abundance of the metabolites, mapped into enrichment
categories, and panel C shows all metabolic pathways
arranged according to the scores from enrichment analysis
tv axis) and topology analysis (x axis). Analysis of the
differences between the two datasets indicated that the
beta-oxidation of fatty acids, linolenic acid metabolism,
TRP metabolisms and sphingolipid metabolism were over-
represented (Fig. 2, panel A). The very early CPR phase
(2 h) showed plasma changes, although modest, in the
composition of free fatty acids (FFA) compared to control.
For example there was a generally lower level of unsatu-
rated FFA (e.g. linoleic, acid, docosahexaenoic acid) and
saturated acids (e.g. capric, myristic and dodecanoic acids).
Rats from the early CPR interval also had lower plasma
levels for sphingolipids such as sphiganine-l-phosphate
and sphingosine l-phosphate, Interestingly, striking dif-
ferences from controls were seen in various intermediates
of TRP catabolism through either kynurenine or a series of
indoles in the early post-resuscitation phase (e.g. low level
of indoxyl; higher levels of 5-hydroxyindolacetic acid,
formyl-5-hydroxykynurenamine, 4-(2-aminophenyl)-2,4-
dioxobutanoate, KYNA, indolelactic acids) (Fig. 2, panel
B). Pathway analysis (Fig. I, panel C) showed that the TRP
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metabolism was more likely to be significantly perturbed as
a consequence of early CPR and, depending on the location
on the plot, changes in the metabolites might have an
impact on the pathway as inferred from pathway analysis
reported in Supplementary Table S4.
3.3 Absolute quantitation of circulating tryptophan
metabolites
Because TRP metabolism was one of the most important
pathways perturbed during the early post-resuscitation
phase, we explored whether the major route of TRP
catabolism, the kynurenhine pathway (KP) and the TRP
metabolism to serotonin metabolite, played a role
throughout a longer post-resuscitation observational period
of prolonged duration. Figure 3 gives a schematic view of
the TRP catabolism.
We developed a highly sensitive and specific isotope
dilution LC-MSIMS method for accurately quantifying
tryptophan (TRP), t-kynurenine (KYN), kynurenic acid
(KYNA), 3-hydroxyanthranilic acid (3-HAA), 5-hydroxy-
anthranilic acid (5-HAA), 5-hydroxyindoleacetic acid
(5-HIAA) in rat plasma at 2 and 4 h after resuscitation,
compared to controls. Deuterated metabolites were added
to plasma samples as internal standards.
We assessed the assay performance in terms of linearity,
sensitivity and analytical recovery. The instrumental sen-
sitivity was good and the IQLs ranged from 0.0015 to
0.25 pmoVinjected. LOQs in rat plasma ranged between
0.55 and 6 nM, except for 5-HIAA (40 nM) (Supplemen-
tary Table SS). The recoveries in rat plasma were higher
than 60 % for all the metabolites (Supplementary Table
SS). The analytical response was linear for all the com-
pounds in the range of concentrations measured in rat
plasma and the inter-day correlation factors (r2) were
~0.9994 with standard deviations (SD) !S0.OOO7(Supple-
mentary Table S6). Instrumental repeatability, assessed
using replicate injections of standard mixtures and rat
plasma, was generally !SIO % except for 5-HAA that
ranged from 10.6 to 17.2 % (Supplementary Table S6).
Figure 4 shows the mean rat plasma concentrations of
TRP and its metabolites KYN, KYNA, 3-HAA, 5-HAA
and 5-HIAA measured over the intervals after resuscitation
in each of the six rats per group. Plasma levels in rats not
subjected to CA were taken as the baseline concentration.
Significant changes in plasma concentrations of TRP
and the metabolites showed significant differences from
controls 2 and 4 h after resuscitation. TRP decreased sig-
nificantly at both times (Tukey HSD p < 0.05). Interest-
ingly, the concentrations of KYN, KYNA and 5-HIAA
almost doubled in the 2 h after resuscitation (Tukey HSD
p < 0.05) and then dropped back to baseline towards 4 h,
although only KYNA and 5-HIAA reached significance
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Fig. I PCA score plots of the
plasma profiling of rats not
subjected to cardiac arrest as
control (CTR) and rats
subjected to cardiac arrest and
cardiopulmonary resuscitation.
euthanized 2 h after
resuscitation (CPR2h). Panel A
with the positive ESI dataset.
Panel B with the negative ESI
dataset (see "Materials and
methods" section)
A
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B
between 2 and 4 h after CPR. The exception was 3-HAA,
whose concentration rose significantly at 2 h and was still
significantly higher than baseline at 4 h. 5-HAA did not
significantly differ from baseline at any time. As reported
in Table 2, changes in plasmatic levels of TRP, KYNA,
3-HAA and 5-H1AA were significantly correlated with dif-
ferent echocardiographic data. For example, the decrease in
ejection fraction, cardiac output and stroke volume observed
in animal following ROSC was inversely related with the
increase in 3-HAA plasmatic level, but directely related with
TRP concentration.
4 Discussion
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Emerging metabolome profiling technologies offer the
possibility of identifying novel biomarkers and pathways
activated in cardiovascular diseases; however, applications
to post-resuscitation myocardial dysfunction in the set-
ting of CA are still lacking. We used a global LC-MS
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metabolomics approach to obtain a comprehensive view of
changes in plasma metabolites associated with CPR in an
established, widely accepted rat model.
We first adopted an unbiased strategy towards profiling
as many plasma metabolites as possible in the very early
post-resuscitation phase (CPR 2 h) after CA in rats. The
profiling data was then used to detect altered biochemical
processes using bioinforrnatics-based pathway mapping.
Statistically significant signatures can be obtained in rats
plasma in the very early CPR period compared to control
rats at baseline. Many biochemical alterations were in line
with those already reported in the literature about cardio-
vascular dysfunctions, supporting the feasibility and
robustness of our explorative untargeted LC-MS strategy.
For example, there were changes in the plasma levels of
some saturated and unsaturated fatty acids (FA), with an
overall tendency to decrease in the early CPR phase. This
de-regulation have significant energetic and functional
consequences on the heart, affecting the delivery of FFA to
the myocardium and their utilization during ischemia and
~ Springer
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Fig. 2 Metabolic pathway analyses related to the metabolites that
specifically differ in the two datasets (rat CTR and rats CPR2h)
utilizing the MetaboAnalyst functional interpretation tools. Panel A
graphic summary of metabolite set enrichment analysis; the horizon-
tal bars summarize the main metabolite sets identified in this analysis;
the bars are colored based on their p values and the bar length is
the post-ischemic period. The involvement of FA beta-
oxidation in rats in the early CPR phase is consistent with
the decrease in the myocardial capacity for this process in
~ Springer
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based on the -fold enrichment. Panel B shows the difference in
abundance of the metabolite subset mapped into the enrichment
categories. Panel C shows all metabolic pathways arranged according
to enrichment analysis (y axis) and topology analysis (x axis) scores
(see "Materials and methods" section)
rodent models of heart failure (Lopaschuk et al. 2010) and
in clinical settings, as the rates of FA uptake and oxidation
were low in patients with dilated cardiomyopathy (Jaswal
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et al. 2011; Neglia et al. 2007). Our findings are in
accordance with a general reduction in oxidative fuel
metabolism and greater reliance on anaerobic metab-
olism for energy revealed by metabolomics analysis
(Turer et al. 2009) in clinical settings of myocardial
ischem ia/reperfusion.
There is convincing body of the role of sphyngolipids in
cardiovascular dysfunctions (Knapp 20 II) and in particular
for S lP, which has potent cardioactive properties against
ischemia-reperfusion injury (Baranowski and Gorski
20 II). In line with these observations, in rat plasma from
o
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5-hydroxykynuremlne
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Natura Reviews IDrug Discovery
3-HAO 3-hydroxyanthrunilic acid oxidase. QPRT quinolinic-ucid
phosphoribosyl transferase. From Stone and Darlington, Nature
Reviews. 2002. The underlined metabolites are those quantified by
LC-MRM-MS in this study
the early CPR phase, we found a reduction in the level of
SIP, which could lessen its protective action on cardio-
myocyte viability (Knapp et al. 2009).
Analysis of rat plasma using a comprehensi ve LC-MS
platform also identified metabolites of the essential amino
acid TRP catabolism that had not, to our knowledge, been
previously associated with any post-resuscitation syn-
drome. We identified what we believe to be novel changes
in plasma after CPR.
The targeted LC-MRM-MS platform with stable-iso-
tope dilution method enabled us to unambiguously quantify
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Fig. 4 Rat plasma concentrations of tryptophan and its metabolites at
different cardiopulmonary resuscitation phases (CPR). Each bar
represents the metabolites' plasma concentration as mean ± SD
(n == 6 rats/group). Asterisks mark significant differences in expres-
sion (one-way ANOV A, Tukey-Kramer HSD, p < 0.05). CTR rats
not subjected to cardiac arrest, as control, CPR2h and CPR4h rats
subjected to cardiac arrest and cardiopulmonary resuscitation. eutha-
nized respectively at 2 and 4 h after resuscitation, TRP tryptophan,
KYN L-kynurenine, KYNA kynurenic acid, 3-HAA 3-hydroxyanthra-
nilic acid, 5-HAA 5-hydroxyanthranilic acid, 5-H/AA 5-hydroxyin-
doleacetic acid
the statistically meaningful changes of TRP and its
metabolites throughout the post-resuscitation observational
periods. The TRP metabolites analyzed mapped along two
distinct routes: (i) the methoxyindoles pathway that regu-
lates the conversion of TRP into the neurotransmitter
serotonin and (ii) the kynurenine pathway (KP), through
%l Springer
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which TRP is metabolized towards neuroactive kynure-
nines and nicotinamide adenine dinucleotide (NAD) (refer
to Fig. 2).
Methodological refinements. including optimization of
MS conditions. and deuterated standards resulted in a
sensitive. selective and accurate method for the simulta-
neous measurements of TRP, KYN, KYNA, 3-HAA,
5-HAA and 5-HIAA in plasma. Baseline values were
similar to those reported by others (Fukushima et al. 2009;
Midttun et al. 2009; Pawlak et al. 2001; Siassi et al. 1977;
Zheng et al. 2012).
We found the TRP catabolism was mainly altered in the
early CPR phase. More specifically. there was an activation
of the KP with decreases in circulating TRP and increases
in plasma levels of KYN, KYNA and 3-HAA, especially
2 h after CPR.
Since the KP is mainly activated during inflammation
(Mandi and Vecsei 2012), these results come as no surprise
because activation of the inflammatory cytokine cascade.
chemokine upregulation and ultimately recruitment of
inflammatory leukocytes and reactive astrogliosis have
been reported after CA and play major roles in the final
outcome (Meybohm et al. 2009). As the KP is activated by
pro-inflammatory stimuli, the reported anti-inflammatory
effect of KYNA, through the inhibition of TNFIX,provides
an interesting feed-back mechanism in immune responses
(Wang et al. 2006). Therefore in our model, KP activation
might have been a consequence of the acute immune and
inflammatory responses.
Kynurenine pathway activation has also been reported in
the pathogenesis of vasoplegia and hypotension during
septic shock (Adams Wilson et al. 2012). During systemic
inflammation. the expression of indoleamine-2.3-dioxy-
genase (IDO). responsible for the conversion of TRP to
L-KYN, is induced and contributes to the dysregulation of
vascular tone (Wang et al. 2010). The increased IDO activity
accounted for the greater production ofL-KYN, the precursor
of both KYNA and 3-HAA that directly mediates arterial
relaxation (Changsirivathanathamrong et al. 2011). When
this enzyme was inhibited. there was clear protection against
hypotension, with reduced mortality (Jung et al. 2009).
Hypotension also occurs during CPR (Krismer et al. 2006)
and we cannot exclude that the raised levels of KYN. KYNA
and 3-HAA at 2 h account for vascular tone alteration with
systemic hypotension after successful resuscitation. Indeed
in our rat model there was a significant decrease of hemo-
dynamic parameters (e.g. mean arterial and coronary per-
fusion pressure) in the early CPR phase.
Interestingly, in the very early phase of CPR there was
an increase in the plasma concentration of 5-HIAA, the
MAO-derived end-product of serotonin (5-HT). which is in
turn an oxidative metabolite of TRP along the methoxy-
indole pathway (see Fig. 3). This might indicate that
serotonin and its metabolite contribute to the deterioration
of peripheral blood flow in the early CPR phase, in
accordance with recent findings of a high plasma level of
5-HIAA in subjects with metabolic syndrome in the setting
of vascular injury (Fukui et al. 2012). The specific role of
these TRP metabolites in the regulation of blood pressure
warrant further investigation.
The KP activation attracted our attention also because
mounting evidence indicates its significant role in many
neurological disorders (Braidy et al. 2009; Gulaj et al. 20 I0;
Zadori et al. 2009). The activation results in production of
neuroactive and neurotoxic intermediates, closely related to
the pathogenesis of depression. schizophrenia. Huntington
disease. seizure. and other neuro-inflammatory and vascular
diseases (Changsirivathanathamrong et al. 20 II; Chen et al.
2010; Gulaj et al. 2010; Myint 2012; Stoy et al. 2005; Wang
et al. 2010; Wonodi et al. 2011). Specifically, 3-HAA.
besides its role in immunoregulation (Lopez et al. 2008;
Morita et al. 200 I), is a neurotoxin that can reduce choline
acetyltransferase activity similarly to quinolinic acid, a
3-HAA derivative end-product. known to be a potent exci-
totoxic N-methyl-d-aspartate (NMDA) receptor agonist
(Chen and Guillemin 2009). In addition, 3-HAA can cause
oxidative stress, by increasing the production of ROS
(Goldstein et al. 2000). KYNA. instead, has been identified
as an endogenous NMDA and 1X7nicotinicacetylcholine
receptor antagonist (Hilmas et al. 200 I ; Stone 1993) and has
been shown to be neuroprotective in clinically relevant
animal models of brain ischemia (Andine et al. 1988; Nozaki
and Beal 1992).
In the context of CPR, increased KYNA formation
might serve to counteract the negative effect of 3-HAA
metabolites through the NMDA receptor in order to
maintain homeostasis in the KP pathway. In our model the
KYNA concentration had dropped to baseline by 4 h after
CPR, while 3-HAA remained elevated. suggesting that a
neurotoxic profile might persist at 4 h after CPR. Similar
changes in KP metabolites have been found in acute
ischemic stroke patients where elevated levels of plasmatic
KYNA and 3-HAA were associated more with the initial
stroke severity than long-term outcome and correlated with
the stroke-induced inflammatory response (Brouns et al.
2010). Similarly, peripheral TRP catabolism started to
increase before or immediately after stroke and was related
to inflammatory response and oxidative stress. with a major
change in 3-HAA level (Darlington et al. 2007). The fact
that changes in circulating KP metabolites can be easily
detected after cerebral injury indicates that kynurenines
produced in the brain in response to stroke can cross the
blood-brain barrier into the peripheral bloodstream (Fukui
et al. 199I; Reinhard 2004).
A first limitation in the present study is the lack of
investigation on rat brain recovery, that is a long-term
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outcome. However this work was aimed at identifying very
early modifications in the CPR setting and indeed this
investigation had the capability to find correlation between
the activation of the KP and different indicators of early
post-resuscitation myocardial dysfunctions. A second
caveat may be the use of intact animals as control rather
than sham. We preferred to use intact animals to assess the
physiological basal levels of TRP and metabolites. Nev-
ertheless. animals used as healthy control. underwent
anaesthesia (as the CA animals) for echocardiography and
were surgically instrumented for blood collection. Indeed.
any possible effects of anaesthesia on KP has been there-
fore taken into account.
5 Concluding remarks
Mass spectrometry-based metabolomics strategies (from
untargeted to targeted) once again offer promise for the
discovery of potential biomarkers in resuscitation after
cardiac arrest. despite some limitations intrinsic to the
technology (e.g. partial metabolome coverage).
Our study provides the first demonstration of KP acti-
vation early following resuscitation from cardiac arrest.
Changes in TRP metabolism might account for the severity
of hemodynamic instability and vascular tone alterations
after successful resuscitation. Moreover our results sug-
gests and may anticipate that imbalances between benefi-
cial and neurotoxic kynurenine metabolites might have a
role in the neurological outcome. Further studies are in
progress clarify the prognostic value of TRP metabolites in
the CPR outcome (Ristagno O. et al. 2012 in preparation).
and if these specific metabolites offer promising features.
paving the way to alternative tools for understanding the
mechanisms of CA outcome.
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